AMERICAN PSYCHIATRIC ASSOCIATION
1999 ANNUAL MEETING
The Clinician

Washington, DC • May 15 - 20, 1999
Dear Colleagues and Guests:

Welcome to the 152nd Annual Meeting of the American Psychiatric Association. This is the occasion when organized psychiatry displays its might in one of the largest educational, social and political medical gatherings in the world. The theme for 1999 is easy to remember, "The Clinician." I chose this theme because it represents the professional lives of most psychiatrists. I want to pay tribute to the attitudes, the skills and the knowledge of those who see patients day in and day out. Research has given precision to our diagnoses and effectiveness to our treatments. We are winning the war against anxiety and mood disorders, the psychoses, chemical dependence and the disorders resulting from structural damage to the brain. Psychotherapy and psychotropics are increasingly better targeted.

We are going to dialogue about new initiatives in mental health financing. Radical reform is possible with the use of tax exemptions-vouchers, defined contributions (as opposed to the fine benefits), and consolidation of programs to enhance individual control. Our presentations here are going to show that the business community can join us in the protection of the working community. Employees are not costs but assets, the human capital is the best source of profits, and the employers should work better with physicians and not with insurance companies. This meeting has presentations on individual initiatives, including cooperatives, alliances of small employers and medical savings accounts.

The Annual Meeting will have multiple programs divided among clearly defined tracks. Those interested in specific clinical issues, special populations, diverse settings, new research, new systems of reimbursement, new clinical strategies, and new findings that apply to the young, the old, women, rural populations, prisoners and others can focus more easily, while enjoying our rich display of progress in clinical knowledge.

While in Washington, DC, join us in visiting our legislators, talk to those who make rules in Washington, visit the best museums in the world, march with us for justice for the mentally ill, visit the psychiatric office of the future, and have the most fun in your life.

I want to congratulate the Scientific Program and Local Arrangement Committees for this remarkable and extremely successful meeting. For the coming year we are off to a super beginning which will ensure further advances for our patients and our profession. I wish to recognize the efforts of our Annual Meeting staff in organizing and making coherent, a complex law of daily challenges. Working in concert with the staff in the Meetings and Exhibit Management Office, they have again produced a miracle of organization, innovation and transformation into the future.

Welcome to Washington.

Sincerely,

Rodrigo A. Munoz, M.D.
President
American Psychiatric Association
Dear APA Members and Guests:

Welcome to Washington, DC, and the 152nd Annual Meeting of the American Psychiatric Association. This exciting city, with its vibrancy, cultural diversity and excitement, provides a perfect setting for the presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme "The Clinician," chosen by our President, Dr. Rodrigo A. Muñoz. I draw your attention to the Presidential Symposium scheduled on Tuesday at 2:00 p.m., entitled "State Medicaid Programs: Access and Quality for Mental Health Care."

The Local Arrangements Committee, under the excellent guidance of its Chairperson, Dr. Richard S. Epstein, has developed a wide array of programs that will help you take advantage of our Nation’s Capital. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 5:00 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. A very special Convocation is planned for this year, with a musical political satire performance by a local group called the Capitol Steps. The Convocation will begin Monday, May 17, at 7:30 p.m.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, which will be offered to APA members only.

A special aspect of our 1999 scientific program will be a series of collaborative sessions with the National Institute of Mental Health. Selected offerings in the various program formats will present exciting research discoveries and are designated throughout this book.

You will also note in the Program Book that we are continuing with our expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field. I call your attention to the forum on "The Globalization of Psychiatry: Challenges and Opportunities” in which our President, Dr. Rodrigo A. Muñoz, and the WPA President, Dr. Norman Sartorious will participate. This Forum is scheduled on Monday, May 17, at 12 noon.

I strongly encourage you to fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in the opinions of the members regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to Washington. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Pedro Ruiz, M.D.
Chairperson
Scientific Program Committee
APA 152nd ANNUAL MEETING

Washington, DC  May 15-20, 1999

KEY LOCATIONS - CONVENTION CENTER

Administrative Office  Room 6, Lower Level
American Journal of Psychiatry  APA Resource Center
APA Exhibits Guide  Exhibit Halls A/B, Upper Level
APA Resource Center  Room 3, Lower Level
A/V Preview Room  Exhibit Halls A/B, Upper Level
CME Course Enrollment  Daily Bulletin
Daily Bulletin  Room 16, Lower Level
Education Office  Room 19, Lower Level
Exhibit Office  Lobby, Lower Level
Information/Locator Center  Rooms 1/2, Lower Level
Lost & Found  Lobby, Lower Level
Meetings Management  Rooms 1/2, Lower Level
Message Center  Lobby, Lower Level
On-Site Job Bank and Placement Center  APA Resource Center
Psychiatric Services  APA Resource Center
Registration  Exhibit Halls A/B, Upper Level
Scientific Program Office  Room 7, Lower Level

FIRST AID

Located on the Lower Level, Convention Center. Hours of operation: Friday, May 14, through Thursday, May 20, 7:00 a.m.-6:00 p.m. Information on emergency services may be found on page 2 of the Leisure Time Activities Brochure.

COURTESY SHUTTLE BUS SERVICE

Your registration badge is needed to ride the shuttle buses. Bus service will be available beginning at 7:30 a.m. on Saturday, May 15, operate daily throughout the meeting until 11:00 p.m., and conclude on Thursday, May 20, at 6:00 p.m. Route maps and schedules are included in the registration packet and published in the APA Exhibits Guide.

LOCAL ARRANGEMENTS COMMITTEE

HOSPITALITY CENTER

Located in the Lower Level Lobby, Convention Center. Hours of operation: Saturday, May 15, 12 noon-5:30 p.m.; Sunday, May 16, to Wednesday, May 19, 9:00 a.m.-5:30 p.m.; and Thursday, May 20, 9:00 a.m.-12 noon. Tickets for leisure time activities will be available at the Tour Desk located in the Lower Level Lobby, Convention Center.

EXHIBITS

Commercial and educational exhibits are located in Exhibit Halls A/B, Upper Level, Convention Center, along with the Publishers' Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center and Publishers' Bookfair will open on Saturday, May 15, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 16, 11:00 a.m.-5:00 p.m.; Monday and Tuesday, May 17-18, 10:00 a.m.-8:00 p.m.; and Wednesday, May 19, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 19. Please refer to the APA Exhibits Guide for additional information on participating companies.

INFORMATION/LOCATOR CENTER

Located in the Lower Level Lobby, Convention Center and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER

Located in the Lower Level Lobby, Convention Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Center.

APA RESOURCE CENTER

Located in Exhibit Halls A/B, Upper Level, Convention Center. Hours of operation: Saturday, May 15, 11:00 a.m.-5:00 p.m.; Sunday, May 16, 8:00 a.m.-5:00 p.m.; Monday and Tuesday, May 17-18, 10:00 a.m.-6:00 p.m.; and Wednesday, May 19, 10:00 a.m.-3:00 p.m. See the back cover of this book for APA programs and services in the APA Resource Center.

APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The computerized Job Bank gives you the opportunity to walk away with information on hundreds of job openings available to psychiatrists throughout the country. Employers can list available positions onsite. Psychiatrists and employers should stop by the booth to find out how they can access information in the Job Bank database throughout the year.

PRESS OFFICE

Located in the APA Communications Center, Rooms 10/11/12, Lower Level, Convention Center. Hours of operation: Saturday, May 15, 12 noon-5:00 p.m.; Sunday-Wednesday, May 16-19, 8:00 a.m.-6:00 p.m.; and Thursday, May 20, 8:00 a.m.-1:00 p.m. The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences and Master Educator Clinical Consultations.

DAILY BULLETIN

The Daily Bulletin accepts written requests from APA members for publicity of component, committee and allied group events as space allows. Four issues are published. Since the issue for Saturday/Sunday is preprinted, information cannot be added on site. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off at the APA Communications Center. The deadlines are noon prior to the date of publication.
CENTER FOR INTERNATIONAL GUESTS
Bienvenidos, Wilkommen, Bienvenue, Welcome!
Located in the Dolley Madison Ballroom, Madison Hotel. Hours of operation: Saturday, May 15-Wednesday, May 19, 8:00 a.m.-6:00 p.m.; and Thursday, May 20, 8:00 a.m.-3:00 p.m. All visitors from outside of the U.S. and Canada are invited. These activities are sponsored by Pfizer International Pharmaceuticals.

BUSINESS CENTERS
Convention Center
Location: H Street Lobby
Hours of operation: 7:30 a.m.-5:00 p.m., Monday-Friday

Grand Hyatt
Location: Level 1B
Hours of operation: 8:00 a.m.-5:00 p.m., Monday-Friday

Marriott Metro Center
Location: Main Lobby
Hours of operation: 7:00 a.m.-11:00 p.m., Monday-Friday

Renaissance Washington
Location: Ballroom Level
Hours of operation: 8:00 a.m.-5:00 p.m., Monday-Friday

Capital Hilton
Location: Main Lobby
Hours of operation: 8:00 a.m.-2:00 p.m., Saturday
7:00 a.m.-6:00 p.m., Monday-Friday

REGISTRATION
ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE ONLY
Located in Exhibit Halls A/B, Upper Level, Convention Center.
Hours of operation: Saturday, May 15, 10:00 a.m.-5:00 p.m.; Sunday, May 16, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 17-19, 7:30 a.m.-6:00 p.m.; and Thursday, May 20, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS
Full-Time Registration .......................................................... $185.00
Members-in-Training (Member Class MT)................................. 70.00
Daily Registration .................................................................. 95.00
(all "Member" categories except Medical Students).................. 0
Medical Students.................................................................... 0

NONMEMBERS
Full-Time Registration ........................................................... $525.00
Nonmember Residents, Students, Advocacy
Group Members or Mental Health Chaplains ........................... 90.00
Daily Registration (all "Nonmember" categories)..................... 265.00
Medical Students................................................................. 0

GUEST REGISTRATION
One only per full-time registrant ............................................. 95.00
Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address.
APA members cannot register as a "guest"; they must register as an APA member.
One-Day Exhibit Hall Only Pass............................................. 25.00

On-site fees can be paid by cash, check, money order, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hrs. per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, New Research Program and Abstracts Book, and Syllabus. Guest registrants do not receive a registration bag or the Program Book, APA Exhibits Guide, New Research Program and Abstracts Book, or Syllabus.

NAME BADGES
Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, Black-Temporary Convention Personnel.

CME COURSE ENROLLMENT
TICKET PURCHASE REQUIRED FOR CME COURSES
Located in Exhibit Halls A/B, Upper Level, Convention Center.
Hours of operation: Saturday, May 15, 10:00 a.m.-5:00 p.m.; Sunday, May 16, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 17-19, 7:30 a.m.-6:00 p.m.; and Thursday, May 20, 7:30 a.m.-2:00 p.m. Tickets for CME Courses #4-97 not sold by April 12 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 15. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION
Located in the APA Resource Center and staffed during the Resource Center’s hours. The exhibit includes paintings, photography, ceramics and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH
Located in the Lower Level Lobby, Convention Center. Hours of operation: Saturday, May 15, through Wednesday, May 19, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary’s program schedule and information on membership.
APA PERIODICALS

The American Journal of Psychiatry and Psychiatric Services will be located in the APA Periodicals Exhibit in the APA Resource Center and staffed during Resource Center hours. Staff of both journals will be available to answer authors’ questions and to receive papers submitted for publication. Each journal publishes only original material not published elsewhere in any form and not being considered for publication elsewhere. Five copies and a disk are required for The American Journal of Psychiatry; six copies are required for Psychiatric Services. Persons who wish to contact editors or reporters of Psychiatric News should inquire at the APA Administrative Office, Room 6, Lower Level, Convention Center, where an editor can be paged. They may also leave written announcements, suggestions for articles, or letters to the editor for the newspaper’s consideration.

CONTINUING MEDICAL EDUCATION CREDIT

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, a Debate, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposia, and Workshops. Other program activities are designated Category 2; these include Research Consultations With, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and some Media Sessions, Lectures and Workshops. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions attended on the back page of the Certificate of Attendance found in the front of the 1999 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires participation in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Office of Education at the APA. Staff will be available at the Office of Education booth in the APA Resource Center to answer any of your questions about CME.

IV

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning a completed form (to the APA Administrative Staff Office, Scientific Program Office, Information/Locator Center or APA Resource Center, all located in the Convention Center) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

We expect “sell out” attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

• Please find seating as far forward as possible.
• Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
• Store materials under chairs to maximize seating capacity.
• Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
• If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the Convention Center.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm will clearly identify them. Registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.
CHILD CARE SERVICE

For the convenience of meeting registrants and their families, the APA, with assistance from the Local Arrangements Committee, has made arrangements for child care during the meeting. The child care service will be located in the Renaissance Washington Hotel. Hours of operation will be Sunday, May 16, to Thursday, May 20, 7:30 a.m.-6:30 p.m. Staffing will be available for children ages six months to 12 years.

GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Program Office in the Convention Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

Floor Plans for the Convention Center, Grand Hyatt, Marriott Metro Center, and Renaissance Washington .... VI-XI
City Map .... XII
Special Acknowledgments .. XIII-XIV
Format Descriptions .... XV-XVI
Disclosure Information .... XVII-XXVIII
Saturday Sessions 1-2
Sunday Sessions 3-10
Monday Sessions 11-31
Audiotape Sales Information 32
Tuesday Sessions 33-57
Call for 2000 Annual Meeting Papers 58
Wednesday Sessions 59-82
Thursday Sessions 83-98
Topic Index 99-109
Participant Index 110-120
1999 Institute on Psychiatric Services 121
American Psychiatric Press, Inc., Bookstore 122-123
Industry-Supported Symposia 124-143
APA Resource Center Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge and Dining Facilities in the Convention Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2000 May 13-18 Chicago, IL
2001 May 5-10 New Orleans, LA
2002 May 18-23 Philadelphia, PA
2003 May 17-22 San Francisco, CA
2004 May 1-6 New York, NY
2005 May 21-26 Atlanta, GA

APA CLINICAL MEETINGS

THE INSTITUTE ON PSYCHIATRIC SERVICES

1999 October 29-Nov. 2 New Orleans, LA
2000 October 25-29 Chicago, IL
2001 October 10-14 Orlando, FL
2002 October 9-13 Philadelphia, PA
2003 October 29-Nov. 2 Boston, MA
2004 October 6-10 Atlanta, GA
2005 October 5-9 San Diego, CA

Tentative program schedules and hotel information for the 1999 Institute are available at the Future Meetings Booth in the APA Resource Center and the Information/Locator Center, both located in the Convention Center.
MARRIOTT METRO CENTER

3RD FLOOR

PARIS
SALON A
SALON B
SALON C
SALON D
GRAND BALLROOM

PRE-FUNCTION

MEN
WOMEN
LONDON
NEW YORK

GROUP REGISTRATION

SOUTH LOBBY

LOBBY LEVEL

2ND FLOOR

EXECUTIVE BOARD ROOM

EXECUTIVE BOARD ROOM

MONTREAL
WASHINGTON

SOUTH LOBBY

ELEV LOBBY

GUEST LOBBY
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Breakfast Symposium, "Controversies and Treatment Strategies in Bipolar Disorders," Monday, May 17, and Tuesday, May 18, 7:00 a.m.

American Academy of Psychiatry and the Law: co-sponsorship of the Manfred S. Guttmacher Lecture, Sunday, May 16, 2:00 p.m.

American Association of Psychiatric Administrators: co-sponsorship of the Administrative Psychiatry Award Lecture, Tuesday, May 18, 2:00 p.m.

American Psychiatric Foundation: co-support of the APA Award for Research in Psychiatry.

American Society of Clinical Psychopharmacology: co-support of the Industry-Supported Symposium, "Recent Advances in Psychopharmacology," Wednesday, May 19, 7:00 p.m.

Association for Research in Personality Disorders: co-support of the Industry-Supported Symposium, "Complexity, Pharmacologic, Management Issues in BPD," Sunday, May 16, 1:30 p.m.

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Thursday, May 20, 9:00 a.m.

Association of Women Psychiatrists: co-sponsorship of the Alexandra Symonds Award Lecture, Wednesday, May 15, 11:00 a.m.

Bayer Corporation, Pharmaceutical Division: support of the Industry-Supported Symposium, "Alzheimer's Disease: Translating Clinical Trials into Clinical Care," Tuesday, May 18, 7:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposium, "Depression: Achieving Remission and Compliance: Clinical Challenges and Solutions," Sunday, May 16, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "New Clinical Advances in Managing Anxiety and Depressive Disorders Throughout the Life Cycle," Monday, May 17 and Tuesday, May 18, 7:00 a.m.; co-support of the Industry-Supported Symposium, "Recent Advances in Psychopathology," Wednesday, May 19, 7:00 p.m.; support of the Solomon Carter Fuller Award Lecture, Monday, May 18, 5:00 a.m., and Reception, the APA Auxiliary reception and tea, and the APA/Bristol-Myers Squibb Fellowship Program and reception.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program; co-sponsorship of the AIDS Education Program, Tuesday, May 18 and Wednesday, May 19, 9:00 a.m.; and support of Practice Research Network (PRN) Annual Meeting activities.

Eli Lilly, Inc., Pfizer, Inc.: support of the Industry-Supported Symposium, "Longitudinal Aspects of Alzheimer's Disease Management," Sunday, May 16, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "A Decade of Serotonergic Studies: Beyond Depression," Sunday, May 16, 9:00 a.m.; "Atypical Antipsychotics Also Mood Stabilizers?" Sunday, May 16, 1:30 p.m.; the Industry-Supported Breakfast Symposium, "Mood and Psychotic Disorders in Women: An Update on Treatment," Wednesday, May 19 and Thursday, May 20, 7:00 a.m.; the Simon Bolivar Award Lecture, Thursday, May 20, 9:00 a.m.; the APA/Lilly Resident Research Awards; the Daniel X. Freedman Congressional Fellowship, the IMG Hospitality Suite; and partial support of the New Research Abstracts and Program Book.

Forest Laboratories, Inc.: support of the Industry-Supported Symposium, "The Complex Face of Depression: Clinical Challenges in the Diagnosis and Treatment of Depressive Disorders," Saturday, May 15, 7:00 p.m.; and "Managing Depression Across the Life Cycle," Tuesday, May 17, 7:00 p.m.

Foundations' Fund for Research in Psychiatry: co-support of the APA Award for Research in Psychiatry.

Glaxo Wellcome Inc.: co-support of the Industry-Supported Symposium, "Complexity, Pharmacologic, Management Issues in BPD," Sunday, May 16, 1:30 p.m.; support of the Industry-Supported Symposium, "Gender Issues in Diagnosis and Response to Treatment," Tuesday, May 18, 7:00 p.m.; the APA/Glaxo Wellcome Fellowship Program and reception; and the American Psychiatric Foundation reception and "Monuments by Moonlight" tour.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Thursday, May 20, 9:00 a.m.

HealthCare Technology Systems: support of the Industry-Supported Symposium, "Treating Depression: Effectiveness Without Extravagance," Wednesday, May 19, 7:00 p.m.

Hoechst Marion Roussel: support of the travel program for female residents; and the Luncheon for Women in Psychiatry, Wednesday, May 19, 12:30 p.m.

International Academy for Biomedical and Drug Research: support of the Industry-Supported Symposium, "Treatment-Resistant Depression: United States and European Perspectives," Sunday, May 16, 9:00 a.m.

Ittleson Foundation, Inc.: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposium, "Typical Patients, Atypical Care: An Interactive Case Study," Sunday, May 16, 5:00 a.m.; "Mood and the Mind: The Science and Art of New and Emerging Treatment Alternatives," Sunday, May 16, 1:30 p.m.; the Industry-Supported Breakfast Symposium, "Assessment and Treatment of Psychiatric Disorders in the Elderly," Wednesday, May 19 and Thursday, May 20, 7:00 a.m.; the Early Career Psychiatrists' Dinner/Forum, Tuesday, May 18, 7:00 p.m., the reception for the Kun-Po Soo awardees; the American Psychiatric Institute for Research and Education/Janssen Research Scholars in Severe Mental Illness Program; and partial support of the shuttle bus system.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Monday, May 17, 2:00 p.m.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.


Merck & Co., Inc.: support of the William C. Menninger Memorial Convocation Lecture, Monday, May 17, 7:30 p.m.; the "Office of the Future" exhibit; and an unrestricted educational grant in support of various scientific sessions.

National Institute of Mental Health: co-support of the Seymour D. vestibmark Award for Psychiatric Education Lecture, Wednesday, May 19, 9:00 a.m.; APA Office of Research Annual Meeting activities for research trainees; and the Program for Minority Research Training in Psychiatry (PMRTP).
SPECIAL ACKNOWLEDGMENTS

National Institute on Alcohol Abuse and Alcoholism: support of the APA Office of Research Annual Meeting activities for research trainees.

National Institute on Drug Abuse: support of the APA Office of Research/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposia, "Redefining Treatment-Resistant Schizophrenia," Saturday, May 15, 7:00 p.m.; and Clinical Implications of New Dementia Research," Tuesday, May 18, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposia, "Optimizing Treatment Outcome in Depression," Sunday, May 15, 9:00 a.m.; "Time and Depression," Wednesday, May 19, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Strategies and Tactics to Manage Depressed Patients," Monday, May 17, and Tuesday, May 18, 7:00 a.m.; and the Holocaust Memorial Museum Tour.

Parke-Davis: support of the Industry-Supported Symposium, "The Interface Between Depression and Dementia," Wednesday, May 19, 7:00 p.m.

Professional Risk Management Services, Inc.: support of the Manfred S. Guttmacher Award Lecture, Sunday, May 16, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposium, "Optimizing Wellness Across the Life Cycle of Schizophrenia," Sunday, May 16, 7:00 p.m. "Unmasking Depression and Comorbid Conditions: Clinical Challenges, Solutions and Unanswered Questions," Tuesday, May 18, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Anxiety Disorders: From Scientific Research to Clinical Practice," Wednesday, May 19 and Thursday, May 20, 7:00 a.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 17, 7:00 a.m.; the "Abstractions-On-Disk" Program; the APA Daily Bulletin newspaper; the pre-meeting publication, Perspective; and the registration portfolio.

Pfizer International Pharmaceuticals: support of the International Fellowship Program, the Office of International Affairs, a daily visitor center for international delegates, and the APA Office of Research activities for research trainees.


Roche Laboratories, a member of the Roche Group: support of the Benjamin Rush Award Lecture, Monday, May 17, 11:00 a.m.

Scios Pharmaceuticals: support of the Assembly/Board of Trustees Reception, Friday, May 14.

Sheppard Pratt Health System: support of the Warren Williams Speaker's Awards.


Solvay Pharmaceuticals, Inc.: co-support of the Industry-Supported Symposium, "Suicide: Clinical/Risk Management Issues for Psychiatrists," Sunday, May 15, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Novel Approaches to the Treatment of Impulsivity," Wednesday, May 19 and Thursday, May 20, 7:00 a.m.; and support of the beverage service in the exhibit hall.

Suicide Research Division of the National Mental Illness Screening Project and McLean Hospital: co-support of the Industry-Supported Symposium, "Suicide: Clinical/Risk Management Issues for Psychiatrists," Sunday, May 15, 7:00 p.m.

Synthelabo: support of the Industry-Supported Symposium, "Intervening During the Prodromal Phase of Schizophrenia," Sunday, May 16, 1:30 p.m.

van Ameringen Foundation, Inc.: support of the APA Office of Research Annual Meeting activities for research trainees and health services researchers.

Watson Laboratories: support of the Industry-Supported Symposium, "What Makes an Antipsychotic Atypical?" Tuesday, May 18, 7:00 p.m.

Wyeth-Ayerst Laboratories: support of the Industry-Supported Symposium, "Clinical Frontiers in the Sleep/Psychiatry Interface," Sunday, May 16, 7:00 p.m. "Antidepressant Combinations for Drug-Resistant and Intolerant Cases," Wednesday, May 15, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Anxiety and Depression: Cause or Effect?" Monday, May 17 and Tuesday, May 18, 7:00 a.m.; the APA/Wyeth-Ayerst Psychiatric Research Fellowship; the Resident, Medical Student, Training Directors Luncheon; and the Alexandra Symonds Award Lecture, Wednesday, May 19, 11:00 a.m.

Zeneca Pharmaceuticals Group: support of the Industry-Supported Breakfast Symposium, "Beyond Efficacy in Psychosis: Patient Satisfaction, Compliance and Outcomes," Monday, May 17 and Tuesday, May 18, 7:00 a.m.; the George Tarjan Award Lecture, Tuesday, May 18, 2:00 p.m., the George Tarjan Award reception, and the APA/CMHS and APA/Zeneca Fellow's reception.
FORMAT DESCRIPTIONS

ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research, and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry, and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

AIDS EDUCATION PROGRAM
APA’s AIDS Program Office presents a two-day clinical update on the neuropsychiatric and psychosocial aspects of HIV disease and AIDS.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

DEBATE
A controversial topic in psychiatry will be debated by experts in the field, including psychiatrists and non-psychiatrists. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. The debate is moderated by someone who has expertise in the topic area. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FORUMS
These are informal presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. Lecturers are invited by the Program Committee.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These are a series of 90-minute, clinically-based seminars with outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA PROGRAMS
A media program may involve the showing of a videotape or computer software demonstration, followed by discussion. Specialized sessions focus on production or consumer/family issues.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Oral/Slide, which are twelve-minute presentations with three minutes for discussion; Posters, which are visual, self-explanatory presentations; and Young Investigators’ Sessions, with presentations from young investigators, residents, medical students, and research or clinical fellows.

NIH WORKSHOP
This three-hour workshop clarifies the grant making process for psychiatrists contemplating applying for an NIH grant. Representatives from NIAAA, NIDA and NIMH will discuss how to prepare a successful application for NIH research support.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be five, three- and one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series, to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports (formerly Paper Sessions) are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each report. There is no formal discussant.
SOCIAL SECURITY WORKSHOP
Social Security Administration (SSA) officials present the history/background of SSA disability programs (including new legislative initiatives), describe how psychiatrists can best serve applicants for benefits, and review the clinical information required to expedite the disability determination process. During this three-hour session, time is allocated for group discussion of evaluation of impairments, what constitutes adequate evidence to support disability decisions, etc.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
The American Psychiatric Association requires disclosure of the existence of any and all significant financial interest(s) or other affiliation(s) a presenter has with any commercial supporter(s) of these educational activities, and/or with the manufacturer(s) of any and all commercial product(s) and/or provider(s) of any and all commercial services discussed in the scientific program. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial supporter by way of an acknowledgment in the printed program or syllabus. This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgements about the presentation.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter’s name, the manufacture’s name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening Inc.</td>
<td>36</td>
</tr>
<tr>
<td>Howard Abikoff, Ph.D.</td>
<td>Shire Richwood Pharmaceutical Company</td>
<td>76</td>
</tr>
<tr>
<td>Donald E. Addington, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Zeneca Pharmaceuticals; Janssen Pharmaceutical and Research Foundation; Abbott Laboratories</td>
<td>96</td>
</tr>
<tr>
<td>Jean M. Addington, Ph.D.</td>
<td>Eli Lilly and Company, Janssen Pharmaceutical and Research Foundation; Hoechst Marion Roussel</td>
<td>96</td>
</tr>
<tr>
<td>W. Stewart Agran, M.D.</td>
<td>Eli Lilly and Company</td>
<td>1</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Glaxo Wellcome Inc.; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Janssen Pharmaceutical and Research Foundation</td>
<td>11, 14, 25, 34, 74</td>
</tr>
<tr>
<td>Ralph S. Albertini, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>77</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutical and Research Foundation</td>
<td>95</td>
</tr>
<tr>
<td>Trina B. Allen, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>21</td>
</tr>
<tr>
<td>Carol L. Alter, M.D.</td>
<td>Bristol-Myers Squibb (employer)</td>
<td>44</td>
</tr>
<tr>
<td>Lori L. Altshuler, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>83</td>
</tr>
<tr>
<td>Peter M. Aupperle, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>35</td>
</tr>
<tr>
<td>Ross J. Baldessarini, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>James C. Bailenger, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Hoffman-LaRoche; Abbott Laboratories; Pharmacia &amp; Upjohn Company, Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutical and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Ciba Geigy Corporation, Pharmaceutical Division</td>
<td>33</td>
</tr>
<tr>
<td>Richard Balon, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>43, 92</td>
</tr>
<tr>
<td>Barbara D. Bartlik, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Glaxo Wellcome Inc.</td>
<td>93</td>
</tr>
<tr>
<td>Charles M. Beasley, Jr., M.D.</td>
<td><em>Pass the Boards</em></td>
<td>69</td>
</tr>
<tr>
<td>Carl C. Bell, M.D.</td>
<td>Eli Lilly and Company</td>
<td>29, 52, 96</td>
</tr>
<tr>
<td>Donald W. Black, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Soo Borson, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Zeneca Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company</td>
<td>11, 95</td>
</tr>
<tr>
<td>Paula M. Bortnichak, M.D.</td>
<td>Burtex Labs</td>
<td>52</td>
</tr>
<tr>
<td>Jonathan F. Borus, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>50, 79</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutical and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Tharon C. Bowden, M.D.</td>
<td>Cadence Medical Software</td>
<td>63</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>26, 49, 59, 79</td>
</tr>
<tr>
<td>Alan F. Breier, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>91</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Ortho-Biotech; Janssen Pharmaceutical and Research Foundation; Roxane Laboratories; Bristol-Myers Squibb</td>
<td>28, 44, 96</td>
</tr>
</tbody>
</table>
**DISCLOSURE INDEX**

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory J. Brown, M.D.</td>
<td>Oronaron Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>21</td>
</tr>
<tr>
<td>Richard A. Brown, Ph.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>The Psychological Corporation</td>
<td>3, 6, 34</td>
</tr>
<tr>
<td>Don S. Browning, Ph.D.</td>
<td>University of Chicago (employer)</td>
<td>85, 91</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Zena Pharmaceuticals; Watson Laboratories, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Marian J. Butterfield, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories</td>
<td>65, 76</td>
</tr>
<tr>
<td>Daniel J. Buysse, M.D.</td>
<td>Searle; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals</td>
<td>34</td>
</tr>
<tr>
<td>Alexander Bystritsky, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Parke-Davis, Division of Warner-Lambert Company; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Hoffman-LaRoche; Ciba Geigy Corporation, Pharmaceutical Division</td>
<td>52</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>Abbott Laboratories; Merck &amp; Co., Inc.; Glaxo Wellcome Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>34</td>
</tr>
<tr>
<td>Jose M. Canive, M.D.</td>
<td>Otsuka Pharmaceuticals; Hoechst Marion Roussel; Sanofi Pharmaceuticals, Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Marc G. Caron, Ph.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.</td>
<td>80</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>9</td>
</tr>
<tr>
<td>Aravinda Chakravarti</td>
<td>Genomica, Inc.; Affymetrix, Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Jacquelyn B. Chang, M.D.</td>
<td>Zena Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Diana Chapa, M.D.</td>
<td>Zena Pharmaceuticals</td>
<td>15</td>
</tr>
<tr>
<td>Dennis S. Chaney, M.D.</td>
<td>Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>5, 80</td>
</tr>
<tr>
<td>K.N. Roy Chengappa, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Zena Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Rhode-Poulenc Rorer Pharmaceuticals; Johnson and Johnson; Hoechst Marion Roussel; Novartis Pharmaceuticals Corporation; PRI</td>
<td>6</td>
</tr>
<tr>
<td>James C.Y. Chou, M.D.</td>
<td>“Pass the Boards!”</td>
<td>1</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Zena Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>22, 42</td>
</tr>
<tr>
<td>Anita L.H. Clayton, M.D.</td>
<td>Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>54</td>
</tr>
<tr>
<td>Paula J. Clayton, M.D.</td>
<td>Forest Laboratories, Inc.; Bristol-Myers Squibb</td>
<td>8, 13</td>
</tr>
<tr>
<td>Kathleen F. Clougherty, M.S.W.</td>
<td>National Institute of Mental Health; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; American Psychiatric Press, Inc.; Eli Lilly and Company</td>
<td>3</td>
</tr>
<tr>
<td>Alan J. Cohen, M.D.</td>
<td>Pharmexan</td>
<td>93</td>
</tr>
<tr>
<td>Bruce M. Cohen, M.D.</td>
<td>Eli Lilly and Company</td>
<td>97</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>59, 69, 83, 98</td>
</tr>
<tr>
<td>Mitchell J.M. Cohen, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>Jilka Cohen-Mansfield, Ph,D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>54</td>
</tr>
<tr>
<td>Lillian Comas-Diaz, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>96</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td>Abbott Laboratories; Zena Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Zenith-Coldine; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>4</td>
</tr>
<tr>
<td>Kathryn M. Connor, M.D.</td>
<td>Madis Biotechnical, Inc. Botanicals, Inc.</td>
<td>94</td>
</tr>
<tr>
<td>Edwin H. Cook, Jr., M.D.</td>
<td>Applied Biosystems</td>
<td>28</td>
</tr>
<tr>
<td>Ian A. Cook, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company</td>
<td>82</td>
</tr>
<tr>
<td>Jeremy D. Coplan, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>11</td>
</tr>
<tr>
<td>Leonardo Cortese, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Zena Pharmaceuticals; Lundbeck</td>
<td>92</td>
</tr>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Zena Pharmaceuticals; Abbott Laboratories; Eisai Inc.</td>
<td>9, 13, 35, 53</td>
</tr>
<tr>
<td>Jonathan R.T. Davidson, M.D.</td>
<td>Glaxo Wellcome Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.; Bristol-Myers Squibb; Parke-Davis, Division of Warner-Lambert Company; Warner Biotechnical, Inc.; Wyeth-Ayerst Laboratories; Hoffman-LaRoche; Organon Inc.; Andol; Lichtwer Pharma</td>
<td>4, 37, 94</td>
</tr>
<tr>
<td>Michael Davidson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Synthetabo</td>
<td>6</td>
</tr>
<tr>
<td>John M. Davis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>71</td>
</tr>
<tr>
<td>Charles DeBattista, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Solis Nova Pharmaceuticals, SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; National Alliance for Research on Schizophrenia &amp; Depression; National Institute of Mental Health; Pharmacia &amp; Upjohn Company, Inc.; PharmaPrint/ABA</td>
<td>25</td>
</tr>
<tr>
<td>Concetta M. DeCaria, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Jose E. De La Gandara, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.; Hoechst Marion Roussel; Takeda Pharmaceuticals; Merck &amp; Co., Inc.</td>
<td>64</td>
</tr>
</tbody>
</table>

**XXVIII**
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Organon Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>2, 5</td>
</tr>
<tr>
<td>Davangere P. Devanand, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; National Institute of Mental Health</td>
<td>79</td>
</tr>
<tr>
<td>Ruth A. Dickson, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Zeneica Pharmaceuticals; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>59, 83</td>
</tr>
<tr>
<td>Lisa B. Dixon, M.D.</td>
<td>Abbott Laboratories</td>
<td>33, 50, 57</td>
</tr>
<tr>
<td>John P. Docherty, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Zeneica Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>49, 97</td>
</tr>
<tr>
<td>Karl Doghranji, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>8, 71</td>
</tr>
<tr>
<td>Rachelle S. Doody, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.</td>
<td>9</td>
</tr>
<tr>
<td>P. Murali Doraiswamy, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Hoechst Marion Roussel; Glaxo Wellcome Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Roxanne Dryden-Edwards, M.D.</td>
<td>Abbott Laboratories</td>
<td>86</td>
</tr>
<tr>
<td>James D. Duffy, M.D.</td>
<td>Zeneica Pharmaceuticals; Abbott Laboratories</td>
<td>13</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Geoffrey Duyk, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Astra-Hassie; Pharmacia &amp; Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; American Home Products; Monsanto; Astra Draco; Exelixis Pharmaceuticals, Inc. (employer); Millennium; Artemis; Bristol-Myers Squibb; Merck &amp; Co., Inc.</td>
<td>28</td>
</tr>
<tr>
<td>Jane L. Eisen, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>33</td>
</tr>
<tr>
<td>Graham J. Emslie, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
<td>54, 61</td>
</tr>
<tr>
<td>Larry Ereshefsky, Pharm.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Hoechst Marion Roussel; Otsuka Pharmaceuticals; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Zeneica Pharmaceuticals; Watson Laboratories, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Javier I. Escobar, M.D.</td>
<td>Eli Lilly and Company</td>
<td>34</td>
</tr>
<tr>
<td>Dwight L. Evans, M.D.</td>
<td>Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Abbott Laboratories</td>
<td>11, 33</td>
</tr>
<tr>
<td>Brian A. Fallon, M.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Abbott Laboratories</td>
<td>20, 34</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.; Glaxo Wellcome Inc.; Knoll Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Synthelabo; Lorex Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Litchwer Pharma</td>
<td>2, 5, 43</td>
</tr>
<tr>
<td>Jan A. Fawcett, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Frank G. Feeley, J.D.</td>
<td>Professional Risk Management Services</td>
<td>15</td>
</tr>
<tr>
<td>Wayne S. Fenton, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>20, 50</td>
</tr>
<tr>
<td>Reid Finlayson, M.D.</td>
<td>Homewood Health Centre Inc. (employer)</td>
<td>16</td>
</tr>
<tr>
<td>Kathleen M. Fisher, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Manor Health Care</td>
<td>52</td>
</tr>
<tr>
<td>Laurie M. Flynn</td>
<td>Zeneica Pharmaceuticals</td>
<td>11, 33, 43, 70, 71, 76</td>
</tr>
<tr>
<td>Laura J. Fochtmann, M.D.</td>
<td>Eli Lilly and Company</td>
<td>92</td>
</tr>
<tr>
<td>Allen J. Frances, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>44</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Roujer Poulenc; American Home Products; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Charter Medical</td>
<td>70</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>National Institute of Mental Health; Hartford Foundation; Jewish Healthcare Foundation; Eli Lilly and Company; MacArthur Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Organon Inc.; National Alliance for Research on Schizophrenia &amp; Depression (NARSAD)</td>
<td>5, 26</td>
</tr>
<tr>
<td>Alan Frazer, Ph.D.</td>
<td>Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>80, 82</td>
</tr>
<tr>
<td>Mary A. Fridstad, Ph.D.</td>
<td>American Psychiatric Press, Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>34, 75</td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
<td>14, 26, 48, 57</td>
</tr>
<tr>
<td>Albert C. Gaw, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>57</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Bristol-Myers Squibb; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Hoechst Marion Roussel; Forest Laboratories, Inc.; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; Scios Nova Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>80</td>
</tr>
<tr>
<td>Charles J. George, M.S.</td>
<td>Deerfield Behavioral Health Network</td>
<td>53</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>S. Nassir Ghaemi, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation</td>
<td>13</td>
</tr>
<tr>
<td>J. Christian Gillin, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>6</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; DuPont Pharma; Merck &amp; Co., Inc.; Bristol-Myers Squibb; Glaxo Wellcome Inc.</td>
<td>28</td>
</tr>
<tr>
<td>William M. Glazer, M.D.</td>
<td>Watson Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Zeneca Pharmaceuticals</td>
<td>53, 54</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>42, 81</td>
</tr>
<tr>
<td>Robert M. Goisman, M.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>13</td>
</tr>
<tr>
<td>James M. Gold, Ph.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation</td>
<td>50</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Eli Lilly and Company</td>
<td>91</td>
</tr>
<tr>
<td>Robert N. Golden, M.D.</td>
<td>Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Eli Lilly and Company</td>
<td>11</td>
</tr>
<tr>
<td>Stephen M. Goldfinger, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; William Mercer &amp; Co.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>70, 86</td>
</tr>
<tr>
<td>Toby D. Goldsmith, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.</td>
<td>39</td>
</tr>
<tr>
<td>Michael G. Goldstein, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division (employee); Glaxo Wellcome Inc.; McNeill Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Sano Corporation; Dupont Pharma; Merck &amp; Co., Inc.; Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.; National Institute of Mental Health; Helen Dowling Institute for Biopsychosocial Medicine</td>
<td>49</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Scios Nova Pharmaceuticals</td>
<td>13, 85</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>Abbott Laboratories; Zeneca Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Intemeron; Pharmacia &amp; Upjohn Company, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.</td>
<td>2, 6, 17, 66, 98</td>
</tr>
<tr>
<td>Tana A. Grady-Weliky, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Robert P. Granacher, Jr., M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>12</td>
</tr>
<tr>
<td>John F. Greiden, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>4, 5</td>
</tr>
<tr>
<td>Alan I. Green, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Zeneca Pharmaceuticals; Otsuka Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Hoechst-Marion Roussel</td>
<td>2</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>76</td>
</tr>
<tr>
<td>John H. Greist, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Bristol-Myers Squibb; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation; Wyeth-Ayerst Laboratories; Healthcare Technology Systems (employer)</td>
<td>4, 83</td>
</tr>
<tr>
<td>Carlos M. Grilo, Ph.D.</td>
<td>National Institutes of Health; Eli Lilly and Company</td>
<td>69</td>
</tr>
<tr>
<td>George T. Grossberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Zeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation</td>
<td>54, 59</td>
</tr>
<tr>
<td>Alan M. Gruenberg, M.D.</td>
<td>American Home Products; Forest Laboratories, Inc.; Abbott Laboratories</td>
<td>42</td>
</tr>
<tr>
<td>John G. Gunderson, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>7, 78</td>
</tr>
<tr>
<td>Sanjay Gupta, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>51</td>
</tr>
<tr>
<td>Thomas G. Guthrell, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>11, 33</td>
</tr>
<tr>
<td>Mark H. Halm, M.D.</td>
<td>Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>34</td>
</tr>
<tr>
<td>Katherine A. Halm, M.D.</td>
<td>Eli Lilly and Company</td>
<td>1, 17, 73, 89</td>
</tr>
<tr>
<td>Thomas E. Hansen, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation</td>
<td>45</td>
</tr>
<tr>
<td>Richard C. Harrington, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Nina Hartley, M.D.</td>
<td>Adam &amp; Eve</td>
<td>93</td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company</td>
<td>4</td>
</tr>
<tr>
<td>Herbert Hendin, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Marvin I. Herz, M.D.</td>
<td>Zeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>40</td>
</tr>
<tr>
<td>David B. Herzog, M.D.</td>
<td>Eli Lilly and Company</td>
<td>73, 74</td>
</tr>
</tbody>
</table>

XX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert M.A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>8, 77, 82</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Abbott Laboratories; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>56, 59, 77, 83</td>
</tr>
<tr>
<td>John R. Hughes, M.D.</td>
<td>Abbott Laboratories; Adcare Association; Addiction Research Foundation; Ads International Consumers Union; Advanstar; Alza Pharmaceuticals; American Academy of Addiction Psychiatry; American Association of Physicians in Alcoholism and Addictions; American Cynamid; American Medical Association; American Medical Video; American Pharmaceutical Association; American Psychiatric Association; Anestia Corporation; Boehringer Ingelheim; Brookside Hospital; Bruno &amp; Bruno; Cadeucus Foundation; Cahners Health Communications; Cheshire Communication; Ciba Geigy Corporation; Pharmaceutical Division; College of Problems of Drug Dependence; Consumers Report; Cooley Hospital; David Crostee, Inc.; DuPont Pharma; DynaGen Corporation; Edelman Communications; Elsevier Publishing; Eli Lilly and Company; Fire &amp; Associates; Glaxo Wellcome Inc.; Goodkind, Labaton, Rudoff &amp; Sucharow; Healthcare Communications Network; Health Values; Henry Ford Hospital; Hoechst Marion Roussel; Marion-Merrell Dow; Lakeside, Humphrey, Farrington and McLain; Interactive Networks; Interactive Technologies; International Council on Alcoholism and Addictions; International Food Information Council; International Life Science Institute; Intramedical Health Services; J. Wiley and Sons; Journal of Practical Psychiatry and Behavioral Health; Lederle Laboratories; Lifespan Stop Smoking Program; MacMillan Publishing; Manchester Mental Health Association; Manisses Communications; McNeil Pharmaceuticals; Medco Management, Inc.; Medical Age Publishing; Medical Economics; Medical Marketing Group; Medical Clinical of South Carolina; Medical University of Southern California; Memorial Sloan Kettering Cancer Center; Miller Fenwick; Miriam Hospital; Montefiore Hospital; National Coffee Manufacturers; National Institutes of Health; Ness, Motley and Associates; Neuromedical Technologies, Inc.; Neuroscience Ventures; New England Journal of Medicine; New York State; Nissen &amp; Lumsden; Orbs, Inc.; Palo Alto Center for Disease Prevention; Parke-Davis, Division of Warner-Lambert Company; Patient Care; Pharmac &amp; Upjohn Company, Inc.; Pinney Associates; Corporate Health Policies; Plenum Press; Porter Novelli; Princeton Scientific; Proctor &amp; Gamble; Sage Publications; Sandler Communication; Sano; SmithKline Beecham Pharmaceuticals; Southern Medical Association; Springer-Verlag; St. Peters Medical Center; Symedoo; University of Connecticut Medical School; University of Pittsburgh; University of Vermont; Veteran's Administration; Washington University; Weil, Gotshal &amp; Manges; Wilkerson Group; Wilmer, Cutler &amp; Pickering</td>
<td>26</td>
</tr>
<tr>
<td>Michael C. Hughes, M.D.</td>
<td>Eli Lilly and Company; United Health Care; Johnson and Johnson; First Health Group Corporatoin; Ivax</td>
<td>17, 45</td>
</tr>
<tr>
<td>Steven E. Hyler, M.D.</td>
<td>Nilo Software &amp; Video</td>
<td>1, 3, 9, 15, 25, 36, 48, 67</td>
</tr>
<tr>
<td>Douglas G. Jacobs, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Kay R. Jamison, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Phillip G. Janick, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutical and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Zeneca Pharmaceuticals; Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>49, 71</td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eisai Inc.; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Eli Lilly and Company; Organon Inc.; Janssen Pharmaceutical and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Searle; Pharmacia &amp; Upjohn Company, Inc.; Roche Laboratories, a member of the Roche Group; Healthcare Technology Systems (employer)</td>
<td>79</td>
</tr>
<tr>
<td>Dillip V. Jeste, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Zeneca Pharmaceuticals</td>
<td>51, 76, 83, 94, 95</td>
</tr>
<tr>
<td>Russell T. Joffe, M.D.</td>
<td>Wyeth-Ayerst Laboratories (Canada); SmithKline Beecham Pharmaceuticals (Canada); Bristol-Myers Squibb; Organon Inc. (Canada); Eli Lilly and Company (Canada); Janssen Pharmaceutical and Research Foundation</td>
<td>8, 25, 26, 34,</td>
</tr>
<tr>
<td>Billy E. Jones, M.D.</td>
<td>Magellan Behavioral Health</td>
<td>13</td>
</tr>
<tr>
<td>Lewis L. Judd, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>David A. Kahn, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutical and Research Foundation; Abbott Laboratories</td>
<td>49, 97</td>
</tr>
<tr>
<td>Ned H. Kalin, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Abbott Laboratories; Dupont Pharma; AstraMerck Group, Division of Merck &amp; Co.; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutical and Research Foundation</td>
<td>6, 95</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Novartis Pharmaceuticals Corporation; Scios Nova Pharmaceuticals; Abbott Laboratories; Zeneca Pharmaceuticals; Lundbeck</td>
<td>9, 11, 52, 96</td>
</tr>
<tr>
<td>Harry Karlinsky, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>48</td>
</tr>
<tr>
<td>Wayne J. Katon, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>4, 50</td>
</tr>
<tr>
<td>Cornelius L. Katona, M.D.</td>
<td>Eli Lilly and Company; Bayer Corporation, Pharmaceutical Division; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
</tbody>
</table>

DISCLOSURE INDEX
## DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ira R. Katz, M.D.</td>
<td>Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Zeneca Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation</td>
<td>95</td>
</tr>
<tr>
<td>David J. Katzelnick, M.D.</td>
<td>Ciba Geigy Corporation, Pharmaceutical Division; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.; Abbott Laboratories; Astra/Merck Group, Division of Merck &amp; Co.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Watson Laboratories, Inc.; Pharmac &amp; Upjohn Company, Inc.; Johnson and Johnson; Healthcare Technology Systems (employer); Novartis Pharmaceuticals Corporation</td>
<td>4, 79</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals</td>
<td>7, 49</td>
</tr>
<tr>
<td>Gabor I. Keitner, M.D.</td>
<td>Bristol-Myers Squibb; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>91</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc; Eli Lilly and Company; Organon Inc.; Merck &amp; Co., Inc.</td>
<td>8, 54</td>
</tr>
<tr>
<td>Charles H. Kellner, M.D.</td>
<td>Somatics; Mecta; Glaxo Wellcome Inc.; Ohmeda</td>
<td>26, 76, 92</td>
</tr>
<tr>
<td>Jeffrey E. Kelsey, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.</td>
<td>79</td>
</tr>
<tr>
<td>Justine M. Kent, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>33</td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Healthcare Systems Technology</td>
<td>4, 79</td>
</tr>
<tr>
<td>Terence A. Ketler, M.D.</td>
<td>Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Glaxo Wellcome Inc.; Johnson and Johnson; Eli Lilly and Company;</td>
<td>34</td>
</tr>
<tr>
<td>Paul A. Kettl, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Manor Health Care</td>
<td>52, 87</td>
</tr>
<tr>
<td>Steven A. King, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>46</td>
</tr>
<tr>
<td>Rachel G. Klein, Ph.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>James H. Kocsis, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; Eli Lilly and Company</td>
<td>79</td>
</tr>
<tr>
<td>Marcia Koller, M.S.W.</td>
<td>Fox Farils; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>47</td>
</tr>
<tr>
<td>Lill C. Kopala, M.D.</td>
<td>Medical Research Council of Canada; Zeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>6, 33, 96</td>
</tr>
<tr>
<td>Lorin M. Koran, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.; Akzo-Nobel; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>11, 33</td>
</tr>
<tr>
<td>Susan G. Korstein, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Henry R. Kranzler, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Lipha Pharmaceuticals; SmithKline Beecham Pharmaceuticals</td>
<td>4</td>
</tr>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company</td>
<td>54, 79, 98</td>
</tr>
<tr>
<td>Andrew D. Kryzal, M.D.</td>
<td>Mecta Corporation</td>
<td>75, 76</td>
</tr>
<tr>
<td>Vinod Kumar, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>20</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>Stanley P. Kutcher, M.D.</td>
<td>Abbott Laboratories; Boehringer Ingelheim; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Lundbeck; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb</td>
<td>6, 61</td>
</tr>
<tr>
<td>Y.W. Francis Lam, Pharm.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>35</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Osuka Pharmaceuticals</td>
<td>52, 57, 68, 74</td>
</tr>
<tr>
<td>Yves Lecrubier, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Synthelabo; Eli Lilly and Company</td>
<td>6, 52</td>
</tr>
<tr>
<td>Ellen Leibenluft, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>25, 54</td>
</tr>
<tr>
<td>Henrietta L. Leonard, M.D.</td>
<td>Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>Andrew F. Leuchter, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals</td>
<td>69, 82</td>
</tr>
<tr>
<td>Izhak Levav, M.D.</td>
<td>Eli Lilly and Company</td>
<td>27</td>
</tr>
<tr>
<td>Alan I. Levenson, M.D.</td>
<td>Psychiatrists' Purchasing Group, Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Saul M. Levin, M.D.</td>
<td>Center for Substance Abuse Treatment</td>
<td>21, 39, 91</td>
</tr>
<tr>
<td>Freda C. Lewis-Hall, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>6, 57, 77</td>
</tr>
<tr>
<td>Alfred J. Lewy, M.D.</td>
<td>Melatonin Patents</td>
<td>22</td>
</tr>
<tr>
<td>Peter F. Liddle, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>73</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; Zeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>2, 49, 67</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Eli Lilly and Company</td>
<td>3, 62, 67, 77</td>
</tr>
<tr>
<td>Elizabeth H.B. Lim, M.D.</td>
<td>Healthcare Technology Systems</td>
<td>79</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Marsha M. Linehan, Ph.D.</td>
<td>Linehan Training Group; Guilford Press; Roxanne Laboratories; Glaxo Wellcome Inc.</td>
<td>7, 13, 49</td>
</tr>
<tr>
<td>R. Bruce Lydiard, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Glaxo Wellcome Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Roche Laboratories, a member of the Roche Group; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories</td>
<td>11, 33</td>
</tr>
<tr>
<td>Jose R. Maldonado, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; CME, Inc.</td>
<td>4, 43, 60</td>
</tr>
<tr>
<td>Hussein K. Marji, M.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.; Organon Inc.; Abbott Laboratories</td>
<td>97</td>
</tr>
<tr>
<td>Eric Marcel</td>
<td>Hoechst Marion Roussel (employer)</td>
<td>56</td>
</tr>
<tr>
<td>John S. March, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Eli Lilly and Company</td>
<td>59, 76</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; Zeneca Pharmaceuticals; Otsuka Pharmaceuticals; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb</td>
<td>21, 71, 79</td>
</tr>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; National Institute of Mental Health; Eli Lilly and Company; American Psychiatric Press, Inc.; Organon Inc.</td>
<td>3, 8, 26, 33</td>
</tr>
<tr>
<td>Charles R. Mamar, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Abbott Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Searle, Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals</td>
<td>28, 83</td>
</tr>
<tr>
<td>Stephen D. Martin, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>26</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Abbott Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Searle, Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals</td>
<td>7, 77, 95</td>
</tr>
<tr>
<td>Barbara J. Mason, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Danna Mauch, Ph.D.</td>
<td>Magellan Health Services, Inc. (employer)</td>
<td>48</td>
</tr>
<tr>
<td>J. Stephen McDaniel, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.</td>
<td>22, 43</td>
</tr>
<tr>
<td>Christopher J. McDoyle, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company</td>
<td>76</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutical and Research Foundation; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Zeneca Pharmaceuticals</td>
<td>7, 77, 95</td>
</tr>
<tr>
<td>Thomas H. McGlashan, M.D.</td>
<td>Eli Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Synthélabo</td>
<td>2, 6, 69, 78</td>
</tr>
<tr>
<td>Patrick D. McGorry, Ph.D.</td>
<td>Synthélabo</td>
<td>6</td>
</tr>
<tr>
<td>Thomas A. Meillman, M.D.</td>
<td>Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td>33, 66</td>
</tr>
<tr>
<td>Herbert Y. Meizler, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Synthélabo</td>
<td>2</td>
</tr>
<tr>
<td>Samantha E. Meizler-Brody, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>15</td>
</tr>
<tr>
<td>Julien Mendlewicz, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>W. Walter Menninger, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Vanguard; Merck &amp; Co., Inc.</td>
<td>30, 43, 59, 64, 83</td>
</tr>
<tr>
<td>Barnett S. Meyers, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>Zeneca Pharmaceuticals; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>11</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Abbott Laboratories; Eisai Inc.; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; National Institute on Aging; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; Pine Rest Nursing Center; Mt. Sinai Department of Psychiatry; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Glaxo Wellcome Inc.</td>
<td>35</td>
</tr>
<tr>
<td>Shaila Miftari, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals (Canada)</td>
<td>2, 74</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>1, 74</td>
</tr>
<tr>
<td>Richard Mohs, Ph.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutical and Research Foundation</td>
<td>76</td>
</tr>
<tr>
<td>John C. Morris, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Searle; Bayer Corporation, Pharmaceutical Division; Dupont Pharma; Glaxo Wellcome Inc.; Hoechst Marion Roussel; Hoffman-LaRoche; Parke-Davis, Division of Warner-Lambert Company; Sigma Tau Pharmaceutical; SmithKline Beecham Pharmaceuticals; Abbott Laboratories; Covance; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Johnson and Johnson; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>9, 53</td>
</tr>
<tr>
<td>Andrew Moss, Ph.D.</td>
<td>Agouron</td>
<td>81</td>
</tr>
<tr>
<td>Helen G. Muhtibauer, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation</td>
<td>42</td>
</tr>
<tr>
<td>Benoît H. Mulsant, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>59, 83</td>
</tr>
<tr>
<td>Henry A. Nasrallah, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>11, 33</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Wyeth-Ayerst Laboratories; Bayer Corporation, Pharmaceutical Division; Ciba Geigy Corporation, Pharmaceutical Division; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>5</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Abbott Laboratories; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Synta; Organon Inc.; Janssen Pharmaceutica and Research Foundation; Pharmacia &amp; Upjohn Company, Inc.; Zeneca Pharmaceuticals; Forest Laboratories, Inc.; Astra/Merck Group, Division of Merck &amp; Co.; Merck &amp; Co., Inc.; Sanofi Pharmaceuticals, Inc.</td>
<td>6, 72, 80, 95</td>
</tr>
<tr>
<td>Thomas C. Neylan, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>Raymond S. Niara, Ph.D.</td>
<td>Glaxo Wellcome Inc.; Sano Corporation; SmithKline Beecham Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Andrew A. Neurenberg, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.</td>
<td>11, 77, 79, 80</td>
</tr>
<tr>
<td>Philip T. Ninan, M.D.</td>
<td>Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb; Organon Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>11</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Glaxo Wellcome Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Samuel O. Okpaku, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb</td>
<td>69</td>
</tr>
<tr>
<td>John M. Oldham, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>7, 28, 38, 62, 70</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>2, 22</td>
</tr>
<tr>
<td>Patricia I. Ordonez, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>88</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Barbara L. Parry, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>74, 97</td>
</tr>
<tr>
<td>Dean O. Perkins, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation, Hoechst Marion Roussel</td>
<td>27</td>
</tr>
<tr>
<td>Ronald C. Peterson, M.D.</td>
<td>Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Katharina A. Phillips, M.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Gate; Wyeth-Ayerst Laboratories</td>
<td>77, 98</td>
</tr>
<tr>
<td>David Pickard, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>2, 4</td>
</tr>
<tr>
<td>Teresa A. Pigott, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Ciba Geigy Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Pharmacia &amp; Upjohn Company, Inc.; Watson Laboratories; Glaxo Wellcome Inc.; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Sanofi Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Organon Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Harold Alan Pincus, M.D.</td>
<td>American Psychiatric Association (employer)</td>
<td>22, 27, 38, 70, 77, 98</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>5, 59, 83</td>
</tr>
<tr>
<td>Bruce G. Pollock, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.; Forest Laboratories, Inc.; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>59, 79, 83, 97</td>
</tr>
<tr>
<td>Charles W. Popper, M.D.</td>
<td>Abbott Laboratories; Shire Richwood Pharmaceutical Company; Pharmacia &amp; Upjohn Company, Inc.; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.</td>
<td>61</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company</td>
<td>26</td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>54</td>
</tr>
<tr>
<td>Sheldon H. Preskorn, M.D.</td>
<td>Abbott Laboratories; Astra/Merck Group, Division of Merck &amp; Co.; Boots Pharmaceuticals; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Ciba Geigy Corporation, Pharmaceutical Division; Merck &amp; Co., Inc.; Eli Lilly and Company; Searle; Hoechst Marion Roussel; Hoffman-LaRoche; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Rhone-Pouilenc Rorer Pharmaceuticals; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Lundbeck; National Psychopharmacology Laboratories</td>
<td>57</td>
</tr>
<tr>
<td>David W. Preven, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Peter V. Rabins, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company; Bayer Corporation, Pharmaceutical Division; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>9, 76</td>
</tr>
<tr>
<td>Giorgio Racagni, Ph.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Susana Rako, M.D.</td>
<td>Theratech, Inc.; Proctor &amp; Gamble</td>
<td>93</td>
</tr>
<tr>
<td>Mark H. Rapoport, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company; Organon Inc.; Synthelabo; Roche Laboratories, a member of the Roche Group</td>
<td>79, 83</td>
</tr>
<tr>
<td>Judith H.L. Rapoport, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; Shire Richwood Pharmaceutical Company; Novartis Pharmaceuticals Corporation; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>13</td>
</tr>
<tr>
<td>Murray A. Raskind, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>21, 76</td>
</tr>
<tr>
<td>William E. Reichman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bayer Corporation, Pharmaceutical Division; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>35, 75</td>
</tr>
<tr>
<td>Gary J. Remington, M.D.</td>
<td>Watson Laboratories, Inc.</td>
<td>54</td>
</tr>
</tbody>
</table>
## Disclosure Index

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>David V. Reinshaw, M.D.</td>
<td>General Electrical Medical Systems; Bracco Diagnostics; Eli Lilly and Company; Interneuron Pharmaceuticals</td>
<td>2, 4, 26, 34, 49</td>
</tr>
<tr>
<td>Mark A. Riddle, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>97</td>
</tr>
<tr>
<td>Paula D. Riggs, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories</td>
<td>63</td>
</tr>
<tr>
<td>Malcolm D. Roberts, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.</td>
<td>65</td>
</tr>
<tr>
<td>Catherine A. Roca, M.D.</td>
<td>Eli Lilly and Company</td>
<td>83</td>
</tr>
<tr>
<td>Steven J. Romano, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>90</td>
</tr>
<tr>
<td>Marjorie T. Rooney, Ph.D.</td>
<td>American Psychiatric Press, Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Steven P. Ross, M.D.</td>
<td>Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>79, 83</td>
</tr>
<tr>
<td>Jules Rosen, M.D.</td>
<td>Fox FarSight Productions, Inc.</td>
<td>47</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Organon Inc.; Lichiner Pharma; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>54, 95</td>
</tr>
<tr>
<td>Richard N. Rosenthal, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>26, 93</td>
</tr>
<tr>
<td>Anthony J. Rothschild, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Abbott Laboratories; Bristol-Myers Squibb; Janssen Pharmaceutical and Research Foundation; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>11, 43</td>
</tr>
<tr>
<td>David R. Rubinow, M.D.</td>
<td>Distal Products; TAP Pharmaceuticals; Ciba Geigy Corporation, Pharmaceutical Division; Upshure-Smith; Eli Lilly and Company</td>
<td>59, 98</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Glaxo Wellcome Inc.; Janssen Pharmaceutical and Research Foundation; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Abbott Laboratories; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals</td>
<td>54, 95</td>
</tr>
<tr>
<td>Neal D. Ryan, M.D.</td>
<td>Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Organon Inc.</td>
<td>6, 76, 80</td>
</tr>
<tr>
<td>Gary S. Sachar, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; SciSano Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; Janssen Pharmaceutical and Research Foundation; Forest Laboratories, Inc.; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>2, 4, 26, 34, 49</td>
</tr>
<tr>
<td>Harold A. Sackeim, Ph.D.</td>
<td>Mecta Corporation; SmithKline Beecham Pharmaceuticals</td>
<td>60, 76, 83, 92</td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Zenea Pharmaceuticals; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb</td>
<td>1</td>
</tr>
<tr>
<td>Carl Saltzman, M.D.</td>
<td>Zenea Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Janssen Pharmaceutical and Research Foundation; Forest Laboratories, Inc.; Eli Lilly and Company</td>
<td>59</td>
</tr>
<tr>
<td>Mary Sano, Ph.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Hoechst Marion Roussel; Janssen Pharmaceutical and Research Foundation; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories</td>
<td>53</td>
</tr>
<tr>
<td>Shekhar Saxena, M.D.</td>
<td>World Health Organization (employer)</td>
<td>70</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; Bristol-Myers Squibb</td>
<td>17, 49, 80, 95</td>
</tr>
<tr>
<td>Peter J. Schmidt, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>54, 83</td>
</tr>
<tr>
<td>Lon S. Schneider, M.D.</td>
<td>Janssen Pharmaceutical and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bayer Corporation, Pharmaceutical Division; Wyeth-Ayerst Laboratories; Somerset; Roche Laboratories, a member of the Roche Group; Parke-Davis, Division of Warner-Lambert Company</td>
<td>54, 94, 95</td>
</tr>
<tr>
<td>Nina R. Schoeler, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutical and Research Foundation; Otsuka Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Dean Schuyler, M.D.</td>
<td>Eli Lilly and Company</td>
<td>23</td>
</tr>
<tr>
<td>Rajiv P. Sharma, M.D.</td>
<td>Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>71</td>
</tr>
<tr>
<td>M. Tracie Shea, Ph.D.</td>
<td>Organon Inc.</td>
<td>78, 80</td>
</tr>
<tr>
<td>M. Katherine Shear, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Hoffman-LaRoche; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.; Forest Laboratories, Inc.</td>
<td>2, 98</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories; American Medical Association; Anclote Foundation; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Eisai Inc.; Forest Laboratories, Inc.; International Clinical Research; Janssen Pharmaceutical and Research Foundation; Kall Duphia Laboratories, Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.; National Institute of Drug Abuse; National Institutes of Health; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Quintiles; Watson Laboratories, Inc.; SmithKline Beecham Pharmaceuticals; Synthelabo; Tampa General Hospital/University Psychiatric Center; TAP Pharmaceuticals; Warner Chilcott Pharmaceutical Company; Worldwide Clinical Trials; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; World Health Zeneca Pharmaceuticals; Organization; Pierre Fabre; Lundbeck; Alza Pharmaceuticals; Layton Bioscience; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; National Anxiety Foundation; Philadelphia College of Pharmacy &amp; Science; Lilly Research Laboratories, a division of Eli Lilly and Company; Connecticut &amp; Ohio Academies of Family Physicians; CPC Coleum Medical Center; USF Friends of Research in Psychiatry; National Anxiety Awareness Program; Anxiety Disorders Resource Center; APA Task Force on Treatments of Psychiatric Disorders; APA Task Force on Benzodiazepine Dependency; National Depressive &amp; Manic-Depressive</td>
<td>XXV</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Richard C. Shelton, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Rhone-Poulenc Rorer Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>4, 40, 52, 57</td>
</tr>
<tr>
<td>Winston W. Shen, M.D.</td>
<td>Eli Lilly and Company</td>
<td>7, 79</td>
</tr>
<tr>
<td>Marjorie L. Shuer, M.D.</td>
<td>Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals</td>
<td>4, 69, 90</td>
</tr>
<tr>
<td>Larry J. Siever, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Glaxo Wellcome Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>35</td>
</tr>
<tr>
<td>Kenneth R. Silik, M.D.</td>
<td>Forest Laboratories, Inc.; Glaxo Wellcome Inc.</td>
<td>7, 49</td>
</tr>
<tr>
<td>Gregory E. Simon, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Healthcare Technology Systems</td>
<td>79</td>
</tr>
<tr>
<td>George M. Simpson, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>88</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.</td>
<td>54, 94</td>
</tr>
<tr>
<td>Mary Kay Smith, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Ohio Academy of Physicians</td>
<td>43</td>
</tr>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Zeneca Pharmaceuticals; Scios Nova Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Paul H. Soloff, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>7, 20</td>
</tr>
<tr>
<td>Wesley E. Sowers, M.D.</td>
<td>Deerfield Behavioral Health Network</td>
<td>53</td>
</tr>
<tr>
<td>Margaret G. Spinelli, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Glaxo Wellcome Inc.; Yamanouchi</td>
<td>52</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Bayer Corporation, Pharmaceutical Division; Yamanouchi</td>
<td>49</td>
</tr>
<tr>
<td>Hans Steiner, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Hoechst Marion Roussel; St. Joseph's Hospital (employer)</td>
<td>53, 79</td>
</tr>
<tr>
<td>Meir Steiner, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Hoechst Marion Roussel; St. Joseph's Hospital (employer)</td>
<td>63</td>
</tr>
<tr>
<td>Donna E. Stewart, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals</td>
<td>4, 52</td>
</tr>
<tr>
<td>Andrew L. Stoll, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Organon Inc.; Abbott Laboratories</td>
<td>19</td>
</tr>
<tr>
<td>Zachary N. Stowe, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
<td>54, 74</td>
</tr>
<tr>
<td>James J. Strain, M.D.</td>
<td>Microcares</td>
<td>50</td>
</tr>
<tr>
<td>Ana Suarez, M.P.H.</td>
<td>American Psychiatric Association (employer)</td>
<td>22</td>
</tr>
<tr>
<td>David L. Sultzter, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company</td>
<td>35, 79</td>
</tr>
<tr>
<td>Trey Sunderland, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Lundbeck; Eisai Inc.; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>35</td>
</tr>
<tr>
<td>Norman Sussman, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Robert A. Sweet, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>8, 11</td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Merck &amp; Co., Inc.; Abbott Laboratories; Astra/Merck Group, Division of Merck &amp; Co.; Hoechst Marion Roussel; Synthélabo</td>
<td>52</td>
</tr>
<tr>
<td>Steven D. Targum, M.D.</td>
<td>Eli Lilly and Company</td>
<td>20</td>
</tr>
<tr>
<td>Pierre N. Tarot, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; Somerset; Takeda Pharmaceuticals; Sanofi Pharmaceuticals, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Martin H. Teicher, M.D.</td>
<td>Copley Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>61</td>
</tr>
<tr>
<td>Linda Teri, Ph.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals Corporation</td>
<td>53</td>
</tr>
</tbody>
</table>
### DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Organon Inc.; U.S. Pharmaceuticals; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Lippa Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; International Academy for Biomedical and Drug Research; Healthcare Technology Systems</td>
<td>1, 2, 4, 75</td>
</tr>
<tr>
<td>Kenneth S. Thompson, M.D.</td>
<td>Deerfield Behavioral Health Network</td>
<td>53</td>
</tr>
<tr>
<td>Mauricio F. Tohen, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>51</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc. (employer)</td>
<td>15</td>
</tr>
<tr>
<td>Madhukar H. Trivedi, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; International Academy for Biomedical and Drug Research</td>
<td>4, 11</td>
</tr>
<tr>
<td>Manuel Trujillo, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>38</td>
</tr>
<tr>
<td>Bedithan Ustun, M.D.</td>
<td>World Health Organization (employer)</td>
<td>70</td>
</tr>
<tr>
<td>Eduardo R. Val, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories</td>
<td>21, 27</td>
</tr>
<tr>
<td>Bessel A. van der Kolk, M.D.</td>
<td>Eli Lilly and Company</td>
<td>17, 81</td>
</tr>
<tr>
<td>Adele C. Viguera, M.D.</td>
<td>Eli Lilly and Company</td>
<td>58, 69</td>
</tr>
<tr>
<td>Pierre Vincent, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc. (Canada); Boehringer Ingelheim; Pharmacia &amp; Upjohn Company, Inc. (Canada)</td>
<td>13</td>
</tr>
<tr>
<td>Joseph R. Volpicelli, M.D.</td>
<td>Dupont Pharma</td>
<td>68</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company</td>
<td>50</td>
</tr>
<tr>
<td>Peter J. Welden, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals; Johnson and Johnson</td>
<td>7, 9</td>
</tr>
<tr>
<td>Richard D. Weiner, M.D.</td>
<td>Mecta, Corporation</td>
<td>60, 76, 92</td>
</tr>
<tr>
<td>Myra M. Weissman, Ph.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.</td>
<td>2, 25, 98</td>
</tr>
<tr>
<td>Elizabeth B. Weller, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Abbott Laboratories; Forest Laboratories, Inc.</td>
<td>2, 16, 95</td>
</tr>
<tr>
<td>Timothy E. Wiltens, M.D.</td>
<td>Abbott Laboratories; Alza Pharmaceuticals; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Eli Lilly and Company; Medevac, National Institute of Drug Abuse; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richmond Pharmaceutical Company; Solvay Pharmaceuticals Laboratories</td>
<td>63</td>
</tr>
<tr>
<td>John W. Winkelmann, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; Cephalon</td>
<td>71</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories; Boots Pharmaceuticals; Bristol-Myers Squibb; Watson Laboratories, Inc.; Distax Products; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>13</td>
</tr>
<tr>
<td>William C. Winshing, M.D.</td>
<td>Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Merck &amp; Co., Inc.; Osuka Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Hoechst Marion Rousell; Novartis Pharmaceuticals Corporation; Organon Inc.; Zeneca Pharmaceuticals</td>
<td>71</td>
</tr>
<tr>
<td>Thomas N. Wise, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Glaxo Wellcome Inc.; Bristol-Myers Squibb</td>
<td>12, 50, 54, 85</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories</td>
<td>52, 74, 96</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindstreet (employer)</td>
<td>1, 45, 87</td>
</tr>
<tr>
<td>Richard J. Wyatt, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Zeneca Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Eli Lilly and Company</td>
<td>81</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company</td>
<td>1, 10, 73</td>
</tr>
<tr>
<td>Rachel Yehuda, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>22</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; SmithKline Beecham Pharmaceuticals; American Home Products; Wyeth-Ayerst Laboratories</td>
<td>25</td>
</tr>
<tr>
<td>L. Trevor Young, M.D.</td>
<td>Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company</td>
<td>25</td>
</tr>
<tr>
<td>Stuart C. Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>11, 33, 59</td>
</tr>
<tr>
<td>Thomas Yuschok, M.D.</td>
<td>Dupont Pharma</td>
<td>65</td>
</tr>
<tr>
<td>John M. Zajecka, M.D.</td>
<td>Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Glaxo Wellcome Inc.; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Zeneca Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Organon Inc.</td>
<td>5, 7</td>
</tr>
<tr>
<td>Mary C. Zanarini, Ed.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Abbott Laboratories; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>21, 95</td>
</tr>
<tr>
<td>Carlos A. Zarate, Jr., M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Abbott Laboratories; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>Deborah A. Zarin, M.D.</td>
<td>American Psychiatric Association (employer)</td>
<td>38, 70, 77</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; National Institute of Drug Abuse; Glaxo Wellcome Inc.; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Dupont Pharma</td>
<td>22, 50, 93</td>
</tr>
<tr>
<td>Robert B. Zipursky, M.D.</td>
<td>Eli Lilly and Company (Canada); Zeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>96</td>
</tr>
</tbody>
</table>
### DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td>42</td>
</tr>
</tbody>
</table>

**Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following member is participating in an Industry-Supported Symposium and will not receive any compensation:**

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>11</td>
</tr>
</tbody>
</table>

**The following presenters on this year’s scientific program failed to return the APA disclosure form. The presenter’s name and the page number(s) the presenter appears on in this Program Book are listed below:**

- Stanley E. Althof, Ph.D. 38
- Mariano Bassi, M.D. 78
- Carla Cantor 12
- Lilía C. Clemente 43
- Barbara J. Coffey, M.D. 61
- Margaret Delorme 21
- Gregory L. Fricchione, M.D. 27
- Mindy J. Fulllove, M.D. 38
- Vincenzo Gatti, M.D. 78
- Gaston Harnois, M.D. 94
- Angela M. Hegarty, M.D. 44
- Ellen L. Holland, M.D. 64
- Karen Hopenwasser, M.D. 44
- B.J. Horn 97
- Peyton H. Hurt, M.D. 37
- Albert A. Hyman, M.D. 86
- Richard R. Irons, M.D. 16
- Margaret F. Jensvold, M.D. 64
- Bonnie S. Kaufman, M.D. 10
- Thomas A.M. Kramer, M.D. 15, 25, 71
- Joan E. Klinian, M.D. 21
- Sudeep Kundu, Ph.D. 1
- Julie Lieb, M.D. 12
- Marguerita Lightfoot, Ph.D. 49
- John T. Maisberger, M.D. 48
- John McCarthy 21
- Emily A. McCort, M.D. 97
- Diane E. Meier, M.D. 29
- Carmine Munizza, M.D. 78
- Patricia A. Newton, M.D. 38
- Suzanne Parizot, M.D. 56
- Becky H. Rowan, M.Ed. 29
- Pablo Sanchez 70
- Pier L. Scapicchio 78
- David Shaffer, M.D. 98
- Arlene G. Sherer, M.D. 44
- Michael Stark, M.D. 94
- Douglas Ward, M.D. 34
- Frank E. Yeomans, M.D. 12
SATURDAY, MAY 15, 1999

152ND ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-3
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1
8:00 a.m.-12 noon
Rooms 8/9, Meeting Room Level, Renaissance Washington
SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS
Director: Neil E. Robinson, M.D.
Faculty: Ronne E. Binder, M.D., Sharyn A. Lenhart, M.D., Michael F. Myers, M.D.

COURSE 2
8:00 a.m.-12 noon
Room 15, Meeting Room Level, Renaissance Washington
PSYCHODYNAMIC TREATMENT OF PANIC DISORDER
Co-Directors: Fredric N. Busch, M.D., Barbara L. Milrod, M.D.
Faculty: Meriamne B. Singer, M.D.

COURSE 3
8:00 a.m.-12 noon
Congressional Hall A, Ballroom Level, Renaissance Washington
HOW TO PASS THE BOARDS! THE PART II ORAL EXAM
Co-Directors: Steven E. Hyler, M.D., James C.Y. Chou, M.D.

9:00 a.m. Sessions

COURSES 4-7
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 4
9:00 a.m.-4:00 p.m.
Room 2, Meeting Room Level, Renaissance Washington
TRANSPERSONAL PSYCHIATRY: THEORY AND PRACTICE
Co-Directors: Allan B. Chinen, M.D., Bruce W. Scotton, M.D.
Faculty: Seymour Boorstein, M.D., Elizabeth F. Targ, M.D., John F. Hiatl, M.D., William W. Foote, M.D., Francis G. Lu, M.D., Bruce S. Victor, M.D.

COURSE 5
9:00 a.m.-4:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington
THERAPEUTIC INTERVENTIONS IN EATING DISORDERS
Director: David C. Jimerson, M.D.
Faculty: W. Stewart Agras, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 6
9:00 a.m.-4:00 p.m.
Room 7, Meeting Room Level, Renaissance Washington
INTRODUCTION TO PSYCHODYNAMIC GROUP PSYCHOTHERAPY
Director: Hillel I. Swiller, M.D.
Faculty: Milton L. Wainberg, M.D.

COURSE 7
9:00 a.m.-4:00 p.m.
Room 11, Meeting Room Level, Renaissance Washington
OUTCOMES: USE OF RATING SCALES
Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.
Faculty: C. Raymond Bingham, Ph.D., Sudeep Kundu, Ph.D.

1:00 p.m. Sessions

COURSES 8-12
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 8
1:00 p.m.-5:00 p.m.
Room 5, Meeting Room Level, Renaissance Washington
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 9
1:00 p.m.-5:00 p.m.
Room 6, Meeting Room Level, Renaissance Washington
LEARN CHIPS: A NEW CHILDREN'S DIAGNOSTIC INTERVIEW
Co-Directors: Mary A. Fristad, Ph.D., Marijo T. Rooney, Ph.D.
COURSE 10  1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS WITH THE
POSITIVE AND NEGATIVE SYNDROME SCALE
Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 11  1:00 p.m.-5:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington
ASSESSMENT AND TREATMENT OF NICOTINE DEPENDENCE
Director: Michael G. Goldstein, M.D.
Faculty: Raymond S. Niura, Ph.D., Richard A. Brown, Ph.D.

COURSE 12  1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington
PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM
Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.B., Deirdre M. Ryan, M.B., Maria R. Corral, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-3

INDUSTRY-SUPPORTED SYMPOSIUM 1
7:00 p.m.-10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt
THE COMPLEX FACE OF DEPRESSION: CLINICAL CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE DISORDERS
Supported by Forest Laboratories, Inc.
Chp.: David J. Kupfer, M.D.
A  Diagnosis and Treatment of Childhood Mania
   Elizabeth B. Weller, M.D., Ronald A. Weller, M.D.
B  Treatment of Adolescent Depression
   Richard C. Harrington, M.D.
C  Decision Points in the Treatment of Bipolar Depression
   Gary S. Sachs, M.D.
D  Therapy for Traumatic Grief
   M. Katherine Shear, M.D., Ellen Frank, Ph.D., Holly G. Prigerson, Ph.D., Rona E. Parnes, M.D., Charles F. Reynolds III, M.D.
E  A Life-Cycle Approach to the Diagnosis and Treatment of Depressive Disorders
   David J. Kupfer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
7:00 p.m.-10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton
REDEFINING TREATMENT-RESISTANT SCHizophrenia
Supported by Novartis Pharmaceuticals Corporation
Chp.: Alan I. Green, M.D.
A  Natural Course and Outcome of Schizophrenia
   Thomas H. McGlashan, M.D.
B  Pathogenesis of Treatment and Resistance in Schizophrenia
   Jeffrey A. Lieberman, M.D.
C  Alleviation of Functional Impairment in Treatment-Resistant Schizophrenia
   Herbert Y. Meltzer, M.D., Susan R. McGurk, Ph.D.
D  Early Intervention: Approach to Comorbid Substance Abuse/Substance Use Disorder
   Alan I. Green, M.D.
Discussant: David Pickar, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington
SPECTRUM OF DEPRESSION: NEW TREATMENT APPROACHES
Supported by Pharmacia & Upjohn Company, Inc.
Chp.: Jack M. Gorman, M.D.
A  Role of Norepinephrine in Depression
   Pedro L. Delgado, M.D., Francisco A. Moreno, M.D.
B  Alternatives to SSRIs in the Treatment of Depression
   Jack M. Gorman, M.D.
C  Treatment of Severe Depression
   Michael E. Thase, M.D.
D  New Approaches to the Treatment of Refractory Depression
   Maurizio Fava, M.D.
E  Social Functioning with the New Treatments for Depression
   Myrna M. Weissman, Ph.D.
SUNDAY, MAY 16, 1999
152ND ANNUAL MEETING

8:00 a.m. Sessions

COURSES 13-20
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Room 2, Meeting Room Level, Renaissance Washington

DSM-IV CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY
Director: Russell F. Lim, M.D.
Faculty: Francis G. Lu, M.D., Candace M. Fleming, Ph.D., J. Charles Ndlela, M.D., Roberto Lewis-Fernandez, M.D., Michael W. Smith, M.D.

COURSE 14 8:00 a.m.-12 noon
Room 7, Meeting Room Level, Renaissance Washington
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!
Director: Steven E. Myter, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

COURSE 15 8:00 a.m.-12 noon
Rooms 8/9, Meeting Room Level, Renaissance Washington

SKILLS FOR MENTORS AND PROTÉGÉS
Co-Directors: Paul Rodenhauser, M.D., Ramona Dvorak, M.D.
 Faculty: Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

COURSE 16 8:00 a.m.-12 noon
Rooms 12/13/14, Meeting Room Level, Renaissance Washington

COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW
Director: Paul R. Miller, M.D.
Faculty: Margaret Nazarey, M.S.N.

COURSE 17 8:00 a.m.-12 noon
Room 15, Meeting Room Level, Renaissance Washington

PSYCHIATRY AND PRIMARY CARE: SHARING CARE
Director: Nick S. Kates, M.B.
Faculty: Marilyn Craven, M.D., Jonathan S. Davine, M.D.

COURSE 18 8:00 a.m.-12 noon
Room 16, Meeting Room Level, Renaissance Washington

INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowitz, M.D.
Faculty: Kathleen F. Clougherty, M.S.W.

COURSE 19 8:00 a.m.-12 noon
Congressional Hall A, Ballroom Level, Renaissance Washington
ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

COURSE 20 8:00 a.m.-12 noon
Congressional Hall B, Ballroom Level, Renaissance Washington

THE PSYCHIATRIST AS EXPERT WITNESS
Director: Phillip J. Resnick, M.D.

9:00 a.m. Sessions

COURSES 21-25
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 21 9:00 a.m.-4:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington

DIAGNOSTIC CHALLENGES IN NEUROPSYCHIATRY
Co-Directors: Patricia I. Rosebush, M.D., Michael F. Mazurek, M.D.
Faculty: Sarah Garside, M.D., Anthony J. Levinson, M.A.

COURSE 22 9:00 a.m.-4:00 p.m.
Room 4, Meeting Room Level, Renaissance Washington

ASSESSMENT AND TREATMENT OF PATIENTS WITH MENTAL RETARDATION
Director: Ruth M. Ryan, M.D.

COURSE 23 9:00 a.m.-4:00 p.m.
Room 5, Meeting Room Level, Renaissance Washington

ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.
SUNDAY

COURSE 24  9:00 a.m.-4:00 p.m.
Room 6, Meeting Room Level, Renaissance Washington

BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D., Thomas Nagy, Ph.D.

COURSE 25  9:00 a.m.-4:00 p.m.
Room 11, Meeting Room Level, Renaissance Washington

TUTORING IMGs BY IMGs TO PASS THE ORAL ABPN EXAM

Co-Directors: Winston W. Shen, M.D., Norma C. Panahon, M.D.
Faculty: F. Moises Gaviria, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 4-8

INDUSTRY-SUPPORTED SYMPOSIUM 4
9:00 a.m.-12 noon
Constitution Ballroom, Level 3B, Grand Hyatt

TYPICAL PATIENTS, ATYPICAL CARE: AN INTERACTIVE CASE STUDY
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Prakash S. Masand, M.D.

A  Psychosis: A Clinical Case Study
   Prakash S. Masand, M.D.

B  Long-Term Management Issues in Schizophrenia
   David Pickar, M.D.

C  Bipolar Disorder: Novel Strategies
   Gary S. Sachs, M.D.

D  Cognitive Functioning and Its Effect on Everyday Outcome
   Philip D. Harvey, Ph.D., Evelyn M. Howanitz, M.D., M. Parrella

E  Real-World Outcomes with Novel Antipsychotics
   Robert R. Conley, M.D., Robert W. Buchanan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
9:00 a.m.-12 noon
Independence Ballroom, Level 5B, Grand Hyatt

SOCIAL IMPACT OF ANXIETY DISORDERS: NEW DATA AND IMPLICATIONS FOR OUTCOME
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Jonathan R.T. Davidson, M.D.

A  Economic Burden of Anxiety Disorders
   Ronald C. Kessler, Ph.D.

B  The Direct and Indirect Costs of Social Anxiety Disorders in Managed Care Patients
   David J. Katzelnick, M.D., Kenneth A. Kobak, Ph.D., Cindy P. Helstad, Ph.D., John H. Greist, M.D.

C  Treatment-Seeking for Medically Unexplained Symptoms: Relationship with GAD and Panic Disorder
   Wayne J. Katon, M.D., Mike Von Korff, M.D.

D  Anxiety and Substance Use Disorders: Prevalence, Diagnosis and Treatment
   Henry R. Kranzler, M.D.

E  How Treatable Are Anxiety Disorders?
   David V. Sheehan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
9:00 a.m.-12 noon
Presidential Ballroom, Second Floor, Capital Hilton

TREATMENT-RESISTANT DEPRESSION: UNITED STATES AND EUROPEAN PERSPECTIVES
Supported by the International Academy for Biomedical and Drug Research

Chp.: Lewis L. Judd, M.D.
Co-Chp.: Julien Mendlewicz, M.D.

A  Treatment-Resistant Depression: Guidelines for Early Diagnosis and Recognition
   Lewis L. Judd, M.D.

B  Risk Factors in Treatment-Resistant Depression
   Michael E. Thase, M.D.

C  Treatment Algorithms in Treatment-Resistant Depression: European Perspective
   Julien Mendlewicz, M.D.

D  Treatment Algorithms in Treatment-Resistant Depression: United States Perspective
   Madhukar H. Trivedi, M.D.

E  Treatment Resistance in Geriatric Depression
   Cornelius L. Katona, M.D.

Discussants: Giorgio Racagni, Ph.D., Julien Mendlewicz, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
9:00 a.m.-12 noon
Grand Ballroom, Ballroom Level, Renaissance Washington

A DECADE OF SEROTONIN STUDIES: BEYOND DEPRESSION
Supported by Eli Lilly and Company

Chp.: John F. Greden, M.D.

A  OCD: Serotonin Specificity Sans Pareil
   John H. Greist, M.D.
B  Panic Disorder: Etiology and Treatment
   Mark H. Pollack, M.D.

C  Dysthymic Disorder: SSRI Treatment Update
   David L. Dunner, M.D.

D  Premenstrual Dysphoric Disorder: A Role for Serotonin?
   Tana A. Grady-Weilky, M.D.

E  The Neuropathology and Treatment of PTSD: A Focus on Serotonin
   Dennis S. Charney, M.D.

Discussant: John F. Greden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8
9:00 a.m.-12 noon
Renaissance Ballroom, Ballroom Level, Renaissance Washington

OPTIMIZING TREATMENT OUTCOME IN DEPRESSION
Supported by Organon Inc.

Chp.: Maurizio Fava, M.D.

A  Approaches to the Enhancement of Patient Compliance
   Pedro L. Delgado, M.D.

B  Management of Nonresponse and Intolerance: Switching Strategies
   Maurizio Fava, M.D.

C  Combined Drug Treatments: Pros and Cons
   J. Craig Nelson, M.D.

D  Clinical Issues in Long-Term Treatment with Antidepressants
   John M. Zajecka, M.D.

E  Combining Psychotherapy and Pharmacotherapy: What Are the Advantages?
   Ellen Frank, Ph.D., David J. Kupfer, M.D., Robert A. Karp, M.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only)
12:30 p.m.-1:30 p.m.
Rooms 30/31, Lower Level, Convention Center
CALL TO ORDER
Rodrigo A. Muñoz, M.D., President

ANNOUNCEMENT OF ELECTION OF OFFICERS AND TRUSTEES; AND RESULTS OF BALLOTING ON AMENDMENTS TO THE CONSTITUTION AND BY-LAWS
Edward C. Kirby, Jr., M.D., Chairperson.
Committee of Tellers

REPORTS TO THE MEMBERSHIP

Secretary: Paul S. Appelbaum, M.D.
Treasurer: Maria T. Lymbarski, M.D.
Speaker, Assembly: Donna M. Norris, M.D.
Speaker, Elect, Assembly: Alfred Herzog, M.D.
Chairperson, Constitution and By-Laws Committee:
   Robert J. McDevitt, M.D.
Chairperson, Elections Committee:
   Shreekumar S. Vinekar, M.D.
Chairperson, Membership Committee:
   Bernard A. Katz, M.D.
Medical Director: Steven M. Mirmi, M.D.
Chairperson of the Eleven Councils:

FORUM

ADJOURNMENT

1:00 p.m. Sessions

COURSES 26-30
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 26 1:00 p.m.-5:00 p.m.
Room 7, Meeting Room Level, Renaissance Washington

DREAM TRANSLATION: AN EMPIRICALLY-BASED APPROACH
Director: Milton Kramer, M.D.

COURSE 27 1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington

CONCEPTUAL TOOLS FOR PSYCHOTHERAPY SUPERVISION
Co-Directors: Paul Rodenhauser, M.D., Ramona Dvorak, M.D.
Faculty: Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.
TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS

Director: Susan R. Downs, M.D.
Faculty: Freda C. Lewis-Hall, M.D., Ellen Haller, M.D., Silvia W. Olarte, M.D., Evelyn Lee, Ed.D.

ALTERNATIVE APPROACHES TO UNDERSTANDING HUMANS

Director: Richard D. Chessick, M.D.

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 9-13

INDUSTRY-SUPPORTED SYMPOSIUM 9
1:30 p.m.-4:30 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

MOOD AND THE MIND: THE SCIENCE AND ART OF NEW AND EMERGING TREATMENT ALTERNATIVES
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Ned H. Kalin, M.D.
Co-Chp.: Jack M. Gorman, M.D.

A The Role of Early Adverse Life Experience in the Development of Mood Disorders
Charles B. Nemeroff, M.D.

B Bipolar Disorder and the Effectiveness of Atypical Antipsychotics
K.N. Roy Chengappa, M.D.

C What Can We Expect from New Therapeutic Approaches to Schizoaffective and Mood Disorders?
Jack M. Gorman, M.D.

D The Anxiety/Depression Dimension of Schizophrenia: How Important Is It?
Lili C. Kopala, M.D.

E Polypharmacy: New Ways of Combining Drug Therapies for Better Results
S. Nassir Ghaemi, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
1:30 p.m.-4:30 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

ANXIETY AND DEPRESSION IN THE ADOLESCENT: CLINICAL IMPLICATIONS OF EMERGING DATA
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Neal D. Ryan, M.D.

A Current Status of the Diagnosis and Treatment of Depression and Anxiety in Adolescents
Karen D. Wagner, M.D.

B Developments in the Treatment of Adolescent Depression
Rachel G. Klein, Ph.D.

C Treatment of the Adolescent with OCD
Henrietta L. Leonard, M.D.

D Social Phobia/Social Anxiety Disorder
Stanley P. Kutcher, M.D.

E Safety Considerations for the Use of Antidepressants in Children and Adolescents
Neal D. Ryan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
1:30 p.m.-4:30 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

INTERVENING DURING THE PRODROMAL PHASE OF SCHIZOPHRENIA
Supported by Synthelabo

Chp.: Herbert Y. Meltzer, M.D.
Co-Chp.: Thomas H. McGlashan, M.D.

A Cognitive Function and the Course of Schizophrenia
Herbert Y. Meltzer, M.D., Suzanne Zachary, Ph.D., William T. Summerfelt, Ph.D.

B Predicting Schizophrenia
Michael Davidson, M.D., Abraham Reichenberg, M.A., Jonathan Rabinowitz, D.S.W., Mark Weiser, M.D., Zeev Kaplan, M.D., Mordehai Mark, M.D.

C Prepsychotic Intervention in Schizophrenia: A Stitch in Time?

D Prodromal Signs: Crucial Information at Both the Theoretical and Practical Level
Yves Lecrubier, M.D.

E The Prodrome: Clinical Features and Early Detection
Thomas H. McGlashan, M.D.

Discussant: Yves Lecrubier, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 12
1:30 p.m.-4:30 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

ARE ATYPICAL ANTIPSYCHOTICS ALSO MOOD STABILIZERS?
Supported by Eli Lilly and Company

Chp.: Paul E. Keck, Jr., M.D.

A Pharmacologic Mechanisms of Mood Stabilization Among Atypical Antipsychotics
Paul E. Keck, Jr., M.D.

B Atypical Antipsychotics: Treatment of Acute Mania
Susan L. McElroy, M.D.

C Atypical Antipsychotics: Treatment of Depression
Richard C. Shelton, M.D.

D Efficacy and Tolerability of Maintenance Pharmacotherapy in Bipolar Disorders
John M. Zajecka, M.D.

E Health Beliefs and Compliance in Bipolar Disorder
Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
1:30 p.m.-4:30 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

COMPLEXITY: PHARMACOLOGIC MANAGEMENT ISSUES IN BPD
Association for Research in Personality Disorders
Supported by Glaxo Wellcome Inc.

Chp.: Kenneth R. Silk, M.D.
Co-Chp.: John M. Oldham, M.D.

A Psychobiologic Underpinnings of BPD
Larry J. Siever, M.D., Antonia S. New, M.D., Harold W. Koenigsberg, M.D., Monte S. Buchsbaum, M.D., Rachel Yehuda, Ph.D., Joel Gelernter, M.D., Robert A. Grossman, M.D.

B Symptom-Driven Algorithms As Guides to the Pharmacologic Treatment of BPD
Paul H. Soloff, M.D.

C Combining Psychopharmacology with the Dialectical Behavior Therapy of BPD
Marsha M. Linehan, Ph.D.

D The Impact of Psychopharmacology on Psychological and Interpersonal Issues in the Treatment of BPD
John G. Gunderson, M.D.

E Issues Created by a Psychopharmacologist/Psychotherapist Split in the Treatment of BPD
Kenneth R. Silk, M.D.

Discussant: John M. Oldham, M.D.

2:30 p.m. Session

LECTURE 1
2:30 p.m.-4:00 p.m.
Rooms 32/33, Lower Level, Convention Center
AAP/JAPA's MANFRED S. GUTTMACHER AWARD LECTURE

Daniel Brown, Ph.D., Alan W. Schefflin, J.D., D. Corydon Hammond, Ph.D.

False Memory Lawsuits: The Weight of the Scientific and Legal Evidence

Chp.: Robert L. Sadoff, M.D.
Co-Chp.: Brian Crowley, M.D.

In recent years, several hundred malpractice lawsuits have been filed by former patients or third parties against therapists for allegedly implanting false memories of abuse. Daniel Brown, Ph.D., Alan W. Schefflin, J.D., and D. Corydon Hammond, Ph.D. authors of Memory, Trauma Treatment and the Law, examine weaknesses in the available scientific evidence and the forensic fact pattern, including the medical record and the historical and contextual evidence, that have been used to support plaintiffs' complaints. They discuss efforts that are needed to avoid malpractice litigation and develop the standard of care in trauma treatment including identifying risk factors and establishing practice guidelines for clinicians treating patients who report abuse. Dr. Daniel Brown is Assistant Clinical Professor in Psychology at Harvard Medical School and Adjunct Professor at Simmons School of Social Work in Boston. He is also in private practice in Cambridge, Massachusetts, with specialties in trauma, behavioral medicine and forensic psychology. He is the author of ten books, including three textbooks on hypnosis. Dr. Brown currently serves as consultant and expert witness to the United Nations International War Crimes Tribunal for the former Yugoslavia. He received his doctoral degree in religion and psychological studies from the University of Chicago and completed a research fellowship in social-behavioral science at Harvard Medical School. Professor Alan Schefflin is Professor of Law at Santa Clara University Law School in Santa Clara, Califomia. He has been judicially recognized in federal and state courts as an expert on mind and behavior control, suggestion and suggestibility, memory and hypnosis. He is the author of six books and more than three dozen articles book chapters and book reviews on psychological, psychiatric and legal issues. His book, Trance on Trial, received the Manfred S. Guttmacher Award from the American Psychiatric Association and the American Academy of Psychiatry and the Law in 1991. He was a primary author, along with Dr. Hammond, of the 1995 book, Clinical Hypnosis and Memory: Guidelines for Clinicians and for (Continued on next page)
7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 14-18

INDUSTRY-SUPPORTED SYMPOSIUM 14
7:00 p.m.-10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

CLINICAL FRONTIERS IN THE SLEEP/PSYCHIATRY INTERFACE
Supported by Wyeth-Ayerst Laboratories

Chp.: Karl Doghramji, M.D.

A Insomnia and Hypersomnolence: Old Problems with Newer Treatments
   Karl Doghramji, M.D.

B Emerging Links Between Depression and Sleep
   J. Christian Gillin, M.D.

C Management of Sleep Disturbances in PTSD
   Thomas C. Neylan, M.D.

D Pain and Sleep: Neurobiological and Clinical Issues
   Mitchell J.M. Cohen, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
7:00 p.m.-10:00 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

DEPRESSION: ACHIEVING REMISSION AND COMPLIANCE:
CLINICAL CHALLENGES AND SOLUTIONS
Supported by Bristol-Myers Squibb

Chp.: Paula J. Clayton, M.D.

A Selecting the Right Antidepressant for Your Patient
   Norman Sussman, M.D.

B Psychotherapy of Chronic Depression: Efficacy, Tolerability, Compliance and Cost
   John C. Markowitz, M.D.

C Chronic Depression: Psychotherapy and Pharmacotherapy: Additive or Synergistic?
   Martin B. Keller, M.D.

D Maximizing Response in Partial and Nonresponders to Antidepressants
   Russell T. Joffe, M.D., William M. Singer, M.D., Anthony J. Levitt, M.D.

Discussant: Robert M.A. Hirschfeld, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 16
7:00 p.m.-10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

LONGITUDINAL ASPECTS OF ALZHEIMER'S DISEASE MANAGEMENT
Supported by Eisai Inc., Pfizer Inc.

Chp.: Peter V. Rabins, M.D.
Co-Chp.: Rachelle S. Doody, M.D.

A The Pre-Alzheimer's Disease Condition
John C. Morris, M.D.

B Behavior Management Over the Course of Alzheimer's Disease
Jeffrey L. Cummings, M.D.

C Disease-Modifying Agents and Study Designs
Ronald C. Petersen, M.D.

D Modeling Progression: Implications for Treatment
Rachelle S. Doody, M.D.

E Management Approaches Adapted to the Stage of Alzheimer's Disease
Peter V. Rabins, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

SUICIDE: CLINICAL/RISK MANAGEMENT ISSUES FOR PSYCHIATRIS
Suicide Research Division of the National Mental Illness Screening Project and McLean Hospital Bipolar and Psychotic Disorders Program
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Douglas G. Jacobs, M.D.
Co-Chp.: Ross J. Baldessarini, M.D.

A A Protocol for the Assessment of Suicide
Douglas G. Jacobs, M.D.

B Bipolar Disorder and Suicide
Kay R. Jamison, Ph.D.

C Lithium Discontinuation and Suicide
Ross J. Baldessarini, M.D.

D Profiles of Completed Suicide
Jan A. Fawcett, M.D.

E Suicide, Assisted Suicide and Euthanasia
Herbert Hendin, M.D.

F Liability and Suicide
Thomas G. Guthrell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
7:00 p.m.-10:00 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

OPTIMIZING WELLNESS ACROSS THE LIFE CYCLE OF SCHIZOPHRENIA
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: Daniel E. Casey, M.D.

A Managing the First Episode
John M. Kane, M.D.

B Meeting Long-Term Treatment Goals: Relapse Prevention and More
Nina R. Schooleer, Ph.D.

C Improving Compliance and Building Alliances
Peter J. Weiden, M.D., Annette Zygmunt, M.S.

D Schizophrenia Towards the End of the Life Cycle
Trey Sunderland, M.D.

E Morbidity and Mortality in Schizophrenia
Daniel E. Casey, M.D.

MEDIA SESSIONS 1-2

MEDIA SESSION 1 7:00 p.m.-10:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

A CONTEMPORARY PERSPECTIVE ON RELATIONSHIPS
Chp.: Steven E. Hyler, M.D.

1 In the Company of Men
(93 minutes)

Distributor: Sony Classics
550 Madison Avenue, 8th Floor
New York, NY 10022

In the Company of Men (1997) won several awards at the Sundance Film Festival. It was written and directed by Neil LaBute, who has been referred to as the Mormon version of David Mamet. It is rated R for language and emotional abuse. It is not a film for kids. The plot summary is that two junior executives, Chad (Aaron Eckhart) and Howard (Matt Malloy), are on a six-week business trip. The women in their lives have recently hurt both of them. To get even they devise a plan whereby they will find a vulnerable woman, romance her, and then when the time is right, dump her. They find Christine, an attractive and deaf office assistant (played by Stacy Edwards of TV's "Chicago Hope.") They set their scheme into motion, but everything doesn't go exactly as planned. Roger Ebert, of the Chicago Sun Times, gave this film four stars saying: "Now there is true evil." Alona Wartofsky, of the Washington Post wrote, "couples who see this film walk in the theater hand-in-hand...when they leave they are no longer touching. The women's arms are grimly folded across their chests. The men sling out of the theater." Bring someone that you love (or hate) to see this film.

Discussant: Eve Leeman, M.D.
MEDIA SESSION 2  7:00 p.m.-10:00 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

BERTOLUCCI'S THE LAST EMPEROR: MULTIPLE TAKES:
A PSYCHOANALYTIC, CINEMATIC AND HISTORIC
EXPLORATION
Forum for the Psychoanalytic Study of Film

Co-Chps.: Francis G. Lu, M.D., Bruce H. Sklarew, M.D.

2 The Last Emperor
(90 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

Bernardo Bertolucci's epic film tells the dramatic history of Pu Yi, the
last of the Emperors of China. Placed on the throne at age three, he
reigned briefly in the Forbidden City before becoming a puppet
emperor of Japan's Manchukuo. Imprisoned by the Communist
government, he was released to die as an obscure gardener. The
discussion will focus on the psychological, political and cinematic
themes in the Last Emperor drawn from the recent book Bertolucci's
The Last Emperor: Multiple Takes. It won nine Academy Awards
including Best Picture for 1987.

Discussant: Bonnie S. Kaufman, Ph.D.

Washington National Cathedral - Begun in 1907 and completed in
1990, the Washington National Cathedral stands as one of the
world's largest churches. President Woodrow Wilson's tomb is
housed in the cathedral, along with countless examples of Gothic-
style stonework and stained glass. (Photo courtesy of the
Washington, DC Convention and Visitors Association/1991.)
MONDAY, MAY 17, 1999
152ND ANNUAL MEETING

7:00 a.m. Sessions

PART I OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 19-23

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 19, PART I
7:00 a.m.-8:30 a.m.
Constitution Ballroom, Level 3B, Grand Hyatt

ANXIETY AND DEPRESSION: CAUSE OR EFFECT?
Supported by Wyeth-Ayerst Laboratories
Chp.: R. Bruce Lydiard, M.D.

A Neurobiology of Anxiety and Mood Disorders
Jeremy D. Coplan, M.D.

B Why Do Anxious People Become Depressed?
Philip T. Ninan, M.D., Donald J. Newport, M.D.

C Treatment of Anxious/Depressed Patients
R. Bruce Lydiard, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 20, PART I
7:00 a.m.-8:30 a.m.
Independence Ballroom, Level 5B, Grand Hyatt

NEW CLINICAL ADVANCES IN MANAGING ANXIETY AND DEPRESSIVE DISORDERS THROUGHOUT THE LIFE CYCLE
Supported by Bristol-Myers Squibb
Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A A Guide for the Rational Selection of Antidepressants Based on Their Side-Effect Profiles
Norman Sussman, M.D.

B Long-Term Treatment of Depression: What To Do When Antidepressants Stop Working
Anthony J. Rothschild, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 21, PART I
7:00 a.m.-8:30 a.m.
Presidential Ballroom, Second Floor, Capital Hilton

BEYOND EFFICACY IN PSYCHOSIS: PATIENT SATISFACTION, COMPLIANCE AND OUTCOMES
Supported by Zeneca Pharmaceuticals
Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Laurie M. Flynn

A Antipsychotic Medication and Cognition
Alexander L. Miller, M.D., Dawn I. Velligan, Ph.D., C. Christine Bow-Thomas, Ph.D.

B Practical Management of Agitation and Aggression
Soo Borson, M.D.

C Extrapyramidal Side Effects and Tardive Dyskinesia: Impact on Compliance and Outcome
John M. Kane, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 22, PART I
7:00 a.m.-8:30 a.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

STRATEGIES AND TACTICS TO MANAGE DEPRESSED PATIENTS
Supported by Organon Inc.
Chp.: A. John Rush, M.D.
Co-Chp.: Lorrin M. Koran, M.D.

A Which Baseline Symptom Features Predict Response to Particular Antidepressant Medications?
A. John Rush, M.D.

B Response Versus Remission: A Distinction with a Clinical Difference?
Madhukar H. Trivedi, M.D.

C Are There Faster and Slower Responders to Antidepressant Medication and Who Are They?
Andrew A. Nierenberg, M.D., Amy Farabaugh, M.A., Lindy E. Graham, B.A., Jonathan E. Alpert, M.D., Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 23, PART I
7:00 a.m.-8:30 a.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

CONTROVERSIES AND TREATMENT STRATEGIES IN BIPOLAR DISORDERS
Supported by Abbott Laboratories
Chp.: Dwight L. Evans, M.D.

A Bipolar II: Diagnostic and Therapeutic Controversies
Hagop S. Akiskal, M.D.

B Promises and Predictions for the Atypical Antipsychotics in Bipolar Disorder
Robert N. Golden, M.D.

C Current Update on Bipolar Disorder: Where Do We Go From Here?
Charles L. Bowden, M.D.
MONDAY

RESIDENTS' SESSION
7:00 a.m.-8:30 a.m.
Vista Ballroom, Ballroom Level, Wyndam Washington

MEET THE EXPERTS: SUNNY SIDE-UP
Chp.: Rodrigo A. Muñoz, M.D.
Co-Chp.: Allen Tasman, M.D.

Nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include child and adolescent psychiatry, minority issues, organizational psychiatry, private practice, psychiatry and the law, public and community psychiatry, research, writing and publishing, women's issues, issues related to managed care and many more.

8:00 a.m. Sessions

COURSES 31-35
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 31 8:00 a.m.-12 noon
Room 4, Meeting Room Level, Renaissance Washington
SPECIAL PROBLEMS IN TREATING BORDERLINE PATIENTS
Director: Otto F. Kernberg, M.D.
Faculty: Frank E. Yeomans, M.D., John F. Clarkin, M.D.

COURSE 32 8:00 a.m.-12 noon
Room 7, Meeting Room Level, Renaissance Washington
BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD
Director: Howard E. Book, M.D.

COURSE 33 8:00 a.m.-12 noon
Room 15, Meeting Room Level, Renaissance Washington
ACUPUNCTURE TECHNIQUES IN PSYCHIATRIC PRACTICE
Co-Directors: Antoinette W. Jakobi, M.D., John M. Ackerman, M.D.

COURSE 34 8:00 a.m.-12 noon
Federal Room A, Second Floor, Capital Hilton
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 35 8:00 a.m.-12 noon
South American Room A, Second Floor, Capital Hilton
DEALING WITH RESISTANCE IN ADDICTION PATIENTS
Director: David Mee-Lee, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 27, Lower Level, Convention Center
CHRONIC PAIN SYNDROMES REFRACTORY TO CONVENTIONAL TREATMENTS
Moderator: Barbara A. Palmeri, M.D.
Presenter: Oliver Freudenreich, M.D.
Discussant: Thomas N. Wise, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART I
9:00 a.m.-12 noon
Room 29, Lower Level, Convention Center
TREATING PATIENTS WITH MEDICALLY UNEXPLAINED SYMPTOMS: PART I
Moderator: Arthur J. Barsky III, M.D.
Presenters: Ralph Saintfort, Julie Lieb, M.D.
Discussants: Frank V. deGruy, M.D., Arthur J. Barsky III, M.D., Carla Cantor
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 36-45
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 36 9:00 a.m.-4:00 p.m.
Room 2, Meeting Room Level, Renaissance Washington
TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT
American Academy of Psychiatry and the Law
Director: Robert P. Granacher, Jr., M.D.
COURSE 37 9:00 a.m.-4:00 p.m.  
Room 3, Meeting Room Level, Renaissance Washington  
THE PRACTICAL MANAGEMENT OF PERSONALITY DISORDER  
Director: John Livesley, M.D.

COURSE 38 9:00 a.m.-4:00 p.m.  
Room 5, Meeting Room Level, Renaissance Washington  
DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT  
Director: James F. Masterson, M.D.

COURSE 39 9:00 a.m.-4:00 p.m.  
Rooms 8/9, Meeting Room Level, Renaissance Washington  
SKILLS FOR BUILDING AND LEADING SUCCESSFUL TEAMS  
Co-Directors: des Anges Crusier, Ph.D., Alan L. Podawiltz, D.O.  
Faculty: Harold R. Viets, M.D.

COURSE 40 9:00 a.m.-4:00 p.m.  
Room 16, Meeting Room Level, Renaissance Washington  
INTERPERSONAL PSYCHOTHERAPY  
Director: Scott P. Stuart, M.D.  
Faculty: Michael W. O’Hara, Ph.D.

COURSE 41 9:00 a.m.-4:00 p.m.  
Congressional Hall A, Ballroom Level, Renaissance Washington  
ADVANCES IN NEUROPSYCHIATRY  
American Neuropsychiatric Association  
Co-Directors: C. Edward Coffey, M.D., Jeffrey L. Cummings, M.D.  
Faculty: Mark S. George, M.D., James D. Duffy, M.D.

COURSE 42 9:00 a.m.-4:00 p.m.  
California Room, Second Floor, Capital Hilton  
INTRODUCTION TO BEHAVIOR THERAPY  
Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 43 9:00 a.m.-4:00 p.m.  
Federal Room B, Second Floor, Capital Hilton  
DIAMECTICAL BEHAVIOR THERAPY  
Director: Charles R. Swenson, M.D.  
Faculty: Marsha M. Linehan, Ph.D.

COURSE 44 9:00 a.m.-4:00 p.m.  
Massachusetts Room, Second Floor, Capital Hilton  
MANAGEMENT AND TREATMENT OF THE VIOLENT PATIENT  
Director: Gary J. Maier, M.D.

DEBATE 1 9:00 a.m.-10:40 a.m.  
Grand Ballroom A, Ballroom Level, Marriott Metro Center  
RESOLVED: MEDICAL SAVINGS ACCOUNTS WILL IMPROVE ACCESS TO MENTAL HEALTH CARE  
Moderator: Donna M. Norris, M.D.  
Affirmative: Frederick K. Goodwin, M.D., Pierre Vincent, M.D.  
Negative: Captane P. Thomson, M.D., Arthur L. Lesser, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-2 9:00 a.m.-10:30 a.m.  
These sessions are limited to 25 participants on a first-come, first-served basis.

1. Daniel K. Winstead, M.D., on the Future of Consultation-Liaison Psychiatry  
   Montreal Room, Second Floor, Marriott Metro Center

2. Billy E. Jones, M.D., on Managed Care and Issues for Minorities  
   Washington Room, Second Floor, Marriott Metro Center

LECTURES 2-3

LECTURE 2 9:00 a.m.-10:30 a.m.  
Room 32, Lower Level, Convention Center  
APA'S SOLOMON CARTER FULLER AWARD LECTURE  
TO BE ANNOUNCED

LECTURE 3 9:00 a.m.-10:30 a.m.  
Room 33, Lower Level, Convention Center  
Judith H.L. Rapoport, M.D.  
Childhood-Onset Schizophrenia: What Has It Taught Us?  
Chp.: Paula J. Clayton, M.D.  
Co-Chp.: Charles W. Huffine, Jr., M.D.
These are limited to 25 participants on a first-come, first-served basis.

1 Hagop S. Akiskal, M.D., on Depressive Mixed States Room 35, Lower Level, Convention Center
A CINEMATIC CLASSIC FROM INDIA: THE APU TRILOGY

5 Aparajito: Part II of the Apu Trilogy

(90 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

This is Part II of the cinematic masterpiece The Apu Trilogy (1955-1958) by the great Indian director Satyajit Ray, shown in the restored print. It shows ten-year-old Apu completing school and eventually going to college in Calcutta. His mother loves her son very much and wants him to succeed, but she does not want to be left alone. Ray's cinematic style reveals profound humanism amidst existential and cultural despair. Part I, Pather Panchali, was shown at the 1997 APA Annual Meeting in San Diego.

HANDS-ON WEB WORK

APA Committee on Information Systems

Chp.: Bertram Warren, M.D.
Presenters: Thomas A.M. Kramer, M.D., Cheryl A. Chessick, M.D., Sol Herman, M.D., Steven E. Hyler, M.D.

Presentations and materials will include introduction to Windows technology, Web history and design, and navigation of the Web, specifically including APA's site. Information will be presented in a hands-on format and will include: how to use the Windows environment; exercises to become familiar with a mouse (for the beginning sections); how to use the Web navigation tools; and how to find the information you want when you don't know exactly who or what you are looking for. Skill development will include: how to familiarize yourself with the Web environment; how to find useful sites using search engines; how to find a site again that you like; how to handle searches that are taking too long; how to respond when you get error messages (e.g., can't find this server); how to set preferences and how to download and print from the Web.

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.
Hall D, Lower Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.
Burnham Room, Level 3B, Grand Hyatt

PSYCHIATRY'S FUTURE: MEETING BUSINESS'S UNMET NEEDS
APA Committee on Occupational Psychiatry

Co-Chps.: Leonard T. Sperry, M.D., Rodrigo A. Muñoz, M.D.
Participants: Stephen H. Heidel, M.D., William Wilkerson, Edgardo L. Perez, M.D.

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.
Latrobe Room, Level 3B, Grand Hyatt

PARTNERS IN PRACTICE
APA Auxiliary

Co-Chps.: Harold I. Eist, M.D., Ann M. Eist, B.A.
Participants: Arnold D. Goldman, M.D., Marilyn Goldman, J. Alfred Le Blanc, M.D., Jacquelyn M. Le Blanc

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

ADDITION TRAINING STRATEGIES FOR PSYCHIATRIC RESIDENTS
APA Committee on Training and Education in Addiction Psychiatry

Chp.: David R. McDuff, M.D.
Participants: Richard Bellsisky, M.D., Jeremy A. Herscher, M.D., Jeffrey A. Berman, M.D.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.
Farragut Square Room, Level 5B, Grand Hyatt

CULTURAL PERSPECTIVES ON COMING OUT IN PSYCHIATRY
APA Southern California Psychiatric Society's Committee on Gay, Lesbian and Bisexual Issues

Chp.: Nick M. Gutierrez, M.D.
Participants: William Arroyo, M.D., Clayton L. Chau, M.D., Robert T. Saray, M.D., Kevin P. Hayes, M.D.

COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m.
London Room, Ballroom Level, Marriott Metro Center

UNIQUE ROLE OF INDIVIDUAL SUPERVISION IN PSYCHIATRIC EDUCATION
APA Committee on Graduate Education

Chp.: James W. Lomax II, M.D.
Participants: Carol A. Bernstein, M.D., Jacqueline C. McGregor, M.D., Marjorie E. Waldbaum, M.D.

COMPONENT WORKSHOP 11 9:00 a.m.-10:30 a.m.
Paris Room, Ballroom Level, Marriott Metro Center

SILDENAFIL CITRATE, SEXUAL FUNCTION AND HIV PREVENTION
APA Commission on AIDS

Chp.: Marshall Forstein, M.D.
Participants: Stephen J. Ferrando, M.D., Francisco Fernandez, M.D.
ISSUE WORKSHOP 7
9:00 a.m.-10:30 a.m.
McPherson Square Room, Level SB, Grand Hyatt

TEACHING BOUNDARIES TO CLINICIANS

Chp.: Samia Barakat, M.D.
Participants: Mark A. Prober, M.D., Mark S. Elkin, M.D., Teresa C.I. De Cloedt, M.D.

ISSUE WORKSHOP 8
9:00 a.m.-10:30 a.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

BEYOND MEDICAL SCHOOL: THE M.B.A. ADVANTAGE

Co-Chps.: Arthur L. Lazarus, M.D., M.B.A., Marie L. Zecca

WORKSHOP ON PRIVATE PRACTICE ISSUES
9:00 a.m.-12 noon
Bulfinch/Renwick Rooms, Level 3B, Grand Hyatt

PRIVATE PRACTICE IS ALIVE AND THRIVING

APA Committee on Private Practice

Chp.: Michael C. Hughes, M.D.
Participants: John S. McIntyre, M.D., Norman A. Clemens, M.D., Thomas K. Ciesla, M.D., Maria T. Lymberis, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Rooms 30/31, Lower Level, Convention Center

ADVANCES IN RESEARCH: AN UPDATE FOR THE CLINICIAN

APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chp.: Pedro Ruiz, M.D.

Participants: Alan F. Schatzberg, M.D., on Depression
Igor Grant, M.D., on Neuropsychiatric Disorders
Katherine A. Halmi, M.D., on Eating Disorders
Jack M. Gorman, M.D., on Schizophrenia

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUP 3
11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

H. Steven Moffic, M.D., on Social Psychiatry, Managed Care and the New Millennium
Montreal Room, Second Floor, Marriott Metro Center

THIS SESSION WILL BE AUDIOTAPED.
MEDIA SESSION 6-7

11:00 a.m.-2:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

VIOLENCE: SOCIOCULTURAL PERSPECTIVES

Chp.: Elmore F. Rigamer, M.D.

6 Violence and Video Games

As American society has watched its youngest members become increasingly more violent, the controversy over what precipitates violent behavior has grown. An easy focal point is violence portrayed in the media. Instead of the passive experience of television and movies, video games make children active participants in fantasy worlds, which can often include representations of extremely violent behavior. This presentation will review research on the effects violent video games have on children and adolescents, and will feature a demonstration of violent video games like Carmageddon, Doom, and Duke Nukem. While the majority of studies suggest a short-term connection between violent video games and aggressive behavior, long-term studies have not been conducted. However, research has shown that violent television imagery has three effects: it models aggressive behaviors, it can cause emotional desensitization, and it can increase fear in children (the "mean world" effect). Much consideration should be given to how vulnerable children may understand the basic assumption of violence as a positive activity in many video games.

Discussant: Keith Cheng, M.D.

7 Breaking the Rule of Thumb
(35 minutes)

Distributor: Women Make Movies, Inc.
Distribution Department
462 Broadway, Suite 500E
New York, NY 10013

Combining powerful interviews with documentary footage, this timely and compelling videotape takes a comprehensive look at the issues still confronting battered women 20 years after the beginning of the domestic violence movement. Featuring the stories of three women, one a police officer who went through the Philadelphia family courts to ensure the safety of these women, Breaking the Rule of Thumb examines contemporary domestic violence in terms of changing historical definitions of abuse. Incorporating individual stories into a strong argument for legal reform, filmmaker Andrea Elovson exposes how the seemingly personal gender issues of domestic violence are inextricably tied to flawed ideas of civil justice.

8 Understanding Violence
(30 minutes)

Distributor: Films for Humanities & Science
P.O. Box 2053
Princeton, NJ 08543
This program features Dr. Carl Bell, one of the country’s leading psychiatrists, who focuses on children who have witnessed violence, committed violent acts, or been the victims of violence. In this program, Dr. Bell argues that the cycle of violence in children’s lives can be broken if we act early to deal with their trauma. Children capable of violence must be taught to empathize with the pain in someone else’s life, allowing them to see the painful consequences of violence.

**MEDIA SESSION 7**
**11:00 a.m.-2:00 p.m.**
Auditorium, Meeting Room Level, Renaissance Washington

**COMING APART: FILM AND GENERATION**
Chp.: Harvey R. Greenberg, M.D.
9 Coming Apart
(110 minutes)

**Distributor:** Milton Moses Ginsberg
155 Riverside Drive, Apartment 4A
New York, NY 10024

Milton Moses Ginsberg’s 1969 feature film, *Coming Apart*, not only is a searing portrait of the psychological disintegration (and articulated boundary violations) of a talented mental health professional, it affords insights into the social ferment of the 1960s and 1970s. Ultimately, it represents an impressive experiment in depicting disordered subjective states through radically novel cinema rhetoric. The hero is a Manhattan psychoanalyst who has abandoned his family and moved into a luxury apartment to pursue the illusion of a “free” lifestyle centered around pharmacological and sexual experimentation. He sets up a hidden camera; through its frame, and only through its frame, the viewer perceives a dizzying succession of patients, lovers, friends and relatives. Some “takes” last five to ten minutes, others only a few seconds. The film culminates when a former patient, now an enraged ex-lover, hurls a chair through the one-way mirror and destroys the camera. *Coming Apart* initially received excellent reviews, until a savagely critical piece by Andrew Sarris of the *Village Voice* essentially ended its run. It went on to attain cult status over the succeeding theatrical exhibition.

**MEDICAL UPDATE 1**
**11:00 a.m.-12:30 p.m.**
Rooms 13/14, Lower Level, Convention Center

**MODERN MANAGEMENT OF MENOPAUSE**
Chp.: Frances R. Levin, M.D.
Presenters: Diana L. Dell, M.D., Donna E. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-8**

**SCIENTIFIC AND CLINICAL REPORT SESSION 1**
**11:00 a.m.-12:30 p.m.**
Room 15, Lower Level, Convention Center

**CHALLENGES IN CONSULTATION-LIAISON PSYCHIATRY**

Chp.: Norman B. Levy, M.D.
Co-Chp.: Valapuri Palaniappun, M.D.

11:00 a.m.
2 Description of Psychiatry Consults in Primary Care
William F. Pirl, M.D., B.J. Beck, M.D., Helen I. Kim, M.D.,
Steven A. Safren, Ph.D.

11:30 a.m.
3 Psychosocial Adjustment in Head and Neck Cancer
Mark R. Katz, M.D., Johnathan C. Irish, M.D., Gerald M.
Devins, Ph.D., Gary M. Rodin, M.D., Patrick J. Gullane, M.D.

12 noon
4 Treatment Guidelines for Women After Miscarriage
Jennifer B. Athey, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 2**
**11:00 a.m.-12:30 p.m.**
Room 20, Lower Level, Convention Center

**KLEPTOMANIA AND DISSOCIATIVE IDENTITY DISORDER: REFINING THE PSYCHIATRIC DIAGNOSIS**
Chp.: Cyril Hoschl, M.D.
Co-Chp.: Clifford A. McNaughton, M.D.

11:00 a.m.
5 A Twin Study of Dissociative Experience
Joel F. Paris, M.D., Kerry L. Jang, Ph.D., Hallie Zweig-Frank, Ph.D., John Livesley, M.D.

11:30 a.m.
6 Diagnosis of Dissociative Identity Disorder
Arthur Rofkin, M.D., Can Bulucu, M.D., Madha Mallipeddi, M.D., Eduardo Espiridion, M.D., Barbara Ponieman, M.D., Charles Jin, M.D., Christopher Dennis, M.D.

12 noon
7 Axis I Comorbidity in Kleptomania
Donatella Marazziti, M.D., Silvio Presta, M.D., Chiara Pflanner, M.D., Alfredo Gemignani, M.D., Giovanni B. Cassano, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 3**
**11:00 a.m.-12:30 p.m.**
Rooms 25/26, Lower Level, Convention Center

**FOLLOW-UP ON HEALTH AND MENTAL HEALTH IN THREE SPECIAL POPULATIONS**
Chp.: Edward D. Simmer, M.D.
Co-Chp.: Milton Kramer, M.D.

11:00 a.m.
8 Mentally Healthy Men at Mid Life
Jerry F. Westermeyer, Ph.D.

(Continued on next page)
11:30 a.m.
9 Stress Levels in a Deployed Marine Unit
Keith A. Caruso, M.D., Robert L. Koffmann, M.D., Kenneth P. Sausen, Ph.D., Mark J. Bourne, Ph.D.

12 noon
10 Group Treatment Outcome for Psychopathic Inmates
K. Roy MacKenzie, M.D., Johann Brink, M.D., Amber Hills, B.A., Kerry L. Jang, Ph.D., John Livesley, M.D., Carson Smiley, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 27, Lower Level, Convention Center

CLINICAL RISK FACTORS FOR SUICIDE
Chp.: Fuad T. Antun, M.D.
Co-Chp.: Ruby C. Castilla, M.D.

11:00 a.m.
11 Suicidal Behavior in BPD, Major Depressive Episode and Comorbid BPD Plus Major Depressive Episode
Paul H. Soloff, M.D., Kevin G. Lynch, Ph.D., Thomas Kelly, Ph.D., Kevin M. Malone, M.D., J. John Mann, M.D.

11:30 a.m.
12 Risk Factors for Suicide in Schizophrenia
Wayne S. Fenton, M.D.

12 noon
13 High Serum Cholesterol and Risk of Suicide
Antti Tanakanen, M.D., Erkki Varttinen, M.D., Johannes Lehtonen, M.D., Jaakko Tuomilehto, M.D., Pekka Puska, M.D., Heimo Viinamaki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Conference Theatre, Level 1B, Grand Hyatt

BRAIN CORRELATIONS OF PSYCHOPATHOLOGY
Chp.: F. Moises Gaviria, M.D.
Co-Chp.: Theresa M. Miskimen, M.D.

11:00 a.m.
14 Cognitive Deficits in Children with Lyme Disease
Felice Tager, M.A., Brian A. Fallon, M.D., John Keip, Ph.D., Marian Rissenberg, Ph.D., Michael D. Leibowitz, M.D.

11:30 a.m.
15 CBF in Lyme Encephalopathy
Brian A. Fallon, M.D., John Keip, Ph.D., Isak Prohounik, Ph.D., Ronald Van Heertum, M.D., Felice Tager, M.A., J. John Mann, M.D., Michael R. Liebowitz, M.D.

12 noon
16 Cerebral Activation Pattern During Auditory Hallucinations: A Functional Magnetic Resonance Study
Martin Jandi, D.R., David E. Linden, D.R., Heinrich Lanfermann, P.D., Rainer Goebel, D.R., Professor Konrad Maurer, Professor Friedhelm Zanella, Thomas Dierks, P.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Independence Ballrooms B/C, Level 5B, Grand Hyatt

TREATMENT ISSUES WITH SEROTONERGIC ANTIDEPRESSANTS
Chp.: David C. Jimerson, M.D.
Co-Chp.: Vinod Kumar, M.D.

11:00 a.m.
17 Cost and Effectiveness of SSRIs
H. George Nurnberg, M.D., Peter M. Thompson, M.D., Paula L. Hensley, M.D., Michael P. Dutro, P.D., Susan S. Paine, M.P.H.

11:30 a.m.
18 Treatment of SSRI-Associated Sexual Dysfunction
Steven D. Targum, M.D., David Michelson, M.D.

12 noon
19 Efficacy of Tianeptine in the Treatment of Depressive Disorders: A Study of 316 Outpatients
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D., Nabonita Chakraborty, D.P.M., Prashant Desai, M.D., Jayalakshmi Aiyengar, M.D., David Park, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Independence Ballrooms F/G, Level 5B, Grand Hyatt

ADOLESCENT EXPOSURE TO VIOLENCE
Chp.: Stephen J. Millman, M.D.
Co-Chp.: Kimberly A. Arlinghaus, M.D.

11:00 a.m.
20 School-Based Mourning Groups: Inner-City Violence
Bruce H. Sklarew, M.D., Janice L. Krupnick, Ph.D.

11:30 a.m.
21 Correlates of Community Violence Exposure
Dwain C. Fehon, Psy.D., Carlos M. Grilo, Ph.D., Deborah Lipschitz, M.D., Robin Jilton, Ph.D., Robert Deegan, B.A., Steve Martino, Ph.D.

12 noon
22 Exposure to Violence and Post-Traumatic Stress Symptoms in Urban, Inner-City Adolescents
Deborah Lipschitz, M.D., Carlos M. Grilo, Ph.D., Ann M. Rasmusson, M.D., Walter Anyan, M.D., Steven M. Southwick, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

CULTURAL ISSUES IN BPD

Chp.: Eduardo R. Val, M.D.
Co-Chp.: Sharon C. Harvey, M.D.

11:00 a.m.

23 Homosexuality/Bisexuality Among Women with BPD
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., Tilla F. Ruser, M.D.

11:30 a.m.

24 Survey of Clinician Attitudes Towards BPD
Bruce M. Pfohl, M.D., John G. Gunderson, M.D., Kenneth R. Silk, M.D., Mark Zimmerman, M.D., Janet B.W. Williams, D.S.W., Katharine A. Phillips, M.D., Clive Robins, Ph.D., A. John Rush, M.D.

12 noon

25 DSM-III-R Borderline and Schizotypal Personality Disorders: Discriminating Symptom and Category
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., William S. Edell, Ph.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 12-18

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Rooms 23/24, Lower Level, Convention Center

WHAT SPECIALTY IS FOR ME? RESEARCH, FORENSICS, CHILD AND ADOLESCENT OR GERIATRICS?
APA Assembly Committee of Area Member-in-Training Representatives

Chp.: Judythe S. McKay, M.D.
Participants: Gabriela Cora-Lozatelli, M.D., Patrice A. Harris, M.D., Gregory J. Brown, M.D., Daniel Weintrub, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 36, Lower Level, Convention Center

PEARLS AND PITFALLS OF WORKING WITH ETHNIC CAREGIVERS
APA Committee on Ethnic Minority Eldery

Chp.: Rita R. Hargrave, M.D.
Participants: Dolores Gallagher-Thompson, Ph.D., Gwen Yeo

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room 37, Lower Level, Convention Center

SPECIAL POPULATIONS IN RURAL PSYCHIATRY
APA Corresponding Task Force on Rural Psychiatry

Chp.: Stuart A. Copans, M.D.
Participants: Diane K. Fast, M.D., Stephen A. Cole, M.D., Ben Coplan, B.S.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Lafrobe Room, Level 3B, Grand Hyatt

HELP FOR HIGH-RISK SCHOOLS: MENTORING PROGRAMS THAT WORK
APA Committee on Psychiatry and Mental Health in the Schools

Co-Chps.: Lois T. Flaherty, M.D., Joan E. Kinlan, M.D.
Participants: Margaret Delorme, Trina B. Allen, M.D., John McCarthy

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

INNOVATION IN VETERANS AFFAIRS RESEARCH: MENTAL ILLNESS RESEARCH EDUCATION AND CLINICAL CENTERS
APA Consortium on Special Delivery Settings

Co-Chps.: Laurent S. Lehmann, M.D., Frederick G. Guggenheim, M.D.
Participants: Bruce J. Rounsaville, M.D., Murray A. Raskind, M.D., Stephen R. Marder, M.D., Thomas B. Horvath, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Farragut Square Room, Level 5B, Grand Hyatt

NURSING HOME PSYCHIATRY: PROBLEMS AND SOLUTIONS
APA New Jersey Psychiatric Association

Chp.: Marc I. Rothman, M.D.
Participants: Istvan J.E. Boksay, M.D., Patricia A.J. Kay, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Independence Ballrooms D/E, Level 5B, Grand Hyatt

GENDER EQUITY IN MEDICAL SCHOOL AND RESIDENCY
APA Rhode Island Psychiatric Society

Chp.: Alison M. Heru, M.D.
Participants: Patricia R. Recupero, M.D., Andrea J. Merman

ISSUES 9-15

ISSUE WORKSHOP 9 11:00 a.m.-12:30 p.m.
Room 28, Lower Level, Convention Center

MANAGED CARE VERSUS FEE FOR SERVICE MEDICAID FOR ADOLESCENTS

Chp.: Saul M. Levin, M.D.
Participants: Mady Chalk, Ph.D., Fran Cotter, Craigann Heffinger, Roy Gabriel
ISSUE WORKSHOP 10  11:00 a.m.-12:30 p.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

ANALYZING AND NEGOTIATING YOUR EMPLOYMENT CONTRACT

ISSUE WORKSHOP 11  11:00 a.m.-12:30 p.m.
Burnham Room, Level 3B, Grand Hyatt

LIFE-THREATENING ELDER PSYCHIATRIC EMERGENCIES
Chp.: Michael J. Tueth, M.D.
Participant: Nauphyll S. Zuberi, M.D.

ISSUE WORKSHOP 12  11:00 a.m.-12:30 p.m.
Independence Ballrooms Hll, Level 5B, Grand Hyatt

BRIEF DYNAMIC THERAPY: WHEN LESS IS MORE
Co-Chps.: Carlos Blanco-Jerez, M.D., Donna T. Chen, M.D.
Participants: Lisa A. Mellman, M.D., Eve Caligor, M.D., Alan S. Barasch, M.D., Petros Levounis, M.D.

ISSUE WORKSHOP 13  11:00 a.m.-12:30 p.m.
McPherson Square Room, Level 5B, Grand Hyatt

PATTERNS OF BEHAVIOR IN POPULATIONS OF TRAUMA SURVIVORS: BIOLOGICAL AND CLINICAL ASPECTS
Chp.: Andrei Novae, M.D.
Participants: Rita R. Newman, M.D., Susan Mirow, M.D., Rachel Yehuda, Ph.D., Robert D. Levitan, M.D.

ISSUE WORKSHOP 14  11:00 a.m.-12:30 p.m.
London Room, Ballroom Level, Marriott Metro Center

MANAGEMENT OF COMORBID CONDITIONS IN SCHIZOPHRENIA
Co-Chps.: Michael Y. Hwang, M.D., Lewis A. Opler, M.D.
Participants: Samuel G. Siris, M.D., Douglas M. Ziedonis, M.D., Leslie L. Citrome, M.D.

ISSUE WORKSHOP 15  11:00 a.m.-12:30 p.m.
Paris Room, Ballroom Level, Marriott Metro Center

HIV/AIDS EDUCATION AND TRAINING OF PSYCHIATRISTS
Chp.: Barbara Silver, Ph.D.
Participants: Marshall Forstein, M.D., J. Stephen McDaniel, M.D., Francine Cournos, M.D.

12 noon Sessions

FORUMS 1-2

FORUM 1  12 noon-1:30 p.m.
Rooms 21/22, Lower Level, Convention Center

WHAT'S REALLY GOING ON IN PSYCHIATRY? THE APA PRACTICE RESEARCH NETWORK
Co-Chps.: John S. McIntyre, M.D., Harold Alan Pincus, M.D.
Participants: Terri L. Tanielian, M.A., Ana Suarez, M.P.H., Ivan D. Montoya, M.D.

FORUM 2  12 noon-1:30 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

THE GLOBALIZATION OF PSYCHIATRY: CHALLENGES AND OPPORTUNITIES
Co-Chps.: Rodrigo A. Muñoz, M.D., Norman Sartorious, M.D.
Participants: Robert O. Pasnau, M.D., Steven M. Mirin, M.D., Ahmed M.F. Okasha, M.D., Harold I. Elst, M.D.

1:00 p.m. Sessions

COURSES 46-50
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 46  1:00 p.m.-5:00 p.m.
Room 4, Meeting Room Level, Renaissance Washington

BEYOND MUNCHAUSEN: FACTITIOUS DISORDERS TODAY
Director: Marc D. Feldman, M.D.
Faculty: Charles V. Ford, M.D., Stuart J. Eisendrath, M.D.

COURSE 47  1:00 p.m.-5:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington

TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 48  1:00 p.m.-5:00 p.m.
Federal Room A, Second Floor, Capital Hilton

USE OF MELATONIN/LIGHT IN SLEEP AND MOOD DISORDERS
Director: Alfred J. Lewy, M.D.
For the majority of people diagnosed with a mental illness, the first episode occurs in their late teens or early twenties. It can be a terrifying, disorienting experience. For the making of First Break, three young adults and their families courageously come forward and illuminate, with compelling candor, their personal experiences. Over the course of a year, Simon, Ariadne and Shely allow us to share in the ongoing challenge of living with a diagnosis of mental illness, and its impact on their self-identities and family relationships. As a result, we are provided with a valuable perspective on the hopes, frustrations and achievements of three young adults whose lives have been dramatically changed by a first break. Engaging, honest and compassionate, this film dispels the myths and questions the stigma attached to mental illness, while offering a very human portrait of coping.

Winner, National Health Information Bronze Award.
In this Videotape, Bonnie talks with social worker Andrea Blodgett about the experience of having schizophrenia and what she has learned about coping with this illness. The discussions include the reality of the voices, the need to trust people, checking one's own perceptions and accepting the illness as part of recovery. Bonnie, her parents and Andrea discuss the role of medications, and they try to answer the question, "How much can one expect?" Finally, they explore the nature of recovery and the importance of not giving up hope. Bonnie is a delightful young woman who suffers from paranoid schizophrenia. The love that she and her family members share is clearly apparent in their frank and respectful discussions of their individual perspectives. Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

In this Videotape, Bonnie talks with social worker Andrea Blodgett about the experience of having schizophrenia and what she has learned about coping with this illness. The discussions include the reality of the voices, the need to trust people, checking one's own perceptions and accepting the illness as part of recovery. Bonnie, her parents and Andrea discuss the role of medications, and they try to answer the question, "How much can one expect?" Finally, they explore the nature of recovery and the importance of not giving up hope. Bonnie is a delightful young woman who suffers from paranoid schizophrenia. The love that she and her family members share is clearly apparent in their frank and respectful discussions of their individual perspectives. Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie, her parents and Andrea discuss the role of medications, and they try to answer the question, "How much can one expect?" Finally, they explore the nature of recovery and the importance of not giving up hope. Bonnie is a delightful young woman who suffers from paranoid schizophrenia. The love that she and her family members share is clearly apparent in their frank and respectful discussions of their individual perspectives. Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.

Bonnie's struggle to recover offers a model of hope for patients, families and professionals. Her ability to articulate her feelings and thoughts opens a window to how it feels to have this dreadful disease. It is instructive as well to listen to Bonnie's sister describe her own reactions to the illness that took up so much of her family's emotional energy for so long. Since the completion of taping, Bonnie has graduated from college with a degree in psychology and found full-time employment as a counselor.
Ma Vie en Rose is the first cinematic exploration of gender identity in young children. It is about Ludovic, a 7-year-old French boy who is convinced he is meant to be a girl. The Belgian-born director, Alain Berliner, was present to introduce the film at its Boston Film Festival premiere. He modestly informed us that this was his first full-length feature, as it was for all of the other principals on the production side. And then, with a sense of moral urgency unusual in filmmakers, he said that he had concluded that a film like this needed to be made. Many in Hollywood might share his sentiments, but it is unlikely that such a film could have been made in our bottom-line America. Producer Carole Scotta selected the story (by Chris Vander Stappens) and chose Berliner to direct it because she saw “son audace et sa poésie” as indispensable for realizing the story’s fragile nature. By film industry standards, Scotta’s audacity in producing the film is even more impressive. Ma Vie en Rose has no action, no violence, no romance, no aliens and no natural disasters; not even a recognizable star. It is certainly no comedy and, though it is a film about children, many conventional parents will not want their children to see it. In sum, it has no targeted audience. Yet in a world that genuinely prized and did not just tolerate difference, this film would have been made by Disney. It marks a new, truthful departure in cinematic understanding of difference in human sexuality and gender identity in children. Gay and lesbian themes are now commonplace in films, and audiences seem to take them in stride. It is difficult to know what to make of this. Are we now more tolerant, more empathic, more able to respond emotionally to the gay and lesbian erotica? Or is it that audiences, though more tolerant, have also become as inured to these images as they have to violence? Film has the capacity to deepen and purify the emotions or deaden the sensibilities. The outcome depends on both the filmmaker and his audience. Gay issues pose problems for both.

Discussants: Lawrence Hartmann, M.D., Mary E. Schwab-Stone, M.D., Richard C. Friedman, M.D.

MEDIA SESSION 10 2:00 p.m.-5:00 p.m.
Rooms 12/13/14, Meeting Room Level, Renaissance Washington
HANDS-ON WEB WORK
APA Committee on Information Systems
Chp.: Bertram Warren, M.D.
Presenters: Thomas A.M. Kramer, M.D., Sol Herman, M.D., Steven E. Hyler, M.D.

Presentations and materials will include introduction to Windows technology, Web history and design, and navigation of the Web, specifically including APA’s site. Information will be presented in a hands-on format and will include: how to use the Windows environment; exercises to become familiar with a mouse (for the beginning sections); how to use the Web navigation tools; and how to find the information you want when you don’t know exactly who or what you are looking for. Skill development will include: how to familiarize yourself with the Web environment; how to find useful sites using search engines; how to find a site again that you like; how to handle searches that are taking too long; how to respond when you get error messages (e.g., can’t find this server); how to set preferences and how to download and print from the Web.

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Rooms 13/14, Lower Level, Convention Center
CLINICAL AND THERAPEUTIC APPROACH TO BIPOLAR DEPRESSION
Chp.: Russell T. Joffe, M.D.
A Bipolar I Versus Bipolar II Depression: Contrast with Unipolar
Hagop S. Akiskal, M.D.
B Biological Basis of Bipolar and Unipolar Disorder
L. Trevor Young, M.D., Glenda M. MacQueen, M.D., Jun-Feng Wang, M.D.
MONDAY

C Anticonvulsants for Treatment of Bipolar Depression
Gary S. Sachs, M.D.

D Antidepressants Versus Mood Stabilizers in the Treatment of Bipolar Depression
Russell T. Joffe, M.D., L. Trevor Young, M.D., Janine Robb, R.N.,
Glenda M. MacQueen, M.D., Irene Patellis-Siotis, M.D.

E ECT in Bipolar Disorder
Charles H. Kellner, M.D.

Discussant: Robert M. Post, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2  2:00 p.m.-5:00 p.m.
Room 15, Lower Level, Convention Center

PSYCHIATRIC DIAGNOSIS IN DIVERSE POPULATIONS

Cultural Issues and the Diagnosis of Blacks
Michelle O. Clark, M.D.

C Spirituality and Mystical Experience in Psychiatric Presentation
Elizabeth F. Targ, M.D.

D Cultural Issues in the DSM-IV
Francis G. Lu, M.D.

E Allocating Care Among Diverse Patient Groups
Jodi L. Halpern, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3  2:00 p.m.-5:00 p.m.
Room 20, Lower Level, Convention Center

SUBSTANCE ABUSE: DEVELOPMENTS FOR THE PRACTITIONER
American Academy of Addiction Psychiatry

Chp.: Marc Galanter, M.D.
Co-Chp.: Thomas R. Kosten, M.D.

A Managing the Dually-Diagnosed Patient
Kathleen T. Brady, M.D.

B New Treatments for Smokers
John R. Hughes, M.D.

C Rapid Opioid Detoxification
Thomas R. Kosten, M.D.

D Office-Based Substitution Treatment in Europe
Michael Krausz, Ph.D.

Discussants: Richard N. Rosenthal, M.D., Edward Gottheil, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4  2:00 p.m.-5:00 p.m.
Rooms 21/22, Lower Level, Convention Center

NEW DEVELOPMENTS IN INTERPERSONAL PSYCHOTHERAPY

Chp.: John C. Markowitz, M.D.

A Interpersonal Psychotherapy for PTSD Following Interpersonal Trauma
Janice L. Krupnick, Ph.D., Bonnie L. Green, Ph.D., Jeanne Miranda, Ph.D.

B Interpersonal and Social Rhythm Therapy: A Modification for Bipolar Disorder
Ellen Frank, Ph.D., David J. Kupfer, M.D., Holly A. Swartz, M.D.,
Steve Carter, Ph.D., Debra N. Frankel, A.C.S.W., Patricia R. Houck, M.S.H.

C Interpersonal Psychotherapy with BPD
Laurie A. Gillies, Ph.D., Jacqui B. Brunshaw, M.C., Adrienne T. Chin, B.A.

D Interpersonal Psychotherapy for Dysthymic Disorder
John C. Markowitz, M.D., James H. Kocsis, M.D., Nina L.
Miller, Ph.D., Kathleen F. Clougherty, M.S.W.

E SPECT Changes with Interpersonal Psychotherapy Versus Venlafaxine for Depression
Stephen D. Martin, M.B., Santock S. Rai, M.B., Elizabeth Martin, B.Sc., Mark Richardson, B.Sc., Anna Barnes, B.Sc.,
Robert Royal, B.Sc., Julia Davies, B.Sc.
Discussant: Myrna M. Weissman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5  2:00 p.m.-5:00 p.m.
Room 29, Lower Level, Convention Center

THE ROLE OF PSYCHOTHERAPY IN TODAY'S PSYCHIATRY

Chp.: Paul Chodoff, M.D.

A Psychotherapy: From Fifty Years Ago to Now
Paul Chodoff, M.D.

B Interpersonal Therapeutics for Schizophrenia
William T. Carpenter, Jr., M.D.

C Psychotherapies for Nonpsychotic Disorders
Arnold M. Cooper, M.D., Barbara L. Milrod, M.D.

D Psychotherapy of Personality Disorders
Glen O. Gabbard, M.D.
Discussants: Robert Michels, M.D., Sydney Bloch, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.
Room 33, Lower Level, Convention Center

LIFE CYCLE: THE PSYCHOANALYTIC PERSPECTIVES
American Psychoanalytic Association and American Academy of Psychoanalysis

Chp.: Douglas H. Ingram, M.D.
Co-Chp.: Miriam F. Tasini, M.D.

A Juvenile Precursors of Character Disorders
Clarice J. Kestenbaum, M.D.

B Young Adults with Personality Disorders
Eric R. Marcus, M.D.

C Women's Internal and External Conflicts About Careers
Jean B. Miller, M.D.

D On Falling in Love: A Psychoanalytic and Phenomenologic Study
Richard D. Chessick, M.D.

E Character Pathology and Mid-Life Crisis
Steven T. Levy, M.D.

F The Resonant Relevancy of Infancy to Old Age
Stanley H. Cath, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.
Conference Theatre, Level 1B, Grand Hyatt

PRACTICING AND MEASURING QUALITY CARE FOR SCHIZOPHRENIA

Chp.: John S. McIntyre, M.D.
Co-Chp.: Harold Alan Pincus, M.D.

A The Use of Measures in Clinical Care
Diana O. Perkins, M.D.

B What's Really Going On in the Treatment of Schizophrenia?
Phillip S. Wang, M.D., Joyce C. West, M.P.P., Deborah A. Zarin, M.D., Harold Alan Pincus, M.D.

C Schizophrenia and Practice Guidelines
John S. McIntyre, M.D.

D Does Treatment for Schizophrenia Conform with Practice Guidelines?
Joyce C. West, M.P.P., Deborah A. Zarin, M.D., Phillip S. Wang, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

DR. KARL KAHLBAUM'S CENTENNIAL SYMPOSIUM ON CATATONIA

Chp.: Andrew J. Francis, Jr., M.D.
Co-Chp.: Peter Braunig, M.D.

A Life and Work of Dr. Karl Ludwig Kahlbaum
Peter Braunig, M.D., Stephanie Kruger, M.D.

B Dr. Karl Kahlbaum's Catatonia Revisited
Brendan T. Carroll, M.D.

C SPECT, fMRI and Magnetoencephalographics in Catatonia: Pathophysiology and Mechanisms
Georg Northoff, M.D.

D Catatonic Subtypes and Relation to Other Motor Syndromes
Andrew J. Francis, Jr., M.D.

Discussant: Gregory L. Fricchione, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

COLLECTIVE APPROACHES TO THE CONTROL OF AFFECTIVE DISORDERS

Chp.: Eduardo R. Val, M.D.
Co-Chp.: Itzhak Levav, M.D.

A Treatment of Affective Disorders: Contributions from Services Research
Kathryn M. Magruder, Ph.D.

B Suicide in the Countries of Central and Eastern Europe
Norman Sartorius, M.D.

C Affective Disorders and Primary Care in England
Rachel Jenkins, M.D.

D Initiative on Affective Disorders at the Pan American Health Organization and the World Health Organization
Ivan D. Montoya, M.D., Itzhak Levav, M.D.

Discussants: Leon Eisenberg, M.D., Juan J. López-Ibor, Jr., Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Independence Ballrooms B/C, Level 5B, Grand Hyatt

GENETIC DISSECTION OF THE NERVOUS SYSTEM AND ITS DISORDERS
Collaborative Session with the National Institute of Mental Health

Chp.: Steven O. Moldin, Ph.D.

A Genetic Dissection of the Nervous System and Its Disorders
Aravinda Chakravarti

B Neurogenetic Pathways in Alzheimer's Disease
Rudolph E. Tanzi, Ph.D.

(Continued on next page)
C Genetic Dissection of Complex Behaviors in the Mouse  
Maja Bucan, Ph.D.

D Molecular Genetic Studies of Autistic Disorder  
Edwin H. Cook, Jr., M.D.

E Genetics in a Post-Genomics Era: Applications to Pharmacogenetics  
Geoffrey Duyk, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.  
Independence Ballrooms Die, Level 5B, Grand Hyatt

CHILDHOOD PRECURSORS OF PERSONALITY DISORDERS

Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A Follow-Up Studies of Childhood and Adult Personality Disorders  
Joel F. Paris, M.D.

B Childhood Temperament, Environment and Adult Personality Disorders  
Patricia Cohen, Ph.D., Jeffrey G. Johnson, Ph.D., Stephanie Kasen, Ph.D.

C The Course, Biology and Social Correlates of Conduct Disorder  
Daniel S. Pine, M.D.

D Personality and Proximal Processes  
Stephen J. Donovan, M.D.

E Behavioral Inhibition in Children at Risk for Anxiety Disorders  
Dina R. Hirshfeld, Ph.D., Jerrold F. Rosenbaum, M.D., Joseph Biederman, M.D., Stephen V. Faraone, Ph.D., Jerome Kagan, Ph.D., Nancy Snidman, Ph.D.

Discussant: George E. Vaillant, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.  
Independence Ballrooms F/G, Level 5B, Grand Hyatt

SOMATOFORM DISSOCIATION AND TRAUMA

Chp.: David Spiegel, M.D.

A Somatoform Dissociation in Veterans and Emergency Service Workers  
Charles R. Marmar, M.D., Daniel S. Weiss, Ph.D., Thomas Metzler, Suzanne Best, Alain Brunet, Kumar Vedantam

B Dissociation and Somatization Comparisons in Sexually Abused and Nonabused Girls  
Frank W. Putnam, Jr., M.D., Penny Trickett, Ph.D., Jennie Noll, Ph.D.

C Somatoform Dissociation and Sexual Trauma Predict Pseudo-Epileptic Seizures Better than Psychological Dissociation  
Richard Van Dyck, M.D., Jarl Kuyk, Drs., Philip Spinhoven, Ph.D., Walter V. Emden-Boas, M.D.

D Life Stress and Pain Among Metastatic Breast Cancer Patients  
David Spiegel, M.D., Cheryl Koopman, Ph.D., Lisa Butler, Ph.D., Susan Diamond, C.S.W., Karyn Angell, Ph.D.

E Detecting Somatoform Dissociation in Trauma Survivors Using the SCID-D  
Marlene Steinberg, M.D., Dominic Cicchetti, Ph.D., Bruce J. Rounsaville, M.D.

Discussant: Gary M. Rodin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.  
Independence Ballrooms H/I, Level 5B, Grand Hyatt

SMOKING CESSATION: A NEW FRONTIER

Chp.: Alexander H. Glassman, M.D.
Co-Chp.: Herbert D. Kleber, M.D.

A Smoking Cessation and the Psychiatrist  
Herbert D. Kleber, M.D.

B Conditioning, Drug-Seeking and Addiction  
Barry J. Everitt, Ph.D.

C Cigarette Smoking, Nicotine and Schizophrenia  
Gregory W. Dalack, M.D., James H. Meador-Woodruff, M.D.

D Smoking, Smoking Cessation and Major Depression  
Linio Covey, Ph.D., Alexander H. Glassman, M.D., Fay Stetner, M.P.A.

E Do Treatments for Smoking Cessation Work?  
Alexander H. Glassman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.  
Lafayette Park Room, Level 5B, Grand Hyatt

THE ROLE OF PSYCHIATRISTS IN PALLIATIVE CARE  
Association for Academic Psychiatry

Chp.: Philip R. Muskin, M.D.

A Palliative Care and Medical Education  
Susan D. Block, M.D.

B Psychopharmacology of Palliative Care: What Psychiatrists Must Know  
William Breitbart, M.D.
C Views of Oregon Patients and Their Caregivers on Assisted Suicide
Linda K. Ganzini, M.D., Wendy S. Johnston, M.D.

D Understanding and Teaching the Psychodynamics of Physician-Assisted Suicide
Philip R. Muskin, M.D.

Discussant: Diane E. Meier, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 17
2:00 p.m.-5:00 p.m.
London Room, Ballroom Level, Marriott Metro Center

Cultural Aspects of Psychiatric Practice Across the Americas
Inter American Council of Psychiatric Organizations

Chp.: Carlos Leon-Andrade, M.D.
Co-Chp.: Renato D. Alarcon, M.D.

A Culture and Hispanic Mental Health in the USA
Renato D. Alarcon, M.D.

B Rural and Community Psychiatry in Latin America
Carlos Leon-Andrade, M.D., Roberto E. Chaskel, M.D.

C Symptoms As Cultural Manifestations: A Caribbean Perspective
Sharon C. Harvey, M.D.

D Public Psychiatric Hospital Practice in Argentina
Alberto J. Monchablon, M.D., Nestor F. Marchant, M.D.

E Forensic Psychiatry in Latin America: The Venezuelan Experience
Ruben J. Hernandez-Serrano, M.D., Antonio Pacheco-Hernandez, M.D.

Discussants: Pedro Ruiz, M.D., Rodolfo D. Fahrer, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 18
2:00 p.m.-5:00 p.m.
Paris Room, Ballroom Level, Marriott Metro Center

Violence and Mental Illness

Chp.: Paul S. Appelbaum, M.D.

A Delusions and Violence
Paul S. Appelbaum, M.D.

B Violent Fantasies, Violent Behavior and Mental Illnesses
Jeffrey J. Davis, Ph.D., Thomas Grisso, Ph.D.

C Women, Mental Disorder and Violence
Pamela C. Robbins, John Monahan, Ph.D.

D Neighborhood Conditions and Patient Violence: An Ecological Approach
Eric Silver, Ph.D.

Discussant: John R. Lion, M.D.
THIS SESSION WILL BE AUDIOTAPE.
MONDAY

3:00 p.m. Session

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 4
3:00 p.m.-5:00 p.m.
Hall D, Lower Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:30 p.m. Session

CONVOCATION OF FELLOWS
7:30 p.m.
Hall C, Upper Level, Convention Center

All Fellows, members and registered guests are invited.

Presiding: Rodrigo A. Muñoz, M.D., President

Grand Marshals: Edward C. Kirby, Jr., M.D., Jonas R. Rappeport, M.D.

Marshals: Fred G. Hiltert, M.D., Andrew B. Molcho, M.D.

INTRODUCTION OF LIFE FELLOWS
Allan Tasman, M.D., President-Elect

INDUCTION OF FELLOWS
Allan Tasman, M.D.

INTRODUCTION OF FIFTY-YEAR FELLOWS, LIFE MEMBERS, INTERNATIONAL FELLOWS, DISTINGUISHED FELLOWS, AND HONORARY FELLOW
Rodrigo A. Muñoz, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS
Rodrigo A. Muñoz, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS
Rodrigo A. Muñoz, M.D.

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
W. Walter Menninger, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARDD CHAIRPERSONS
Rodrigo A. Muñoz, M.D.

PRESENTATION OF AWARDS
Rodrigo A. Muñoz, M.D.

APA Award for Research in Psychiatry
APA/Lilly Resident Research Awards
Award for Patient Advocacy
Human Rights Award
Blanche F. Littleton Award for Research in Child Psychiatry
Kemp Fund Awards for Research Development in Psychobiological Psychiatry
Agnes Purcell McGavin Award
Robert T. Morse Writers Awards
Isaac Ray Award
Robert L. Robinson Awards
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL LECTURE
W. Walter Menninger, M.D.

W. Walter Menninger, M.D., is Chief Executive Officer of the Menninger Foundation, a non-profit center for treatment, education, research and prevention in psychiatry, founded in 1929 by his grandfather (Dr. C.F.), uncle (Dr. Karl), and father (Dr. Will). A Life Fellow of the American Psychiatric Association, he has worked in both the private and public mental health sector and in the federal prison system. He has had an extensive career in psychiatric administration and forensic psychiatry. In 1968, he was appointed by President Lyndon Johnson to be a member of the National Commission on the Causes and Prevention of Violence. He was elected to the Institute of medicine of the National Academy of Sciences in 1972, and he has received honorary degrees from Middlebury College, Washburn University, Ottawa University, and Heidelberg College. He has written extensively for both professional and lay audiences, authoring 10 books, pamphlets or monographs, 10 book chapters, more than 100 journal articles, and nearly 1,000 newspaper columns. Dr. Menninger received his undergraduate degree from Stanford University, and his medical degree from Cornell University Medical School.

Five Minute Intermission

Performance by the Capitol Steps
Musical Political Satire
Performance by the Capitol Steps
Musical Political Satire

The Capitol Steps are a politically correct, hygienic, bipartisan troupe of current and former Congressional staffers, of whom five (plus a pianist) perform at any one show. The group began in 1981, at a Christmas party in the office of the former United States Senator Charles Percy. Like most things in Congress, they never know when to stop. Over the past sixteen years, the Steps have recorded seventeen albums, and appeared on "Good Morning America," "The Today Show," "20/20," "Entertainment Tonight," and "The Late Show." They've had dozens of songs on National Public Radio's "All Things Considered," done national radio shows produced by KCRW, and appeared in their own specials for public television. They've been regularly featured on CNN's "Inside Politics," and, most recently, Off-Broadway.

A Capitol Steps song parody starts long ago, and far away, where some other performer sings a perfectly good melody with words that have nothing to do with Bill Clinton's saxophone skills, Newt Gingrich's haircut, or anything else truly important. Then something funny has to happen (it always does). Typically the Republicans goof up and the Democrats party. Or the Democrats goof up and the Republicans party. That's what we call the two party system.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for the 1999 Annual Meeting...

Live recordings will be available for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Convention Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Webside: www.mobiltape.com
7:00 a.m. Sessions

PART II OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 19-23

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 19, PART II
7:00 a.m.-8:30 a.m.
Constitution Ballroom, Level 3B, Grand Hyatt

ANXIETY AND DEPRESSION: CAUSE OR EFFECT?
Supported by Wyeth-Ayerst Laboratories

Chp.: R. Bruce Lydiard, M.D.

A  Impact of Depression on the Course of Anxiety Disorders
   Jane L. Eisen, M.D., Martin B. Keller, M.D., Robert Stout, Ph.D.

B  Anxious Depression: Clinical Characteristics and Treatment Options
   James C. Ballenger, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 20, PART II
7:00 a.m.-8:30 a.m.
Independence Ballroom, Level 5B, Grand Hyatt

NEW CLINICAL ADVANCES IN MANAGING ANXIETY AND DEPRESSIVE DISORDERS THROUGHOUT THE LIFE CYCLE
Supported by Bristol-Myers Squibb

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A  Emerging Clinical Strategies for Comprehensive Treatment of PTSD
   Thomas A. Mellon, M.D.

B  New Advances in the Treatment of Panic Disorder
   Justine M. Kent, M.D., Laszlo A. Papp, M.D., Jeremy D. Coplan, M.D., Jack M. Gorman, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 21, PART II
7:00 a.m.-8:30 a.m.
Presidential Ballroom, Second Floor, Capital Hilton

BEYOND EFFICACY IN PSYCHOSIS: PATIENT SATISFACTION, COMPLIANCE AND OUTCOMES
Supported by Zeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Laurie M. Flynn

A  Hyperprolactinemia and Sexual Dysfunction: Relationship to Patient Satisfaction and Adherence
   Lili C. Kopala, M.D.

B  Involving the Caregiver to Optimize Outcomes in Psychosis
   Laurie M. Flynn

8:00 a.m. Sessions

COURSES 51-58
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 51 8:00 a.m.-12 noon
Room 5, Meeting Room Level, Renaissance Washington

WRITING ABOUT CLINICAL EXPERIENCES

Director: John S. Strauss, M.D.

COURSE 52 8:00 a.m.-12 noon
Rooms 8/9, Meeting Room Level, Renaissance Washington

PATHOLOGICAL GAMBLING

Co-Directors: James R. Westphal, M.D., Jill A. Rush, M.D.
Faculty: Lee Stevens, M.D.
COURSE 53 8:00 a.m.-12 noon
Room 16, Meeting Room Level, Renaissance Washington
DOING RESEARCH ON A SHOESTRING BUDGET
Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 54 8:00 a.m.-12 noon
Congressional Hall A, Ballroom Level, Renaissance Washington
ADVANCED ASSESSMENT AND TREATMENT OF ADD
Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

COURSE 55 8:00 a.m.-12 noon
Congressional Room, Second Floor, Capital Hilton
ANTICONVULSANTS IN ADULT PSYCHIATRY
Co-Directors: Joseph R. Calabrese, M.D., Russell T. Joffe, M.D.
Faculty: Mark A. Frye, M.D., Terence A. Kelter, M.D., Gary S. Sachs, M.D.

COURSE 56 8:00 a.m.-12 noon
Federal Room A, Second Floor, Capital Hilton
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 57 8:00 a.m.-12 noon
Massachusetts Room, Second Floor, Capital Hilton
DELIRIUM IN THE GENERAL HOSPITAL
Director: Peter J. Manos, M.D.
Faculty: Edwin H. Cassem, M.D., Frank Adams, M.D., J. Hampton Atkinson, Jr., M.D.

COURSE 58 8:00 a.m.-12 noon
Senate Room, Second Floor, Capital Hilton
UNDERSTANDING AND MANAGING CHRONIC INSOMNIA
Director: Jack D. Edinger, Ph.D.
Faculty: Daniel J. Buysse, M.D., W. Vaughn McCall, M.D.

9:00 a.m. Sessions

AIDS EDUCATION PROGRAM 1
9:00 a.m.-12 noon
Room 38, Upper Level, Convention Center
CLINICAL AND NEUROPSYCHIATRIC DIMENSIONS OF HIV DISEASE
APA Commission on AIDS

COURSE 59 9:00 a.m.-4:00 p.m.
Room 5, Meeting Room Level, Renaissance Washington
PERSONNEL MANAGEMENT FOR CLINICIAN/MANAGERS
Director: Stephen M. Soltys, M.D.
Faculty: William Noyes, M.P.A., Joseph J. Parks III, M.D., Roberta Gardine, M.P.A., Brenda Ratliff, M.D., Mark Binkley, J.D.
TUESDAY

COURSE 60  9:00 a.m.-4:00 p.m.
Room 7, Meeting Room Level, Renaissance Washington

THE ASSESSMENT AND TREATMENT OF CHILD MOLESTERS

Director: John M.W. Bradford, M.B.
Faculty: Gene G. Abel, M.D., David M. Greenberg, M.B.

COURSE 61  9:00 a.m.-4:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington

INTEGRATIVE COUPLE THERAPY: SKILLS AND TECHNIQUES

Co-Directors: Lois S. Slovik, M.D., James L. Griffith, M.D.

COURSE 62  9:00 a.m.-4:00 p.m.
California Room, Second Floor, Capital Hilton

PERSONALITY AND POLITICAL BEHAVIOR
International Society for Political Psychology

Director: Jerrold M. Post, M.D.

COURSE 63  9:00 a.m.-4:00 p.m.
Federal Room B, Second Floor, Capital Hilton

DEMENTIA: ADVANCED DIAGNOSIS AND TREATMENT

Director: William E. Reichman, M.D.
Faculty: Jeffrey L. Cummings, M.D., David L. Sultzer, M.D.,
Jacobo E. Mintzer, M.D., Peter M. Aupperle, M.D.

COURSE 64  9:00 a.m.-4:00 p.m.
Pan American Room, Second Floor, Capital Hilton

RATIONAL USE OF HORMONE-REPLACEMENT THERAPY IN
POSTMENOPAUSAL WOMEN

Director: Marjorie L. Shuer, M.D.
Faculty: Joel T. Hargrove, M.D., Y.W. Francis Lam, Pharm.D.

COURSE 65  9:00 a.m.-4:00 p.m.
South American Room A, Second Floor, Capital Hilton

RAPID SINGLE-SESSION ASSESSMENT IN THE AGE OF
MANAGED CARE

Director: Shawn C. Shea, M.D.

DISCUSSION GROUP 4

9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Gabriela Cora-Locatelli, M.D., on Surviving the Boards (For Residents Only)
Washington Room, Second Floor, Marriott Metro Center

LECTURES 8-9

LECTURE 8

9:00 a.m.-10:30 a.m.
Room 32, Lower Level, Convention Center

Herbert Pardes, M.D.

Psychiatry’s Shifting Foundation: Research Up, Reimbursement Down, Managed Care Challenged

Co-Chp.: Claire C. Holderness, M.D.

Psychiatry has come a long way from the first half of the 20th Century when it focused on inpatient care, heavy use of state hospitals and psychoanalytic treatment, but gave scant attention to diagnosis and psychopharmacology. From the 1950s through the late 1990s waves of interest include deinstitutionalization, community mental health, development of the DSM, psychopharmacology and neuroscience. Herbert Pardes, M.D., traces the evolution of psychiatry, examines trends in research that are likely to influence psychiatry and offers a template for psychiatry’s going forward. Dr. Pardes is Vice President for Health Sciences, Dean of the Faculty of Medicine and Lawrence C. Kolb Professor and Chairman of the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University in New York City. From 1978 to 1984 he was Director of the National Institute of Mental Health. He has served as president of the American Psychiatric Association and of the American Association of Chairmen of Departments of Psychiatry. He is a member of the Editorial Board of several journals, including the Journal of Nervous and Mental Disease, Community Mental Health Journal and the Journal of Child and Adolescent Psychiatry. He has received the Distinguished Service Award from the National Alliance for Mental Illness, the Scientific Research Leadership Award from the National Alliance for Research on Schizophrenia and Depression and the Seymour D. Vesterman Award for Psychiatric Education and the Distinguished Service Award from the American Psychiatric Association. He received his medical degree from the State University of New York College of Medicine and completed his psychiatric residency at Kings County Hospital, both in Brooklyn, New York. He received his psychoanalytic training at the New York Psychoanalytic Institute.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.
MASTER EDUCATOR CLINICAL CONSULTATIONS 5-7

9:00 a.m.-10:30 a.m.
Room 33, Lower Level, Convention Center

Steven E. Hyman, M.D.
How Neuroscience Continues to Change Psychiatry
Collaborative Session with the National Institute of Mental Health

Chp.: Carol A. Tamminga, M.D.
Co-Chp.: Ilise D. Lomardo, M.D.

Neuroscience is fundamentally altering our concepts of mental illness and holds promise of providing improved treatments and eventually preventive strategies. Steven E. Hyman, M.D., Director of the National Institute of Mental Health (NIMH), discusses current neuroscience approaches to the study of mental illness, including genetics, molecular and cellular neuroscience and cognitive and integrative neuroscience, and examines the challenges psychiatry faces in incorporating these approaches into its practice. Under Dr. Hyman's leadership, NIMH has been reorganized to orient basic science research around the Institute's clinical and public health mission, emphasizing effective use of technologies and rapid clinical application of new knowledge. At Harvard Medical School, Dr. Hyman was Professor of Psychiatry and Director of the Interfaculty Initiative in Mind, Brain and Behavior, a program focused on clinical and policy issues surrounding brain research. He has received several awards for his contributions to research, including the Nancy Pritzker Award for his work on mood disorders. In addition to his scientific writings, Dr. Hyman has authored and edited several basic and clinical textbooks. Dr. Hyman received his medical degree from Harvard Medical School, completed his psychiatric residency at McLean Hospital and was a clinical fellow in neuropsychiatry at Massachusetts General Hospital in Boston, where he also received postdoctoral training in molecular biology. Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

6 Robert Cancro, M.D., on Office Management of Schizophrenic Disorders
New York Room, Ballroom Level, Marriott Metro Center

7 Max Fink, M.D. and C. Edward Coffey, M.D., on Contemporary Practice of ECT
Montreal Room, Second Floor, Marriott Metro Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 11-13

MEDIA SESSION 11
9:00 a.m.-11:00 a.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

MULTICULTURAL WOMEN'S PERSPECTIVES ON DIVERSITY

Chp.: John Luo, M.D.

15 The Way Home
(92 minutes)

Distributor: World Trust
5920 San Pablo Avenue
Oakland, CA 94608

World Trust is a nonprofit organization that in 1994 launched Heart-to-Heart Conversations, a national program of public dialogue designed to help people share deep feelings about race and culture. Through these conversations, participants are encouraged to look deeply within themselves, to discover and recognize their embedded assumptions, and to challenge them as part of the process of transformation. In 1996, World Trust initiated The Women's Video Project. Over the course of eight months, 64 women, representing a cross-section of cultures in America, came together to share their experiences of oppression through the lens of race. Separated into eight ethnic councils (Indigenous, African American, Arab, Asian, European American, Jewish, Latina, and multiracial), the women explore their stories of identity, oppression and resistance. It is the intention of World Trust to use this video as a catalyst for powerful learning, healing and transformation.

MEDIA SESSION 12
9:00 a.m.-12 noon
Congressional Hall B, Ballroom Level, Renaissance Washington

USING COMPUTERS FOR MEDICAL RECORDS AND TREATMENT PLANNING

Chp.: Steven E. Hyler, M.D.

16 Computerizing Medical Records for a Large Outpatient Division
Steven E. Hyler, M.D.

The acute outpatient division of the St. Luke's-Roosevelt Hospital Medical Center covers much of the west side of Manhattan in New
York City. The clinic includes an access center for all new evaluations, an outpatient center for ongoing treatment, and a transitional day hospital. There are more than 1,200 patients who are treated there by at least 50 different clinicians. Each week over 20 new patients are evaluated and referred for treatment. The amount of paperwork generated by the clinic to clinically manage the patients, keep track of staff activity, satisfy government agencies, third party payers and managed care organizations, ensure accreditation by JCAHO, etc., is overwhelming. This presentation will focus on the implementation of a new computerized medical records system at the clinic from the perspective of: 1) the department chairman; 2) the chief financial officer; 3) the clinic director; and 4) the clinician. This presentation will include a demonstration of the TIER system, by Sequest Technologies, which was chosen by the medical center for the task of computerizing the medical records of the clinic at first, then the whole department.

17 Using An Access-Based Relational Database
James H. Grubbs, M.D.

Clinicians are under increasing pressure to better manage data. Computer-based databases provide clear advantages over paper-based records. However, using several databases (i.e., one each for clinical, financial and outcome data, etc.) can be costly in terms of both time and money. Relational databases which are integrated internally and can be connected to applications outside the database itself, such as word processing and analytical programs, are powerful tools used to streamline the capturing of data in a non-redundant way, allowing them to be used productively. Microsoft Access is a readily available relational database program that can be integrated with a number of other commercially available programs. When Access is packaged with Word and Excel it forms the basis of Microsoft Office. BIMS is a clinically useful relational database created out of Microsoft Office 97. This session will provide a thorough demonstration of BIMS, including all aspects of the applications. The applications will be demonstrated during the presentation. After the presentation, all audience members who desire one will receive a copy of BIMS via e-mail.

18 Computer-Assisted Assessment Psychotherapy Education and Research (CAPER) Treatment Planner
Peter F. Fore, M.D.

Development of written plans is a complex and time-consuming task for clinicians. Assuring that treatment plans are prepared according to Joint Commission on Accreditation of Healthcare Organizations (JCAHO) standards is a complex and time-consuming problem for administrators. The CAPER Treatment Planner, which is PC-based software that the clinician uses to generate individual treatment plans, eases these tasks. The clinician selects from a menu of pre-set phrases in four categories: 1) problems (diagnoses and behavioral manifestations); 2) long-term goals; 3) short-term goals; and 4) interventions. Each phrase can be edited by the clinician. The pre-set phrases can be modified by the system operator or the clinician. Efforts have been made to write the pre-set phrases to satisfy the JCAHO requirement for measurable goals. The system can run on an individual personal computer or a network. It is highly customizable and can be used for both inpatients and outpatients. A large urban VA medical center has recently satisfied JCAHO standards with this system. This medical center integrated the PC-generated plans with the VA's computer system (DHCP) by uploading the plans to the VA's computer system for permanent storage and wide access in patients' electronic records.

MEDIA SESSION 13  9:00 a.m.-11:00 a.m.
Auditorium, Meeting Room Level, Renaissance Washington

FILM AND HEALING: MAYA, COMPASSION AND I - THOU IN CHAPLIN'S CITY LIGHTS

Chp.: Francis G. Lu, M.D.

City Lights is Charlie Chaplin's great masterpiece about the power of courage and compassion in the healing process. It tells the story of a tramp's love for a blind flower girl, whose sight he eventually restores. Yet in one of the cinema's greatest moments, the heart of compassion emerges from the veils of illusionary daily life to show the power of caring and gratitude. The laser disc version to be shown will bring together an archive print with a 1992 re-recording of the original soundtrack by Chaplin.

NEW RESEARCH ORAL/SLIDE SESSIONS 5-6
9:00 a.m.-10:30 a.m.

5 SCHIZOPHRENIA
Rooms 23/24, Lower Level, Convention Center

6 PERSONALITY DISORDERS AND STRESS
Rooms 25/26, Lower Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

RESEARCH ADVANCES IN MEDICINE
9:00 a.m.-11:00 a.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

RESEARCH ADVANCES IN HERBAL AND ALTERNATIVE MEDICINE: BIOLOGICAL AND CLINICAL EFFECTS

Chp.: Philip R. Muskin, M.D.
Participants: Jonathan R.T. Davidson, M.D., on St. John's Wort: Should We Be Using It for Depression?
Richard P. Brown, M.D., on Overlooked Psychotropics: Herbs and Nutrients for the Year 2000
Catherine Crone, M.D., on Herbal Medicine: A Consultation-Liaison Psychiatry Perspective on Usage Patterns, Benefits and Complications

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

REVIEW OF PSYCHIATRY: PART II
9:00 a.m.-12:30 p.m.
Rooms 30/31, Lower Level, Convention Center

MALE PSYCHOSEXUALITY
Chp.: Richard C. Friedman, M.D.
Co-Chp.: Jennifer I. Downey, M.D.

6 Male Sexual Fantasy and Behavior: Selected Clinical Issues
Richard C. Friedman, M.D.

7 Male Heterosexuality
Stephen B. Levine, M.D.

8 The Evaluation and Treatment of Erectile Dysfunction
Stanley E. Althof, Ph.D., Allen D. Seftel, M.D.

9 Casualties of Recovered Memory Therapy: The Impact of False Allegations of Incest on Accused Fathers
Harold I. Lief, M.D., Janet M. Feltkewicz, B.A.

10 Fatherhood As a Transformation of the Self: Toward a New Psychology of Boys and Men
William S. Pollack, Ph.D.

WORKSHOPS

COMPONENTS 19-27

COMPONENT WORKSHOP 19 9:00 a.m.-10:30 a.m.
Rooms 13/14, Lower Level, Convention Center

LEGAL UPDATE: MANAGED CARE, PRIVACY AND SEX OFFENDERS
APA Council on Psychiatry and Law and APA Commission on Judicial Action
Chp.: Renee L. Binder, M.D.
Participants: J. Richard Ciccone, M.D., Paul S. Appelbaum, M.D., Howard V. Zonana, M.D.

COMPONENT WORKSHOP 20 9:00 a.m.-10:30 a.m.
Room 15, Lower Level, Convention Center

MAKING ORDER OUT OF CHAOS: RESIDENTS AND INSTITUTIONS
APA Committee of Residents and Fellows
Chp.: Derek G. Puddester, M.D.
Participants: Lori Simon, M.D., Geoffrey M. Gabriel, M.D., Tracey L. Irvin, M.D., Julie Holman, M.D.

COMPONENT WORKSHOP 21 9:00 a.m.-10:30 a.m.
Room 20, Lower Level, Convention Center

TASK FORCE ON QUALITY INDICATORS: STATUS REPORT
APA Task Force on Quality Indicators
Co-Chps.: John M. Oldham, M.D., Deborah A. Zarin, M.D.
Participants: Harold Alan Pincus, M.D., Lloyd I. Sederer, M.D., Charles E. Riordan, M.D.

COMPONENT WORKSHOP 22 9:00 a.m.-10:30 a.m.
Room 28, Lower Level, Convention Center

FIRST IMPRESSIONS: ASSUMPTIONS EXPOSED
APA/CNTR for Mental Health Services Minority Fellowship and APAZenea Minority Fellowship
Co-Chps.: Petros Levounis, M.D., Evaristo O. Akerleie, M.D.
Participants: Yesh Dhaiber, M.D., Khanh-Trang T. Nguyen, M.D.

COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m.
Room 36, Lower Level, Convention Center

THE HEALING WAYS OF THE ANISHINABE OJIBWE PEOPLE
APA Committee of American Indian, Alaska Native and Native Hawaiian Psychiatrists
Co-Chps.: Robert C. Palmer, M.D., Blackwolf Jones, M.S.

COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m.
Conference Theatre, Level 1B, Grand Hyatt

MEDICATIONS IN ADDICTION THERAPY
APA Council on Addiction Psychiatry and American Academy of Addiction Psychiatry
Chp.: Sheldon I. Miller, M.D.
Participants: Thomas R. Kosten, M.D., Richard T. Suchinsky, M.D., James A. Halikas, M.D.

COMPONENT WORKSHOP 25 9:00 a.m.-10:30 a.m.
Bulfinch/Renwick Rooms, Level 3B, Grand Hyatt

LOST IN DIVERSITY MAINSTREAM
APA Committee of Black Psychiatrists
Co-Chps.: Michelle O. Clark, M.D., Sheryl D. Jones, M.D.
Participants: Chester M. Pierce, M.D., Patricia A. Newton, M.D., Mindy J. Fullilove, M.D.

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m.
Burnham Room, Level 3B, Grand Hyatt

SUBSTANCE ABUSE, VIOLENCE AND THE HISPANIC FAMILY
APA Committee of Hispanic Psychiatrists
Chp.: Silvia W. Olarte, M.D.
Participants: Eugenio M. Rothe, M.D., Ana E. Campo-Bowen, M.D., Manuel Trujillo, M.D., Oscar E. Perez, M.D.
TUESDAY

COMPONENT WORKSHOP 27
Latrobe Room, Level 3B, Grand Hyatt

TREATING HOMOSEXUALS: DO'S AND DONT'S
APA New York County District Branch's Committee on Gay and Lesbian Issues
Co-Chps.: Kenneth B. Ashley, M.D., John A. Gosling, M.D.
Participants: Richard O. Hire, M.D., Anand Pandya, M.D., Steven T. Wozniak, M.D., Michael Schneider, Psy.D., Ariel Shidlo, Ph.D.

ISSUES 16-24

ISSUE WORKSHOP 16
9:00 a.m.-10:30 a.m.
Rooms 21/22, Lower Level, Convention Center

CHILDREN OF PSYCHIATRIST PARENTS: PART II
Co-Chps.: Leah J. Dickstein, M.D., Michelle Riba, M.D.
Participants: Ann Rosenthal, Pauline Langsley, M.D., Marcelo L. Olarte, Steven G. Dickstein, B.A., Erica Riba, Lawrence Hartmann, M.D.

ISSUE WORKSHOP 17
9:00 a.m.-10:30 a.m.
Room 37, Lower Level, Convention Center

UNDERSTANDING THE DYNAMICS OF ABUSIVE RELATIONSHIPS
Chp.: Gary J. Maier, M.D.

ISSUE WORKSHOP 18
9:00 a.m.-10:30 a.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

GAY AND LESBIAN SUBSTANCE ABUSE TREATMENT: CULTURAL COMPETENCY TRAINING
Chp.: H. Levin, M.D.
Participant: Edwin Craft, D.Sc.

ISSUE WORKSHOP 19
9:00 a.m.-10:30 a.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

CLINICAL RESPONSES TO MANAGED HEALTH CARE
Chp.: Harold J. Bursztain, M.D.
Participants: Alan A. Stone, M.D., Bryant L. Welch, Ph.D., Patricia Illingworth, Ph.D., Rodney J.S. Deaton, M.D.

ISSUE WORKSHOP 20
9:00 a.m.-10:30 a.m.
Farragut Square Room, Level 5B, Grand Hyatt

THE INTERNATIONAL WAR CRIMES TRIBUNAL: PSYCHIATRY'S ROLE
Chp.: Landy F. Spar, M.D.
Participant: John F. Fergusson, M.Div.

ISSUE WORKSHOP 21
9:00 a.m.-10:30 a.m.
McPherson Square Room, Level 5B, Grand Hyatt

POEMS ON PSYCHIATRY
Chp.: Charles R. Joy, M.D.

ISSUE WORKSHOP 22
9:00 a.m.-10:30 a.m.
Grand Ballroom A, Ballroom Level, Marriott Metro Center

CLINICAL SKILLS ASSESSMENT AND PSYCHIATRY TRAINING
Chp.: Nyapati R. Rao, M.D.
Participant: Sidney H. Weissman, M.D.

ISSUE WORKSHOP 23
9:00 a.m.-10:30 a.m.
London Room, Ballroom Level, Marriott Metro Center

CASE FORMULATION: THREE ALTERNATIVE VIEWPOINTS
Chp.: Marcia J. Kaplan, M.D.
Participants: Lawson R. Wulsin, M.D., Toby D. Goldsmith, M.D.

ISSUE WORKSHOP 24
9:00 a.m.-10:30 a.m.
Paris Room, Ballroom Level, Marriott Metro Center

LEADERSHIP IN ORGANIZATIONAL TRANSITIONS
Chp.: Stewart Gabel, M.D.

11:00 a.m. Sessions

DISCUSSION GROUP 5
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.
David A. Goldberg, M.D., on Evidence-Based Medicine and Current Psychiatric Practice
Montreal Room, Second Floor, Marriott Metro Center

LECTURES 10-11

LECTURE 10
11:00 a.m.-12:30 p.m.
Room 32, Lower Level, Convention Center
Frank W. Putnam, Jr., M.D.
Childhood Maltreatment and Adverse Outcomes: A Prospective Developmental Approach
(Continued on next page)
TUESDAY

CHILDHOOD MAINTREATMENT: AN INCIDENCE OF MORE THAN ONE MILLION CASES A YEAR IS INCREASING/ASSOCIATED WITH A HOST OF NEGATIVE OUTCOMES RANGING FROM PTSD, DISASSOCIATIVE DYSFUNCTION, BPD, AND SOMATIZATION DISORDER TO DEPRESSIVE SYMPTOMS, SUICIDALITY, AND SELF-MUTILATION. RECENT EPIDEMIOLOGIC STUDIES INDICATE A CONTINUOUS RISK FACTOR FOR SUBSTANCE ABUSE, HIV INFECTION, AND HIGH RATES OF MENTAL HEALTH CARE UTILIZATION. YET THE VARYING HETEROGENEITY OF OUTCOMES RAISES QUESTIONS ABOUT THE SPECIFICITY OF MAINTREATMENT AS A CONTRIBUTING FACTOR.

Drawing on a decade of prospective longitudinal data on development and psychopathology, the study of the effects of trauma over the life span. His most recent book, Dissociation in Children and Adolescents: A Developmental Perspective, examines the role of trauma and adverse family environments on child development. Dr. Putnam received his medical degree from Indiana University School of Medicine in Indianapolis, completed his residency in adult psychiatry at Yale University in New Haven, Connecticut, and received his training in child and adolescent psychiatry from the Children's Hospital National Medical Center in Washington, DC.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPE.

LECTURE 11
11:00 a.m.-12:30 p.m.
Room 33, Lower Level, Convention Center

Marvin I. Herz, M.D.
Early Intervention Strategies in Different Phases of Schizophrenia: How Effective?

Chp.: Francine Cournois, M.D.
Co-Chp.: Michael C. Dufot, M.D.

Early intervention in the treatment of schizophrenia may take place during the prodromal phase with the aim of preventing illness onset, during the early phases of a first schizophrenic episode and during the prodromal phase of relapse for patients who have had prior psychotic episodes. Marvin I. Herz, M.D., reviews the results of research on early intervention at these various stages of the disorder. Dr. Herz is Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Attending Psychiatrist at Strong Memorial Hospital in Rochester, New York. He chaired the American Psychiatric Association Work Group that developed the Practice Guideline for the Treatment of Schizophrenia. The current president of the American College of Psychiatry, Dr. Herz is a Life Fellow of the American Psychiatric Association. He has received the Stanley Dean Award for Research in Schizophrenia from the American College of Psychiatrists. He is the associate editor of the International Journal of Psychosomatics and the author of numerous scientific articles and book chapters. Dr. Herz graduated from the Chicago Medical School, completed his psychiatric residency at the Psychosomatic and Psychiatric Institute of Michael Reese Hospital in Chicago, and received his certificate in psychoanalysis from the Columbia University Center for Psychoanalytic Training and Research in New York City.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE.

MASTER EDUCATOR CLINICAL CONSULTATIONS 8-9
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

8 Clarice J. Kestenbaum, M.D., on Multimodal Psychotherapy of Bipolar Adolescents
Room 35, Lower Level, Convention Center

9 David V. Sheehan, M.D., on Anxiety and Mood Disorders
New York Room, Ballroom Level, Marriott Metro Center

MEDIA SESSION 14-15
11:00 a.m.-2:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

THE TRAUMA OF GENOCIDE: SOCIAL AND PERSONAL HEALING
Chp.: Cheryl A. Kennedy, M.D.

20 Crimes Against Humanity: Justice Pursued
(48 minutes)

Distributor: Films for Humanities & Science
P.O. Box 2053
Princeton, NJ 08543

The program featured from this series is Justice Pursued. Rwanda, Argentina, East Germany and Bosnia have been the focus for the most heinous acts of the last 20 years. In this program, Gerald Gahima, Rwanda's Minister of Justice, has the unenviable job of tracking down hundreds of Rwandans accused of perpetrating hideous
atrocities against their neighbors during that country's recent civil war. We follow Gahima to Israel where, in an emotional meeting with a former Nazi-hunter, Gahima receives advice on how to proceed. A survivor details the torture and murder of thousands of young Argentines. In East Germany, newly discovered Stasi training tapes paint a brutal portrait of political repression behind the Berlin Wall, while in Bosnia, efforts to track down the perpetrators of ethnic cleansing are ongoing.

21 Secrets of S-21: Legacy of a Cambodian Prison
(30 minutes)
Distributor: Films for Humanities & Science
P.O. Box 2053
Princeton, NJ 08543

In the Cambodian city of Phnom Penh stands a compound that once served as a high school. During the bloody rule of the Khmer Rouge, it was a prison where 17,000 men, women and children were incarcerated, and only four emerged alive. In this documentary, two American photographers painstakingly piece together the details of the genocide that took place at S-21 through thousands of photos left behind by prison officials. The photos and interviews with former prison guards and prisoners reveal a world built on power, fear and total disregard for human life and dignity. A BBC production.

22 When Helping Hurts: Sustaining Trauma Workers
(50 minutes)
Distributor: Gifts From Within
RR1, Box 5158
Camden, ME 04843

This video was produced for trauma workers, international relief workers, and those exposed to trauma due to their professions or volunteer work. It outlines the symptoms of secondary traumatization and compassion fatigue and what organizations and supervisors can do to prevent or reduce their effects on trauma workers. Noted therapists discuss ways of recognizing these conditions in yourself and others, plus the means of treatment and prevention.

MEDIA SESSION 15 11:00 a.m.-2:00 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

BEYOND STEREOTYPES: EXPLORING AMERICAN INDIAN CULTURAL IDENTITY
Chp.: R. Dale Walker, M.D.

23 Smoke Signals
(88 minutes)
Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

This Sundance Film Festival award-winning film shows in rich, humorous detail the cultural identity and cultural relations issues faced by young American Indians today. The first film ever produced, directed and acted by American Indians, it is a refreshing and amusing portrayal breaking many stereotypes. Two Coeur d'Alene Indians, tough, brooding Victor and likable, nerdy Thomas, travel from their Idaho reservation to Phoenix to retrieve the remains of Victor's dead father and discover some truths about themselves along the way. Through the help of Thomas and his father's final friend Suzy, Victor is able to find resolution and peace.

MEDICAL UPDATE 2
11:00 a.m.-12:30 p.m.
Rooms 13/14, Lower Level, Convention Center

ADVANCES IN THE TREATMENT OF HIV INFECTION
Chp.: Randall D. Marshall, M.D.
Presenter: Gary L. Simon, M.D.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.

1 Fawzy I. Fawzy, M.D., on Psychosocial Interventions As an Integral Part of Comprehensive Cancer Care
Washington Room, Second Floor, Marriott Metro Center

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 9-16

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Room 15, Lower Level, Convention Center

CULTURAL AND RACE ISSUES IN MENTAL ILLNESS
Chp.: Ahmed M.F. Okasha, M.D.
Co-Chp.: Bernardo Ng, M.D.

11:00 a.m.
26 Management of Major Depression in Hispanic Patients in the Primary Care Setting
David Mischoulon, M.D., Rachel McColl, B.A., Shauna Howarth, B.A., Isabel T. Lagomasino, M.D., Jonathan E. Aipert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.
11:30 a.m.
27 Effect of Race on Residential Treatment Outcomes
Kathleen M. Stack, M.D., Jorge A. Cortina, M.D., Carl Samples, C.R.D., Mario G. Zapata, M.D., Lisa Fore Arcand, Ed.D.
12 noon
28 Eating Disorders: A True Western-Culture-Bound Syndrome?
Katarzyna Bisaga, M.D., Albert C. Gaw, M.D.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Room 20, Lower Level, Convention Center

CURRENT ISSUES IN FORENSIC PSYCHIATRY

Chp.: Leslie L. Citrome, M.D.
Co-Chp.: David C. Dunstone, M.D.

11:00 a.m.
29 Incompetent, Unrestorable Patients: A New Approach
Howard H. Sokolov, M.D.

11:30 a.m.
30 Effect of Outpatient Commitment on Treatment Compliance
in Schizophrenia
Barbara M. Rohland, M.D., Christopher Richards, M.A.,
James E. Rohrer, Ph.D.

12 noon
31 Schizophrenic Violence: Relationship to Symptoms
Menahem Krakowski, M.D., Pal Czobor, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Rooms 25/26, Lower Level, Convention Center

PROGNOSTIC FACTORS IN THE TREATMENT OF
SCHIZOPHRENIA

Chp.: Alan M. Gruenberg, M.D.
Co-Chp.: Roger Peele, M.D.

11:00 a.m.
32 Premorbid Associality and Neuropsychological Status
Marshall L. Silverstein, Ph.D., George Mavrolefteros, M.D.,
David Close, M.A.

11:30 a.m.
33 Negative Symptoms and Functioning in Schizophrenia
Ellen S. Herbener, Ph.D., Martin Harrow, Ph.D.

12 noon
34 Do Schizoaffective Patients Have a Chronic Course?
Martin Harrow, Ph.D., Ellen S. Herbener, Ph.D., Joseph F.
Goldberg, M.D., Kalman J. Kaplan, Ph.D., Marshall L.
Silverstein, Ph.D., Rajiv P. Sharma, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room 27, Lower Level, Convention Center

DEPRESSION AND THE LIFE CYCLE IN WOMEN

Chp.: C. Deborah Cross, M.D.
Co-Chp.: Joanne H. Ritvo, M.D.

11:00 a.m.
35 Past Depression and Middle-Aged Women’s Health
Joyce T. Bromberger, Ph.D., Howard M. Kravitz, M.P.H.,
Adriana Cordal, M.D.

11:30 a.m.
36 Symptom Expression in Postpartum Mood Disturbance
Ruta M. Nonacs, M.D., Lee S. Cohen, M.D., Sarah A.
Howlett, B.A.

12 noon
37 The Use of Nortriptyline for Prevention of Postpartum
Depression in a High-Risk Group of Women
Kathleen S. Peindl, Ph.D., Katherine L. Wisner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Conference Theatre, Level 1B, Grand Hyatt

BURNING ISSUES IN PSYCHIATRIC EDUCATION

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Sidney Zisook, M.D.

11:00 a.m.
38 Effects of Managed Care on Psychiatric Education
Amy C. Brodkey, M.D., Cynthia Weiner, M.S., Frederick S.
Sierles, M.D.

11:30 a.m.
39 Impact of Patient Suicide on Psychiatric Trainees
Ronald Ruskin, M.D., Isaac Sakinofsky, M.D., Michael
Bagby, Ph.D., Susan Dickens, M.A.

12 noon
40 A Model Psychopharmacology Curriculum
Ira D. Glick, M.D., Nicholas G. Ward, M.D., Donald F.
Klein, M.D., P. Murali Doraiswamy, M.D., Jessica R.
Osterheld, M.D., David S. Janowsky, M.D., David W.
Preven, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Independence Ballrooms B/C, Level 5B, Grand Hyatt

DIAGNOSIS AND TREATMENT OF MENSTRUAL CYCLE
DISORDERS

Chp.: Helen G. Muhlbauer, M.D.
Co-Chp.: Professor Dr. Wolfgang Gaebel

11:00 a.m.
41 Variability of Depressive Symptoms During the Menstrual
Cycle
Hadine Joffe, M.D., Lee S. Cohen, M.D.
SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Independence Ballrooms F/G, Level 5B, Grand Hyatt

COMORBIDITY OF ANXIETY AND DEPRESSION

Chp.: Richard Balon, M.D.
Co-Chp.: Anthony J. Rothschild, M.D.

11:00 a.m.
44 Comparison of Social Functioning in Patients with Anxious Depression Versus MDD
Shamsah B. Sonawalla, M.D., Laura Polania, B.A., Mark G. Pingol, B.A., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

11:30 a.m.
45 Anxiety Disorders in Major Depression
Maurizio Fava, M.D., Meredith A. Rankin, B.A., Emma Wright, B.S., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Joel Pava, Ph.D., Jerrold F. Rosenbaum, M.D.

12 noon
46 Depression and Anxiety Comorbidity Using the Prime-MD
Mary Kay Smith, M.D., Denis J. Lynch, Ph.D., Rollin Nagel, M.A., Marijo B. Tamburrino, M.D.

THIS SESSION WILL BE AUDIOTAPELED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

HIV AND PSYCOIMMUNOLOGY

Chp.: J. Stephen McDaniel, M.D.
Co-Chp.: Clayton L. Chau, M.D.

11:00 a.m.
47 The Option of Euthanasia for HIV Disease in Europe
Panayiotis I. Vyras, M.D., Roberta Andraghetti, M.D., Bob Colebunders, M.D., Nikos A. Papadopoulos, B.Sc., Ioannis N. Nestoros, M.D.

11:30 a.m.
48 Immunological Status Versus Depression As Predictors of Quality of Life in HIV-Infected Individuals
Jose R. Maldonado, M.D., Dennis Israelski, M.D., Cheryl Koopman, Ph.D., Cheryl Gore-Felton, Ph.D., Susan Diamond, C.S.W., Aaron M. Chapman, M.D., David Spiegel, M.D.

12 noon
49 Diurnal Cortisol and Early Cancer Mortality
David Spiegel, M.D., Sandra E. Sephton, M.S., Robert M. Sapolsky, Ph.D., Helena C. Kraemer, Ph.D.

THIS SESSION WILL BE AUDIOTAPELED.
<table>
<thead>
<tr>
<th>Component Workshop 32</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Burnham Room, Level 3B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Homophobia Hurts Families: How Parents, Families and Friends of Lesbians and Gays Can Help</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Daniel W. Hicks, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Leslie G. Goransson, M.D., William W. Van Stone, M.D., Catherine Tuerk, R.N., Lanette Graves</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 33</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Health Awareness Education for Medical Students</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Michael J. Vergare, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Leah J. Dickstein, M.D., Carolyn B. Robinowitz, M.D., Steven G. Dickstein, B.A., Julie Holman, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 34</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Paris Room, Ballroom Level, Marriott Metro Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Managed Care Funding for Psychiatric Consults</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Carol L. Alter, M.D., Francisco Fernandez, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant: Steven I. Altchuler, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 27</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Latrobe Room, Level 3B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychiatry and Religion: Conceptual Considerations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Avak A. Howsepian, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Robert W. Hierholzer, M.D., John G. Donnelly, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 28</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Farragut Square Room, Level 5B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spiritual and Ethical Issues in End-of-Life Care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Christina M. Puchalski, M.D., Ellen Fox, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: William Breitbart, M.D., Francis G. Lu, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 29</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Independence Ballrooms D/E, Level 5B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How to Write and Publish in Psychiatry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Carol C. Nadelson, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Sydney Bloch, M.D., Nancy C. Andreasen, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 30</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Independence Ballrooms H/I, Level 5B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sexual Harassment in School: Context and Curricula</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Patricia R. Recupero, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Anne T. Ryan, Ed.D., E. Kathleen Farrel, Ed.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 31</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>McPherson Square Room, Level 5B, Grand Hyatt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Family Values: Lesbian and Gay Family Constellations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Ellen Haller, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Margery S. Sved, M.D., Victoria L. Harris, M.D., Mark H. Townsend, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 32</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Grand Ballroom A, Ballroom Level, Marriott Metro Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Perils and Problems in Sexual Harassment Cases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Rita R. Newman, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Angela M. Hegarty, M.D., Annette J. Hollander, M.D., Arlene G. Sherer, M.D., Sharyn A. Lenhart, M.D., Karen Hopenwasser, M.D., Louise F. Fitzgerald, Ph.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tuesday

Issue Workshop 33
11:00 a.m.-12:30 p.m.
London Room, Ballroom Level, Marriott Metro Center
Prescribing Controlled Substances: Risk Management
Chp.: Lance P. Longo, M.D.
Participants: Norman S. Miller, M.D., Brian J. Johnson, M.D.

12 noon Sessions

Forums 3-4

Forum 3
12 noon-1:30 p.m.
Rooms 21/22, Lower Level, Convention Center
Safe Schools and Dangerous Kids: Pathways to Violence
Chp.: James Garbarino, Ph.D.

Forum 4
12 noon-1:30 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center
Can We Talk? Psychotherapy by Psychiatrists in Managed Care
APA Commission on Psychotherapy by Psychiatrists
Chp.: Norman A. Clemens, M.D.
Participants: Robert A. Kimmich, M.D., Judith H. Gold, M.D.,
Michael C. Hughes, M.D., William H. Sledge, M.D., Anthony M.
D’Agostino, M.D.

New Research Poster Session 7
12 noon-2:00 p.m.
Hall D, Lower Level, Convention Center
Schizophrenia, Neurobiology, Neuropsychiatry and Biological Psychiatry
For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

1:00 p.m. Sessions

Courses 66-74
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 66
1:00 p.m.-5:00 p.m.
Room 2, Meeting Room Level, Renaissance Washington
Medical-Legal Aspects of Assessment in the Workplace
Director: Ronald L. Schouten, M.D., J.D.
Faculty: Sara Eddy, J.D., Brian L. Grant, M.D., C. Donald Williams, M.D.

Course 67
1:00 p.m.-5:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington
ECT: New Directions in Practice and Research
Director: Richard L. Jaffe, M.D.
Faculty: C. Edward Coffey, M.D., Max Fink, M.D.

Course 68
1:00 p.m.-5:00 p.m.
Room 6, Meeting Room Level, Renaissance Washington
Partial Hospitalization for Patients with BPD
Director: Lawrence L. Kennedy, M.D.

Course 69
1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington
Cognitive-Behavioral Treatment of Specific Phobias
Co-Directors: Martin M. Antony, Ph.D., Richard P. Swinson, M.D.

Course 70
1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington
Video Review of Neuropsychiatric Conditions
Director: Thomas E. Hansen, M.D.
Faculty: Edward C. Lauterbach, M.D., Dietrich P. Blumer, M.D.,
Andrew J. Francis, Jr., M.D.

Course 71
1:00 p.m.-5:00 p.m.
Congressional Hall A, Ballroom Level, Renaissance Washington
Herbal Medicine in Psychiatry
Director: Richard P. Brown, M.D.
Faculty: Lorraine Innes, M.D.

Course 72
1:00 p.m.-5:00 p.m.
Federal Room A, Second Floor, Capital Hilton
Dual Diagnosis: Basic Principles of Successful Intervention
Director: Kenneth Minkoff, M.D.

Course 73
1:00 p.m.-5:00 p.m.
Massachusetts Room, Second Floor, Capital Hilton
The Advanced Practice of Psychotherapy
Director: T. Byram Karasu, M.D.
TUESDAY

COURSE 74  
1:00 p.m.-5:00 p.m.  
South American Room B, Second Floor, Capital Hilton  

THE EVALUATION AND MANAGEMENT OF PAIN  
Director: Steven A. King, M.D.  

2:00 p.m. Sessions  

LECTURES 12-13  

LECTURE 12  
2:00 p.m.-3:30 p.m.  
Room 32, Lower Level, Convention Center  
APA'S GEORGE TARJAN AWARD LECTURE  
Silvia W. Olarte, M.D.  

Doctor Where Are You From? The International Medical Graduate in the U.S.  
Chp.: Norma C. Panahon, M.D.  
Co-Chp.: Jambor V. Ananth, M.D.  

International medical graduates (IMGs) constitute 20 percent of the physician workforce in the United States and 23 percent of the membership of the American Psychiatric Association. Compared with psychiatrists who are American medical graduates, psychiatrists who are IMGs are overrepresented in city, county and state psychiatric hospitals and underrepresented in solo office practice, group office practices and medical school and university positions. In a recent survey, 900 APA members who are IMGs were asked about their graduate medical specialization in their country of origin, specialization and subspecialization in the U.S., current patterns of practice, board certification, academic involvement, and participation in research. Silvia W. Olarte, M.D., discusses the survey findings and their implications for the future IMGs in American psychiatry. Dr. Olarte is Clinical Professor of Psychiatry at New York Medical College in Valhalla, New York, and Training and Supervising Psychoanalyst at the College’s Psychoanalytic Institute. She is also Associate Adjunct Psychiatrist at Lenox Hill Hospital, Associate Attending Psychiatrist at Metropolitan Hospital Center and is in the private practice of clinical psychiatry and psychoanalysis in New York City as well. Dr. Olarte is chairperson of the Committee of Hispanic Psychiatrists and Deputy Representative for the Hispanic Caucus to the APA Assembly. She is a fellow and past president of the American Academy of Psychoanalysis. Dr. Olarte is a graduate of Cuyo National University Medical School in Mendoza, Argentina. She completed her residency in psychiatry at Elmhurst City Hospital in Queens, New York, and at Metropolitan Hospital Center, where she also completed a  

LECTURE 13  
2:00 p.m.-3:30 p.m.  
Room 38, Upper Level, Convention Center  
APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE  
Carolyn B. Robinowitz, M.D.  

Women in Medical Leadership: How Far Baby?  
Chp.: William H. Reid, M.D.  
Co-Chp.: Paul Rodenhauser, M.D.  
The increased number of women in medicine has not been reflected by a proportional increase in their representation in higher levels of medical management. Carolyn B. Robinowitz, M.D., examines factors related to women's attainment of leadership positions and describes how institutions and organizations can change to address inequities that can undermine the success of women leaders. Dr. Robinowitz is Dean and Professor of Psychiatry at Georgetown University School of Medicine. From 1975 through 1994 she was a staff member at the American Psychiatric Association, serving as the first Director of the Office of Education, as Deputy Medical Director and as Senior Deputy Medical Director and Chief Operating Officer. The current president of the American College of Psychiatrists, Dr. Robinowitz was the first woman psychiatrist to be elected a director of the American Board of Psychiatry and Neurology and its only woman president. She has received numerous awards for her psychiatric leadership, including the Distinguished Service Award and the Seymour D. Vesterman Award from the APA. Dr. Robinowitz graduated from Washington University School of Medicine in St. Louis, completed her general psychiatric residency at the Bronx Municipal Hospital Center in Bronx, New York, and completed a residency and fellowship in child psychiatry at Children's Hospital in Washington, D.C.  

MEDIA SESSIONS 16-18  

MEDIA SESSION 16  
2:00 p.m.-5:00 p.m.  
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center  

COPING WITH EMOTIONAL ASPECTS OF MEDICAL ILLNESS AND PHYSICIAN SUICIDE  
Chp.: Ian E. Alger, M.D.  

Women in Medical Leadership: How Far Baby?  
Chp.: William H. Reid, M.D.  
Co-Chp.: Paul Rodenhauser, M.D.  
The increased number of women in medicine has not been reflected by a proportional increase in their representation in higher levels of medical management. Carolyn B. Robinowitz, M.D., examines factors related to women's attainment of leadership positions and describes how institutions and organizations can change to address inequities that can undermine the success of women leaders. Dr. Robinowitz is Dean and Professor of Psychiatry at Georgetown University School of Medicine. From 1975 through 1994 she was a staff member at the American Psychiatric Association, serving as the first Director of the Office of Education, as Deputy Medical Director and as Senior Deputy Medical Director and Chief Operating Officer. The current president of the American College of Psychiatrists, Dr. Robinowitz was the first woman psychiatrist to be elected a director of the American Board of Psychiatry and Neurology and its only woman president. She has received numerous awards for her psychiatric leadership, including the Distinguished Service Award and the Seymour D. Vesterman Award from the APA. Dr. Robinowitz graduated from Washington University School of Medicine in St. Louis, completed her general psychiatric residency at the Bronx Municipal Hospital Center in Bronx, New York, and completed a residency and fellowship in child psychiatry at Children's Hospital in Washington, D.C.  

This session will be audiotaped.  

Women in Medical Leadership: How Far Baby?  
Chp.: William H. Reid, M.D.  
Co-Chp.: Paul Rodenhauser, M.D.  
The increased number of women in medicine has not been reflected by a proportional increase in their representation in higher levels of medical management. Carolyn B. Robinowitz, M.D., examines factors related to women's attainment of leadership positions and describes how institutions and organizations can change to address inequities that can undermine the success of women leaders. Dr. Robinowitz is Dean and Professor of Psychiatry at Georgetown University School of Medicine. From 1975 through 1994 she was a staff member at the American Psychiatric Association, serving as the first Director of the Office of Education, as Deputy Medical Director and as Senior Deputy Medical Director and Chief Operating Officer. The current president of the American College of Psychiatrists, Dr. Robinowitz was the first woman psychiatrist to be elected a director of the American Board of Psychiatry and Neurology and its only woman president. She has received numerous awards for her psychiatric leadership, including the Distinguished Service Award and the Seymour D. Vesterman Award from the APA. Dr. Robinowitz graduated from Washington University School of Medicine in St. Louis, completed her general psychiatric residency at the Bronx Municipal Hospital Center in Bronx, New York, and completed a residency and fellowship in child psychiatry at Children's Hospital in Washington, D.C.  

This session will be audiotaped.  

Women in Medical Leadership: How Far Baby?  
Chp.: William H. Reid, M.D.  
Co-Chp.: Paul Rodenhauser, M.D.  
The increased number of women in medicine has not been reflected by a proportional increase in their representation in higher levels of medical management. Carolyn B. Robinowitz, M.D., examines factors related to women's attainment of leadership positions and describes how institutions and organizations can change to address inequities that can undermine the success of women leaders. Dr. Robinowitz is Dean and Professor of Psychiatry at Georgetown University School of Medicine. From 1975 through 1994 she was a staff member at the American Psychiatric Association, serving as the first Director of the Office of Education, as Deputy Medical Director and as Senior Deputy Medical Director and Chief Operating Officer. The current president of the American College of Psychiatrists, Dr. Robinowitz was the first woman psychiatrist to be elected a director of the American Board of Psychiatry and Neurology and its only woman president. She has received numerous awards for her psychiatric leadership, including the Distinguished Service Award and the Seymour D. Vesterman Award from the APA. Dr. Robinowitz graduated from Washington University School of Medicine in St. Louis, completed her general psychiatric residency at the Bronx Municipal Hospital Center in Bronx, New York, and completed a residency and fellowship in child psychiatry at Children's Hospital in Washington, D.C.  

This session will be audiotaped.
Using segments from the videotape, *Whose Death Is It Anyway?* and video material depicting several family situations, this presentation will provide the opportunity to discuss guidelines to help families cope with the painful ambiguities of threatened loss during an illness. Using a systems model that integrates different kinds of illnesses with the family's denial, psychological/physical loss, difficulties surrounding end-of-life decisions and transgenerational experiences will be discussed. Various issues highlighted in the video will be examined, and the group will interact with one another in sharing their expertise and experience.

**Discussant:** Anita Menfi, M.Ed.

**25 When All Is Said and Done**

(28 minutes)

**Distributor:** Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

This video is devoted to the terminally ill and their family members, demonstrating ways in which dying can become a time for forgiveness, letting go and connectedness. The viewer has the opportunity to witness several family meetings between family members and the individuals who are dying. During this sacred time, family members openly share issues that have rarely been spoken of before and say goodbye to each other. The stories shared are powerful examples of encouragement and support that will help professionals in their work with the dying and their families.

**26 When Physicians Commit Suicide: Reflections of Those Left Behind**

(23 minutes)

**Distributor:** Media Services Center
St. Paul Hospital
1081 Burrard Street
Vancouver, BC, Canada V6Z 1Y6

When physicians kill themselves the heartache for family, work colleagues, friends and their patients is profound. Many “survivors” struggle with feelings of disbelief, guilt, remorse and anger. Shame and a conspiracy of silence often preclude an open discussion of the physician’s life and legacy. In this videotape, survivors of physician loved ones who have committed suicide talk about their loss, their journey of healing, and the reactions of physician colleagues, friends and family, and make wise suggestions to us in the health professions who treat physicians and their families. Also included are the poignant works of a physician who, struggling with major depression, attempted suicide during her residency. Grateful to be alive, she explains not only the pain of depression but that it is a treatable illness. Her message is full of compassion and hope for physicians who live with depression. This videotape should further diminish the stigma associated with mental illness in physicians. The target audience is medical students and physicians (and their families), medical school deans, directors of training programs, medical licensing board personnel, physician well-being committees, hospital administrators, all professionals who treat ill physicians and the countless survivors who have lost loved ones to suicide.

**Discussants:** Michael F. Myers, M.D., Carla Fine

**MEDIA SESSION 17 2:00 p.m.-5:00 p.m.**

Congressional Hall B, Ballroom Level, Renaissance Washington

**UP-TO-DATE PSYCHIATRY THROUGH THE INTERNET**

Chp.: Rima Styra, M.D.

**27 Geriatrics: Women's and Men's Health**

Rima Styra, M.D.

**28 Psychopharmacology Tips**

Robert C. Hsiung, M.D.

**29 Forensic Psychiatry**

Harold J. Bursztajn, M.D.

The Internet lends itself to being an ever-expanding resource of up-to-date information for the practicing psychiatrist. In this presentation, we will cover several categories of Web sites: women’s/men’s health, geriatrics, psychopharmacology and forensics. Information on aging from preventative aspects to treatment considerations for the public and the health care professional has been provided by numerous sites. Women’s health issues on the World Wide Web have been linked to such major resources as the American Medical Association; however, men’s health resources tend to be more scattered throughout the Web. Psychopharmacology will be covered by exploring Psychopharmacology Tips, which is an innovative resource on the Web. Practical suggestions will be submitted by the audience, then selected, edited, indexed and adapted for the Web by the presenter. The ease of use and the utility of Psychopharmacology Tips, as well as the role of such a resource, including clinical, ethical, legal and technical issues, will be discussed. The Web has become a valuable research tool as well as a gateway for interdisciplinary access to psychiatry. The presenter will explain the uses of the Web to collaborate with medical professionals and other medical specialties around forensic psychiatry issues. Moreover, a review and analysis will be made of how to make psychiatric knowledge accessible to other professionals such as attorneys and risk managers.

**30 The Treatment of Depression in Long-Term Care: Interactive CD-ROM Training**

Jules Rosen, M.D., Marcia Kollar, M.S.W.

An interactive video CD-ROM entitled “The Treatment of Depression” will be demonstrated. This is one of a series of 12 computer-based training modules designed to educate the staff of nursing homes. Using the latest interactive, computer-based video technology, you will see nursing home residents, their families and caregivers tell their stories in a documentary-style format that demonstrates key principles of caring for the elderly in nursing homes. Nursing home
staff participate in decision making and assessments through the use of interactive technology. In this module, the nonpharmacological principles of treatment for depression are presented through the stories of two residents. Aunt Ginny was near death from her depression until she began treatment after being put in a nursing home. Through the special efforts of a treatment team and one special relationship with an employee, Ginny experienced a total recovery. A second story is about Gertrude. Through the words of her son Paul, the staff learned who Gertrude was for the 95 years of her life prior to coming to the nursing home. Through this understanding (assessment), they were able to construct a behavioral treatment plan that contributed to her recovery. The third vignette includes an interactive exercise in which the viewer conducts an assessment and constructs a treatment plan for Delores based on her on-camera interview.

31 A World Wide Web Survey of Physician Knowledge of Alzheimer’s Disease
Harry Karlinsky, M.D.

Determining current physician knowledge of Alzheimer’s Disease is the first step towards identifying what information needs to be more effectively disseminated to physicians. To accomplish this objective we are conducting a survey using the Internet, a powerful new research tool. With the University of British Columbia Ethics Committee’s approval, physicians can now view a World Wide Web site concerning the clinical diagnosis of Alzheimer’s (www.alzheimerdrsvy.com) and submit their results online to 32 self-evaluation questions. Twelve of these questions are based on short videos depicting simulated clinical interactions. Demographics of the responding physicians are also elicited and include gender, age, medical specialty, type of practice, years in professional practice, country of practice, and percentage of clinical practice related to geriatrics and Alzheimer’s. Since the site’s launch on June 15, 1998, 30 physicians from eight countries have participated in the survey. The mean percentage of correct responses is 79%. Only 33% of the respondents viewed the entire survey, with a significant drop-off in participation. Implications for future survey design will be discussed, as will the general advantages (timeliness, minimal cost, wide distribution) and disadvantages (biased subject response, malicious data) of conducting health research on the Internet.

MEDIA SESSION 18 2:00 p.m.-5:00 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

A FRENCH PERSPECTIVE ON BPD: BETTY BLUE

Chp.: Steven E. Hyler, M.D.

32 Betty Blue
(120 minutes)

Distributor: Cargo Films
9 rue Ambroise Thomas
73009 Paris, France

First a precautionary note: Betty Blue is in French with English subtitles. It is R rated, containing explicit scenes of nudity, sex and violence. Anyone who feels that they might be offended should consider not viewing this film. Children under 16 should definitely not attend. Made in 1986, Betty Blue was adapted from the book entitled 37 degrees 2 Le Matin. The screenplay was written by Jean-Jacques Beineix and Philippe Djian, who wrote the original novel. Jean-Jacques Beineix, who is better known for the film Diva, directed it. Jean-Hughes Anglade plays the role of Zorg, and Beatrice Dalle plays Betty. Zorg is a handyman who is working at a bungalow colony on the French Riviera. He is a slovenly housekeeper but diligent worker who writes in his spare time. Into his life walks Betty, a beautiful young woman who is wild and unpredictable. After an argument with Zorg’s employer they leave and Betty gets a job at a restaurant. She keeps after Zorg to get his books published, but all he gets are rejection letters. This makes Betty fly into a rage. She gets more and more out of control. Zorg watches helplessly as the woman he loves goes slowly insane. Can love conquer all? The film was wildly popular in France but received mixed reviews in the United States. For teachers of psychopathology and diagnosis, Betty presents a textbook (DSM-IV) example of BPD.

PRESIDENTIAL SYMPOSIUM
2:00 p.m.-5:00 p.m.
Room 27, Lower Level, Convention Center

STATE MEDICAID PROGRAMS: ACCESS AND QUALITY FOR MENTAL HEALTH CARE

Chp.: Rodrigo A. Muñoz, M.D.
Co-Chp.: Donna M. Norris, M.D.
Participant: Mary Jane England, M.D.
Discussants: Commissioner Bruce Bullen, Roy C. Wilson, M.D., Danna Mauch, Ph.D., Robert Bernstein, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: PART III
2:00 p.m.-5:30 p.m.
Rooms 30/31, Lower Level, Convention Center

COUNTERTRANSFERENCE IN PSYCHIATRIC TREATMENT

Chp.: Glen O. Gabbard, M.D.

11 An Overview of Countertransference: Theory and Technique
Glen O. Gabbard, M.D.

12 Countertransference in General Psychiatry
Marcia K. Goin, M.D.

13 Countertransference in the Treatment of the Suicidal Borderline Patient
John T. Malsberger, M.D.

14 Countertransference Issues with Antisocial Personality Disorders
John R. Lion, M.D.

15 Countertransference and Assisted Suicide
Francis T. Varghese, M.B., Brian J. Kelly, M.B.
SYMPOSIA 19-37

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Rooms 13/14, Lower Level, Convention Center

MEDICATION CONTROVERSIES IN BIPOLAR DISORDER

Chp.: David A. Kahn, M.D.
Co-Chp.: John P. Docherty, M.D.

A Mood Stabilizing Medication
Paul E. Keck, Jr., M.D.

B The Role of Antipsychotics in Bipolar Disorder
Philip G. Janicak, M.D.

C Bipolar Depression
Gary S. Sachs, M.D.

D Novel Treatment Strategies for Refractory Bipolar Disorder
Andrew L. Stoll, M.D.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Room 15, Lower Level, Convention Center

THE ETHICS OF SCHIZOPHRENIA RESEARCH

Chp.: Paul S. Appelbaum, M.D.

A Overview of the Controversy
Paul S. Appelbaum, M.D.

B An Overview of the National Bioethics Advisory Commission's Report and Recommendations
James F. Childress, Ph.D.

C Ethical Issues in Clinical Research: An Investigator's Perspective
Jeffrey A. Lieberman, M.D.

D Evolving Procedures to Address Research Ethics
William T. Carpenter, Jr., M.D.

E Clinical Trials of Treatments for Schizophrenia
Robert J. Levine, M.D.

Discussant: Steven E. Hyman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Room 20, Lower Level, Convention Center

GROUP THERAPY FOR PERSONS LIVING WITH HIV/AIDS

Chp.: Alan F. Schatzberg, M.D.

A Enhancing Coping Skills in Group Psychotherapy for People with HIV/AIDS
Jeffrey A. Kelly, Ph.D.

B Interventions for Positive Youth: Are Groups the Right Modality?
Marguerita Lightfoot, Ph.D., Martha Lee, Ph.D., Mary J. Rotheram-Borus, Ph.D.

C Bereavement Groups and Distress After Subsequent Loss
Kari Goodkin, M.D., Nancy T. Blaney, Ph.D., Teri Baldeiwicz, Ph.D., Jack Burkhalter, Ph.D., Barbara Leeds, Joshua Cohen

D Supportive-Expressive Group Therapy for HIV/AIDS
Cheryl Koopman, Ph.D., Jose R. Maldonado, M.D., Cheryl Gore-Felton, Ph.D., Dennis Israelki, M.D., Catherine Classen, Ph.D., Michele Gill, B.Sc., David Spiegel, M.D.

Discussants: Ellen Stover, Ph.D., David Spiegel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Rooms 21/22, Lower Level, Convention Center

TREATMENT OF SUICIDAL BEHAVIOR IN PERSONS WITH PERSONALITY DISORDERS

Chp.: Barbara Stanley, Ph.D.

A Suicidal Behavior in Persons with Personality Disorders
Barbara Stanley, Ph.D.

B Psychopharmacology of Suicidal Behavior in Persons with Personality Disorders
Larry J. Siever, M.D., Antonia S. New, M.D., Harold W. Koenigsberg, M.D.

C Psychotherapy of Suicidal Patients with Personality Disorders
Marsha M. Linehan, Ph.D.

D Clinical Management of the Suicidal Personality Disordered Patient
Rebecca A. Dulit, M.D.

Discussant: J. John Mann, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Rooms 23/24, Lower Level, Convention Center

SUBSTANCE ABUSE AND COMORBIDITY

Chp.: Frances R. Levin, M.D.
Co-Chp.: David M. McDowell, M.D.

A Treatment of PTSD and Substance Use Disorders
Kathleen T. Brady, M.D.

B Evaluation of Depression in Substance Abuse
David M. McDowell, M.D., Frances R. Levin, M.D., Edward V. Nunes, M.D., Herbert D. Kleber, M.D.

(Continued on next page)
TUESDAY

C  Diagnosis and Treatment: Substance Abusers with ADHD
Frances R. Levin, M.D., David M. McDowell, M.D., Suzette Evans, Ph.D., Herbert D. Kleber, M.D., Andrew Sia, B.A.

D  Dual Diagnosis: Schizophrenia and Substance Abuse
Douglas M. Ziedonis, M.D.

E  Axis II in Drug Abusers: Relation to Axis I
Bruce J. Rounsaville, M.D., Roel Verheul, Ph.D., Henry R. Kranzler, M.D.

Discussant: Edward V. Nunes, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24  2:00 p.m.-5:00 p.m.
Rooms 25/26, Lower Level, Convention Center

BIOLOGY OF EATING DISORDERS: CLINICAL IMPLICATIONS
Chp.: Laurel Mayer, M.D.
Co-Chp.: B. Timothy Walsh, M.D.

A  Perturbations in Metabolic Rate in Persons with Anorexia Nervosa
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Michael Rosenbaum, M.D., Rudolph J. Leibel, M.D., Richard N. Pierson, M.D.

B  Metabolic Signals and Body Weight in Persons with Bulimia Nervosa
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Eran D. Metzger, M.D., Jeffrey M. Levine, M.D.

C  Eating Behavior in Patients with Eating Disorders
Michael J. Devlin, M.D.

D  Gastric Function in Persons with Bulimia Nervosa
Ellen Zimmerli, Ph.D., B. Timothy Walsh, M.D., Harry Kisseleff, Ph.D., Janet Guss, B.A.

E  Orbital Frontal Serotonin Changes in Recovered Bulimics
Walter H. Kaye, M.D., Carolyn Melzer, M.D., Julie L. Price, M.D., Claire McConaha, B.S.N., Guido Frank, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25  2:00 p.m.-5:00 p.m.
Room 29, Lower Level, Convention Center

DEMONSTRATING PSYCHIATRY’S IMPACT ON MEDICAL CARE AND COST
Chp.: Jonathan F. Borus, M.D.
Co-Chp.: Arthur J. Barsky III, M.D.

A  Proving Medical Psychiatry Is Worth Its Cost
Jonathan F. Borus, M.D., Arthur J. Barsky III, M.D., Lisa A. Carbone, M.D., Alison Fife, M.D., Gregory L. Fricchione, M.D., Sarah L. Minden, M.D., Rais A. Khan, M.D.

B  Cost-Offset from Psychiatric Interventions in Medicine
James J. Strain, M.D.

C  Predictors of Delirium Following Abdominal Aortic Aneurysm
Sarah L. Minden, M.D., Lisa A. Carbone, M.D., Arthur J. Barsky III, M.D., Jonathan F. Borus, M.D., Alison Fife, M.D., Gregory L. Fricchione, M.D., John Orav, Ph.D.

D  Mental Disorders in Primary Care and Medical Utilization
Lisa A. Carbone, M.D., Arthur J. Barsky III, M.D., John Orav, Ph.D.

E  Cost-Offset Versus Cost-Effectiveness: Which Paradigm for Psychiatric Treatment Trials?
Wayne J. Katon, M.D., Mike Von Korff, M.D.

Discussants: Thomas N. Wise, M.D., James L. Levenson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26  2:00 p.m.-5:00 p.m.
Room 33, Lower Level, Convention Center

NEW TREATMENT TARGETS IN SCHIZOPHRENIA
Chp.: Wayne S. Fenton, M.D.

A  Pharmacological Treatment of Negative Symptoms
Robert W. Buchanan, M.D.

B  Cognitive Deficits As Treatment Targets
James M. Gold, Ph.D.

C  Depression and Suicidality As Targets for Intervention in Schizophrenia
Wayne S. Fenton, M.D., Jennifer Crumlish, Ph.D.

D  Approaches to Substance Abuse in Schizophrenia
Fred C. Osher, M.D.

E  The Need and Challenge of Providing Services to Families
Lisa B. Dixon, M.D.

Discussant: Anthony F. Lehman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 27  2:00 p.m.-5:00 p.m.
Conference Theatre, Level 1B, Grand Hyatt

PSYCHIATRIC WORKFORCE: ISSUES AND CHALLENGES
Chp.: Nyapati R. Rao, M.D.
Co-Chp.: Sidney H. Weissman, M.D.

A  Workforce Assumptions: International Perspective
James H. Scully, Jr., M.D., Nyapati R. Rao, M.D.

B  Definition of a Psychiatrist for the New Millennium
Allan Tasman, M.D., Nyapati R. Rao, M.D.
C Estimating Workforce Requirements Based on Patients' Needs
Larry R. Faulkner, M.D., Nyapati R. Rao, M.D.

D Physician Maldistribution and the Role of International Medical Graduates
Nyapati R. Rao, M.D.

E Manpower Issues: Canada’s Experience
Nady El-Guebaly, M.D., Nyapati R. Rao, M.D.

Discussant: Sidney H. Weissman, M.D.
THIS SESSION WILL BE AUDIOTAPE.
C Prospective Study of Tardive Dyskinesia in the Elderly
John M. Kane, M.D.

D Dyskinesia and Ethnicity in Elderly Schizophrenia Patients
William B. Lawson, M.D., Craig N. Karson, M.D.

E Neuroleptic-Induced Parkinsonism in Alzheimer's Disease
Robert A. Sweet, M.D., Benoit H. Mulsant, M.D., Jules Rosen, M.D., Bruce G. Pollock, M.D.

Discussant: Carol A. Tamminga, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32  2:00 p.m.-5:00 p.m.
Independence Ballrooms F/G, Level 5B, Grand Hyatt

VIOLENCE, SOCIAL CHANGE AND WOMEN’S HEALTH
World Psychiatric Association's Task Force on Violence

Chp.: Eliot Sorel, M.D.
Co-Chp.: Marianne C. Kastrap, M.D.

A Broken Hearts: Ischemic Heart Disease, Depression and Gender
Donna E. Stewart, M.D., Susan E. Abbey, M.D., M. Irvine, Z. Shner, P. Daly, S. Bisallion

B Violence Against Women in Egypt: A Reading in the Egyptian Context
Aida Self El Dawla, M.D.

C Global Violence Against Women and Children
Marianne C. Kastrap, M.D.

D Violence: A Global Public Health, Behavioral Health and Primary Care Challenge
Eliot Sorel, M.D.

Discussants: Susan J. Blumenthal, M.D., Amelia E. Musacchio de Zan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33  2:00 p.m.-5:00 p.m.
Independence Ballrooms H/I, Level 5B, Grand Hyatt

UNDERSTANDING SCHOOL VIOLENCE

Chp.: Paul A. Kettl, M.D.

A Trends in School Violence
Kathleen M. Fisher, Ph.D.

B A Typology of School Violence
Lois T. Flaherty, M.D.

C Biological and Cultural Causes of Violence
Paul A. Kettl, M.D.

D Violence Prevention in Chicago Public Schools
Carl C. Bell, M.D., Sue Gamm, Ph.D., Paul Vallas, Phillip Jackson

E Problems of and Solutions for School Violence
Paul Jay Fink, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34  2:00 p.m.-5:00 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

CULTURAL AND LANGUAGE CONSIDERATIONS IN DIAGNOSIS

Chp.: David V. Sheehan, M.D.

A Validation of a Structured Interview in European Settings
Yves Lecrubier, M.D.

B Russian Language Assessment of Mental Illness
Alexander Bystritsky, M.D., Marina Bystritsky, M.A.

C The Psychiatric Assessment of Arab Patients
Ossama T. Osman, M.D.

D Psychiatric Diagnosis and Structured Interviews in Hebrew
Raphael E. Bara, M.D., Ilan Levinson, M.D.

E Diagnostic Challenges in Southern African Languages
Kerunne Kelogetswe

Discussant: Norman Sartorius, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35  2:00 p.m.-5:00 p.m.
Grand Ballroom A, Ballroom Level, Marriott Metro Center

PHARMACOLOGY INTERVENTION IN WOMEN AT RISK FOR INFANTICIDE

Chp.: Margaret G. Spinelli, M.D.
Co-Chp.: Katherine L. Wisner, M.D.

A Prevention and Treatment of Postpartum Mood Disorders
Katherine L. Wisner, M.D.

B Maternal Infanticide
Phillip J. Resnick, M.D.

C Infanticide: An Epidemiological Perspective
Paula M. Bortnichak, M.D.

D Mothers Who Kill: Neonaticide and the Law
Michelle Oberman, J.D.

E Neonaticide in America: A Systematic Investigation
Margaret G. Spinelli, M.D., Katherine L. Wisner, M.D., Phillip J. Resnick, M.D., Michelle Oberman, J.D., Paula M. Bortnichak, M.D.
THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 8
3:00 p.m.-5:00 p.m.
Hall D, Lower Level, Convention Center

ANXIETY; ALCOHOL AND SUBSTANCE ABUSE; SUICIDE; VIOLENCE; CHILD AND ADOLESCENT PSYCHIATRY; AND INFANT, CHILDHOOD, AND PERSONALITY DISORDERS

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 24-29

INDUSTRY-SUPPORTED SYMPOSIUM 24 7:00 p.m.-10:00 p.m.
Rooms 39/40, Upper Level, Convention Center

ALZHEIMER'S DISEASE: TRANSLATING CLINICAL TRIALS INTO CLINICAL CARE
Supported by Bayer Corporation, Pharmaceutical Division

Chp.: Jeffrey L. Cummings, M.D.

A Assessment Tools for Global Function
P. Murali Doraiswamy, M.D.

B Scales Used to Assess Cognition
John C. Morris, M.D.

C Activities of Daily Living: A Key Parameter in Alzheimer's Disease
Linda Teri, Ph.D.

D Assessment of Neuropsychiatric Disorders
Jeffrey L. Cummings, M.D.

E Assessment of Disease Progression
Mary Sano, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25 7:00 p.m.-10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

WHAT MAKES AN ANTIPSYCHOTIC ATYPICAL?
Supported by Watson Laboratories, Inc.

Chp.: William M. Glazer, M.D.
Co-Chp.: Stephen M. Stahl, M.D.

A Pharmacological Mechanism of Atypical Antipsychotics
Stephen M. Stahl, M.D.

(Continued on next page)
B Serotonin/Dopamine Antagonism and Atypicality: In Vivo Evidence Using PET
Gary J. Remington, M.D., Stephen M. Stahl, M.D., Peter F. Buckley, M.D., William M. Glazer, M.D.

C Management of Agitation and Aggression: New Pharmacologic Approaches
Peter F. Buckley, M.D.

D Is There Clinical Evidence for Atypical Effects of Loxapine?
William M. Glazer, M.D.

E Use of Intramuscular Antipsychotics in Acute-Care Settings
Larry Ereshefsky, Pharm.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26 7:00 p.m.-10:00 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

UNMASKING DEPRESSION AND COMORBID CONDITIONS: CLINICAL CHALLENGES, SOLUTIONS AND UNANSWERED QUESTIONS
Supported by U.S. Pharmaceuticals, Pfizer Inc.
Chp.: Martin B. Keller, M.D.

A Understanding Depression as a Risk Factor in Vascular Disease
K. Ranga R. Krishnan, M.D.

B Mood Disturbance in Alzheimer's Disease and Other Neuroleptic Illnesses
Pierre N. Tariot, M.D.

C Management of Depression During Pregnancy and Postpartum
Lori L. Altshuler, M.D., Lee S. Cohen, M.D., Martin P. Szuba, M.D., Vivien K. Burt, M.D., Michael J. Gitlin, M.D.

D Addictions: Smoking, Alcohol and Cocaine
Barbara J. Mason, Ph.D.

Discussant: A. John Rush, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27 7:00 p.m.-10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

GENDER ISSUES IN DIAGNOSIS AND RESPONSE TO TREATMENT
Supported by Glaxo Wellcome Inc.
Chp.: Anita L.H. Clayton, M.D.
Co-Chp.: Susan G. Kornstein, M.D.

A Incidence and Treatment of Migraine in Women
Anita L.H. Clayton, M.D.

B Gender Issues in the Assessment and Treatment of Depression
Susan G. Kornstein, M.D.

C Gender Issues in Diagnosis and Treatment of Anxiety Disorders
Teresa A. Pigott, M.D.

D Treatment of Women with Bipolar Disorder
Ellen Leibenluft, M.D.

E Sexual Disorders in Women: Diagnosis and Treatment
Thomas N. Wise, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28 7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

CLINICAL IMPLICATIONS OF NEW DEMENTIA RESEARCH
Supported by Novartis Pharmaceuticals Corporation
Chp.: Gary W. Small, M.D.
Co-Chp.: Lon S. Schneider, M.D.

A Early Detection and Prevention of Dementia
Gary W. Small, M.D.

B Translating Treatment Data to the Real World
Lon S. Schneider, M.D.

C Neuroimaging Techniques and Applications
Steven G. Potkin, M.D., Ravi Anand, M.D., Joseph C. Wu, M.D., John Messina, Ph.D., Kirsten Fleming, Ph.D., David Keator, B.S., William E. Bunney, Jr., M.D.

D Recent Findings in Behavioral Intervention
Jiska Cohen-Mansfield, Ph.D.

E Management of Comorbid Conditions
George T. Grossberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 29 7:00 p.m.-10:00 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

MANAGING DEPRESSION ACROSS THE LIFE CYCLE
Supported by Forest Laboratories, Inc.
Chp.: Jerrold F. Rosenbaum, M.D.

A Depression in Children and Adolescents
Graham J. Emslie, M.D.

B Course and Treatment of Mood Disorders During Pregnancy and the Postpartum Period
Zachary N. Stowe, M.D.

C Depression in the Perimenopausal Woman
Peter J. Schmidt, M.D., Catherine A. Roca, M.D., David R. Rubinow, M.D.

D Long-Term Management of Recurrent Adult Depression
Jerrold F. Rosenbaum, M.D.

E Late-Life Depression: Biologic Vulnerability, Phenomenology and Course
Barnett S. Meyers, M.D., Robert C. Young, M.D., Balkrishna Kalayam, M.D., George S. Alexopoulos, M.D.
MEDIA SESSIONS 19-20

MEDIA SESSION 19 7:00 p.m.-10:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

AIDS: MULTICULTURAL PERSPECTIVES
Chp.: Marshall Forstein, M.D.
Co-Chp.: Joyce Y. Chung, M.D.

33 Odo Ya! Life with AIDS
(58 minutes)
Distributor: Filmmakers Library
124 East 40th Street
New York, NY 10016

This is the affirming story of how Candomble, a Brazilian religion of African origin, has become a source of strength and power for a group of AIDS sufferers. Shot in Rio de Janeiro, Sao Paulo and Bahia, it shows the rituals of Candomble and the celebration of carnival. It features the personal struggles and words of wisdom from those whose faith has brought endurance and pride. Rather than denying the sexuality of this African-descendant population, innovative education programs have been developed for its followers. Where other religions preach abstinence, Candomble advocates the use of condoms so that sexuality need not be repressed. This beautifully shot documentary puts the epidemic in a cultural context, showing how this joyful religion helps its followers cope with the illness. An important film for classes in medical anthropology, folklore and religion, and Latin-American culture.

34 Rainmakers Thailand
(26 minutes)
Distributor: The Multimedia Group of Canada
5225 Berri Street, #200
Montreal, PQ, Canada H2J 2S4

Jongsada Suwanchondee kicked her heroin habit only to discover she was HIV positive. Through support groups, Jongsada has found new hope and now helps others understand the disease and its impact.

35 Women and HIV: Four Stories
(47 minutes)
Distributor: Julie Axelrod and Dorothy Chin
300 UCLA Medical Center Plaza, Suite 1512
Los Angeles, CA 90095

Women and HIV: Four Stories is a documentary that chronicles how four Los Angeles women of different ages and ethnic groups tackled life after learning they are HIV positive. Each has a unique story to tell, and through their stories, we are educated and touched by the daily challenge of living with a life-threatening illness. Jennifer: Infected in her teens, Jennifer now has two children and a new relationship. She is the typical young woman of today, except that she has HIV. She is Vietnamese and openly shares how difficult it has been to be young, Asian and living with the virus. Christine: Christine never had the experience of just being HIV positive. When she was diagnosed in 1988, she already had AIDS. Despite her many medical challenges, she has continued to work, and poignantly shares her feelings about her life. Martha: Martha found out when she was diagnosed after she was married. She and her husband, both dealing with HIV, also face language barriers and discrimination, which add to the burden of living with the virus. Charlon: Charlon is a single mother with a household of six. She cares for her children, her grandchildren, and others who come to her for help. She has been clean and sober for 10 years, and with that sobriety, started a new life.
C Sleep in PTSD: Findings from Chronic, Recent and Acute Stages  
Thomas A. Mellman, M.D., Daniella David, M.D., Bruce Nolan, M.D.

D Physiological and Subjective Assessment of Families Bereaved After the Oklahoma City Bombing  
Phoebe M. Tucker, M.D., Betty Pfefferbaum, M.D., Brian T. Maynard, B.A., Scott M. Rainwater, Shajitha Nawaz, M.S.

E The Neuroarcheology of Child Maltreatment: Evidence for Altered Neurodevelopment Following Traumatic Abuse  
Bruce D. Perry, M.D.

Discussant: Robert J. Ursano, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39  7:00 p.m.-10:00 p.m.  
Independence Ballrooms B/C, Level 5B, Grand Hyatt

NEW VIEWS ON PLAY IN ADULTS
Chp.: Lenore C. Terr, M.D.

A Play in the Lives of Retirees: A Sixty-Year Study  
George E. Vaillant, M.D.

B Emily Dickinson: Play Becomes Poetry  
John F. McDermott, Jr., M.D.

C Risk-Taking As a Dangerous or Healthy Mechanism  
Lynn E. Ponton, M.D.

D Beyond Love and Work: Why Adults Need to Play  
Lenore C. Terr, M.D.

Discussant: Robert Michels, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40  7:00 p.m.-10:00 p.m.  
Independence Ballrooms D/E, Level 5B, Grand Hyatt

UNDERSTANDING AND TREATING PATHOLOGICAL GAMBLING
Chp.: Marc N. Potenza, M.D.

A Pathological Gambling: Major Public Health Concern  
Marvin A. Steinberg, Ph.D.

B Assessing Pathological Gambling  
Ken C. Winters, Ph.D.

C Multimodal Behavior Therapy for Pathological Gamblers  
Iver E. Hand, M.D., Julia V. Schinckel, Ph.D., Brigitte Friedrich, B.N.

D Psychopharmacology of Pathological Gambling  
Marc N. Potenza, M.D., Stephanie S. O'Malley, Ph.D.

E Neurobiology of Pathological Gambling  
Eric Hollander, M.D., Concorįta M. DeCarli, Ph.D., Charles Cartwright, M.D., Sherle Novotny, M.D., Jared Finkell, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41  7:00 p.m.-10:00 p.m.  
Independence Ballrooms F/G, Level 5B, Grand Hyatt

FRENCH AND AMERICAN PSYCHIATRY: VIVE LA DIFFERENCE!
Chp.: Jean-Michel Thirun, M.D.

Co-Chp.: John A. Talbott, M.D.

A Suburb's Psychosis  
Thierry Tremine, M.D., F. Regis Cousin, M.D.

B American Indians in Urban Areas: Dealing with Cultural Differences  
James W. Thompson, M.D.

C The Protection of the Well-Being (Rights) of the Mentally Ill  
Eric Marcel

D The Protection of the Rights of the Mentally Ill in America  
Carl P. Malmquist, M.D.

E What Place for Henri Ey (1900-1977) in a Picture of French Psychiatry in 1998?  
Suzanne Parizot, M.D., Jean-Pierre Losson

F Adolf Meyer and 20th Century Psychiatry  
Paul R. McHugh, M.D.

Discussants: Jean-Charles Pascal, M.D., Yves Thoret, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42  7:00 p.m.-10:00 p.m.  
Independence Ballrooms H/I, Level 5B, Grand Hyatt

ARAB CULTURAL PERSPECTIVES ON THE ASSESSMENT AND TREATMENT OF ANXIETY DISORDERS
Chp.: Abdel F. Amin, M.D.

Co-Chp.: Ossama T. Osman, M.D.

A Anxiety Disorders and Transcultural Factors in Diagnosis and Treatment  
Ossama T. Osman, M.D.

B The Cultural Context of Anxiety Disorders in Egypt  
Adel Sadek, M.D.

C The Study of Panic Disorder in Egypt  
Afaf H. Khalil, M.D.

D Comorbidity of Social Phobia Among Saudi Patients  
Ibrahim Al-Khodair, M.D.
SYMPOSIUM 44  7:00 p.m.-10:00 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

PRESCRIBING PSYCHOTROPICS FOR DIVERSE POPULATIONS
APA Council on National Affairs

Chp.: Albert C. Gaw, M.D.
Co-Chp.: Rodrigo A. Muñoz, M.D.

A  Clinical and Pharmacologic Considerations When
Prescribing Psychotropics for Culturally Diverse
Populations
Sheldon H. Preskorn, M.D., Mujeeb U. Shad, M.D., Annie
Harvey, Ph.D., W. Dale Horst, Ph.D.

B  Issues in Ethnic Responses to Psychotropic Medication
William B. Lawson, M.D., John O. Gaston, M.D.

C  Psychotropics and Women
Freda C. Lewis-Hall, M.D.

D  Ethnicity and Psychotropic Drug Responses
Keh-Ming Lin, M.D.

E  Overcoming Psychotropic Drug Non-Compliance: A
Cultural Perspective
Albert C. Gaw, M.D., John A. Nichols, Psy.D.

THIS SESSION WILL BE AUDIOTAPED.
CALL FOR PAPERS

PRESIDENT'S THEME:

"The Doctor-Patient Relationship"

Allan Tasman, M.D.
President

Pedro Ruiz, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td></td>
</tr>
<tr>
<td>Symposium-Part A</td>
<td>June 4, 1999</td>
</tr>
<tr>
<td>Course</td>
<td>September 7, 1999</td>
</tr>
<tr>
<td>Media</td>
<td>September 7, 1999*</td>
</tr>
<tr>
<td>Reports</td>
<td>September 7, 1999</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 7, 1999</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue and Innovative: September 7, 1999 Component: October 1, 1999</td>
</tr>
<tr>
<td>New Research</td>
<td>January 6, 2000</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

*A single copy of the media item must be included with submission material.

For complete submission forms, contact the APA toll free at 1-888-357-7924 and speak directly with an Answer Center Coordinator.
7:00 a.m. Sessions

PART I OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 30-34

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART I
7:00 a.m.-8:30 a.m.
Rooms 39/40, Upper Level, Convention Center

NOVEL APPROACHES TO THE TREATMENT OF IMPULSIVITY
Supported by Solvay Pharmaceuticals, Inc. and Pharmacia & Upjohn Company, Inc.

Chp.: Eric Hollander, M.D.

A Novel Approaches to the Treatment of Pathological Gambling
Eric Hollander, M.D., Concetta M. DeCaria, Ph.D., Tomer Begaz, B.A., Jared Finkell, B.A., Sherie Novotny, M.D., Charles Cartwright, M.D.

B Treatment of Compulsive Shopping and Sex Addiction
Donald W. Black, M.D.

C The Relationship Between OCD and Impulsivity
Joseph Zohar, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART I
7:00 a.m.-8:30 a.m.
Constitution Ballroom, Level 3B, Grand Hyatt

MOOD AND PSYCHOTIC DISORDERS IN WOMEN: AN UPDATE ON TREATMENT
Supported by Eli Lilly and Company

Chp.: Lee S. Cohen, M.D.
Co-Chp.: Ruth A. Dickson, M.D.

A Effects of Gonadal Steroids on Brain and Behavior
David R. Rubinow, M.D., Peter J. Schmidt, M.D.

B Mood and Psychotic Disorders in Women During the Childbearing Years
Lee S. Cohen, M.D.

C Course and Treatment of Bipolar Illness During Pregnancy and the Postpartum Period
Adèle C. Viguera, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART I
7:00 a.m.-8:30 a.m.
Independence Ballroom, Level 3B, Grand Hyatt

ANXIETY DISORDERS: FROM SCIENTIFIC RESEARCH TO CLINICAL PRACTICE
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Chp.: Mark H. Pollack, M.D.

A Recognition and Prevention of Anxiety in Children and Adolescents
John S. March, M.D.

B Panic Disorder: Initial Treatment Strategies and Beyond
Mark H. Pollack, M.D.

C Management Strategies for PTSD
Kathleen T. Brady, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART I
7:00 a.m.-8:30 a.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

ASSESSMENT AND TREATMENT OF PSYCHIATRIC DISORDERS IN THE ELDERLY
Supported by Johnson & Johnson

Chp.: W. Walter Menninger, M.D.

A Adaptational Changes in Late Life
W. Walter Menninger, M.D.

B Advances in the Treatment of Agitation in the Elderly
Stuart C. Yudofsky, M.D.

C Treating Psychiatric Disorders in the Nursing Home
George T. Grossberg, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART I
7:00 a.m.-8:30 a.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

ADVANCES IN THE TREATMENT OF GERIATRIC DEPRESSION
Supported by SmithKline Beecham Pharmaceuticals

Chp.: Bruce G. Pollock, M.D.

A Pharmacology of Antidepressants Pertinent to Older Patients
Bruce G. Pollock, M.D.

B Treating Severe Melancholic Depression: New Data
Benito H. Mulsant, M.D., Bruce G. Pollock, M.D., Robert Nebes, Ph.D., Mark D. Miller, M.D., John T. Little, M.D., Jackie Stack, M.S.N., Charles F. Reynolds III, M.D.

C Treating Depression in the Oldest-Old: Findings from the Harvard/HRCA Study
Carl Salzman, M.D.

Discussant: Benito H. Mulsant, M.D.
WEDNESDAY

8:00 a.m. Sessions

COURSES 75-80
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 75
8:00 a.m.-12 noon
Room 4, Meeting Room Level, Renaissance Washington

INSANITY DEFENSE EVALUATIONS
Director: Phillip J. Resnick, M.D.

COURSE 76
8:00 a.m.-12 noon
Rooms 8/9, Meeting Room Level, Renaissance Washington

HOW TO MEASURE OUTCOMES WITHOUT BREAKING THE BANK
Co-Directors: Gabriel Kaplan, M.D., James R. Westphal, M.D.

COURSE 77
8:00 a.m.-12 noon
Room 16, Meeting Room Level, Renaissance Washington

INDIVIDUAL AND COMMUNITY INTERVENTIONS IN DISASTER
Co-Directors: Michael Blumenfield, M.D., Ann E. Norwood, M.D.
Faculty: Robert J. Ursano, M.D., Jon A. Shaw, M.D.

COURSE 78
8:00 a.m.-12 noon
Pan American Room, Second Floor, Capital Hilton

DUAL DIAGNOSIS: ADVANCED CLINICAL APPLICATION
Director: Kenneth Minkoff, M.D.

COURSE 79
8:00 a.m.-12 noon
Senate Room, Second Floor, Capital Hilton

AUTISM AND ASPERGER'S SYNDROME ACROSS THE LIFE SPAN
Co-Directors: Kerim M. Munir, M.D., Ludwik S. Szymanski, M.D.

COURSE 80
8:00 a.m.-12 noon
South American Room B, Second Floor, Capital Hilton

PSYCHIATRIC DISORDERS RELATED TO EPILEPSY
Director: Dietrich P. Blumer, M.D.
Faculty: John Barry, M.D.

PSYCHIATRIC AND CLINICAL MANIFESTATIONS
APA Commission on AIDS
Chp.: Marshall Forstein, M.D.

A Mood Disorders and HIV Disease
Stephen J. Ferrando, M.D.

B Psychosis and HIV Disease
Francine Courous, M.D.

C Somatic Symptoms and Their Psychotherapeutic Implications
Marshall Forstein, M.D.

CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Room 27, Lower Level, Convention Center

REFRACTORY DEPRESSION AND ECT
Moderator: Mark D. Beale, M.D.
Presenter: Teresa A. Rummans, M.D.
Discussants: Harold A. Sackeim, Ph.D., Richard D. Weiner, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 81-86
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 81
9:00 a.m.-4:00 p.m.
Room 2, Meeting Room Level, Renaissance Washington

HYPNOSIS IN PSYCHIATRY
Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D., Thomas Nagy, Ph.D.

COURSE 82
9:00 a.m.-4:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington

MULTIMODAL THERAPY FOR SEVERE EATING DISORDERS
Director: Kathryn J. Zerbe, M.D.
Faculty: Mae S. Sokol, M.D.

COURSE 83
9:00 a.m.-4:00 p.m.
Room 7, Meeting Room Level, Renaissance Washington

ASSESSING THREATS AND VIOLENCE AT WORK AND HOME
Director: James R. Missett, M.D.
Faculty: Paul S.D. Berg, Ph.D.
COURSE 84 9:00 a.m.-4:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS
Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

COURSE 85 9:00 a.m.-4:00 p.m.
Congressional Hall A, Ballroom Level, Renaissance Washington

A CLINICIAN’S GUIDE TO FUNCTIONAL BRAIN IMAGING
Co-Directors: Daniel G. Amen, M.D., Joseph C. Wu, M.D.
Faculty: Matthew S. Stubblefield, M.D.

COURSE 86 9:00 a.m.-4:00 p.m.
Congressional Room, Second Floor, Capital Hilton

PRACTICAL TECHNIQUES IN CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Director: Charles W. Popper, M.D.
Faculty: Barbara J. Coffey, M.D., Daniel F. Connor, M.D., Graham J. Emslie, M.D., Stanley P. Kutcher, M.D., Martin H. Teicher, M.D.

DISCUSSION GROUPS 6-7
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

6 Herbert D. Kleber, M.D., on Treatment of Addictions: Myths and Realities
Montreal Room, Second Floor, Marriott Metro Center

7 James W. Lomax II, M.D., on Spiritual Issues for Psychodynamic Psychiatry (For Residents Only)
Washington Room, Second Floor, Marriott Metro Center

LECTURES 14-15

LECTURE 14
9:00 a.m.-10:30 a.m.
Room 33, Lower Level, Convention Center

APA’S SEYMOUR D. VESTERMARK AWARD LECTURE
G. Alan Stoudemire, M.D.
Quo Vadis Psychiatry
Chp.: Jerald Kay, M.D.
Co-Chp.: Troy L. Thompson II, M.D.

LECTURE 15
9:00 a.m.-10:30 a.m.
Room 38, Upper Level, Convention Center

Criminal Profiling: Using the Tools of the Past Today
Caleb Carr
Chp.: Paula G. Panzer, M.D.
Co-Chp.: David M. McDowell, M.D.

Caleb Carr, a New York City native, has worked extensively in screenplay development for various film production companies, as well as in the theater. He was the co-founder of The Joker’s Institute, an independent theatrical company that staged both repertory works and productions of his own plays, all of which he directed and often served.
MASTER EDUCATOR CLINICAL CONSULTATIONS 10-11

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

10 Nada L. Stotland, M.D., on the Depressed Woman
Room 35, Lower Level, Convention Center

11 John M. Oldham, M.D., on Integrated Treatment of BPD
New York Room, Ballroom Level, Marriott Metro Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 21-23

MEDIA SESSION 21 9:00 a.m.-11:00 a.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

INTEGRATIVE MEDICINE: IMPLICATIONS FOR PSYCHIATRY
Chp.: Francis G. Lu, M.D.

37 Alternative Medicine
(29 minutes)

Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

Alternative, or complimentary, health systems are being integrated into American culture. From Chinese medicine to homeopathy to chiropractic, many features and systems can now be found in our physicians' offices. This video provides an overview of Chinese medicine, acupuncture, ayurveda, homeopathy, herbalism, naturopathy, osteopathy, massage and chiropractic. People explain how they're using one or more of these in their health care. We hear from some of the leading practitioners in the field of alternative medicine: Andrew Weil, M.D., Christiane Northrup, M.D., Fredi Kronenberg, M.D., and Nancy Lonsdorf, M.D.

38 The Faith Factor
(50 minutes)

Distributor: National Institute for Health Care Research
6110 Executive Boulevard, Suite 908
Rockville, MD 20852

This videotaped lecture presents a review of the empirical research and literature correlating religion/spirituality with physical and mental health as well as quality of life. Given by master lecturer Dale A. Matthews, M.D., Associate Professor of Medicine at Georgetown University School of Medicine in Washington, DC, the presentation focuses on an aspect of caring for the total person which is becoming increasingly important in both clinical care and medical school education. Addressing a medical student class, Dr. Matthews combines his knowledge of the scientific literature with a heartfelt passion for this previously neglected area.

MEDIA SESSION 22 9:00 a.m.-11:00 a.m.
Congressional Hall B, Ballroom Level, Renaissance Washington

TREATMENT ALGORITHMS AND PRACTICE MANAGEMENT
Co-Chps.: Russell F. Lim, M.D., John Luo, M.D.

39 Algorithm for the Pharmacotherapy of Schizophrenia
David N. Osser, M.D.

This is an internet expert system for advising psychiatrists in strategies to optimize the pharmacotherapy of schizophrenia. It covers first-onset patients, relapse management, unsatisfactory response, and when to use depot medications. A panel of seven Massachusetts psychopharmacologists and a subcommittee of the Alliance for the Mentally Ill of Massachusetts reviewed an earlier text version and provided detailed editorial commentary, which has been incorporated into the 266 files of this program. This application is a virtual psychopharmacology consultant. It asks the consultee questions about a patient and then, when enough information is supplied, displays detailed recommendations. Most question screens have "help" sections with definitions, criteria, differential diagnoses, or related advice. "Comment" screens appear at crucial points with additional explanations. The evidence basis of the clinical pathways is provided in context-sensitive references, which support all critical questions and recommendations. Other features include links to
WEDNESDAY

accessory prescribing information, capacity to store and retrieve consultation data on specific patients, potential to aggregate data on patient outcomes at each decision point, a feedback system for users to send comments to the developers at any time, and a function to view recently added material. As Internet access increases, disease management systems like this may become increasingly valuable to psychiatrists.

40 Booting Up Your Practice
Theron C. Bowers, M.D.

Although the computer is a common tool in many or most psychiatric practices, its use remains confined to primarily administrative jobs such as billing and scheduling. As a cognitive-based specialty with a primary task of collecting and evaluating patient information, electronic database management has numerous potential benefits for psychiatrists in all areas of practice. This presentation will explore issues regarding computerized clinical database management in psychiatric practice and will examine potential barriers and challenges in maintaining electronic records. It will also illustrate the benefits and goals of an efficient computerized clinical system by demonstrating a patient-tracking computer program based on a relational database. Using this program, the presenters will show the basic requirements of a patient-tracking system, such as records of progress notes, mental status examinations and medications. They will also demonstrate more advanced and specialized features in tracking a patient's progress and monitoring medication side effects. Finally, there will be instructions on implementing a computerized record-keeping system in private practice with a focus on effectively utilizing data in a variety of clinical reports.

MEDIA SESSION 23
9:00 a.m.-11:00 a.m.
Auditorium, Meeting Room Level, Renaissance Washington

THE STORY OF ADELE H: A STUDY OF OBSESSIVE AND UNREQUITED LOVE

Chp.: Seana H. Shaw, M.D.

41 The Story of Adele H.
(97 minutes)

Distributor: MGM/UA Home Video
10000 West Washington Boulevard
Culver City, CA 90232

The Story of Adele H. is a poignant and realistic portrayal of obsessive and unrequited love. The film is based on the diaries of Adele Hugo, the youngest daughter of the great novelist Victor Hugo. The film is true to life and portrays Adele's inability to form sustained loving attachments. She was consumed with the obsessive pursuit of an unavailable man who did not return her attentions. Adele most likely was severely depressed. Director Francois Truffaut portrays Adele's melancholy and her obsessive quests to secure the attention, love and promise of marriage from Lt. Pinson, an English soldier. Lt. Pinson, however, has no interest in her. In spite of repeated rejections, Adele is unrelenting and obsessively stalks him. Her fixation on this hopeless relationship never yields to the reality of the situation, and her loss of reality extends to disorientation and psychosis. Adele kept a diary for many years and described her passions and longings. The diary was not discovered until this century. It was in code and not deciphered until modern times. Adele Hugo's life and diary are of literary importance. Truffaut's film, based on these diaries, stimulated interest in the Hugo family and in the tragic life of Adele.

NEW RESEARCH ORAL/SLIDE SESSIONS 9-10
9:00 a.m.-10:30 a.m.

9 MOOD DISORDERS
Rooms 23/24, Lower Level, Convention Center

10 DEPRESSIVE DISORDERS AND SUICIDAL BEHAVIOR
Rooms 25/26, Lower Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

REVIEW OF PSYCHIATRY: PART IV
9:00 a.m.-12:30 p.m.
Rooms 30/31, Lower Level, Convention Center

DISRUPTIVE DISORDERS IN CHILDREN

Chp.: Robert L. Hendren, D.O.

16 ADHD
Timothy E. Wilens, M.D.

17 Conduct Disorder
Hans Steiner, M.D.

18 Oppositional Defiant Disorder
Joseph M. Rey, M.D.

19 Substance Abuse and Disruptive Behavior Disorders
Paula D. Riggs, M.D.

20 Violence and Mental Disorders in Youth
Jerry M. Wiener, M.D.

SOCIAL SECURITY WORKSHOP
9:00 a.m.-12 noon
Paris Room, Ballroom Level, Marriott Metro Center

DISABILITY EVALUATION UNDER SOCIAL SECURITY
Social Security Administration, APA Office of Quality Improvement and Psychiatric Services and APA Consortium on Organized Service Systems

Chp.: Jerome E. Shapiro, M.D.
Co-Chp.: Dale N. Cox, B.S.

63
WEDNESDAY

WORKSHOPS

COMPONENTS 35-39

COMPONENT WORKSHOP 35  9:00 a.m.-10:30 a.m.
Room 28, Lower Level, Convention Center
CURRENT ISSUES ON ABUSE AND MISUSE OF PSYCHIATRY
APA Committee on International Abuse of Psychiatry and
Psychiatrists and APA Committee on Abuse and Misuse of
Psychiatry in the United States
Chp.: Jose E. De La Gandara, M.D.
Participants: Abraham I. Halpem, M.D., Houshang G. Hamadani, M.D.,
Margaret F. Jensvold, M.D., Rigoberto Rodriguez, M.D., Andrew
Siegel, M.D.

COMPONENT WORKSHOP 36  9:00 a.m.-10:30 a.m.
Room 29, Lower Level, Convention Center
EXECUTIVE ROLES FOR PSYCHIATRISTS IN THE 21ST
CENTURY
APA Committee on Psychiatric Administration and Management
Chp.: Philip E. Veenhuis, M.D.
Participants: Dave M. Davis, M.D., W. Walter Menninger, M.D.,
Gary E. Miller, M.D., Stuart B. Silver, M.D.

COMPONENT WORKSHOP 37  9:00 a.m.-10:30 a.m.
Farragut Square Room, Level 5B, Grand Hyatt
FUNDING MANAGED CARE AND PUBLIC PSYCHIATRIC
SERVICE TODAY
APA Consortium on Funding for Services
Chp.: Arthur T. Meyerson, M.D.
Participants: Richard C. Lippincott, M.D., Michael English, Ph.D.,
Steven M. Katz, M.D.

COMPONENT WORKSHOP 38  9:00 a.m.-10:30 a.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center
OUTPATIENT DETOXIFICATION TREATMENT SERVICES
APA Committee on Treatment Services for Addicted Patients
Chp.: Joseph A. Virzi, M.D.
Participants: George F. Kолоднер, M.D., Charles P. O'Brien, M.D.

COMPONENT WORKSHOP 39  9:00 a.m.-10:30 a.m.
London Room, Ballroom Level, Marriott Metro Center
CULTURALLY COMPETENT CARE OF LESBIAN, GAY,
BISEXUAL AND TRANSGENDERED PATIENTS
APA Northern California Psychiatric Society's Committee on Lesbian,
Gay, Bisexual and Transgender Issues
Chp.: Dan H. Karasic, M.D.
Participants: Karin L. Hastik, M.D., Eugene Lee, M.D.

ISSUES 34-47

ISSUE WORKSHOP 34  9:00 a.m.-10:30 a.m.
Rooms 13/14, Lower Level, Convention Center
SILDENAFIL CITRATE: A SEX THERAPIST'S PERSPECTIVE
Chp.: Richard Kogan, M.D.
Participants: Kenneth P. Rosenberg, M.D., Ellen L. Hollander, M.D.

ISSUE WORKSHOP 35  9:00 a.m.-10:30 a.m.
Room 15, Lower Level, Convention Center
THE U.S. HEALTH CARE FINANCING ADMINISTRATION
REPORT: COMPLIANCE IN THE RESIDENT OUTPATIENT CLINIC
Chp.: Sherri Hansen-Grant, M.D.
Participants: Stephen J. Weiler, M.D., Nancy E. Barklage, M.D.

ISSUE WORKSHOP 36  9:00 a.m.-10:30 a.m.
Room 20, Lower Level, Convention Center
THE MID-CAREER CLINICIAN: CHOICES AND CHALLENGES
Chp.: Julie K. Pease, M.D.
Participants: Benjamin Crocker, M.D., John F. Zerner, M.D.

ISSUE WORKSHOP 37  9:00 a.m.-10:30 a.m.
Rooms 21/22, Lower Level, Convention Center
RESIDENTS CONDUCTING PSYCHODYNAMIC
PSYCHOTHERAPY
Chp.: Leah J. Dickstein, M.D.
Participants: William R. Hartman, M.D., Artie A. Bates, M.D.

ISSUE WORKSHOP 38  9:00 a.m.-10:30 a.m.
Room 36, Lower Level, Convention Center
CLINICAL ASPECTS OF HIV AND AIDS AMONG HISPANICS
Chp.: Pedro Ruiz, M.D.
Participants: Lourdes M. Domínguez, M.D., Humberto L.
Martinez, M.D., Francisco Fernandez, M.D., Ricardo Galbis, M.D.

ISSUE WORKSHOP 39  9:00 a.m.-10:30 a.m.
Room 37, Lower Level, Convention Center
COPING WITH MALPRACTICE
Chp.: Kenneth C. Olson, M.D.
Participant: Larry Riley, J.D.

ISSUE WORKSHOP 40  9:00 a.m.-10:30 a.m.
Conference Theatre, Level 1B, Grand Hyatt
TEACHING BRIEF THERAPY IN A MANAGED CARE CLINIC
Chp.: Nancy B. Kaltreider, M.D.
Participants: Ellen Haller, M.D., Jacquelyn B. Chang, M.D.
**WEDNESDAY**

**ISSUE WORKSHOP 41**
9:00 a.m.-10:30 a.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

**SPECT IMAGING: CLINICAL APPLICATION FOR DIAGNOSIS**
Co-Chps.: Malcolm D. Roberts, M.D., Thomas Yuschok, M.D.

**ISSUE WORKSHOP 42**
9:00 a.m.-10:30 a.m.
Buflfinch/Renwick Rooms, Level 3B, Grand Hyatt

**ETHICAL BOUNDARIES IN ALTERNATIVE THERAPIES**
Co-Chps.: Antoinette W. Jakobi, M.D., Lisa M. Rosica, D.O.

**ISSUE WORKSHOP 43**
9:00 a.m.-10:30 a.m.
Burnham Room, Level 3B, Grand Hyatt

**THE USE OF SPIRITUALITY GROUPS IN PSYCHIATRIC TREATMENT**
Chp.: Nalini V. Juthani, M.D.
Participants: David B. Marcotte, M.A., Ricardo Bernal, M.D.

**ISSUE WORKSHOP 44**
9:00 a.m.-10:30 a.m.
Latrobe Room, Level 3B, Grand Hyatt

**MODELS OF PSYCHIATRIC CARE FOR NATIVE COMMUNITIES**
Co-Chps.: Cornelia Wieman, M.D., Gary A. Chaimowitz, M.D.
Participant: Andrew Hackett, M.D.

**ISSUE WORKSHOP 45**
9:00 a.m.-10:30 a.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

**VIOLENCE DENIED BEGETS MORE VIOLENCE**
Co-Chps.: Levon Z. Boyajian, M.D., Haikaz M. Grigorian, M.D.
Participants: Alice Kassabian, D.S.W., Diane Kupelian, Ph.D.

**ISSUE WORKSHOP 46**
9:00 a.m.-10:30 a.m.
McPherson Square Room, Level 5B, Grand Hyatt

**MEDICAL SCHOOL RESPONSE TO STUDENT SUICIDE**
Chp.: Donald A. Misch, M.D.
Participants: Ruth-Marie Fincher, M.D., Mason Thompson, M.D.

**ISSUE WORKSHOP 47**
9:00 a.m.-10:30 a.m.
Grand Ballroom A, Ballroom Level, Marriott Metro Center

**CLINICAL AND FORENSIC ASPECTS OF SEXUAL HARASSMENT**
Chp.: Malkah T. Notman, M.D.
Participants: Linda M. Jorgenson, J.D., Elissa P. Benedek, M.D., Carl P. Malmquist, M.D.

**11:00 a.m. Sessions**

**DISCUSSION GROUP 8**
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.

Francisco Fernandez, M.D., on Challenges in HIV Care for Psychiatrists
Montreal Room, Second Floor, Marriott Metro Center
LECTURE 17
11:00 a.m.-12:30 p.m.
Room 38, Upper Level, Convention Center
Evan Stark, Ph.D.

Framing and Reframing Battered Women in Mental Health Settings: New Approaches to Understanding and Treatment
Chp.: Carole L. Warshaw, M.D.
Co-Chp.: Gail E. Robinson, M.D.

Evan Stark, Ph.D., presents a critical review of what is known about the causes and consequences of woman battering and discusses intervention and treatment strategies in mental health settings. Drawing on case material from his clinical and forensic practice, Dr. Stark describes the dynamics of coercive control in battering relationships and discusses strategies for assessing risks to all parties involved, including children. He evaluates theories of etiology and current approaches to diagnosis, treatment and prevention and delineates therapeutic dilemmas in work with victims and perpetrators. Dr. Stark is Associate Professor of Public Administration and Social Work at Rutgers University in Newark, New Jersey, and Co-Director of the Domestic Violence Training Project in New Haven, Connecticut. A founder of one of the first battered women’s shelters in the U.S., Dr. Stark has done pioneering research and worked as a therapist with violent men. From the late 1970s through the 1980s, Dr. Stark and Dr. Anne Flinkraft conducted a series of research projects that identified domestic violence as the leading cause of female injury and as a major factor in child abuse and a range of women’s health and mental health problems. The findings of this work are summarized in their book Women at Risk: Domestic Violence and Women’s Health. The recipient of numerous awards for his contribution to women’s health, Dr. Stark has served as a consultant to the Centers for Disease Control and Prevention, the National Institute of Justice, the U.S. Military and child protection agencies in several states. He has also served as chairperson of the U.S. Surgeon General’s Working Group on Domestic Violence. Dr. Stark received his doctoral degree in sociology from the State University of New York in Binghamton and his master’s degree in social work from Fordham University in Tarrytown, New York.

FRONTIERS OF SCIENCE LECTURE SERIES

THESE SESSIONS WILL BE AUDIOTAPED.

12 Robert Michels, M.D., on Psychodynamic Psychotherapy
Room 35, Lower Level, Convention Center

13 Jack M. Gorman, M.D., on Treatment-Refractory Depression
New York Room, Ballroom Level, Marriott Metro Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 24-26

MEDIA SESSION 24
11:00 a.m.-2:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

HOMOSEXUALITY: FROM HOMOPHOBIC PREJUDICE TO GAY/LESBIAN UNDERSTANDING
Chp.: Dan H. Karasic, M.D.

42 Kamikaze Summer
(60 minutes)

Distributor: The Cinema Guild
1897 Broadway, Suite 506
New York, NY 10019-5904

Starting from San Francisco, a gay man and a lesbian take an extended tour around the states in the West, where anti-gay sentiment has been active, politically, and where there is an attempt to limit and deprive gay and lesbian citizens of political power. The couple interview many different groups who have an anti-gay and anti-lesbian agenda and through this exposure, demonstrate the political power of the anti-gay movement.

43 Pride Divide
(57 minutes)

Distributor: Filmakers Library
124 East 40th Street
New York, NY 10016

From the producers of the award winning Last Call at Maud’s comes this groundbreaking exploration of the gender gap between gays and lesbians. Politically united against global homophobia, they are poles apart on many life issues. Oddly enough, their struggle of male versus female mirrors many traditional conflicts inherent in straight relationships. The gay and lesbian community is not immune to gender conditioning. Here is the classic battle of the sexes from a new perspective, leavened with humor. The film looks at the issues around male domination versus female submission: promiscuousness versus commitment, exaltation of the body versus the spirit, AIDS support versus breast cancer support. We hear about the subtle chauvinism by gay activists who excluded lesbians from their political and social life, especially in the conformist 1950s. Now, however, both sides seem willing to discuss these differences openly. Individuals involved in this dialogue include Martin Duberman, Barney Frank, Barbara Gittings, Simon LeVay, Camille Paglia and others. This lively film is sure to rouse discussion.

MASTER EDUCATOR CLINICAL CONSULTATIONS 12-13
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.
MEDIA SESSION 25 11:00 a.m.-12 noon
Congressional Hall B, Ballroom Level, Renaissance Washington

ASK THE EXPERTS ABOUT COMPUTERS AND YOUR PRACTICE

Co-Chps.: Russell F. Lim, M.D., John Luo, M.D.

Ask the Experts About Computers and Your Practice
Rima Styra, M.D., Steven E. Hyler, M.D.

MEDIA SESSION 26 11:00 a.m.-12:30 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

PSYCHODRAMA AND THERAPEUTIC EDUCATION

Chp.: Ian E. Alger, M.D.

44 Behind the Mask: Teaching Spontaneous Theater
(50 minutes)

Distributor: Ian E. Alger, M.D.
500 East 77th Street, #132
New York, NY 10162

This video presentation is a collage of six discrete examples of the teaching of spontaneous therapeutic theater. This method promotes the enactment of emotional conflicts through role play and fosters the expansion of an individual's repertoire in actual life. In other applications of this method, special hats and puppets are used in acting and reenacting feelings with emotional and social depth, paying special attention to plays and spontaneous creations evoked during the sessions. Dr. Ferruccio A. Di Cori is a psychiatrist who has practiced in both the United States and Italy and who currently presents an intense course in his methods at the University of Rome, where he is Professor of Psychiatry in the Department of Literature. In its six segments, the tape shows a monologue by a girl who experiences sleep-walking; two people struggling to unravel misinterpretations; a young woman expressing various aspects of herself through her vocal intonations; two girls enacting their mutual narcissism in pantomime; symbolic drawings and the attempts to interpret them; and the power of musical background in affecting free association. The audience at the presentation will be engaged in discussion by the presenter, and exploration of ways in which these techniques can be applied to their own clinical milieu and work will be explored.

Discussant: Ferruccio A. Di Cori, M.D.

MEDICAL UPDATE 3
11:00 a.m.-12:30 p.m.
Rooms 13/14, Lower Level, Convention Center

MANAGEMENT OF LOW BACK PAIN

Chp.: Roger Peele, M.D.
Presenter: Richard E. Grant, M.D.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 Jeffrey A. Lieberman, M.D., on Scientific, Methodological and Ethical Issues in Schizophrenia Research
Washington Room, Second Floor, Marriott Metro Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 17-25

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Room 15, Lower Level, Convention Center

DEPRESSION AND SUICIDE IN SCHIZOPHRENIA

Chp.: Rodolfo D. Fahrer, M.D.
Co-Chp.: Pinkhas Sirota, M.D.

11:00 a.m.

50 Life Events Trigger Depression in Early Schizophrenia
Joseph Ventura, Ph.D., Keith H. Nuechterlein, Ph.D., Kenneth L. Subotnik, Ph.D., Michael J. Gitlin, M.D., Julie Sharou, B.A., Jim Mintz, Ph.D.

11:30 a.m.

51 National Collaborative Study of Early Psychosis and Suicide: An Introduction
Ioline D. Henter, M.A., Ezra S. Susser, M.D., Ramin Mojtabai, M.D., Richard Jed Wyatt, M.D.

12 noon

52 Clinical Correlates of Insight in Psychotic Disorders
Giovanni B. Cassano, M.D., Stefano Pini, M.D., Liliana Dell’Osso, M.D., Marco Salettoni, M.D., Giovanni Maracci, M.D., Alessandra Papasogli, M.D., Serena Vignoli, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Room 20, Lower Level, Convention Center

PSYCHIATRIC ISSUES IN THE PUBLIC HEALTHARENA

Chp.: Richard A. Fields, M.D.
Co-Chp.: John Wallace, M.D., J.D.

11:00 a.m.

53 What the States Are Doing to Provide Services to Families of Adults with Severe Mental Illness
Lisa B. Dixon, M.D., Howard H. Goldman, M.D., Abdighani Hirad, M.S.

(Continued on next page)
11:30 a.m.
54 The Effects of Education About Depression in Primary Care
   Christopher Thompson, M.D.

12 noon
55 The Association Between Psychiatric Comorbidity and Retention in a Sample of Women Attending Comprehensive Addiction Treatment
   Catherine A. Nageotte, M.D., Thomas M. Brady, M.P.H.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Rooms 25/26, Lower Level, Convention Center

SCREENING AND TREATMENT OF SUBSTANCE ABUSE
Chp.: Jean L. Cadet, M.D.
Co-Chp.: Caroline O. Abolade, M.D.

11:00 a.m.
56 Enhancing Treatment of Cocaine-Dependent Mothers
   Joseph R. Volpicelli, M.D., John Monterosso, Irene Markman, M.S., Janet I. Filing, Ph.D., Charles P. O'Brien, M.D.

11:30 a.m.
57 Naltrexone Plus Cognitive-Behavior Therapy for Alcoholism
   Raymond F. Anton, M.D., Darlene H. Moak, M.D., L. Randolph Waid, Ph.D., Patricia K. Latham, Ph.D., James K. Dias, Ph.D.

12 noon
58 The Drug Abuse Screening Test for Adolescents
   Steve Martino, Ph.D., Carlos M. Grilo, Ph.D., Dwain C. Fehon, Psy.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Room 27, Lower Level, Convention Center

NEW ISSUES IN DIAGNOSIS AND TREATMENT OF ANXIETY DISORDERS
Chp.: William B. Lawson, M.D.
Co-Chp.: William Guy, M.D.

11:00 a.m.
59 Integrated Therapy of Panic Disorder: A Controlled Study
   Gabriella Ba, M.D., Caterina Vigano, M.D.

11:30 a.m.
60 Long-Term Antidepressant Treatment of Panic/Agoraphobia
   Matig R. Mavissakalian, M.D., James Perel, Ph.D.

12 noon
61 Recognition and Management of a Subgroup of OCD and Tic Disorders
   Susan E. Swedo, M.D.
   THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Independence Ballrooms B/C, Level 5B, Grand Hyatt

NEONATAL AND CHILDHOOD EXPOSURE TO PSYCHOTROPICS

Chp.: Roslyn Seligman, M.D.
Co-Chp.: Lisa A. Spurlock, M.D.

11:00 a.m.
68 Psychotropic Medication Trends in Preschoolers
   Julie M. Zito, Ph.D., Daniel J. Safer, M.D., James F.
   Gardner, S.C.M., Susan Dosreis, B.S., Linda W. Phelps, M.A.,
   Richard E. Johnson, Ph.D.

11:30 a.m.
69 Neonatal Outcome Associated with Lithium Use During
   Pregnancy
   Adele C. Viguera, M.D., Lee S. Cohen, M.D., Ruta M.
   Nonacs, M.D., Lynn R. Grush, M.D.

12 noon
70 Maternal Use of Psychotropics During Lactation:
   Quantifying Infant Exposure
   Lee S. Cohen, M.D., Zachary N. Stowe, M.D., Aoife M.
   Murray, M.A., Heather Groninger, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Independence Ballrooms F/G, Level 5B, Grand Hyatt

AXIS II COMORBIDITY

Chp.: Samuel O. Okpaku, M.D.
Co-Chp.: Ahsan A. Naseem, M.D.

11:00 a.m.
71 Axis II Comorbidity with BPD in Adolescents
   Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., William S.
   Edell, Ph.D., Thomas H. McGlashan, M.D.

11:30 a.m.
72 Axis I Comorbidity with DSM-IV Axis II Disorders
   Thomas H. McGlashan, M.D., Carlos M. Grilo, Ph.D., Leslie C.
   Morey, Ph.D., Andrew E. Skodol II, M.D., Robert Stout, Ph.D.,
   M. Tracie Shea, Ph.D., John G. Gunderson, M.D.

12 noon
73 Comorbidity Among Patients with DSM-IV Personality
   Disorders
   Carlos M. Grilo, Ph.D., Thomas H. McGlashan, M.D., Andrew E.
   Skodol II, M.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D.,
   Mary C. Zanarini, Ed.D., John G. Gunderson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

NEW HORIZONS IN DEPRESSION

Chp.: Kenneth M. Rogers, M.D.
Co-Chp.: Charles M. Beasley, Jr., M.D.

11:00 a.m.
74 Diagnostic Stability of MDD
   John W. Goethe, M.D., Bonnie L. Szarek, R.N.

11:30 a.m.
75 Methylfolate As an Adjunct in SSRI Refractory Depression
   Jonathan E. Alpert, M.D., Mark G. Pingol, B.A., Meredith A.
   Rankin, B.A., Margarita L. Delgado, B.A., David Mischou, M.D.,
   Andrew A. Nierenberg, M.D., John J. Worthington III, M.D.,
   Shamsah B. Sonawalla, M.D., Maurizio Fava, M.D.

12 noon
76 Brain Function and the Placebo Response
   Andrew F. Leuchter, M.D., Ian A. Cook, M.D., Elise Witte, Ph.D.,
   Michelle Abrams, R.N., Sandy Veneman, Ph.D., Susan
   Rosenberg-Thomp, M.N., Sebastian H.J. Uijtdehaa, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 40-43

COMPONENT WORKSHOP 40 11:00 a.m.-12:30 p.m.
Rooms 23/24, Lower Level, Convention Center

EXAMINING GLOBAL PSYCHIATRISTS' TRAINING CURRICULA
   APA Committee on International Education

Co-Chps.: Winston W. Shen, M.D., Michael J. Napoletano, M.D.
Participants: David G. Fort, M.D., F. Moises Gaviria, M.D.,
   Suzane M. Renaud, M.D., Miguel A. Leibovich, M.D., John B.
   Sikorski, M.D., Eugenio M. Rothe, M.D., Pedro Ruiz, M.D.

COMPONENT WORKSHOP 41 11:00 a.m.-12:30 p.m.
Room 28, Lower Level, Convention Center

CURRENT AND FUTURE TRENDS IN THE ASSESSMENT AND
   DIAGNOSIS OF INFANTS, TODDLERS AND PRE-SCHOOLERS
   APA Committee on Pre-School Children

Co-Chps.: Harry H. Wright, M.D., Kyle D. Prueitt, M.D.
Participants: Robert N. Emde, M.D., Michael S. Scheeringa, M.D.

COMPONENT WORKSHOP 42 11:00 a.m.-12:30 p.m.
Farragut Square Room, Level 5B, Grand Hyatt

ETHICAL CHALLENGES IN RISK-BASED CONTRACTING
   APA Committee on Managed Care

Co-Chps.: Barry F. Chaitin, M.D., Joanne H. Ritvo, M.D.
Participants: Anthony M. D’Agostino, M.D., Edward Gordon, M.D.
COMPONENT WORKSHOP 43
11:00 a.m.-12:30 p.m.
Independence Ballrooms D/E, Level 5B, Grand Hyatt

DISABILITY IN MENTAL DISORDERS FOR PSYCHIATRISTS
APA Committee on Psychiatric Diagnosis and Assessment

Co-Chps.: Frederick G. Guggenheim, M.D., Bedirhan Ustun, M.D.
Participants: Cille Kennedy, Ph.D., Shekhar Saxena, M.D., Harold Alan Pincus, M.D.

ISSUES 48-56

ISSUE WORKSHOP 48
11:00 a.m.-12:30 p.m.
Room 36, Lower Level, Convention Center

CLINICIAN-EDUCATOR TRACK IN RESIDENCY TRAINING

Chp.: Michael D. Jibson, M.D.
Participants: Anita R. Kumar-Gill, M.D., Donna J. Champine, M.D.

ISSUE WORKSHOP 49
11:00 a.m.-12:30 p.m.
Room 37, Lower Level, Convention Center

SPIRITUAL/RELIGIOUS ASSESSMENT IN CLINICAL WORK

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: David B. Larson, M.D.

ISSUE WORKSHOP 50
11:00 a.m.-12:30 p.m.
Bulfinch/Renwick Rooms, Level 3B, Grand Hyatt

WHEN PSYCHIATRISTS LIVE WITH MENTAL ILLNESS
National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Elizabeth A. Baxter, M.D., Mark L. Dembert, M.D., Suzanne E. Vogel-Scibilia, M.D., Laurie M. Flynn

ISSUE WORKSHOP 51
11:00 a.m.-12:30 p.m.
Burnham Room, Level 3B, Grand Hyatt

ETHICAL DILEMMAS IN TREATING THE HOMELESS MENTALLY ILL

Co-Chps.: David M. Band, M.D., Stephen M. Goldfinger, M.D.
Participants: Marcella A. Maguire, Ph.D., Lien A. Hung, M.D., Donald C. Chuah, M.D., Mihaela Boran, M.D., Alexander A. Meskl, M.D.

ISSUE WORKSHOP 52
11:00 a.m.-12:30 p.m.
Latrobe Room, Level 3B, Grand Hyatt

THE PSYCHIATRIST AND PARKINSON’S DISEASE

Co-Chps.: David M. Roane, M.D., John D. Rogers, M.D.

ISSUE WORKSHOP 53
11:00 a.m.-12:30 p.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

BIOBEHAVIORAL TREATMENT OF ADDICTIVE DISORDERS

Chp.: Richard J. Frances, M.D.
Participants: Sheldon I. Miller, M.D., Sheila B. Blume, M.D., Frances R. Levin, M.D., Lionel Solursch, M.D., Robert B. Millman, M.D.

ISSUE WORKSHOP 54
11:00 a.m.-12:30 p.m.
Independence Ballrooms H/I, Level 5B, Grand Hyatt

THE MEDIA AND REACHING OUT TO THE UNDERSERVED

Co-Chps.: Gabriela Cora-Locateili, M.D., Elmer E. Huerta, M.D.
Participant: Pablo Sanchez

ISSUE WORKSHOP 55
11:00 a.m.-12:30 p.m.
McPherson Square Room, Level 5B, Grand Hyatt

DEATH IN THE FAMILY: FAMILY TRADITION AND THE WILL

Chp.: Gerald Schneiderman, M.D.
Participant: Felice Kirsh, L.L.B.

ISSUE WORKSHOP 56
11:00 a.m.-12:30 p.m.
London Room, Ballroom Level, Marriott Metro Center

IS RETRAINING FOR CLINICIANS NECESSARY?

Co-Chps.: Daniel Castellanos, M.D., Sanford I. Cohen, M.D.
Participants: Michael J. Bennett, M.D., Paul Jay Fink, M.D.

12 noon Sessions

FORUMS 5-7

FORUM 5
12 noon-1:30 p.m.
Rooms 21/22, Lower Level, Convention Center

HATE FOR LOVING: HOW SOCIETAL OPPRESSION IMPACTS LESBIAN AND GAY MENTAL HEALTH

Chp.: Daniel W. Hicks, M.D.
Participants: Jeanine Cogan, Ph.D., Lynn S. Feldman, D.O., Mark H. Townsend, M.D., Neil C. Williams, M.D., Randy Pumphrey, D.Div.

FORUM 6
12 noon-1:30 p.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

UPDATE ON THE PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH BPD
APA Steering Committee on Practice Guidelines

Co-Chps.: John S. McIntyre, M.D., Deborah A. Zarin, M.D.
Participant: John M. Oldham, M.D.
WEDNESDAY

FORUM 7 12 noon-1:30 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

MANAGING THE PROCESS OF CHANGE: QUALITY, FINANCING AND PATIENTS' RIGHTS
Chp.: Eliot Sorel, M.D.
Participants: Rachel Jenkins, M.D., Laurie M. Flynn, Darrel A. Regier, M.D.

NEW RESEARCH POSTER SESSION 11
12 noon-2:00 p.m.
Hall D, Lower Level, Convention Center

MOOD, SEXUAL AND GENDER IDENTITY DISORDERS, CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY; AND FORENSIC PSYCHIATRY

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 27
12:30 p.m.-2:00 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

JAZZ ALIVE!

Chp.: Edward K. Rynearson, M.D.

45 Robert Altman's Jazz 34: Remembrances of Kansas City Swing
(75 minutes)

Distributor: Rhapsody Films
42-2 Becket Hill Road
Lyme, CT 06371

This tribute to Kansas City's great 1930's scene brings together more than 20 of today's finest musicians for an extended jam session. With Joshua Redman, James Carter et al.

1:00 p.m. Sessions

COURSES 87-92
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 87 1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington

RELATIONAL THEORY AND KEY CLINICAL APPLICATIONS
Director: Jean B. Miller, M.D.
Faculty: Stella L. Blackshaw, M.D., Judith V. Jordan, Ph.D., Michael F. Myers, M.D.

COURSE 88 1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington

DISASTER PSYCHIATRY: ADVANCED TOPICS
Co-Directors: Robert J. Ursano, M.D., Michael Blumenfield, M.D.
Faculty: Ann E. Norwood, M.D., James R. Rundell, M.D., Arieh Y. Shalev, M.D.

COURSE 89 1:00 p.m.-5:00 p.m.
Congressional Hall B, Ballroom Level, Renaissance Washington

COMPUTER SURVIVAL GUIDE 1999
Co-Directors: Robert S. Kennedy, M.A., Thomas A.M. Kramer, M.D.

COURSE 90 1:00 p.m.-5:00 p.m.
Senate Room, Second Floor, Capital Hilton

DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.
Faculty: John M. Davis, M.D., Stephen R. Marder, M.D., Rajiv P. Sharma, M.D., William C. Wirshing, M.D.

COURSE 91 1:00 p.m.-5:00 p.m.
South American Room A, Second Floor, Capital Hilton

MALPRACTICE LIABILITY AND RISK MANAGEMENT

Director: Eugene L. Lowenkopf, M.D.
Faculty: Abe M. Rychik, J.D., Richard G. Hersh, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
South American Room B, Second Floor, Capital Hilton

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE

Director: Karl Doghramji, M.D.
Faculty: Thomas D. Hurwitz, M.D., John W. Winkelman, M.D.

2:00 p.m. Sessions

LECTURES 18-19

LECTURE 18
2:00 p.m.-3:30 p.m.
Room 32, Lower Level, Convention Center
Juan J. López-Ibor, Jr., Ph.D.

Personality Disorders Are Personality Disorders
Chp.: Pedro Ruiz, M.D.
Co-Chp.: Ann S. Maioney, M.D.

(Continued on next page)
WEDNESDAY

Psychiatry has had many problems in conceptualizing personality disorders. Sufficient clinical psychopathological and biological data now exist to consider these disorders from a broad perspective that includes both psychological and biological aspects. Juan J. López-Ibor, Jr., M.D., discusses models of personality and neurobiologic functioning that provide insights into the biological basis of behavior and differentiate pathological and normal forms of personality and behavior. Dr. López-Ibor, president-elect of the World Psychiatric Association, is Full Professor of Psychiatry and Head of the Psychiatric Unit of the San Carlos Hospital of the Complutense University of Madrid, Spain, and Coordinator for Mental Health for Madrid Area 7, which has about 700,000 inhabitants. He is a fellow or member of more than 47 national or international scientific societies and a member of the World Health Organization International Classification of Disorders (ICD-10) Task Force. The author or editor of 14 books and more than 200 papers in scientific journals, Dr. López-Ibor is a member of the Editorial Boards of several journals, including Comprehensive Psychiatry and General Hospital Psychiatry. Dr. López-Ibor received his medical and doctoral degrees from the Complutense University of Madrid and completed his psychiatric training at the University of Frankfurt in Germany, the Maudsley and Saint Bartholomew Hospitals in London, England, and the Cantonal Hospital of Vaud in Switzerland. International Psychiatrist Lecture Series

MEDIA SESSIONS 28-29

MEDIA SESSION 28 2:00 p.m.-5:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

THE PHYSICALLY CHALLENGED: SOCIAL AND LONGITUDINAL PERSPECTIVES

Chp.: John M. Dluhy, M.D.
46 My Country
(60 minutes)

Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

By telling the stories of three people with disabilities and their struggle for equal rights under the law, this film draws a powerful parallel between the efforts of disability rights activists and the civil rights struggle of the 1960s. It will be great for disability awareness programs and for discussions of disability rights issues. It should be a part of every college curriculum on disabilities.

47 Best Man: "Best Boy" and All of Us Twenty Years Later
(90 minutes)

Distributor: Only Child Motion Pictures, Inc.
P.O. Box 184
Beverly Hills, CA 90213

Filmmaker and psychotherapist Ira Wohl revisits his developmentally disabled cousin, Philly. Twenty years ago the two collaborated on
the Oscar-winning film, Best Boy. Now, at age 70, Philly gets ready for his bar mitzvah. Best Boy charts Philly's move out of his parent's home into a group residence and follows him as he achieves greater independence. The first film did not simply record Philly's story, but actually contributed to his development. In Best Man, Wohl looks at Philly's life 20 years later and plants the idea of having a bar mitzvah. This first person documentary examines Philly's relationship with Ira, with his peers at the residence, and the death of their parents. Wohl offers a warm portrait of the extended family and reveals the importance of family and tradition. Best Man is a celebration of loving kindness in the face of life's inevitable changes and challenges.

MEDIA SESSION 29 2:00 p.m.-5:00 p.m.
Auditorium, Meeting Room Level, Renaissance Washington

CREATING CONSUMERISM: HOW ADVERTISING SHARES OUR REALITY

Chp.: Richard E. D'Alli, M.D.

48 The Ad and the Ego
(57 minutes)

Distributor: California Newsreel
149 9th Street, Suite 420
San Francisco, CA 94103

You'll never look at an ad in the same way after screening The Ad and the Ego, the first comprehensive examination of advertising's impact on our culture of consumption. The film artfully combines clips from over 1200 familiar television ads with insights from some of our most astute media critics, resulting in a cultural psychoanalysis of late 20th century America and its principal inhabitants, Consumer Man and Woman. The average American is exposed to 1500 ads a day. This constant stream of messages sells us not just products but values, identities and our sense of what is "normal." Media theorist Stuart Ewen argues that advertising creates a "psychology of need," generating a boundless hunger for things; one thing you'll never hear in an ad is, "You're OK." The Ad and the Ego demonstrates the critical connections between consumerism, our debased public discourse, environmental degradation, and our blind faith in economic growth at any cost. This film will cause every viewer to take more seriously the central role of advertising in our society and our psyche.

49 Barbie Nation
(53 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

The Barbie doll is not just the world's most popular toy; she's a Rorschach test for our times and us. Barbie Nation is an investigation into the Barbie fad. It tells the story of the rise and fall of Ruth Handler, the woman who invented Barbie and co-founded Mattel, Inc., the world's largest toy company. Barbie Nation also visits Barbie conventions and an anti-Barbie demonstration; girls' play dates and Barbie Web pages. Everybody has a Barbie story, and the stories are about sexuality and sex roles, body image, breast cancer, anorexia, childhood development and the changing role of women in society.

Discussant: Jonathan M. Metzl, M.D.

REVIEW OF PSYCHIATRY: PART V
2:00 p.m.-5:30 p.m.
Rooms 3031, Lower Level, Convention Center

SCHIZOPHRENIA IN A MOLECULAR AGE

Chp.: Carol A. Tamminga, M.D.

21 The Multidimensional Phenotype of Schizophrenia
Peter F. Liddle, M.D.

22 The Implications of Early Sensory Processing and Subcortical Involvement for Cognitive Dysfunction in Schizophrenia
John Gruzelier, Ph.D.

23 Disruption of Information Flow Within Cortical-Limbic-Circuits and the Pathophysiology of Schizophrenia
Anthony A. Grace, Ph.D.

24 Functional Neuroimaging Applied to the Syndrome of Schizophrenia: Symptom, Treatment and Etiologic Observations
Henry H. Holcomb, M.D.

25 Molecular Biology and Antipsychotic Medications
S. Charles Schulz, M.D.

SYMPOSIUM 45-65

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Rooms 13/14, Lower Level, Convention Center

EATING DISORDERS: ORIGINS, TREATMENTS AND OUTCOMES

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A The Genetics of Anorexia Nervosa: New Findings
Walter H. Kaye, M.D., David S. Goldman, M.D., Wade H. Berrettini, M.D., Katherine A. Halmi, M.D., Price Foundation Study Group

B Bulimics with Substance Use Disorders
Marcia E. Rorty, Ph.D., Joel Yager, M.D., Stephen A. Wonderlich, Ph.D., Elizabeth Rossetto, Ph.D.

C Anorexia Nervosa: Prevention of Relapse
Katherine A. Halmi, M.D., W. Stewart Agras, M.D., James E. Mitchell, M.D., Scott J. Crow, M.D.

(Continued on next page)
WEDNESDAY

D Treatment of Bulimia Nervosa Patients Who Do Not Respond to Cognitive-Behavior Therapy
James E. Mitchell, M.D., Katherine A. Halmi, M.D., W. Stewart Agras, M.D., G. Terrence Wilson, Ph.D., Scott J. Crow, M.D.

E Treatment and Relapse in Eating Disorders
David B. Herzog, M.D., Elizabeth Ekeblad, B.A., Sherrie Selwyn, B.A., Cara Greenwood, B.A., Mark A. Blais, Ph.D., Andrea Flores, M.Ed., David Dorer, Ph.D.

BIPOLAR DISORDER: FROM RESEARCH TO THE COMPLEXITIES OF CLINICAL CARE

Chp.: William B. Lawson, M.D.

A Recent Genetic Findings in Bipolar Disorder
John I. Nurnberger, Jr., M.D., J. Raymond DePaulo, Jr., M.D., Mary C. Blehar, Ph.D., Elliott S. Gershon, M.D., Tatiana Foroud, Ph.D., Theodore A. Reich, M.D.

B What Do Animal Models Tell Us About Bipolar Disorder?
Aimee R. Mayeda, M.D., John R. Hofstadter, Ph.D.

C Spectrum of Mixed States: With Mania and Hypomania
Hagop S. Akiskal, M.D.

D Ethnicity and Treatment of Bipolar Disorder
William B. Lawson, M.D.

E Challenges in Treating Women with Bipolar Disorder
Katherine L. Wisner, M.D.

Discussant: Rodrigo A. Muñoz, M.D.

NEW INSIGHTS INTO TREATING POSTPARTUM DEPRESSION

Chp.: Susanne I. Steinberg, M.D.

A Postpartum Anxiety and Mood Disorders: Effect on Infant Development
Deirdre M. Ryan, M.B., Shaila Misri, M.D., Pratibha Reeyee, M.D.

B Paroxetine Levels in the Mother-Infant Dyad
Shaila Misri, M.D., Diana Carter, M.B., Deirdre M. Ryan, M.B.

C Medications During Pregnancy and Lactation: Defining Exposure
Zachary N. Stowe, M.D., Amy Hostetter, B.S., James C. Ritchie, Ph.D.

D Men Construct Fatherhood by Trial and Error: A Chilean and Canadian Study
Susanne I. Steinberg, M.D., Francois Bellavance, Ph.D., Enrique Jadresic, M.D., Daniela Zalaquett, M.D., Daniela Solori, M.A., Eric Belzlie, M.Sc.

E Sleep Deprivation in Pregnancy and Postpartum Depression
Barbara L. Parry, M.D., Megan Curran, B.A., Christine Stuenkel, B.S., Megumi Yokomizo, B.A., Leslie W. Tarn, M.D., Katherine A. Powell, J. Christian Gillin, M.D.

Cultural Issues for Psychiatrists and Patients

Chp.: Leah J. Dickstein, M.D.

A Gender As a Cultural Issue
Leah J. Dickstein, M.D.

B Back-Drop Culture and Latinos: Clinical Impact
Silvia W. Olarte, M.D.

C Gay Men and Lesbians: Culture Based on Social Stigma
Robert P. Cabaj, M.D.

D Clinical Work with African-American Women
Marilyn L. Martin, M.D.

E Psychiatric Diagnosis in American Indians
Ilenna M. Norton, M.D.

Discussant: Pedro Ruiz, M.D.
SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Rooms 25/26, Lower Level, Convention Center

THYROID HORMONE: NEUROBIOLOGY

Chp.: Mark A. Frye, M.D.

A CSF and Serum Iodothyronine in Depression
Mark A. Frye, M.D.

B The Use of Thyroid Hormones to Diminish the Cognitive Side Effects of Psychiatric Treatments
Robert A. Stern, Ph.D.

C T3 Acceleration Trials in Major Depression
Lori L. Altshuler, M.D.

D Adjunctive High-Dose Levothyroxine in Refractory Mood Disorders
Michael Bauer, M.D.

Discussant: Peter C. Whybrow, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.
Room 27, Lower Level, Convention Center

IMPACT OF PARITY AND MANAGED CARE ON MENTAL HEALTH CARE

Chp.: Darrel A. Regier, M.D.
Co-Chps.: Stuart M. Sotsky, M.D., Steven S. Shafstein, M.D.

A The Cost of Mental Health Insurance Parity
Darrel A. Regier, M.D., Sam Zuvekas, Ph.D., Agnes Rupp, Ph.D., Ellen M. Weissman, M.D., Stuart M. Sotsky, M.D., Edwin Hustead, Ph.D., Anne Rosenfeld

B Access to Managed Mental Health Services and Cost: Is There a Trade-Off?
Ellen M. Weissman, M.D., Karen Pettigrew, Ph.D., Stuart M. Sotsky, M.D., Darrel A. Regier, M.D.

C Assessment of Quality in Managed Mental Health Services
Stuart M. Sotsky, M.D., Darrel A. Regier, M.D., Ellen M. Weissman, M.D., Agnes Rupp, Ph.D.

D Financial Incentives in Managed Behavioral Health Care Plans
Agnes Rupp, Ph.D., Stuart M. Sotsky, M.D., Grayson S. Norquist, M.D., Darrel A. Regier, M.D.

E New Perspectives on Mental Health Treatment Needs
William E. Narrow, M.D., Darrel A. Regier, M.D., Agnes Rupp, Ph.D., Donald S. Rae, M.A.

Discussant: Mary Jane England, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 52 2:00 p.m.-5:00 p.m.
Room 29, Lower Level, Convention Center

NEGATIVE SYMPTOMS: BEYOND SCHIZOPHRENIA

Chp.: Igor I. Galynker, M.D.
Co-Chp.: William E. Reichman, M.D.

A Characterization and Treatment of Negative Symptoms in Nonschizophrenia Patients

B The Relationship of Negative Symptoms to Depression and Function in Dementia
William E. Reichman, M.D.

C Negative Symptoms in Frontotemporal Dementia
Bruce L. Miller, M.D., Kyle Boone, Ph.D.

D Negative Symptoms: Principal Component Analyses of Psychometric Scales in Nonschizophrenia Patients
Alexander Prikhojan, M.D., Igor I. Galynker, M.D., Naomi Vilkas, B.A., Richard N. Rosenthal, M.D.

Discussant: Robert S. Marin, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 53 2:00 p.m.-5:00 p.m.
Room 33, Lower Level, Convention Center

BIOLOGICAL DIMENSIONS OF PSYCHOTHERAPY

APA Commission on Psychotherapy by Psychiatrists

Chp.: William H. Sledge, M.D.

A It's Not You, It's Your Brain: Biology Talk in Therapy
Charles A. Morgan III, M.D.

B Toward a Biology of Cognitive-Behavior Therapy
Michael E. Thase, M.D., Jesse H. Wright, M.D.

C Potential Physiological Effects of the Psychotherapies
Molyn Leszcz, M.D.

D Neurobiology of Language in Psychotherapy
William H. Sledge, M.D.

E Genetics, Transference and Psychic Representation
David Reiss, M.D.

Discussant: David Weinberger, M.D.
THIS SESSION WILL BE AUDIOTAPEMED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.
Conference Theatre, Level 1B, Grand Hyatt

OPTIMIZING THE ADMINISTRATION OF ECT

Chp.: Andrew D. Krystal, M.D.

(Continued on next page)
A Resolving the Controversy Between Unilateral and Bilateral ECT: Optimization of ECT
Harold A. Sackeim, Ph.D., Joan Prudic, M.D., Davangere P. Devanand, M.D., Mitchell S. Nobler, M.D., Sarah H. Lisanby, M.D., Shoshana Peyser, C.S.W., Linda Fitzsimons, R.N.

B Comparison of Fixed Versus Titrated Dose in Right Unilateral ECT
W. Vaughn McCall, M.D., David Reboussin, Ph.D., Harold A. Sackeim, Ph.D., Richard D. Weiner, M.D.

C Optimizing ECT in Patients with Very High Seizure Thresholds and Those Taking Benzodiazepines
Richard D. Weiner, M.D., Andrew D. Krystal, M.D., Margaret D. Dean, M.D., Bradley V. Watts, M.D.

D The Role of Ictal EEG Data in Optimizing ECT Treatment
Andrew D. Krystal, M.D., Richard D. Weiner, M.D., Bruce Leber, Ph.D., Joan Prudic, M.D., Davangere P. Devanand, M.D., Harold A. Sackeim, Ph.D.

Discussant: Charles H. Kellner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

PEDIATRIC PSYCHOPHARMACOLOGY
Chp.: Mark A. Riddle, M.D.

A Effects of Long-Term Treatment with Stimulants in Children with ADHD: Findings from Three Randomized Clinical Trials
Howard Abikoff, Ph.D.

B A Randomized Controlled Trial of Lithium Prophylaxis in Adolescent Bipolar Disorder
Neal D. Ryan, M.D.

C OCD Multisite Treatment Studies
John S. March, M.D.

D A Multisite Treatment of Anxiety Disorders
Laurence L. Greenhill, M.D.

E Psychopharmacology of Autism
Christopher J. McDougle, M.D.

F Treatment of Adolescents with Depression: Research Perspectives
Benedetto Vitiello, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

AGING OF PATIENTS WITH SCHIZOPHREANIA
Chp.: Dilip V. Jeste, M.D.
Co-Chp.: Carl I. Cohen, M.D.
C Importance of Gender Analysis of Pharmaceuticals
Freda C. Lewis-Hall, M.D.

D The Public Health Service's Commitment to Women's Mental Health
Wanda Jones, Dr.P.H.

E The Congressional Response to Women's Health Issues
The Honorable Nita Lowey
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.
Independence Ballrooms F/G, Level 5B, Grand Hyatt

THE CLINICAL INTERNET: AMERICAN AND EUROPEAN EXPERIENCES

Chp.: Juan E. Mezzich, M.D.
Co-Chp.: Massimo di Giannantonio, M.D.

A Internet Jungle: Hunting for Patients' Real Advantages
Sergio De Risio, M.D., Massimo di Giannantonio, M.D., Fausta Calvosa, M.D., Benedetto Farina, M.D.

B Clinical Uses of the Internet: Promise, Problems and Perils
Ronald W. Pies, M.D.

C Clinical Uses of the Internet: Some Suggestions
Robert C. Hsiung, M.D.

D Psychotherapy on the Internet
Russell F. Lim, M.D.

E Intranet for Management and Clinical Information Systems
P.M. Furlan, M.D., Manlio Gianmaria, M.D., Stefano Gelati, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.
Independence Ballrooms HI/II, Level 5B, Grand Hyatt

SCIENCE-BASED BEHAVIORAL THERAPIES FOR COCAINE ADDICTION
National Institute on Drug Abuse

Chp.: Lisa S. Onken, Ph.D.

A A Cognitive-Behavioral Approach to Treating Cocaine Addiction
Kathleen M. Carroll, Ph.D.

B Community Reinforcement Approach to Treatment
Stephen T. Higgins, Ph.D.

C Individual Counseling for Cocaine Addiction
Delinda Mercer, Ph.D.

D Relapse Prevention and Contingency Management of Cocaine Abuse
Richard A. Rawson, M.D.

Discussant: Jack D. Blaine, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

PRACTICING EVIDENCE-BASED PSYCHIATRY: BIPOLAR DISORDER

Chp.: John S. McIntyre, M.D.
Co-Chp.: Harold Alan Pincus, M.D.

A Use of Formal Measures in Clinical Care
Jacqueline Samson, Ph.D.

B Clinical Practice Guidelines for Treatment
Robert M.A. Hirschfeld, M.D.

C What's Really Going On in the Treatment of Bipolar Disorder?
Deborah A. Zarin, M.D., Harold Alan Pincus, M.D., Ellen Leibenluft, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Grand Ballroom A, Ballroom Level, Marriott Metro Center

BDD: NEW RESEARCH FINDINGS FOR CLINICAL PRACTICE

Chp.: Katharine A. Phillips, M.D.
Co-Chp.: Eric Hollander, M.D.

A Clinical Features of BDD: Diagnosing an Under-Recognized Disorder
Katharine A. Phillips, M.D.

B Pharmacological Treatment of BDD
Eric Hollander, M.D., Andrea Allen, Ph.D., Concetta M. DeCarlia, Ph.D., Bonnie A. Aronowitz, Ph.D., Charles Cartwright, M.D., Sherie Novotny, M.D.

C Cognitive-Behavior Therapy for BDD
David Veale, M.D.

D BDD in Children and Adolescents
Ralph S. Albertini, M.D., Katharine A. Phillips, M.D.

E BDD with Major Depression
Andrew A. Nierenberg, M.D.

Discussant: Susan L. McElroy, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SHORT-TERM STABILITY OF PERSONALITY DISORDERS

Chp.: Andrew E. Skodol II, M.D.
Co-Chp.: John G. Gunderson, M.D.

A Short-Term Stability of Personality Disorder Diagnoses
M. Tracie Shea, Ph.D., Robert Stout, Ph.D., Regina Dolan, Ph.D., Andrew E. Skodol II, M.D., Leslie C. Morey, Ph.D., Mary C. Zanarini, Ed.D., Charles A. Sanislow, Ph.D.

B Stability of Five-Factor Traits in Personality Disorder
Leslie C. Morey, Ph.D., John G. Gunderson, M.D., Robert Stout, Ph.D., M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D., Thomas H. McGlashan, M.D., Regina Dolan, Ph.D.

C Six-Month Stability of Axis I with Personality Disorder Comorbidity
Thomas H. McGlashan, M.D., Carlos M. Grilo, Ph.D., Leslie C. Morey, Ph.D., Andrew E. Skodol II, M.D., Charles A. Sanislow, Ph.D., M. Tracie Shea, Ph.D., John G. Gunderson, M.D.

D Stability of Psychosocial Functioning in Personality Disorders
Andrew E. Skodol II, M.D., Robert Stout, Ph.D., M. Tracie Shea, Ph.D., Thomas H. McGlashan, M.D., John G. Gunderson, M.D., Leslie C. Morey, Ph.D., Martin B. Keller, M.D.

E Continuity of Treatment for Patients with Personality Disorders
Donna S. Bender, Ph.D., Andrew E. Skodol II, M.D., Robert Stout, Ph.D., Regina Dolan, Ph.D., John G. Gunderson, M.D., M. Tracie Shea, Ph.D., John M. Oldham, M.D.

Discussant: Bruce M. Pfohl, M.D.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
London Room, Ballroom Level, Marriott Metro Center

THE EVOLUTION OF COMMUNITY PSYCHIATRY IN ITALY

Chp.: Pier L. Scapicchio
Co-Chp.: Allan Tasman, M.D.

A Standardized Assessment of Psychiatric Care in Italy
Carmine Munizza, M.D., G. Tibaldi, M.D., M. Zuccolin, M.D., C. Palazz, M.D., E. Scala, M.D., S. Cesano, M.D., R. Dazzi, M.D.

B The Organization of Community Psychiatry: Other than Rehabilitation
Bruno Commodari, M.D., C. Zaffora, M.D., F. Spadaro, M.D., R. Ortoleva, M.D., A. Fallica, M.D., B. Salmeri, M.D.
WEDNESDAY

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 35-40

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m.-10:00 p.m.
Rooms 39/40, Upper Level, Convention Center

THE INTERFACE BETWEEN DEPRESSION AND DEMENTIA
Supported by Parke-Davis

Chp.: Steven P. Roose, M.D.
Co-Chp.: Bruce G. Pollock, M.D.

A Clinical Assessment: Mood, Cognition and Their Interaction in the Elderly
David L. Sultzer, M.D.

B Depressed Mood and Dementia in Elderly Patients in the Community
Davangere P. Devanand, M.D., Karen Marder, M.D., Richard Mayeux, M.D., Mary Sano, Ph.D., Yaakov Stern, Ph.D.

C Treatment of Depression in the Old-Old
Steven P. Roose, M.D.

D Pharmacotherapy of the Cognitively Impaired
Bruce G. Pollock, M.D., Meryl Butters, Ph.D., Robert Nebes, Ph.D.

E Cardiovascular Changes in Depression and Dementia
K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

ANTIDEPRESSANT COMBINATIONS FOR DRUG-RESISTANT AND INTOLERANT CASES
Supported by Wyeth-Ayerst Laboratories

Chp.: Stephen M. Stahl, M.D.

A Cellular Mechanisms of Antidepressant Action
Richard C. Shelton, M.D.

B How to Combine Two Antidepressants for Treatment Synergy and Side-Effect Reductions
Stephen M. Stahl, M.D.

C When is Polypharmacy Good in Treating Major Depression?
Jeffrey E. Kelsey, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m.-10:00 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

RECENT ADVANCES IN PSYCHOPHARMACOLOGY
American Society of Clinical Psychopharmacology
Supported by Bristol-Myers Squibb

Chp.: James W. Jefferson, M.D.

A New Treatments for Schizophrenia
Stephen R. Marder, M.D.

B New Treatments for Bipolar Disorder
Lori L. Altschuler, M.D.

C Removing the Chronicity from Chronic Depression
James H. Kocsis, M.D.

D Treatment of Comorbid Anxiety and Substance Abuse
Kathleen T. Brady, M.D.

E Drug Interactions: A Practical Primer for Clinicians
James W. Jefferson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

TREATING DEPRESSION: EFFECTIVENESS WITHOUT EXTRAVAGANCE
Supported by Healthcare Technology Systems

Chp.: David J. Katzelnick, M.D.

A The Burden of Untreated Depressions
Ronald C. Kessler, Ph.D.

B Can Primary Care Deliver Quality Treatment of Depression?
Elizabeth H.B. Lin, M.D., David J. Katzelnick, M.D., Gregory E. Simon, M.D., Steven D. Pearson, M.D., Wayne J. Katon, M.D.

C Clinical Outcomes CARE Study
David J. Katzelnick, M.D., Gregory E. Simon, M.D., Steven D. Pearson, M.D., Willard G. Manning, Ph.D., Cindy P. Helstad, Ph.D., Henry J. Henk, M.S.

D Cost-Effectiveness of Depression Treatment Programs
Gregory E. Simon, M.D.

E “Dividing the Pie” Between Primary Care Physicians and Psychiatrists
Jonathan F. Borus, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

TIME AND DEPRESSION
Supported by Organon Inc.

Chp.: Andrew A. Nierenberg, M.D.
Co-Chp.: Mark H. Rapaport, M.D.

A Depressive Spectrum Disorder and Treatment
Mark H. Rapaport, M.D.

(Continued on next page)
On the morning of January 29, 1996, a janitor discovered the body of a young Asian male on the tennis courts of Tustin High School in Southern California. He had been stabbed multiple times, his throat was slashed from side to side, and his head had been stomped on. Thien Minh Ly, eldest son, beloved brother, community leader, and recent graduate from UCLA and Georgetown University in Washington, DC, was 24 years old at the time of his death. Letters to Thien attempts to restore the humanity so coldly denied him by his brutal murder. Thien's character is memorialized through anecdotes, tributes, and letters from his family and friends, who address him one year after his death. Full of humor, love, and an abiding, bewildering grief, these stories painstakingly conjure Thien's willingness to try new things, his broad interests, ranging from biology and Shakespeare to Vietnamese culture, and, above all, his strong impact on those who knew him. In this context, director Trac Vu shows us how the discovery of a letter commencing with the boast "Oh, I killed a jap [sic] a while ago," led to the arrest of Thien's young murderers, and he covers the community's struggle to get the district attorney of Orange County, California, and the city of Tustin to declare Thien's murder a hate crime.

Forgotten Fires is a powerful exploration of the devastating consequences of prejudice. Filmed over one year in Manning, South Carolina, following the Ku Klux Klan (KKK) burning of two local African-American churches, the film is a frightening testimony to the emotional and physical violence perpetrated by the KKK. Historically the churches were the emblem of the fight for freedom and equality. Today, their active role in the community makes them a vulnerable target for racial hatred. Surprisingly, though, out of this painful story emerges a moving portrait of a community's ability to forgive and to heal itself. Claiming to stand for the rights of white people, the Klan proclaims that blacks are responsible for the disenfranchisement of whites. One Timothy Welch, a white man, got caught up in these twisted beliefs and set fire to the Macedonian Baptist Church. From the vantage point of prison, Welch reflects upon how his involvement with the Klan led him to racial violence. As a racist he is a hateful figure, but his remorse and desire for forgiveness are genuine and heartfelt. Through interviews with members of both the African-American community and the KKK, Forgotten Fires tells the moving story of Welch's forgiveness and acceptance by the black community in a message of hope for the future of racial harmony.
Hasidim often provoke controversy and arouse remarkably intense feelings among outsiders. On one hand, some condemn the insularity of the Hasidic people as "racist" and their strict division of gender roles as "sexist." Their way of life is derided as "fundamentalist," and their defiant refusal to join the rest of society is perceived as "un-American." Certain Jews criticize the Hasidim for "spiritual arrogance" and are offended by the flagrant demonstration of "differentness" in Hasidic dress and behavior at a time when Jews have assimilated into American society. On the other hand, many Jews feel reassured that Jewish customs, faith and traditions will be perpetuated. They cherish authenticity and steadfastness in the face of temptation. They perceive that Hasidim are freed from the moral complexities and ambiguities they have to face. Others are merely curious about a group of many thousands of people who have been able to survive for more than two centuries without conforming. This film relates the dramatic story of the creation of the post-Holocaust Hasidic communities in the United States, a country that had been labeled "trayfina medina" (impure land) by earlier rabbinical leaders. After the film, a psychiatrist will lead a discussion of Hasidic life from the perspective of three decades of experience with the Hasidic population. Hasid featured in the film will join him.

Discussant: Rabbi Mayer Schiller

SYMPOSIUM 67
Independence Ballrooms D/E, Level 5B, Grand Hyatt

PSYCHIATRIC DISORDERS IN A SPECIAL POPULATION: THE ATHLETE
International Society for Sport Psychiatry

Chp.: Ronald L. Kamm, M.D.

A Pathological Body Image in the Athletic Arena
Antonia L. Baum, M.D.

B Anorexia Athletica and Other Atypical Eating Disorders
Robert W. Burton, M.D.

C Treatment to Keep Athletes Functioning
Ira D. Glick, M.D., Jessica L. Horsfall, M.A.

Expert Panel: Gerald A. Cooney, former world heavyweight boxer, Herb McCauley, professional thoroughbred jockey, and John R. Park, Olympic swimmer, body builder and professional trainer.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68
Independence Ballrooms F/G, Level 5B, Grand Hyatt

EYE MOVEMENT DESENSITIZATION AND REPROCESSING (EMDR)

Chp.: Bessel A. van der Kolk, M.D.

A EMDR: Information Processing Therapy for Trauma
Francine Shapiro, Ph.D.

B EMDR Treatment for Children with Disaster-Related PTSD
Claude M. Chemtob, Ph.D., Joanne Nakashima, M.A., Roger Hamada, P.A.D., John Carlson, P.A.D.

C Neurobiological Dimensions of EMDR: Physiology and Neuroimaging
Bessel A. van der Kolk, M.D., Elizabeth Matthew, M.D., James Hopper, Ph.D., Jennifer Burbridge, M.A., William Simpson, Ph.D.

D Using EMDR in Complex PTSD and Adult Attachment Disorders
Andrew M. Leeds, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69
Independence Ballrooms H/I, Level 5B, Grand Hyatt

MUSIC THERAPY IN PSYCHOSOCIAL CARE AND PAIN MANAGEMENT

Chp.: John S. McIntyre, M.D.
Co-Chp.: Bryan C. Hunter, Ph.D.

(Continued on next page)
A. Music Therapy: An Overview  
   John S. McIntyre, M.D.

B. Music Therapy and Pain Management  
   Joanne V. Loewy, D.A.

C. Music Therapy, Assisted Labor and Delivery  
   Bryan C. Hunter, Ph.D.

D. Creative Music Therapy: Accessing the Healthy Care  
   Kenneth S. Aigen, D.A.

E. Beyond the Sing-Along: Current Trends in Music Therapy Research and Practice with Older Adults  
   Anne W. Lipe, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71  7:00 p.m.-10:00 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

STRATEGIES FOR SELECTING AN ANTIDEPRESSANT MEDICATION
Chp.: Andrew F. Leuchter, M.D.

A. Clinical Symptoms and Antidepressant Mechanism of Action: Any Relation?  
   Robert M.A. Hirschfeld, M.D., William F. Stubberman, M.D., Elise Witte, Ph.D., Andrew F. Leuchter, M.D.

B. Age-Related Differences in Medication Response  
   Ian A. Cook, M.D.

C. Improvements in Social Functioning with Antidepressant Treatment  
   Martha L. Bruce, Ph.D.

D. Brain Function and Selection of Antidepressant Medication  
   Andrew F. Leuchter, M.D., Ian A. Cook, M.D., Elise Witte, Ph.D., William F. Stubberman, M.D., Michelle Abrams, R.N., Sandy Venneman, Ph.D., Jennifer Dunkin, Ph.D.

E. Mechanism of Action of Antidepressants  
   Alan Frazer, Ph.D.

Discussant: Herbert W. Harris, M.D.

THIS SESSION WILL BE AUDIOTAPED.

White House (North Lawn) - The oldest public building in Washington, DC, every president except George Washington has lived in this Palladian-influenced Georgian mansion. A veritable museum in its own right, the White House is open for free tours five days a week. (Photo courtesy of the Washington, DC Convention and Visitors Association.)
THURSDAY, MAY 20, 1999

152ND ANNUAL MEETING

7:00 a.m. Sessions

PART II OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 30-34

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART II
7:00 a.m.-8:30 a.m.
Rooms 39/40, Upper Level, Convention Center

NOVEL APPROACHES TO THE TREATMENT OF IMPULSIVITY
Supported by Solvay Pharmaceuticals, Inc. and Pharmacia & Upjohn Company, Inc.
Chp.: Eric Hollander, M.D.

A Treatment of Impulsivity and Aggressivity in PTSD
Charles R. Marmar, M.D., Frank B. Schoenfeld, M.D., Thomas Metzler, Daniel S. Weiss, Ph.D.

B The Relationship Between Bipolar Spectrum and Impulse Control Disorders
Concetta M. DeCaria, Ph.D., Eric Hollander, M.D., Charles Cartwright, M.D., Sherie Novotny, M.D., Serge A. Mosovich, M.D., Jared Finkell, B.A.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART II
7:00 a.m.-8:30 a.m.
Constitution Ballroom, Level 3B, Grand Hyatt

MOOD AND PSYCHOTIC DISORDERS IN WOMEN: AN UPDATE ON TREATMENT
Supported by Eli Lilly and Company
Chp.: Lee S. Cohen, M.D.
Co-Chp.: Ruth A. Dickson, M.D.

A Gender and the Second Generation of Antipsychotics
Ruth A. Dickson, M.D.

B Estrogen and Mood in Perimenopausal Women
Catherine A. Roca, M.D., Peter J. Schmidt, M.D., David R. Rubinow, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART II
7:00 a.m.-8:30 a.m.
Independence Ballroom, Level 5B, Grand Hyatt

ANXIETY DISORDERS: FROM SCIENTIFIC RESEARCH TO CLINICAL PRACTICE
Supported by U.S. Pharmaceuticals, Pfizer Inc.
Chp.: Mark H. Pollack, M.D.

A Social Phobia: Course, Complications and Therapeutics
John H. Greist, M.D.

B Understanding Quality of Life in Anxiety Disorders
Mark H. Rapaport, M.D., Mark H. Pollack, M.D., Cathryn M. Clary, M.D., Robert Wolkind, M.D.

C Applying Cognitive-Behavior Therapy to Clinical Pharmacotherapy
Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART II
7:00 a.m.-8:30 a.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

ASSESSMENT AND TREATMENT OF PSYCHIATRIC DISORDERS IN THE ELDERLY
Supported by Janssen Pharmaceutical and Research Foundation
Chp.: W. Walter Menninger, M.D.

A Coping with Late Life
W. Walter Menninger, M.D.

B Early Detection and Comorbidity Issues: Dementia and Depression in the Elderly
Stephen M. Aronson, M.D.

C Typical Versus Atypical Antipsychotics in the Elderly
Dilip V. Jeste, M.D., Jonathan P. Lacro, Pharm.D., M. Jackuelyn Harris, M.D., Hoang A. Nguyen, M.D., Enid Rockwell, M.D., Mihaela E. Petersen, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART II
7:00 a.m.-8:30 a.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

ADVANCES IN THE TREATMENT OF GERIATRIC DEPRESSION
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Bruce G. Pollock, M.D.

A Treating Depression in the Older Patient with Comorbid Ischemic Disease
Steven P. Roose, M.D.

B The Current Role of ECT in the Treatment of Geriatric Depression
Harold A. Sackeim, Ph.D.

Discussant: Benoit H. Mulsant, M.D.
8:00 a.m. Sessions

COURSES 93-95
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 93  8:00 a.m.-12 noon
Room 6, Meeting Room Level, Renaissance Washington
ASSESSMENT AND THERAPY OF TRAUMATIC Bereavement
Co-Directors: Edward K. Rynearson, M.D., Jennifer Favell, Ph.D.

COURSE 94  8:00 a.m.-12 noon
Room 7, Meeting Room Level, Renaissance Washington
INTRODUCTION TO CORRECTONAL PSYCHIATRY
Co-Directors: James E. Dillon, M.D., Lee H. Rome, M.D.
Faculty: Richard S. Jackson, M.D.

COURSE 95  8:00 a.m.-12 noon
Room 16, Meeting Room Level, Renaissance Washington
AN INTRODUCTION TO CLINICAL NEURODYNAMICS
Director: William T. Prey, M.D.

9:00 a.m. Sessions

COURSES 96-97
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 96  9:00 a.m.-4:00 p.m.
Room 4, Meeting Room Level, Renaissance Washington
DEPRESSION: INDIVIDUAL/GROUP INTERPERSONAL THERAPY
American Group Psychotherapy Association
Director: K. Roy MacKenzie, M.D.

COURSE 97  9:00 a.m.-4:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington
CLINICAL NEUROPSYCHIATRY: AN UPDATE (IN SPANISH)
Director: F. Moises Gaviria, M.D.
Faculty: Andres M. Kanner, M.D.

LECTURE 20

LECTURE 20
9:00 a.m.-10:30 a.m.
Room 32, Lower Level, Convention Center
APA'S SIMON BOLIVAR AWARD LECTURE
Renato D. Alarcon, M.D.
Hispanic Psychiatry: From Margin to Mainstream
Chair: Silvia W. Olarte, M.D.
Co-Chair: Jose M. Canive, M.D.

The advent of the 21st century offers a unique opportunity for a reassessment of the epistemological bases of American psychiatry and its diverse components. The case of Hispanic/Latino psychiatry in the United States exemplifies the complexities of this process in terms of a reaffirmation of singular characteristics at the workforce and the general population levels. These complexities are also apparent in its struggle to gain recognition from, and full acceptance into, so-called "mainstream" psychiatry.

Renato D. Alarcon, M.D., describes the process by examining three complementary issues: the shaping of a true mestizo identity, a documented series of accomplishments in practice, clinical care and research areas, and Hispanic psychiatry's extraordinary potential as a setting for the in-depth study of biocultural linkages in a variety of clinical phenomena. Dr. Alarcon is Professor and Vice Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Director of the Mental Health Service Line at the Veterans Affairs Medical Center in Atlanta. He is the author of more than 150 articles and book chapters and the author or co-author of ten books, including Personality Disorders and Culture: Clinical and Conceptual Interactions. Between 1994 and 1996, he was president of the American Society of Hispanic Psychiatry and is currently editor of the Society's newsletter. Dr. Alarcon is Vice-Chairperson of APA's Council on International Affairs. He is also a member of NIMH's Clinical Centers and Special Projects Review Committee, regional secretary for North America for the Interamerican Council of Psychiatric Organizations and a member of the National Mental Health Advisory Board to VA Headquarters. He is book review editor for Depression and Anxiety and a member of the Editorial Boards of several psychiatric journals in the United States, Latin America and Spain. A native from Arequipa, Peru, Dr. Alarcon received his medical degree from the Universidad Peruana Cayetano Heredia in Lima and did his residency in psychiatry at the Johns Hopkins Hospital in Baltimore. He received his master's degree in public health from the Johns Hopkins School of Hygiene and Public Health.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

LECTURE 21
9:00 a.m.-10:30 a.m.
Room 33, Lower Level, Convention Center

APA'S OSKAR PFISTER AWARD LECTURE
Don S. Browning, Ph.D.
Internists of the Mind or Doctors of the Soul?

Chp.: George T. Harding IV, M.D
Co-Chp.: Reverend Clark S. Aist, Ph.D.

With recent technical advances, psychiatry has become more precise in treating major mental illnesses. It has also become narrower in scope: psychiatrists no longer try to tell us how to live the good life. However, in limiting its scope, psychiatry may unwittingly fuel the belief that there are no principles or truths governing the good life. Dr. Browning's first book, Atoneinent and Psychotherapy, published in 1966, has been followed by more than 3 decades of major contributions to psychiatry and religion, including his recent work as editor of the two volumes, Religious and Ethical Factors in Psychiatric Practice and Does Psychiatry Need a Public Philosophy? He currently heads a large research project on religion, culture, and the family supported by a grant from the Lilly Endowment, Inc. The project includes a series of 12 books presenting a comprehensive overview of issues at the interface of religion and the family. Dr. Browning received his doctoral degree from the University of Chicago Divinity School.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 14-15
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 Frederick K. Goodwin, M.D., on the Management of Bipolar Disorder
Room 35, Lower Level, Convention Center

15 Thomas N. Wise, M.D., on Consultation-Liaison Psychiatry
New York Room, Ballroom Level, Marriott Metro Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSION 32
9:00 a.m.-11:00 a.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center

THE HOLOCAUST: FROM ONGOING TRAUMA TO STORIES OF HEALING

Chp.: John M. Dluhy, M.D.

53 Silence
(10 minutes)

Distributor: Filmakers Library
124 East 40th Street
New York, NY 10016

A little girl named Tana survived Teresienstadt concentration camp thanks to her resourceful grandmother. After liberation, she lived a comfortable and cultured life with relatives in Sweden. No one spoke of her ordeal. "Forget the past," she was told. Tana knew how to keep silent. This haunting animated film captures the surreal world of a child survivor whose pain has not been recognized or shared. At 20, when Tana left Sweden, she was given letters written by her mother before she was sent to Auschwitz where she perished. Tana now had a bridge to the past, but still couldn't speak of it. It took 50 years for her to break the silence.

54 The Last Transfer
(52 minutes)

Distributor: Zavit Productions Ltd.
58 Dizengoff Street
Tel Aviv, Israel 64332

Fifteen to 45 years in a mental institution? For many Holocaust survivors World War II is not over yet. The Last Transfer follows a group of patients in the psycho-geriatric ward of the Abarbanel Mental Health Center in Israel who cannot escape from their memories. Robot-like G. cannot stop working and H. continues cleaning toilets as she did in the concentration camp over 50 years ago. A. continues looking for her dead child oblivious to the time that has passed. The Last Transfer attempts to examine why these people broke down and were unable to rebuild their lives. Why did mental collapse become their refuge? The film questions whether long hospitalization is the result of the trauma, the war, or the neglect of the Israeli society. The interaction between the massive psychic disintegration due to the holocaust and a chronic, deteriorating course of illness in survivors is discussed.

Discussant: Avner Elizur, M.D.

55 Three Stories
(23 minutes)

Distributor: Filmakers Library
124 East 40th Street
New York, NY 10016

(Continued on next page)
Krakow, Poland was the birthplace of Henryk Vogler, writer and Holocaust survivor, his son Pavel, an artist, and his 11-year-old granddaughter, Sara. Pavel never questioned his father directly about his war experiences, yet he sensed his father’s pain. Pavel and Sara immigrated to America to get Sara the medical treatment she needed. There, half a world away, Sara questioned her father about why her grandfather remained in Krakow after the war. In Jewish day school she had learned that most Jewish survivors left Europe after the war. This led Pavel to take his daughter, a budding artist herself, back to Krakow to learn her grandfather’s story. Grandfather Henryk tells her of the beauty of the medieval city and its cultural past. He recalls that in September 1939 he was the “happiest man in the world,” newly married and about to publish his first novel. War tore his life apart. He recounts the loss of everything he held dear and his own miraculous survival in the concentration camp. With the defeat of the Germans, Henryk returned to his beloved Krakow, the only place where, as a writer, he could express himself in his native language. His literary career flourished. The birth of his son gave life new meaning. This is a beautiful story, filmed with artistry, about the renewal of life and hope.

NEW RESEARCH ORAL/SLIDE SESSIONS 13-14
9:00 a.m.-10:30 a.m.

13 ALCOHOL AND DRUG ABUSE
Rooms 23/24, Lower Level, Convention Center

14 VARIOUS PSYCHIATRIC ISSUES
Rooms 25/26, Lower Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

WORKSHOPS

COMPONENTS 44-50

COMPONENT WORKSHOP 44 9:00 a.m.-10:30 a.m.
Room 15, Lower Level, Convention Center
THE FALLOUT FROM HOSPITAL MERGERS AND CLOSINGS
APA Committee on Physician Health, Illness and Impairment
Co-Chps.: Linda Logsdon, M.D., Richard F. Limoges, M.D.
Participants: Malkah T. Notman, M.D., Carmen T. Webb, M.D.

COMPONENT WORKSHOP 45 9:00 a.m.-10:30 a.m.
Rooms 21/22, Lower Level, Convention Center
BEYOND SEX: GAY ISSUES AND THE GENERAL PSYCHIATRIST
APA Committee on Gay, Lesbian and Bisexual Issues
Co-Chps.: Diana C. Miller, M.D., Leslie G. Goransson, M.D.
Participants: Mark H. Townsend, M.D., Steven J. Lee, M.D., Petros Levounis, M.D.

COMPONENT WORKSHOP 46 9:00 a.m.-10:30 a.m.
Room 29, Lower Level, Convention Center
SYSTEMS OF CARE FOR SERIOUS EMOTIONAL DISORDERED CHILDREN AND ADOLESCENTS
APA Committee on Children with Mental or Developmental Disorders
Chp.: Carl B. Feinstein, M.D.

COMPONENT WORKSHOP 47 9:00 a.m.-10:30 a.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt
HIV PREVENTION: STIGMA AND NAMES-BASED REPORTING
APA New York County District Branch’s AIDS Committee
Chp.: Elizabeth V. Getter, M.D.
Participants: John A.R. Grimaldi, Jr., M.D., Kenneth B. Ashley, M.D., Daniel B. Bauman, M.D., Chloe Niims, M.D.

COMPONENT WORKSHOP 48 9:00 a.m.-10:30 a.m.
Farragut Square Room, Level 5B, Grand Hyatt
TO TELL OR NOT TO TELL: THE IMPAIRED SUPERVISOR
APA/GlaxoWellcome Fellows
Co-Chps.: Clifford A. McNaughton, M.D., Karine J. Igartua, M.D.
Participants: Christopher M. Palmer, M.D., Michael F. Myers, M.D., Trevor I. Prior, M.D.

COMPONENT WORKSHOP 49 9:00 a.m.-10:30 a.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center
NATIONAL HEALTH INSURANCE: A DISTRICT BRANCH VIEW
APA Psychiatric Society of Westchester County, Inc.
Chp.: Timothy B. Sullivan, M.D.
Participants: Steffie Woolhandler, M.D., Tyrone S. Turner, M.D., Captane P. Thomson, M.D.

COMPONENT WORKSHOP 50 9:00 a.m.-10:30 a.m.
London Room, Ballroom Level, Marriott Metro Center
GETTING YOUR PATIENT ON SOCIAL SECURITY INCOME: AN INSIDER’S GUIDE
APA Committee on Poverty, Homelessness and Psychiatric Disorders
Chp.: Stephen M. Goldfinger, M.D.
Participants: Ramanbhai C. Patel, M.D., Manoj R. Shah, M.D., Harvey Bluestone, M.D., Albert A. Hyman, M.D.
ISSUES 57-72

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Rooms 13/14, Lower Level, Convention Center

DSM-IV AND OLD-TIME ROCK AND ROLL
Chp.: Henry B. Nelson III, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Room 20, Lower Level, Convention Center

TO LIVE OR DIE: COMPLEXITIES AT LIFE’S END
Chp.: James W. Lomax II, M.D.
Participants: Sheila M. Loboraprabhu, M.D., John W. Burruss, M.D.

ISSUE WORKSHOP 59 9:00 a.m.-10:30 a.m.
Room 27, Lower Level, Convention Center

TREATMENT RESISTANCE VERSUS RESISTANT TREATERS
Chp.: Michael R. Fox, M.D.

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.
Room 28, Lower Level, Convention Center

TEACHING ASSESSMENT VIA ROLE PLAY: A DEMONSTRATION
Chp.: Julia B. Frank, M.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.
Room 30, Lower Level, Convention Center

SWIMMING WITH THE SHARKS: ORGANIZATION POLITICS
Chp.: Michelle Riba, M.D.
Participants: John S. McIntyre, M.D., Elissa P. Benedek, M.D., Carol A. Bernstein, M.D., Jo-Ellen M. Ryall, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.
Room 31, Lower Level, Convention Center

DOCTOR, LEARN TO SET LIMITS AND REDUCE MALPRACTICE SUITS
Chp.: Miguel A. Leibovich, M.D.
Participants: Sara C. Charles, M.D., Maureen Mondor, R.N.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.
Room 36, Lower Level, Convention Center

VIDEO CASE STUDIES OF COUPLES IN TREATMENT
Chp.: Ian E. Alger, M.D.

ISSUE WORKSHOP 64 9:00 a.m.-10:30 a.m.
Room 37, Lower Level, Convention Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS
Co-Chps.: Judith S. Beck, Ph.D., Jesse H. Wright, M.D.

ISSUE WORKSHOP 65 9:00 a.m.-10:30 a.m.
Conference Theatre, Level 1B, Grand Hyatt

PSYCHIATRY AND POLITICS
Co-Chps.: Paul A. Kettl, M.D., Jay B. Cutler, J.D.

ISSUE WORKSHOP 66 9:00 a.m.-10:30 a.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

PREVENTING SUICIDE: TEAM BUILDING AND MOBILIZING RESOURCES
Chp.: Alex N. Sabo, M.D.

ISSUE WORKSHOP 67 9:00 a.m.-10:30 a.m.
Bulfinch/Renwick Rooms, Level 3B, Grand Hyatt

CULTURE: PERCEPTION AND COMMUNICATION
Co-Chps.: Trevia F. Hayden, M.D., Raina T. Sullivan, M.D.

ISSUE WORKSHOP 68 9:00 a.m.-10:30 a.m.
Burnham Room, Level 3B, Grand Hyatt

BRIDGING TRADITIONS IN PSYCHIATRIC EDUCATION
Co-Chps.: Todd S. Cox, M.D., Irving M. Reti, M.D.
Participants: Sarah A. Reading, M.D., Adam I. Kaplin, M.D., Jennifer L. Payne, M.D.

ISSUE WORKSHOP 69 9:00 a.m.-10:30 a.m.
Latrobe Room, Level 3B, Grand Hyatt

UPDATE ON MENTAL HEALTH IN THE OREGON HEALTH PLAN
Co-Chps.: Bentzon H. McFarland, M.D., David A. Pollack, M.D.
Participants: Magnus Lakovics, M.D., Robert A. George, M.D., Richard H. Angell, M.D.

ISSUE WORKSHOP 70 9:00 a.m.-10:30 a.m.
McPherson Square Room, Level 5B, Grand Hyatt

SAFEGUARDING THE ELECTRONIC PSYCHIATRIC RECORD
Chp.: David P. Olson, M.D.
Toning and Chanting and Music Meet Memories

Chp.: George M. Simpson, M.D.
9:00 a.m.-10:30 a.m.

ISSUE WORKSHOP 72
9:00 a.m.-10:30 a.m.
Paris Room, Ballroom Level, Marriott Metro Center

Clinical Implications of the Cytochrome P450

Chp.: George M. Simpson, M.D.
Participant: Jose de Leon, M.D.

11:00 a.m. Sessions

Lectures 22-23

LECTURE 22
11:00 a.m.-12:30 p.m.
Room 32, Lower Level, Convention Center

Nelba Chavez, Ph.D.
The Co-Recurring Problem of Substance Abuse and Mental Illness and the Federal Response Across the Life Cycle

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Patricia I. Ordonez, M.D.

Nominated by President Clinton on February 25, 1994 and confirmed by the U.S. Senate on July 14, 1994, Nelba Chavez, Ph.D., is the first Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the first Hispanic/Latina to head an agency in the U.S. Department of Health and Human Services in its 200 year history. For three years prior to her appointment as SAMHSA Administrator, Dr. Chavez served as director of Juvenile Probation Services for the city and county of San Francisco. From 1989 to 1991, she headed Chavez and Associates, providing behavioral health consulting and training services to community organizations. In addition, she served as a consultant to the U.S. State Department on issues pertaining to mental health and substance abuse prevention and treatment. Dr. Chavez has served as clinical director, executive director, and chief operating officer of La Frontera in Tucson, Arizona. Under her leadership, La Frontera, a comprehensive, community mental health center providing mental health, drug and alcohol services to adults, children and families, became a national model, recognized by former First Lady Mrs. Rosalyn Carter and HHS as an outstanding example of a comprehensive, community-based mental health organization.

Dr. Chavez' writings on mental health have focused on the cross-cultural aspects of treatment. She has received a number of honors for her work and leadership, including the Distinguished Service Award from the National Association of Professional Asian American Women, the National Health Award from the National Coalition of Hispanic Health and Human Services Organizations, and the National Leadership Award from the Federal of Families for Children's Mental Health Services. An expert on comprehensive systems of care, as well as mental health and substance abuse prevention and treatment, Dr. Chavez earned her bachelor's degree in sociology/psychology from the University of Arizona in Tucson, a master's of social welfare from the University of California at Los Angeles and a doctorate from the University of Denver in Colorado.

This session will be audiorecorded.

LECTURE 23
11:00 a.m.-12:30 p.m.
Room 38, Upper Level, Convention Center

Grace Couchman, M.D.

Technological Advances in Infertility Therapy: Impact on Biology and Patients

Chp.: Diana L. Dell, M.D.
Co-Chp.: Lesly T. Megla, M.D.

The field of reproductive medicine has made tremendous advances in the past two decades, and infertile or subfertile couples of reproductive age now have several options for pursuing conception. Grace M. Couchman, M.D. reviews recent research about infertility and describes clinical and laboratory procedures for current interventions in reproductive medicine, including in vitro fertilization, intracytoplasmic sperm injection, blastocyst transfers, and use of donor gametes. She discusses the expected pregnancy outcomes for these therapies and explores their impact on patients. Dr. Couchman is Assistant Professor in the Division of Reproductive Endocrinology at Duke University Medical Center in Durham, North Carolina. Her research interests include protein tyrosine kinase intra-cellular messengers in the human endometrium and leiomyomata and intracytoplasmic sperm injection and male factor infertility. A fellow of the American College of Obstetricians and Gynecologists, Dr. Couchman is the author of several papers and book chapters on reproductive physiology. She received her medical degree from the University of Colorado School of Medicine in Denver and trained in obstetrics and gynecology at Duke University Medical Center. Dr. Couchman then completed a research fellowship at the Laboratory of Reproductive and Developmental Toxicology at the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina. She also completed a fellowship in reproductive endocrinology and infertility fellowship at Duke University Medical Center.

Frontiers of Science Lecture Series

This session will be audiorecorded.
MASTER EDUCATOR CLINICAL CONSULTATIONS 16-17
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

16 Katherine A. Halmi, M.D., on Anorexia and Bulimia Nervosa
Room 35, Lower Level, Convention Center
17 Carl Eis dorfer, M.D., on Geriatric Psychiatry Patients
New York Room, Ballroom Level, Marriott Metro Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSION 33
11:00 a.m.-2:00 p.m.
Grand Ballrooms C/D, Ballroom Level, Marriott Metro Center
CHILD SEXUAL ABUSE: SOCIOCULTURAL AND CLINICAL PERSPECTIVES
Chp.: John M. Dluhy, M.D.

56 Still Missing
(40 minutes)
Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

It's every parent's worst nightmare. It's law enforcement's most implacable challenge. Almost every day in America a non-family member, most often a child molester, kidnaps a child. Most of these abducted children never return to their families. Still Missing is an extremely important documentary and a very human one. It deals head-on with the terrifying facts of child abduction and gives us information and tools to help prevent these crimes. Still Missing hears from four parents of young children, Jacob Wetterling, Megan Garner, Kevin Collins and Monique Burnett, who were taken from their families. The case studies of the kidnappings are instructive; the deeply personal stories of the parents, their remembrances, and photos and home videos of their lost children make denial impossible. As the video makes clear, far from being the family's fault, child abduction is something that can happen to any family. One of the revelations of Still Missing is that most child molesters are ordinary-looking people who pass unnoticed within society. Yet this video gives concrete ways to protect children from these predators. Still Missing is essential viewing for parents, teachers, law enforcement personnel, criminologists, psychologists, social workers, and all who care about the safety of our children.

57 Sacrifice
(50 minutes)
Distributor: Film Library
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

Each year thousands of girls are recruited from rural Burmese villages to work in brothels in Thailand. Held for years in debt bondage, they suffer extreme abuse by pimps, clients and the police. The trafficking in Burmese girls has soared in recent years as a direct result of political repression in Burma. Human rights abuses, war and ethnic discrimination have displaced thousands of families, leaving them with no means of livelihood. An offer of employment in Thailand is a rare chance for many families to escape extreme poverty. Sacrifice examines the social, cultural and economic forces at work in the selling of Burmese girls into prostitution. It is the story of the valuation and sale of human beings and the efforts of teenage girls to survive a crisis born of economic and political repression.

58 Trying to Get Some Dignity
(58 minutes)
Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

Their stories are empowering, sensitively told, challenging, difficult and ultimately validating and reassuring. They are true stories, which will speak to anyone touched by and concerned with issues of child abuse. Particularly intended for therapists and for those struggling to come to terms with similar experiences in their lives. Trying to Get Some Dignity is also a call to action; a reminder to us that unspeakable events should never have happened in the past and should not be allowed to continue today.

59 Interviewing for Child Sexual Abuse
(38 minutes)
Distributor: Guilford Productions, Inc.
Department D
72 Spring Street
New York, NY 10012

Professionals called upon to interview children about alleged sexual abuse face a complex task. Safeguarding the welfare of these young clients demands a solid understanding of both clinical and legal issues. What are the most critical clinical and legal issues? What are the most appropriate techniques for eliciting reliable accounts of children's experience? How should evaluators structure the interview to avoid legal challenges to their findings? And, without losing sight of forensic considerations, how can the process be made as comfortable as possible for the child? Featuring Kathleen Faller, noted expert in child abuse evaluations, this informative video offers much-needed guidance for mental health and child protection professionals. It is also recommended viewing for lawyers, judges, and law enforcement personnel.

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Rooms 13/14, Lower Level, Convention Center

PROGRESS IN THE TREATMENT OF BREAST CANCER
Chp.: David M. McDowell, M.D.
Presenter: Marc E. Lippman, M.D.
THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

3 Kenneth B. Wells, M.D., on Mental Health Services Research Washington Room, Second Floor, Marriott Metro Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 26-32

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Room 15, Lower Level, Convention Center

NEW ISSUES IN PSYCHIATRIC GENETICS
Chp.: Victor Sierra, M.D.
Co-Chp.: Francis S. Lee, M.D.

11:00 a.m.
77 Polymorphisms in the Serotonin Transporter Gene and Cocaine Dependence
Ashwin A. Patkar, M.D., Wade H. Berrettini, M.D., Bridget Wendel, M.D., Robert Sterling, Ph.D., Edward Gottheil, M.D., Stephen Weinstein, Ph.D.

11:30 a.m.
78 Serotonin Genetic Polymorphism in SAD and Bulimia Nervosa
Robert D. Levitan, M.D., Mario Masellis, M.Sc., James L. Kennedy, M.D., Sidney H. Kennedy, M.D., Allan S. Kaplan, M.D., Franco J. Vaccarino, Ph.D., D. Blake Woodside, M.D.

12 noon
79 Genetic Antecedents of Dopamine Dysfunction in Schizophrenia
Farooq Amin, M.D., Jeremy Silverman, Ph.D., Larry J. Siever, M.D., Christopher J. Smith, B.S., Peter J. Knott, Ph.D., Kenneth L. Davis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Room 20, Lower Level, Convention Center

COMPULSION: EATING AND GAMBLING
Chp.: David G. Krefetz, D.O.
Co-Chp.: Seana H. Shaw, M.D.

11:00 a.m.
80 Assessing Adolescent Perceptions of Gambling Risk
James R. Westphal, M.D., Lera J. Johnson, Ph.D., Jill A. Rush, M.D., Lee Stevens, M.D.

11:30 a.m.
81 Long-Term Treatment of Bulimia Nervosa Following Acute Response: A Comparison of Fluoxetine and Placebo
Steven J. Romano, M.D., Katherine A. Halmi, M.D., Neena Shah, Ph.D., Stephanie Koke, M.S.

12 noon
82 Predictors of Early Treatment Outcome in Anorexia
William T. Howard, M.D., Karen K. Evans, R.N., Charito V. Quintero-Howard, M.D., Wayne A. Bowers, Ph.D., Arnold E. Anderson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Rooms 25/26, Lower Level, Convention Center

CLINICAL RISK FACTORS FOR MENTAL DISORDERS
Chp.: P.M. Furlan, M.D.
Co-Chp.: Vladimir Coric, M.D.

11:00 a.m.
83 Victimization As a Risk Factor for Major Depression
Julio E. Arboleda-Florez, M.D., Terrence J. Wade, Ph.D.

11:30 a.m.
84 Mortality and Morbidity Among Psychiatric Patients in the 1996 Northern Finland Birth Cohort
Matti K. Isohanni, M.D., Irene Isohanni, M.Ed., Peter B. Jones, Ph.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.Sc., Pentti Nieminen, Ph.D., Paula Rantakallio, M.D.

12 noon
85 School Predictors of Hospital-Treated Psychiatric Disorders in the 1996 Northern Finland Birth Cohort
Matti K. Isohanni, M.D., Irene Isohanni, M.Ed., Peter B. Jones, Ph.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.Sc., Pentti Nieminen, Ph.D., Paula Rantakallio, M.D.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

12 noon
88 Ondansetron, a Serotonin Antagonist, Improves Tardive Dyskinesia
Pinkhas Sirota, M.D., Tanya Mosheva, M.D., Hertzel Shabtay, M.D., Nir Giladi, M.D., Amos Korcyn, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Room 29, Lower Level, Convention Center

ANTECEDENTS AND NEW TREATMENTS IN SCHIZOPHRENIA
Chp.: Zafar A. Sharif, M.D.
Co-Chp.: Rachel Jenkins, M.D.

11:00 a.m.
89 Childhood Adversity and Adult Homelessness
Carol L.M. Caton, Ph.D., Patrick E. Shrout, Ph.D., Alan D. Felix, M.D., Sabina Hirshfield, M.A.

11:30 a.m.
90 Comparative Efficacy of Olanzapine and Haloperidol for Patients with Treatment-Resistant Schizophrenia
Alan F. Breier, M.D., Susan H. Hamilton, M.S.

11 noon
91 Low-Frequency Transcranial Magnetic Stimulation in Patients Reporting Voices
Ralph E. Hoffman, M.D., Nashaat N. Boutros, M.D., Robert M. Berman, M.D., Elizabeth Roessler, M.S., Ayse Belger, Ph.D., John H. Krystal, M.D., Dennis S. Charney, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Conference Theatre, Level 1B, Grand Hyatt

OUTCOME STUDIES IN MOOD DISORDERS
Chp.: Gopalakrishna K. Upadhya, M.D.
Co-Chp.: Olavo D. Pinto, M.D.

11:00 a.m.
92 Psychodynamic Psychotherapy of the Suicidal Adolescent Girl
Philip N. Cheifetz, M.D., Shelagh MacDonald, M.S.W.

11:30 a.m.
93 Bipolar Outcome: A 10-Year Follow-Up
Joseph F. Goldberg, M.D., Martin Harrow, Ph.D.

12 noon
94 Families and the Treatment of Chronic Depression
Gabor I. Keitner, M.D., Christine E. Ryan, Ph.D., Ivan W. Miller, Ph.D., Martin B. Keller, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Lafayette Park Room, Level 5B, Grand Hyatt

CONTROVERSIES IN MANAGED CARE
Chp.: Saul M. Levin, M.D.
Co-Chp.: Philip E. Veenhuis, M.D.

11:00 a.m.
95 Declining Mental Health Service Use in a Large Corporation
Robert A. Rosenheck, M.D., Benjamin G. Druss, M.D., D. Leslie, M. Stolar, William H. Sledge, M.D.

11:30 a.m.
96 Discrimination in Utilization Management
Lawrence Y. Kline, M.D.

12 noon
97 Malpractice Liability and Managed Care: Developments
Eugene L. Lowenkopf, M.D., Abe M. Ryckik, J.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 51-56

COMPONENT WORKSHOP 51
11:00 a.m.-12:30 p.m.
Room 33, Lower Level, Convention Center

INTERNISTS OF THE MIND OR DOCTORS OF THE SOUL?
APA Committee on Religion and Psychiatry and APA Council on National Affairs
Chp.: William N. Grosch, M.D.
Participants: Allen R. Dyer, M.D., J. Philip Wogaman, Ph.D., Herbert Pardes, M.D., Allan Tasman, M.D., Don S. Browning, Ph.D., Reverend Clark S. Aist, Ph.D.

COMPONENT WORKSHOP 52
11:00 a.m.-12:30 p.m.
Room 36, Lower Level, Convention Center

DOCUMENTATION REQUIREMENTS AND CODING UPDATE
APA Work Group on Codes and Reimbursements and APA Work Group on Harvard Resource-Based Relative Value Scale Study
Co-Chps.: Chester W. Schmidt, Jr., M.D., Donald J. Scherl, M.D.
Participants: Tracy R. Gordy, M.D., Melodie Morgan-Minott, M.D., Ronald A. Shellow, M.D., Frank T. Rafferty, Jr., M.D., Eugene Cassel, Shelley Stewart, Jay B. Cutler, J.D.

COMPONENT WORKSHOP 53
11:00 a.m.-12:30 p.m.
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

DECLIRIMINALIZING SEVERELY MENTALLY ILL PERSONS
APA Council on Psychiatric Services
Chp.: H. Richard Lamb, M.D.
Participants: Roger Peele, M.D., Cassandra F. Newkirk, M.D.

91
THURSDAY

COMPONENT WORKSHOP 54
11:00 a.m.-12:30 p.m.
Bulfinch/Renwick Rooms, Level 3B, Grand Hyatt

HUMAN FACTORS IN TELEPSYCHIATRY
APA Committee on Telemedical Services
Chp.: David F. McMahon, M.D.
Participants: Norman E. Alessi, M.D., Zebulon C. Taintor, M.D., Charles L. Zaylor, D.O.

COMPONENT WORKSHOP 55
11:00 a.m.-12:30 p.m.
Independence Ballrooms HI, Level 5B, Grand Hyatt

PSYCHIATRIC DIMENSIONS OF DISASTERS
APA Committee on Psychiatric Dimensions of Disasters
Chp.: Robert J. Ursano, M.D.
Participants: Michael Blumenfield, M.D., Ann E. Norwood, M.D.

COMPONENT WORKSHOP 56
11:00 a.m.-12:30 p.m.
London Room, Ballroom Level, Marriott Metro Center

NEW APA PRACTICE RECOMMENDATIONS ON ECT
APA Task Force on Electroconvulsive Therapy
Chp.: Richard D. Weiner, M.D.
Participants: Laura J. Fochtmann, M.D., Charles H. Kellner, M.D., Harold A. Sackeim, Ph.D.

ISSUE WORKSHOP 73
11:00 a.m.-12:30 p.m.
Room 28, Lower Level, Convention Center

TEACHING PSYCHIATRY IN AN AMBULATORY SETTING
Chp.: Richard Balon, M.D.
Participants: Phillip S. Freeman, M.D., Michelle Riba, M.D.

ISSUE WORKSHOP 74
11:00 a.m.-12:30 p.m.
Room 30, Lower Level, Convention Center

TREATING THE STRESSED PHYSICIAN
Chp.: Roy W. Menninger, M.D.
Participants: Michael F. Myers, M.D., Stephen Saeks, Ph.D.

ISSUE WORKSHOP 75
11:00 a.m.-12:30 p.m.
Room 31, Lower Level, Convention Center

HOW TO MAKE AN EFFECTIVE PSYCHIATRIC PRESENTATION
Chp.: Phillip J. Resnick, M.D.

ISSUE WORKSHOP 76
11:00 a.m.-12:30 p.m.
Room 37, Lower Level, Convention Center

PHARMACOTHERAPY OF ADDICTIVE DISORDERS
Co-Chps.: Norman S. Miller, M.D., Raye Litten, Ph.D.

ISSUE WORKSHOP 77
11:00 a.m.-12:30 p.m.
Burnham Room, Level 3B, Grand Hyatt

CLINICAL ISSUES IN GERIATRIC ALCOHOLISM
Co-Chps.: Roland M. Atkinson, M.D., David W. Oslin, M.D.

ISSUE WORKSHOP 78
11:00 a.m.-12:30 p.m.
Latrobe Room, Level 3B, Grand Hyatt

ASSESSMENT AND INTERVENTION OF MOVEMENT DISORDERS
Chp.: Leonardo Cortese, M.D.
Participants: Richard Williams, M.D., Michael Caligiuri, Ph.D.

ISSUE WORKSHOP 79
11:00 a.m.-12:30 p.m.
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

THE WOMAN INTERNATIONAL MEDICAL GRADUATE IN PSYCHIATRY
Chp.: Umadevi Naidoo, M.D.
Participants: Carola Eisenberg, M.D., Maria T. Lymberis, M.D., Esther R. Knight, M.D.

ISSUE WORKSHOP 80
11:00 a.m.-12:30 p.m.
Farragut Square Room, Level 5B, Grand Hyatt

COGNITIVE-BEHAVIOR THERAPY OF SCHIZOPHRENIA
Chp.: David G. Kingdon, M.D.

ISSUE WORKSHOP 81
11:00 a.m.-12:30 p.m.
Independence Ballrooms D/E, Level 5B, Grand Hyatt

MEDICAL SAVINGS ACCOUNT PLANS: PUTTING YOU AND YOUR PATIENTS FIRST
Chp.: David T. Springer, M.D.
Participants: James L. Pendleton, M.D., Howard F. Stock, M.D.

ISSUE WORKSHOP 82
11:00 a.m.-12:30 p.m.
McPherson Square Room, Level 5B, Grand Hyatt

TEACHING PSYCHOTHERAPY IN A MANAGED CARE SETTING
Chp.: James H. Scully, Jr., M.D.
Participants: George W. Ayers, D.S.W., Ronald E. Prier, M.D., Margaret A. Shugart, M.D.
ISSUE WORKSHOP 83   11:00 a.m.-12:30 p.m.
Paris Room, Ballroom Level, Marriott Metro Center

MEDICAID MANAGED CARE IN MARYLAND: EXPANDING ACCESS AND EARLY INTERVENTION FOR CHILDREN AND ADOLESCENTS

Chp.: Albert A. Zachik, M.D.
Participants: Thomas J. Merrick, M.A., Karen Oliver, Ph.D.

12 noon Sessions

FORUMS 8-9

FORUM 8   12 noon-1:30 p.m.
Rooms 21/22, Lower Level, Convention Center

ETHICS AND HUMAN RIGHTS: AN INTERNATIONAL PERSPECTIVE

Chp.: Rodrigo A. Muñoz, M.D.
Co-Chps.: Robert O. Pasnau, M.D., Ahmed M.F. Okasha, M.D.
Participants: Peter B. Grunenberg, M.D., David S. Wahl, M.D., Julio E. Arboleda-Florez, M.D.

FORUM 9   12 noon-1:30 p.m.
Grand Ballroom B, Ballroom Level, Marriott Metro Center

THE PATIENT NAMED SYBIL: DID ISSUES

Chp.: Leah J. Dickstein, M.D.
Participants: Paul Jay Fink, M.D., David Spiegel, M.D., Richard P. Kluft, M.D.

NEW RESEARCH POSTER SESSION 15
12 noon-2:00 p.m.
Hall D, Lower Level, Convention Center

PSYCHOPHARMACOLOGY, BRAIN IMAGING, SLEEP DISORDERS, AND DIAGNOSTIC ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 72-94

SYMPOSIUM 72   2:00 p.m.-5:00 p.m.
Rooms 13/14, Lower Level, Convention Center

SEXUAL MEDICINE: THE HIGHLIGHTS OF THE DECADE

Chp.: Barbara D. Bartlik, M.D.
Co-Chp.: Susan Rako, M.D.
THURSDAY

C Germany: Reconciling Policies
Michael Stark, M.D.

D France, Canada, the European Community and the International Labor Organization
Gaston P. Hamois, M.D., Jacques Dubuis, M.D.

E United States: Managed Disability Care?
Zebulon C. Taintor, M.D.

Discussant: Robert Cancro, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75  2:00 p.m.-5:00 p.m.
Rooms 21/22, Lower Level, Convention Center

ALTERNATIVE THERAPIES IN DEPRESSION AND ANXIETY

Chp.: Kathryn M. Connor, M.D.
Co-Chp.: Jonathan R.T. Davidson, M.D.

A Alternative Therapies in Psychiatric Outpatients
Kathryn M. Connor, M.D., Jonathan R.T. Davidson, M.D., L. Erik Churchill, M.S.

B Botanical Extracts As Anxiolytic Treatments or Adjuncts
Jerry M. Cott, Ph.D.

C Centella Asiatica Decreases the Acoustic Startle Response
Jacques Bradwejn, M.D., Yueping Zhou, M.D., Diana Koszycki, Ph.D., Jakov Shlik, M.D., Martin A. Katzman, M.D., Franco J. Vaccarino, Ph.D.

D Hypericum Perforatum: Its Relevance to Psychiatric Practice
Jonathan R.T. Davidson, M.D.

E The Efficacy of Acupuncture in the Treatment of Depression
John J.B. Allen, Ph.D., Rosa N. Schnyer, Sabrina K. Hitt, M.A., Rachel Mamber, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76  2:00 p.m.-5:00 p.m.
Rooms 23/24, Lower Level, Convention Center

MODEL RESIDENCY PROGRAMS ON RELIGION/SPIRITUALITY

Chp.: Francis G. Lu, M.D.
Co-Chp.: Christina M. Puchalski, M.D.

A The Baylor Curriculum on Religion/Spirituality and Psychiatry
James W. Lomax II, M.D.

B The Psychiatry Residency Award Program at Bronx-Lebanon Hospital
Nalini V. Juthani, M.D.

C The Jefferson Medical College Curriculum on Religion/Spirituality and Psychiatry
Shimon Waldfogel, M.D.

D Residency Training on Religion/Spirituality at Loma Linda University School of Medicine
Donald L. Anderson, M.D., Khushro B. Unwalla, M.D.

E Functions of Faith: A Framework for Therapy at the University of Pittsburgh
Carl A. Jensen, D.M.N.

F Training Programs on Spirituality at California Pacific Medical Center and the University of California at San Francisco
Elizabeth F. Targ, M.D.

G Spirituality and Religion in the Harvard Longwood Residency
John R. Petee, M.D., Mary K. McCarthy, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77  2:00 p.m.-5:00 p.m.
Rooms 25/26, Lower Level, Convention Center

MANAGED CARE VERSUS FEE-FOR-SERVICE MEDICAID FOR ADULTS WITH SEVERE MENTAL ILLNESS

Chp.: Benton H. McFarland, M.D.

A Medicaid Managed Mental Health Care: Overview
A. Michael Wylie, Ph.D.

B Managed Care Systems in Adult Medicaid Clients with Severe Mental Illness in Five States
David L. Shern, Ph.D., M. Susan Ridgely, J.D., Sara A. Steber, M.S.S., Trevor Hadley, Ph.D.

C Service Use by Mentally Ill Persons in Managed Care
Alleen Rothbard, Sc.D., Hanfeng Dai, M.D.

D Outcomes for Medicaid Beneficiaries in Managed Care Versus Fee for Service
Benton H. McFarland, M.D., Roger Boothroyd, Ph.D.

Discussant: Joseph P. Morrissey, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78  2:00 p.m.-5:00 p.m.
Room 27, Lower Level, Convention Center

NEW INSIGHTS INTO DEMENTIA

Chp.: Dilip V. Jeste, M.D.
Co-Chp.: Lon S. Schneider, M.D.

A Genetics of Alzheimer's Disease
Gary W. Small, M.D.
B  Psychosis and Agitation in Dementia
   Dilip V. Jeste, M.D., Enid Rockwell, M.D., Daniel D. Sewell, M.D.,
   Hoang A. Nguyen, M.D., Jonathan P. Lacro, Pharm.D.,
   M. Jackuelyn Harris, M.D.

C  Mechanisms of Depression in Dementia
   George S. Alexopoulos, M.D.

D  Cognitive Enhancers
   Lon S. Schneider, M.D.

E  Behavioral Interventions in Dementia Care
   Soo Borson, M.D., Jim C. Chen, M.D.

Discussant: Ira R. Katz, M.D.
THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

SYMPOSIUM 83  
2:00 p.m.-5:00 p.m.  
Room 33, Lower Level, Convention Center

WHEN YOUR PATIENT SUICIDES AND YOU ARE A RESIDENT

Chp.: Peter Betz, M.D.  
Co-Chp.: Vani A. Rao, M.D.

A Case Presentation and Phenomenology of Suicide  
Peter Betz, M.D.

B Psychological Vulnerabilities in Psychiatric Residents  
James W. Ethier, M.D.

C In the Darkest Hour: The Residency Program Responds  
Edward A. Minor, M.D.

D A Resident's Patient Commits Suicide: Legal Liability  
Vani A. Rao, M.D.

Discussant: Donald A. Misch, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84  
2:00 p.m.-5:00 p.m.  
Conference Theatre, Level 1B, Grand Hyatt

CULTURAL IDENTITY AND MENTAL HEALTH

Chp.: Juan E. Mezzich, M.D.  
Co-Chp.: Lilian Comas-Diaz, Ph.D.

A Bicultural Identification and Its Multi-Ethnic Validation  
Juan E. Mezzich, M.D., Maria A. Ruiperez, Ph.D., Gihyun Yoon, M.D., Carlos Perez, M.D., Jason S. Liu, M.D., Saeed Iqbal, M.D., Syed A. Mahmud, M.D.

B Cultural Identity and Mental Health: Asian-American Perspectives  
Keh-Ming Lin, M.D.

C Alienation and Mental Health: African-American Viewpoints  
Carl C. Bell, M.D.

D Bicultural Issues in Geneva  
Ariel Eytan, M.D.

E Immigration, Culture and Mental Health in Israel  
Yair C. Bar-Eil, M.D., Haim Y. Knobler, M.D.

Discussant: Lilian Comas-Diaz, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85  
2:00 p.m.-5:00 p.m.  
Arlington/Cabin John Rooms, Level 3B, Grand Hyatt

PSYCHIATRIC ISSUES IN DESIRE FOR DEATH

Chp.: Willo Pequegnat, Ph.D.  
Co-Chp.: Ellen Stover, Ph.D.

A Desire for Death Among Cancer and AIDS Patients  
William Breitbart, M.D.

B Coping Style, Depression and Group Therapy in Terminal Illness  
David Spiegel, M.D.

C Treating Terminally Ill Patients with HIV  
Robert L. Klitzman, M.D.

D Desire for Hastened Death in End-Stage AIDS Disease  
Susan Folkman, Ph.D.

Discussant: Samuel C. Klagsbrun, M.D.

SYMPOSIUM 86  
2:00 p.m.-5:00 p.m.  
Roosevelt/Wilson Rooms, Level 3B, Grand Hyatt

IMPROVING EARLY PSYCHOSIS OUTCOMES IN CANADA

Chp.: Donald E. Addington, M.D.

A The Effect of Perinatal Events on Outcome in Early Psychosis  
Liil C. Kopala, M.D.

B Neurocognitive Outcomes in Early Psychosis  
Jean M. Addington, Ph.D.

C Population-Based Programs: Process and Outcome Indicators  
Donald E. Addington, M.D.

D Outcome in a First-Episode Psychosis Cohort  
Ashok K. Mailia, M.D., Ross M.G. Norman, Ph.D., Panth L Voruganti, M.D., Leonardo Cortese, M.D., Rajinder Haricharan, M.D., Rahul Manchanda, M.D.

E Pharmacologic Strategies for First-Episode Psychosis  
Robert B. Zipursky, M.D.

Discussant: Ross M.G. Norman, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87  
2:00 p.m.-5:00 p.m.  
Independence Ballrooms B/C, Level 5B, Grand Hyatt

THE PSYCHOPHARMACOLOGY OF SEVERE MENTAL DISORDERS

Collaborative Session with the National Institute of Mental Health

Chp.: Matthew V. Rudorfer, M.D.  
Co-Chp.: Benedetto Vitiello, M.D.

A New Antipsychotics: Data and Methods  
John M. Kane, M.D.

B Advances in the Treatment of Childbearing-Aged Women  
Katherine L. Wisner, M.D.
C Mood Stabilizers and Signal Transduction Regulation
Husseini K. Manji, M.D.

D Antipsychotics in Child and Adolescent Psychiatry
Robert J. Nicolson, M.D., Marge Lenane, M.S.W., Sanjiv Kumra, M.D., Judith H.L. Rapoport, M.D.

E Isozyme-Specific Drug Metabolism in the Elderly
Bruce G. Pollock, M.D.

Discussant: A. John Rush, M.D.
THIS SESSION WILL BE AUDIOTAPE.
D Gonadal Steroids and Perimenopausal Depression  
David R. Rubinow, M.D.

E Depressed Grandmothers, Mothers and Children  
Myrna M. Weissman, Ph.D.

Discussants: Lee S. Cohen, M.D., M. Katherine Shear, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94  
2:00 p.m.-5:00 p.m.
Paris Room, Ballroom Level, Marriott Metro Center

DRUG-INDUCED DISEASE: WHAT EVERY PSYCHIATRIST NEEDS TO KNOW  
Food and Drug Administration

Chp.: Stephen A. Goldman, M.D.

A Premarketing Drug Safety Evaluation: What Goes into the Label?  
Thomas P. Laughren, M.D.

B Drug-Induced Disease: Pharmacokinetic and Pharmacodynamic Considerations  
Charles J. Ganley, M.D.

C Clinical Assessment, Work-Up and Reporting of Adverse Drug Events  
Stephen A. Goldman, M.D.

Discussant: Jack M. Gorman, M.D.
THIS SESSION WILL BE AUDIOTAPED.
# 1999 Annual Meeting
## Topic Areas for the Scientific Program

### Disorders
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Cognitive Disorders (Dementia, Delirium, Amnestic, etc.)
5. Dissociative Disorders
6. Eating Disorders
7. Infant and Childhood Disorders
8. Mental Retardation (Child/Age, Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Premenstrual Dysphoric Disorder
12. Schizophrenia and Other Psychotic Disorders
13. Sexual and Gender Identity Disorders
14. Sleep Disorders
15. Somatoform Disorders
16. Other Disorders Not Listed Above

### Practice Areas
17. Administration
18. Private Practice
19. Public Sector
20. University
21. HMO
22. Other

### Subspecialty Areas or Special Interests
23. Addiction Psychiatry
24. Biological Psychiatry
25. Brain Imaging
26. Child and/or Adolescent Psychiatry
27. Community Psychiatry and Prevention
28. Consultation-Liaison and Emergency Psychiatry
29. Cross-Cultural and Minority Psychiatry
30. Diagnostic Issues
31. Epidemiology
32. Ethics
33. Forensic Psychiatry
34. Genetics
35. Geriatric Psychiatry
36. Neurobiology
37. Neuropsychiatry
38. Psychiatric Education
39. Psychiatric Rehabilitation
40. Psychoanalysis
41. Psychopharmacology
42. Research Issues
43. Social Psychiatry
44. Stress
45. Suicide
46. Violence, Trauma and Victimization

### Treatments
47. Behavior and Cognitive Therapies
48. Combined Pharmacotherapy and Psychotherapy
49. Couple and Family Therapies
50. Group Therapy
51. Individual Psychotherapies
52. Psychopharmacology
53. Other Somatic Therapies
54. Treatment Techniques and Outcome Studies

### Other Issues
55. Computers
56. Creativity and the Arts
57. Gay and Lesbian Issues
58. Gender Issues
59. Health Services Research
60. Historical Questions
61. Human Rights
62. Managed Care and Health Care Funding
63. National Institute of Mental Health Track
64. Political Questions
65. Professional and Personal
66. Religion, Spirituality and Psychiatry
67. Resident and Medical Student Concerns
68. Presidential Theme: The Clinician
69. Stigma/Advocacy

---

**GUIDE TO USING THE TOPIC INDEX**

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
TOPIC INDEX

DISORDERS Page #

TOPIC 1: AIDS AND HIV-RELATED DISORDERS

AIDS EDUCATION PROGRAMS
1 Clinical and Neuropsychiatric Dimensions of HIV Disease 34
2 Psychiatric and Clinical Manifestations 60

DISCUSSION GROUP
8 Challenges in HIV Care for Psychiatrists 65

MEDIA PRESENTATIONS
33 Odo Ya! Life with AIDS 55
34 Rainmakers Thailand 55
35 Women and HIV: Four Stories 55

MEDICAL UPDATE
2 Advances in the Treatment of HIV Infection 41

SCIENTIFIC AND CLINICAL REPORT
48 Immunological Status Versus Depression As Predictors of Quality of Life in HIV-Infected Individuals 43

SYMPOSIA
21 Group Therapy for Persons Living with HIV/AIDS 49
28 Psychiatry in the Second Decade of the HIV Pandemic 51

WORKSHOPS – COMPONENTS
11 Sildenafil Citrate, Sexual Function and HIV Prevention 16
47 HIV Prevention: Stigma and Names-Based Reporting 86

WORKSHOPS – ISSUES
15 HIV/AIDS Education and Training of Psychiatrists 22
38 Clinical Aspects of HIV and AIDS Among Hispanics 64

TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS

CME COURSES
11 Assessment and Treatment of Nicotine Dependence 2
35 Dealing with Resistance in Addiction Patients 12
72 Dual Diagnosis: Basic Principles of Successful Intervention 45
78 Dual Diagnosis: Advanced Clinical Application 60

MEDIA PRESENTATIONS
3 Confessions of a Rabid Dog 14
4 One for the Road 14

SCIENTIFIC AND CLINICAL REPORTS
56 Enhancing Treatment of Cocaine-Dependent Mothers 68
57 Naltrexone Plus Cognitive-Behavior Therapy for Alcoholism 68
58 The Drug Abuse Screening Test for Adolescents 68

SYMPOSIA
3 Substance Abuse: Developments for the Practitioner 26
65 Relapse in Co-Occurring Disorders 78
73 Update on Treatment of Stimulant Abuse 93

WORKSHOP – COMPONENT
38 Outpatient Detoxification Treatment Services 64

TOPIC 3: ANXIETY DISORDERS

CME COURSE
69 Cognitive-Behavioral Treatment of Specific Phobias 45

INDUSTRY-SUPPORTED SYMPOSIA
5 A Twin Study of Dissociative Experience 19
6 Diagnosis of Dissociative Identity Disorder 19

TOPIC 4: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)

CME COURSES
57 Delirium in the General Hospital 34
63 Dementia: Advanced Diagnosis and Treatment 35

SYMPOSIA
28 Clinical Implications of New Dementia Research 54

TOPIC 5: DISSOCIATIVE DISORDERS

FORUM
9 The Patient Named Sybil: DID issues 93

SCIENTIFIC AND CLINICAL REPORTS
5 A Twin Study of Dissociative Experience 19
6 Diagnosis of Dissociative Identity Disorder 19

TOPIC 6: EATING DISORDERS

CME COURSES
5 Therapeutic Interventions in Eating Disorders 1
82 Multimodal Therapy for Severe Eating Disorders 60

MASTER EDUCATOR CLINICAL CONSULTATION
16 Anorexia and Bulimia Nervosa 89

SYMPOSIA
24 Biology of Eating Disorders: Clinical Implications 50
45 Eating Disorders: Origins, Treatments and Outcomes 73

TOPIC 7: INFANT AND CHILDHOOD DISORDERS

CME COURSES
30 ADD in Children and Adolescents 6
79 Autism and Asperger's Syndrome Across the Life Span 60

SCIENTIFIC AND CLINICAL REPORT
20 School-Based Mourning Groups: Inner-City Violence 20

TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)

CME COURSE
22 Assessment and Treatment of Patients with Mental Retardation 3
### TOPIC INDEX

#### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 Premorbid Associality and Neuropsychological Status</td>
<td>42</td>
</tr>
<tr>
<td>33 Negative Symptoms and Functioning in Schizophrenia</td>
<td>42</td>
</tr>
<tr>
<td>34 Do Schizoaffective Patients Have a Chronic Course?</td>
<td>67</td>
</tr>
<tr>
<td>50 Life Events Trigger Depression in Early Schizophrenia</td>
<td>67</td>
</tr>
<tr>
<td>51 National Collaborative Study of Early Psychosis and Suicide: An Introduction</td>
<td>67</td>
</tr>
<tr>
<td>52 Clinical Correlates of Insight in Psychotic Disorders</td>
<td>67</td>
</tr>
<tr>
<td>75 Genetic Antecedents of Dopamine Dysfunction in Schizophrenia</td>
<td>90</td>
</tr>
<tr>
<td>89 Childhood Adversity and Adult Homelessness</td>
<td>91</td>
</tr>
<tr>
<td>90 Comparative Efficacy of Olanzapine and Haloperidol in Patients Reporting Voices</td>
<td>91</td>
</tr>
</tbody>
</table>

#### SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Practicing and Measuring Quality Care for Schizophrenia</td>
<td>27</td>
</tr>
<tr>
<td>26 New Treatment Targets in Schizophrenia</td>
<td>50</td>
</tr>
<tr>
<td>56 Aging of Patients with Schizophrenia</td>
<td>76</td>
</tr>
<tr>
<td>86 Improving Early Psychosis Outcomes in Canada</td>
<td>96</td>
</tr>
</tbody>
</table>

#### WORKSHOPS – ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Schizophrenia Guidelines: Administrative Challenges</td>
<td>16</td>
</tr>
<tr>
<td>60 Cognitive-Behavior Therapy of Schizophrenia</td>
<td>92</td>
</tr>
</tbody>
</table>

#### TOPIC 13: SEXUAL AND GENDER IDENTITY DISORDERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 The Assessment and Treatment of Child Molesters</td>
<td>35</td>
</tr>
</tbody>
</table>

#### REVIEW OF PSYCHIATRY

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Male Psychosexuality</td>
<td>38</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>72 Sexual Medicine: The Highlights of the Decade</td>
<td>93</td>
</tr>
</tbody>
</table>

#### WORKSHOPS – ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Problematic Excessive Sexual Behavior</td>
<td>16</td>
</tr>
<tr>
<td>34 Sildenafil Citrate: A Sex Therapist’s Perspective</td>
<td>64</td>
</tr>
</tbody>
</table>

#### TOPIC 14: SLEEP DISORDERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 Understanding and Managing Chronic Insomnia</td>
<td>34</td>
</tr>
<tr>
<td>92 Overview and Update of Sleep Disorders Medicine</td>
<td>71</td>
</tr>
</tbody>
</table>

#### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 Clinical Frontiers in the Sleep/Psychotherapy Interface</td>
<td>8</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>93 The Dream 100 Years Later: New Facts, New Theories</td>
<td>98</td>
</tr>
</tbody>
</table>

#### TOPIC 15: SOMATOFORM DISORDERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>74 The Evaluation and Management of Pain</td>
<td>46</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Somatoform Dissociation and Trauma</td>
<td>28</td>
</tr>
<tr>
<td>62 BDD: New Research Findings for Clinical Practice</td>
<td>77</td>
</tr>
</tbody>
</table>

#### TOPIC 16: OTHER DISORDERS NOT LISTED ABOVE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 ADD in Adults</td>
<td>3</td>
</tr>
<tr>
<td>54 Advanced Assessment and Treatment of ADD</td>
<td>34</td>
</tr>
</tbody>
</table>

#### INDUSTRY-SUPPORTED SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Part I: Novel Approaches to the Treatment of Impulsivity</td>
<td>59</td>
</tr>
<tr>
<td>30 Part II: Novel Approaches to the Treatment of Impulsivity</td>
<td>83</td>
</tr>
</tbody>
</table>

### PRACTICE AREAS

#### TOPIC 17: ADMINISTRATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>59 Personnel Management for Clinician-Managers</td>
<td>34</td>
</tr>
</tbody>
</table>

#### LECTURE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Women in Medical Leadership: How Far Baby?</td>
<td>46</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>37 Resource and Care Management Systems: The Level of Care Utilization System for Psychiatric and Addiction Services, Adult and Child Versions</td>
<td>53</td>
</tr>
</tbody>
</table>

#### WORKSHOP – COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>36 Executive Roles for Psychiatrists in the 21st Century</td>
<td>64</td>
</tr>
</tbody>
</table>

#### WORKSHOP – ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 Leadership in Organizational Transitions</td>
<td>39</td>
</tr>
</tbody>
</table>

#### TOPIC 18: PRIVATE PRACTICE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private Practice Is Alive and Thriving</td>
<td>17</td>
</tr>
</tbody>
</table>

#### TOPIC 19: PUBLIC SECTOR

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disability Evaluation Under Social Security</td>
<td>63</td>
</tr>
</tbody>
</table>

#### TOPIC 20: UNIVERSITY

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teaching Psychotherapy in a Managed Care Setting</td>
<td>92</td>
</tr>
</tbody>
</table>

#### TOPIC 21: HMO

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malpractice Liability and Managed Care: Developments</td>
<td>91</td>
</tr>
</tbody>
</table>

#### TOPIC 22: OTHER

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>My Country</td>
<td>72</td>
</tr>
<tr>
<td>Best Man: &quot;Best Boy&quot; and All of Us Twenty Years Later</td>
<td>72</td>
</tr>
</tbody>
</table>

#### WORKSHOP – COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Populations in Rural Psychiatry</td>
<td>21</td>
</tr>
</tbody>
</table>

### SUBSPECIALTY AREAS OR SPECIAL INTERESTS

#### TOPIC 23: ADDICTION PSYCHIATRY

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of Addictions: Myths and Realities</td>
<td>61</td>
</tr>
</tbody>
</table>

#### LECTURE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Co-Recurring Problem of Substance Abuse and Mental Illness and the Federal Response Across the Life Cycle</td>
<td>88</td>
</tr>
</tbody>
</table>
### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td>Polymorphisms in the Serotonin Transporter Gene and Cocaine Dependence</td>
</tr>
</tbody>
</table>

### SYMPOSIA

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Collective Approaches to the Control of Affective Disorders</td>
</tr>
<tr>
<td>64</td>
<td>The Evolution of Community Psychiatry in Italy</td>
</tr>
</tbody>
</table>

### WORKSHOP – COMPONENT

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Psychiatric Dimensions of Disasters</td>
</tr>
</tbody>
</table>

### TOPIC 28: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

### CME COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Whose Death Is It Anyway?</td>
</tr>
</tbody>
</table>

### MEDICAL UPDATE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>Management of Low Back Pain</td>
</tr>
</tbody>
</table>

### RESEARCH ADVANCES IN MEDICINE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>Herbal Medicine: A Consultation-Liaison Psychiatry Prospective on Usage Patterns, Benefits and Complications</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Management of Major Depression in Hispanic Patients in the Primary Care Setting</td>
</tr>
</tbody>
</table>

### TOPIC 29: CROSS-CULTURAL AND MINORITY PSYCHIATRY

### DSM-IV CME COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>DSM-IV Cultural Formulations: Diagnosis and Therapy</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUP

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Managed Care and Issues for Minorities</td>
</tr>
</tbody>
</table>

### LECTURES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>84</td>
<td>Hispanic Psychiatry: From Margin to Mainstream</td>
</tr>
</tbody>
</table>

### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>Aparajito: Part II of the Apu Trilogy</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td></td>
</tr>
</tbody>
</table>

### WORKSHOP – ISSUE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Life-Threatening Elder Psychiatric Emergencies</td>
</tr>
</tbody>
</table>

### TOPIC 27: COMMUNITY PSYCHIATRY AND PREVENTION

### CME COURSE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>71</td>
<td>Disaster Psychiatry: Advanced Topics</td>
</tr>
</tbody>
</table>

### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>First Break</td>
</tr>
<tr>
<td>24</td>
<td>The Bonnie Tapes: Recovering from Mental Illness</td>
</tr>
<tr>
<td>24</td>
<td>Partnership in Recovery: Medicine, Management, Motivation</td>
</tr>
</tbody>
</table>
# TOPIC INDEX

## SYMPOSIA
- 2 Psychiatric Diagnosis in Diverse Populations 26
- 17 Cultural Aspects of Psychiatric Practice Across the Americas 29
- 34 Cultural and Language Considerations in Diagnosis 52
- 41 French and American Psychiatry: Vive La Difference! 56
- 42 Arab Cultural Perspectives on the Assessment and Treatment of Anxiety Disorders 56
- 49 Cultural Issues for Psychiatrists and Patients 74
- 84 Cultural Identity and Mental Health 96

## WORKSHOPS – COMPONENTS
- 13 Pearls and Pitfalls of Working with Ethnic Caregivers 21
- 26 Substance Abuse, Violence and the Hispanic Family 38

## WORKSHOP – ISSUE
- 79 The Woman International Medical Graduate in Psychiatry 92

## TOPIC 30: DIAGNOSTIC ISSUES

### CME COURSES
- 10 Assessing Positive and Negative Symptoms with the Positive and Negative Syndrome Scale 2
- 16 Computer-Assisted Diagnostic Interview 3

### SCIENTIFIC AND CLINICAL REPORT
- 74 Diagnostic Stability of MDD 69

### SYMPOSIA
- 82 Defining Personality in the 21st Century 95

### WORKSHOPS – ISSUES
- 23 Case Formulation: Three Alternative Viewpoints 39
- 57 DSM-IV and Old-Time Rock and Roll 87

## TOPIC 31: EPIDEMIOLOGY

### SCIENTIFIC AND CLINICAL REPORTS
- 83 Victimization As a Risk Factor for Major Depression 90
- 84 Mortality and Morbidity Among Psychiatric Patients 90
- 85 School Predictors of Hospital-Treated Psychiatric Disorders in the 1996 Northern Finland Birth Cohort 90

## TOPIC 32: ETHICS

### CME COURSE
- 45 Medical Ethics 101 13

### SCIENTIFIC AND CLINICAL REPORT
- 47 The Option of Euthanasia for HIV Disease in Europe 43

## SYMPOSIA
- 14 The Role of Psychiatrists in Palliative Care 28
- 20 The Ethics of Schizophrenia Research 49
- 36 Working in a Flawed System: The Ethical Dilemmas 53
- 48 Physician-Assisted Suicide: A Look to the Future 74

## TOPIC 33: FORENSIC PSYCHIATRY

### CME COURSES
- 20 The Psychiatrist As Expert Witness 3
- 56 The Detection of Malignant Mental Illness 34
- 66 Medical-Legal Aspects of Assessment in the Workplace 45
- 75 Insanity Defense Evaluations 60
- 91 Malpractice Liability and Risk Management 71
- 94 Introduction to Corneal Psychiatry 84

### LECTURES
- 1 False Memory Lawsuits: The Weight of the Scientific and Legal Evidence 7
- 15 Criminal Profiling: Using the Tools of the Past Today 61

### SCIENTIFIC AND CLINICAL REPORT
- 29 Incompetent, Unrestorable Patients: A New Approach 42

## TOPIC 34: GENETICS

### SCIENTIFIC AND CLINICAL REPORT
- 78 Serotonin Genetic Polymorphism in SAD and Bulimia Nervosa 90

## TOPIC 35: GERIATRIC PSYCHIATRY

### INDUSTRY-SUPPORTED SYMPOSIA
- 16 Longitudinal Aspects of Alzheimer's Disease Management 9
- 24 Alzheimer's Disease: Translating Clinical Trials Into Clinical Care 53
- 33 Part I: Assessment and Treatment of Psychiatric Disorders in the Elderly 59
- 33 Part II: Assessment and Treatment of Psychiatric Disorders in the Elderly 83
- 34 Part I: Advances in the Treatment of Geriatric Depression 59
- 34 Part II: Advances in the Treatment of Geriatric Depression 83

### MASTER EDUCATOR CLINICAL CONSULTATION
- 17 Geriatric Psychiatry Patients 89

### MEDIA PRESENTATION
- 27 Geriatrics: Women's and Men's Health 47

## SYMPOSIA
- 31 Drugs: Women's Health Issues 90
- 78 New Insights into Dementia 94

### WORKSHOP – COMPONENT
- 17 Nursing Home Psychiatry: Problems and Solutions 21

## TOPIC 36: NEUROBIOLOGY

### LECTURE
- 19 The Persistent Neurobiological Consequences of Early Untoward Life Events: Treatment Implications 72

## TOPIC 37: NEUROPSYCHIATRY

### ADVANCES IN RESEARCH
- Neuropsychiatric Disorders 17

### CME COURSES
- 21 Diagnostic Challenges in Neuropsychiatry 3
- 36 Traumatic Brain Injury: Neuropsychiatric Assessment 12
- 41 Advances in Neuropsychiatry 13
- 70 Video Review of Neuropsychiatric Conditions 45
- 80 Psychiatric Disorders Related to Epilepsy 90
- 95 An Introduction to Clinical Neurodynamics 84
- 97 Clinical Neuropsychiatry: An Update (In Spanish) 84

### SCIENTIFIC AND CLINICAL REPORTS
- 14 Cognitive Deficits in Children with Lyme Disease 20
- 15 CBF in Lyme Encephalopathy 20

## SYMPOSIA
- 8 Dr. Karl Kahlbaum's Centennial Symposium on Catatonia 27
- 92 Advanced Risk Management Issues and Strategies 97

### WORKSHOPS – COMPONENTS
- 19 Legal Update: Managed Care, Privacy and Sex Offenders 38
- 53 Deinstitutionalizing Severely Mentally Ill Persons 91

### WORKSHOP – ISSUE
- 47 Clinical and Forensic Aspects of Sexual Harassment 65

## TOPIC 38: GENETICS

### SCIENTIFIC AND CLINICAL REPORT
- 78 Serotonin Genetic Polymorphism in SAD and Bulimia Nervosa 90

## TOPIC 39: GERIATRIC PSYCHIATRY

### INDUSTRY-SUPPORTED SYMPOSIA
- 16 Longitudinal Aspects of Alzheimer's Disease Management 9
- 24 Alzheimer's Disease: Translating Clinical Trials Into Clinical Care 53
- 33 Part I: Assessment and Treatment of Psychiatric Disorders in the Elderly 59
- 33 Part II: Assessment and Treatment of Psychiatric Disorders in the Elderly 83
- 34 Part I: Advances in the Treatment of Geriatric Depression 59
- 34 Part II: Advances in the Treatment of Geriatric Depression 83

### MASTER EDUCATOR CLINICAL CONSULTATION
- 17 Geriatric Psychiatry Patients 89

### MEDIA PRESENTATION
- 27 Geriatrics: Women's and Men's Health 47

## SYMPOSIA
- 31 Drugs: Women's Health Issues 90
- 78 New Insights into Dementia 94

### WORKSHOP – COMPONENT
- 17 Nursing Home Psychiatry: Problems and Solutions 21

## TOPIC 38: GENETICS

### SCIENTIFIC AND CLINICAL REPORT
- 78 Serotonin Genetic Polymorphism in SAD and Bulimia Nervosa 90

## TOPIC 39: GERIATRIC PSYCHIATRY

### INDUSTRY-SUPPORTED SYMPOSIA
- 16 Longitudinal Aspects of Alzheimer's Disease Management 9
- 24 Alzheimer's Disease: Translating Clinical Trials Into Clinical Care 53
- 33 Part I: Assessment and Treatment of Psychiatric Disorders in the Elderly 59
- 33 Part II: Assessment and Treatment of Psychiatric Disorders in the Elderly 83
- 34 Part I: Advances in the Treatment of Geriatric Depression 59
- 34 Part II: Advances in the Treatment of Geriatric Depression 83

### MASTER EDUCATOR CLINICAL CONSULTATION
- 17 Geriatric Psychiatry Patients 89

### MEDIA PRESENTATION
- 27 Geriatrics: Women's and Men's Health 47

## SYMPOSIA
- 31 Drugs: Women's Health Issues 90
- 78 New Insights into Dementia 94

### WORKSHOP – COMPONENT
- 17 Nursing Home Psychiatry: Problems and Solutions 21

## TOPIC 38: GENETICS

### SCIENTIFIC AND CLINICAL REPORT
- 78 Serotonin Genetic Polymorphism in SAD and Bulimia Nervosa 90
## TOPIC INDEX

### MEDIA PRESENTATIONS (Continued)
- Page #
  - 54 The Last Transfer 85
  - 56 Still Missing 89
  - 57 Sacrifice 89
  - 58 Trying to Get Some Dignity 89
  - 59 Interviewing for Child Sexual Abuse 89

### SCIENTIFIC AND CLINICAL REPORTS
- 22 Exposure to Violence and Post-Traumatic Stress Symptoms in Urban, Inner-City Adolescents 20
- 31 Schizophrenic Violence: Relationship to Symptoms 42

### SYMPOSIA
- 15 Understanding and Dealing with School Violence 29
- 16 Violence and Mental Illness 29
- 32 Violence, Social Change and Women’s Health 52
- 33 Understanding School Violence 52
- 38 The Biology of Trauma 55
- 88 Psychiatry and Crime Victims: Bridging the Gap 97

### WORKSHOPS – ISSUES
- 17 Understanding the Dynamics of Abusive Relationships 39
- 20 The International War Crimes Tribunal: Psychiatry’s Role 39

### TREATMENTS
#### TOPIC 47: BEHAVIOR AND COGNITIVE THERAPIES
##### CME COURSES
- 8 Cognitive Therapy for Severe Mental Disorders 1
- 24 Basic Hypnosis: Principles and Applications 4
- 42 Introduction to Behavior Therapy 13
- 43 Dialectical Behavior Therapy 13
- 50 Cognitive Therapy: The Basics 23
- 81 Hypnosis in Psychiatry 60

#### TOPIC 48: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY
##### INDUSTRY-SUPPORTED SYMPOSIUM
- 15 Depression: Achieving Remission and Compliance: Clinical Challenges and Solutions 8

#### TOPIC 49: COUPLE AND FAMILY THERAPIES
##### CME COURSES
- 49 Families and Medical Illness: An Integrative Treatment Approach 23
- 61 Integrative Couple Therapy: Skills and Techniques 35

##### WORKSHOPS – ISSUES
- 55 Death in the Family: Family Tradition and the Will 70
- 63 Video Case Studies of Couples in Treatment 87

#### TOPIC 50: GROUP THERAPY
##### CME COURSE
- 6 Introduction to Psychodynamic Group Psychotherapy 1

##### MEDIA PRESENTATION
- 44 Behind the Mask: Teaching Spontaneous Theater 67

#### TOPIC 51: INDIVIDUAL PSYCHOTHERAPIES
##### CME COURSES
- 2 Psychodynamic Treatment of Panic Disorder 1
- 18 Interpersonal Psychotherapy 3
- 26 Dream Translation: An Empirically-Based Approach 5
- 29 Alternative Approaches to Understanding Humans 6
- 32 Brief Psychodynamic Psychotherapy: The Core Confictual Relationship Theme Method 12
- 40 Interpersonal Psychotherapy 13
- 73 The Advanced Practice of Psychotherapy 45
- 87 Relational Theory and Key Clinical Applications 71

### FORUM
- 4 Can We Talk? Psychotherapy by Psychiatrists in Managed Care 45

### MASTER EDUCATOR CLINICAL CONSULTATIONS
- 5 The Impact of the Therapist's Life Events on the Conduct of Psychotherapy 36
- 12 Psychodynamic Psychotherapy 66

### RESEARCH CONSULTATION WITH
- 1 Psychosocial Interventions As an Integral Part of Comprehensive Cancer Care 41

### REVIEW OF PSYCHIATRY
- 11 Countertransference in Psychiatric Treatment 48

### SCIENTIFIC AND CLINICAL REPORT
- 92 Psychodynamic Psychotherapy of the Suicidal Adolescent Girl 91

### SYMPOSIAS
- 55 Pediatric Psychopharmacology 76
- 80 Updates on the Textbook of Psychopharmacology 95
- 94 Drug-Induced Disease: What Every Psychiatrist Needs to Know 98

### WORKSHOPS – ISSUES
- 33 Prescribing Controlled Substances: Risk Management 45
- 72 Clinical Implications of the Cytochrome P450 88

### TOPIC 53: OTHER SOMATIC THERAPIES
##### CLINICAL CASE CONFERENCE
- 1 Chronic Pain Syndromes Refractory to Conventional Treatments 12

##### CONTINUOUS CLINICAL CASE CONFERENCES
- 12 Treating Patients with Medically Unexplained Symptoms: Part I
- 34 Treating Patients with Medically Unexplained Symptoms: Part II
<table>
<thead>
<tr>
<th>Topic Index</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CME COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>33 Acupuncture Techniques in Psychiatric Practice</td>
<td>12</td>
</tr>
<tr>
<td>67 ECT: New Directions in Practice and Research</td>
<td>45</td>
</tr>
<tr>
<td>71 Herbal Medicine in Psychiatry</td>
<td>45</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>37 Alternative Medicine</td>
<td>62</td>
</tr>
<tr>
<td>38 The Faith Factor</td>
<td>62</td>
</tr>
<tr>
<td><strong>SYMPOSUM</strong></td>
<td></td>
</tr>
<tr>
<td>54 Optimizing the Administration of ECT</td>
<td>75</td>
</tr>
<tr>
<td><strong>WORKSHOP – COMPONENT</strong></td>
<td></td>
</tr>
<tr>
<td>56 New APA Practice Recommendations on ECT</td>
<td>92</td>
</tr>
<tr>
<td><strong>WORKSHOP – ISSUE</strong></td>
<td></td>
</tr>
<tr>
<td>6 Homeopathic Medicine and Psychiatry</td>
<td>16</td>
</tr>
<tr>
<td><strong>TOPIC 54: TREATMENT TECHNIQUES AND OUTCOME STUDIES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CLINICAL CASE CONFERENCE</strong></td>
<td></td>
</tr>
<tr>
<td>3 Refractory Depression and ECT</td>
<td>60</td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>7 Evidence: Use of Rating Scales</td>
<td>1</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>5 Evidence-Based Medicine and Current Psychiatric Practice</td>
<td>39</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>38 Treating Depression: Effectiveness Without Extravagance</td>
<td>79</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>7 Contemporary Practice of ECT</td>
<td>36</td>
</tr>
<tr>
<td><strong>RESEARCH ADVANCES IN MEDICINE</strong></td>
<td></td>
</tr>
<tr>
<td>Overlooked Psychotropics: Herbs and Nutrients for the Year 2000</td>
<td>37</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>10 Group Treatment Outcome for Psychopathic Inmates</td>
<td>20</td>
</tr>
<tr>
<td>30 Effect of Outpatient Commitment on Treatment Compliance in Schizophrenia</td>
<td>42</td>
</tr>
<tr>
<td>37 The Use of Nortriptyline for Prevention of Postpartum Depression in a High-Risk Group of Women</td>
<td>42</td>
</tr>
<tr>
<td>59 Integrated Therapy of Panic Disorder: A Controlled Study</td>
<td>68</td>
</tr>
<tr>
<td><strong>SYMPOSA</strong></td>
<td></td>
</tr>
<tr>
<td>39 New Views on Play in Adults</td>
<td>56</td>
</tr>
<tr>
<td>68 Eye Movement Desensitization and Reprocessing (EMDR)</td>
<td>81</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>29 International Views on Practice Guidelines</td>
<td>44</td>
</tr>
<tr>
<td>59 Treatment Resistance Versus Resistant Treaters</td>
<td>87</td>
</tr>
<tr>
<td><strong>TOPIC 55: COMPUTERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>89 Computer Survival Guide 1999</td>
<td>71</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>Hands-On Web Work</td>
<td>15</td>
</tr>
<tr>
<td>Hands-On Web Work</td>
<td>25</td>
</tr>
<tr>
<td>16 Computerizing Medical Records for a Large Outpatient Division</td>
<td>36</td>
</tr>
<tr>
<td>18 Computer-Assisted Assessment Psychotherapy Education and Research (CAPER) Treatment Planner</td>
<td>37</td>
</tr>
<tr>
<td>28 Psychopharmacology Tips</td>
<td>47</td>
</tr>
<tr>
<td>29 Forensic Psychiatry</td>
<td>47</td>
</tr>
<tr>
<td>30 The Treatment of Depression in Long-Term Care: Interactive CD-ROM Training</td>
<td>47</td>
</tr>
<tr>
<td>31 A World Wide Web Survey of Physician Knowledge of Alzheimer's Disease</td>
<td>48</td>
</tr>
<tr>
<td>39 Algorithm for the Pharmacotherapy of Schizophrenia</td>
<td>62</td>
</tr>
<tr>
<td>40 Booting Up Your Practice</td>
<td>63</td>
</tr>
<tr>
<td>Ask the Experts About Computers and Your Practice</td>
<td>67</td>
</tr>
<tr>
<td><strong>SYMPOSA</strong></td>
<td></td>
</tr>
<tr>
<td>59 The Clinical Internet: American and European Experiences</td>
<td>77</td>
</tr>
<tr>
<td>61 Telepsychiatry: Why Do It?</td>
<td>95</td>
</tr>
<tr>
<td><strong>WORKSHOP – COMPONENT</strong></td>
<td></td>
</tr>
<tr>
<td>54 Human Factors in Telepsychiatry</td>
<td>92</td>
</tr>
<tr>
<td><strong>WORKSHOP – ISSUE</strong></td>
<td></td>
</tr>
<tr>
<td>70 Safeguarding the Electronic Psychiatric Record</td>
<td>87</td>
</tr>
<tr>
<td><strong>TOPIC 56: CREATIVITY AND THE ARTS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>9 Coming Apart</td>
<td>19</td>
</tr>
<tr>
<td>19 City Lights</td>
<td>37</td>
</tr>
<tr>
<td>36 Regeneration</td>
<td>55</td>
</tr>
<tr>
<td>45 Robert Altman's Jazz 34: Remembrances of Kansas City Swing</td>
<td>71</td>
</tr>
<tr>
<td>48 The Ad and the Ego</td>
<td>73</td>
</tr>
<tr>
<td>49 Barbie Nation</td>
<td>73</td>
</tr>
<tr>
<td><strong>SYMPOSA</strong></td>
<td></td>
</tr>
<tr>
<td>69 Music Therapy in Psychosocial Care and Pain Management</td>
<td>81</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>21 Poems on Psychiatry</td>
<td>39</td>
</tr>
<tr>
<td>71 Toning and Chanting and Music Meet Memories</td>
<td>88</td>
</tr>
<tr>
<td><strong>TOPIC 57: GAY AND LESBIAN ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
<td></td>
</tr>
<tr>
<td>5 Hate for Loving: How Societal Oppression Impacts Lesbian and Gay Mental Health</td>
<td>70</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>42 Kamikaze Summer</td>
<td>66</td>
</tr>
<tr>
<td>43 Pride Divide</td>
<td>96</td>
</tr>
<tr>
<td><strong>WORKSHOPS – COMPONENTS</strong></td>
<td></td>
</tr>
<tr>
<td>9 Cultural Perspectives on Coming Out in Psychiatry</td>
<td>16</td>
</tr>
<tr>
<td>32 Homophobia Hurts Families: How Parents, Families and Friends of Lesbians and Gays Can Help</td>
<td>44</td>
</tr>
<tr>
<td>39 Culturally Competent Care of Lesbian, Gay, Bisexual and Transgendered Patients</td>
<td>64</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>18 Gay and Lesbian Substance Abuse Treatment: Cultural Competency Training</td>
<td>39</td>
</tr>
<tr>
<td>31 Family Values: Lesbian and Gay Family Constellations</td>
<td>44</td>
</tr>
<tr>
<td><strong>TOPIC 58: GENDER ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>27 Gender Issues in Diagnosis and Response to Treatment</td>
<td>54</td>
</tr>
<tr>
<td><strong>LECTURES</strong></td>
<td></td>
</tr>
<tr>
<td>16 Women, Mental Health and Productivity</td>
<td>55</td>
</tr>
<tr>
<td>23 Technological Advances in Infertility Therapy: Impact on Biology and Patients</td>
<td>88</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>3 Gender Issues in Psychiatric Treatment Across the Life Cycle</td>
<td>18</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATION</strong></td>
<td></td>
</tr>
<tr>
<td>41 The Story of Adele H.</td>
<td>63</td>
</tr>
<tr>
<td><strong>MEDICAL UPDATES</strong></td>
<td></td>
</tr>
<tr>
<td>1 Modern Management of Menopause</td>
<td>19</td>
</tr>
<tr>
<td>4 Progress in the Treatment of Breast Cancer</td>
<td>89</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>35 Past Depression and Middle-Aged Women's Health</td>
<td>42</td>
</tr>
<tr>
<td>62 The Rationale for Women-Centered Programming: Gender Differences in the Utilization of Intensive Outpatient Treatment</td>
<td>68</td>
</tr>
<tr>
<td>107</td>
<td></td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>58 Gender: What’s the Difference?</td>
<td>76</td>
</tr>
<tr>
<td><strong>WORKSHOP – ISSUE</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>32 Perils and Problems in Sexual Harassment Cases</td>
<td>44</td>
</tr>
<tr>
<td><strong>TOPIC 59: HEALTH SERVICES RESEARCH</strong></td>
<td></td>
</tr>
<tr>
<td>RESEARCH CONSULTATION WITH</td>
<td></td>
</tr>
<tr>
<td>3 Mental Health Services Research</td>
<td>90</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>53 What the States Are Doing to Provide Services to Families of Adults with Severe Mental Illness</td>
<td>67</td>
</tr>
<tr>
<td>54 The Effects of Education About Depression in Primary Care</td>
<td>68</td>
</tr>
<tr>
<td>55 The Association Between Psychiatric Comorbidity and Retention in a Sample of Women Attending Comprehensive Addiction Treatment</td>
<td>68</td>
</tr>
<tr>
<td>65 Use of Antidepressants in a National Sample</td>
<td>68</td>
</tr>
<tr>
<td><strong>TOPIC 60: HISTORICAL QUESTIONS</strong></td>
<td></td>
</tr>
<tr>
<td>MEDIA PRESENTATION</td>
<td></td>
</tr>
<tr>
<td>55 Three Stories</td>
<td>85</td>
</tr>
<tr>
<td><strong>TOPIC 61: HUMAN RIGHTS</strong></td>
<td></td>
</tr>
<tr>
<td>FORUMS</td>
<td>Page #</td>
</tr>
<tr>
<td>7 Managing the Process of Change: Quality, Financing and Patients’ Rights</td>
<td>71</td>
</tr>
<tr>
<td>8 Ethics and Human Rights: An International Perspective</td>
<td>93</td>
</tr>
<tr>
<td><strong>WORKSHOP – COMPONENT</strong></td>
<td></td>
</tr>
<tr>
<td>35 Current Issues on Abuse and Misuse of Psychiatry</td>
<td>64</td>
</tr>
<tr>
<td><strong>TOPIC 62: MANAGED CARE AND HEALTH CARE FUNDING</strong></td>
<td></td>
</tr>
<tr>
<td>CME COURSE</td>
<td>Page #</td>
</tr>
<tr>
<td>76 How to Measure Outcomes Without Breaking the Bank</td>
<td>60</td>
</tr>
<tr>
<td><strong>DEBATE</strong></td>
<td></td>
</tr>
<tr>
<td>1 Resolved: Medical Savings Accounts Will Improve Access to Mental Health Care</td>
<td>13</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATION</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>13 At What Cost?</td>
<td>24</td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>State Medicaid Programs: Access and Quality for Mental Health Care</td>
<td>48</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>95 Declining Mental Health Service Use in a Large Corporation</td>
<td>91</td>
</tr>
<tr>
<td>96 Discrimination in Utilization Management</td>
<td>91</td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
<td></td>
</tr>
<tr>
<td>51 Impact of Parity and Managed Care on Mental Health Care</td>
<td>75</td>
</tr>
<tr>
<td>77 Managed Care Versus Fee-for-Service Medicaid for Adults with Severe Mental Illness</td>
<td>94</td>
</tr>
<tr>
<td><strong>WORKSHOPS – COMPONENTS</strong></td>
<td></td>
</tr>
<tr>
<td>4 Quality of Mental Health in Puerto Rico</td>
<td>15</td>
</tr>
<tr>
<td>37 Funding Managed Care and Public Psychiatric Service Today</td>
<td>64</td>
</tr>
<tr>
<td>49 National Health Insurance: A District Branch View</td>
<td>86</td>
</tr>
<tr>
<td>50 Getting Your Patient on Social Security Income: An Insider’s Guide</td>
<td>86</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>9 Managed Care Versus Fee for Service Medicaid for Adolescents</td>
<td>21</td>
</tr>
<tr>
<td>83 Medicaid Managed Care In Maryland: Expanding Access and Early Intervention for Children and Adolescents</td>
<td>93</td>
</tr>
<tr>
<td><strong>TOPIC 63: NATIONAL INSTITUTE OF MENTAL HEALTH TRACK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td></td>
</tr>
<tr>
<td>9 How Neuroscience Continues to Change Psychiatry</td>
<td>35</td>
</tr>
<tr>
<td><strong>NIH WORKSHOP</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>NIHAA, NIDA and NIMH Grants and Career Development</td>
<td>25</td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>10 Genetic Dissection of the Nervous System and Its Disorders</td>
<td>27</td>
</tr>
<tr>
<td>30 The Neuroscience of Severe Mental Disorders</td>
<td>51</td>
</tr>
<tr>
<td>57 Cultural Factors in Severe Mental Disorders</td>
<td>76</td>
</tr>
<tr>
<td>87 The Psychopharmacology of Severe Mental Disorders</td>
<td>96</td>
</tr>
<tr>
<td><strong>TOPIC 64: POLITICAL QUESTIONS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CME COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>39 Skills for Building and Leading Successful Teams</td>
<td>13</td>
</tr>
<tr>
<td>62 Personality and Political Behavior</td>
<td>35</td>
</tr>
<tr>
<td><strong>WORKSHOP – COMPONENT</strong></td>
<td></td>
</tr>
<tr>
<td>1 Political Violence and Terrorism at the Millennium</td>
<td>15</td>
</tr>
<tr>
<td><strong>TOPIC 65: PROFESSIONAL AND PERSONAL</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LECTURES</strong></td>
<td></td>
</tr>
<tr>
<td>8 Psychiatry’s Shifting Foundation: Research Up, Reimbursement Down, Managed Care Challenged</td>
<td>16</td>
</tr>
<tr>
<td>12 Doctor Where Are You From? The International Medical Graduate in the U.S.</td>
<td>46</td>
</tr>
<tr>
<td><strong>WORKSHOPS – COMPONENTS</strong></td>
<td></td>
</tr>
<tr>
<td>2 What’s Next? Issues in Mid-Career Development</td>
<td>15</td>
</tr>
<tr>
<td>3 Risk Management Issues in Psychiatric Practice</td>
<td>15</td>
</tr>
<tr>
<td>5 The Changing Face of Psychiatry</td>
<td>15</td>
</tr>
<tr>
<td>26 Recruitment and Retention: It’s Everyone’s Job!</td>
<td>43</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>1 Career Strategies: Stay Generative and Stimulated</td>
<td>16</td>
</tr>
<tr>
<td>7 Teaching Boundaries to Clinicians</td>
<td>17</td>
</tr>
<tr>
<td>36 The Mid-Career Clinician: Choices and Challenges</td>
<td>64</td>
</tr>
<tr>
<td>39 Coping with Malpractice</td>
<td>64</td>
</tr>
<tr>
<td>62 Doctor, Learn to Set Limits and Reduce Malpractice Suits</td>
<td>87</td>
</tr>
<tr>
<td>51 Medical Savings Account Plans: Putting You and Your Patients First</td>
<td>92</td>
</tr>
<tr>
<td><strong>TOPIC 66: RELIGION, SPIRITUALITY AND PSYCHIATRY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CME COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>4 Transpersonal Psychiatry: Theory and Practice</td>
<td>1</td>
</tr>
<tr>
<td>84 Transpersonal Psychiatry: Clinical Applications</td>
<td>61</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td></td>
</tr>
<tr>
<td>21 Internists of the Mind or Doctors of the Soul?</td>
<td>85</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>76 Model Residency Programs on Religion/Spirituality</td>
<td>94</td>
</tr>
<tr>
<td><strong>WORKSHOP – COMPONENT</strong></td>
<td></td>
</tr>
<tr>
<td>51 Internists of the Mind or Doctors of the Soul?</td>
<td>91</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>27 Psychiatry and Religion: Conceptual Considerations</td>
<td>44</td>
</tr>
<tr>
<td>43 The Use of Spirituality Groups in Psychiatric Treatment</td>
<td>65</td>
</tr>
<tr>
<td><strong>TOPIC 67: RESIDENT AND MEDICAL STUDENT CONCERNS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>47 Treating Medical Students and Physicians</td>
<td>22</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUPS</strong></td>
<td></td>
</tr>
<tr>
<td>4 Surviving the Boards (For Residents Only)</td>
<td>35</td>
</tr>
<tr>
<td>7 Spiritual Issues for Psychodynamic Psychiatry (For Residents Only)</td>
<td>51</td>
</tr>
<tr>
<td><strong>RESIDENTS’ SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>Meet the Experts: Sunny Side-Up</td>
<td>12</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>38 Effects of Managed Care on Psychiatric Education</td>
<td>42</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>83 When Your Patient Suicides and You Are a Resident</td>
<td>95</td>
</tr>
<tr>
<td><strong>WORKSHOPS – COMPONENTS</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>10 Unique Role of Individual Supervision in Psychiatric Education</td>
<td>16</td>
</tr>
<tr>
<td>12 What Specialty is for Me? Research, Forensics, Child and Adolescent or Geriatrics?</td>
<td>21</td>
</tr>
<tr>
<td>18 Gender Equity in Medical School and Residency</td>
<td>21</td>
</tr>
<tr>
<td>20 Making Order Out of Chaos: Residents and Institutions</td>
<td>38</td>
</tr>
<tr>
<td>33 Health Awareness Education for Medical Students</td>
<td>44</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>5 American Board of Psychiatry and Neurology Update: A Guide Particularly for Residents to Understand the Requirements to Sit for the ABPN Examination</td>
<td>16</td>
</tr>
<tr>
<td>46 Medical School Response to Student Suicide</td>
<td>65</td>
</tr>
<tr>
<td><strong>TOPIC 68: PRESIDENTIAL THEME: “THE CLINICIAN”</strong></td>
<td>Page #</td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>51 Writing About Clinical Experiences</td>
<td>33</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>44 Prescribing Psychotropics for Diverse Populations</td>
<td>57</td>
</tr>
<tr>
<td>66 Sexual Behavior and Substance Use Research with the Mentally Ill</td>
<td>81</td>
</tr>
<tr>
<td>79 Suicidality: Diagnosis and Treatment</td>
<td>95</td>
</tr>
<tr>
<td>85 Psychiatric Issues in Desire for Death</td>
<td>96</td>
</tr>
<tr>
<td><strong>WORKSHOPS – ISSUES</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>19 Clinical Responses to Managed Health Care</td>
<td>39</td>
</tr>
<tr>
<td>58 To Live or Die: Complexities at Life’s End</td>
<td>87</td>
</tr>
<tr>
<td><strong>TOPIC 69: STIGMA/ADVOCACY</strong></td>
<td>Page #</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>5 Beyond Medicine: Education, Advocacy, Help and Hope</td>
<td>18</td>
</tr>
</tbody>
</table>
### APA 152ND ANNUAL MEETING

#### PARTICIPANT INDEX

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbey, Susan E.</td>
<td>Ba, Gabriella</td>
</tr>
<tr>
<td>Adel, Gene G.</td>
<td>Babb, Suzann M.</td>
</tr>
<tr>
<td>Abduloff, Howard</td>
<td>Babcock, Susan M.</td>
</tr>
<tr>
<td>Abolade, Caroline O.</td>
<td>Bagby, R. Michael</td>
</tr>
<tr>
<td>Abrams, Michelle</td>
<td>Baird, Alagail</td>
</tr>
<tr>
<td>Ackerman, John M.</td>
<td>Baldessarni, Ross J.</td>
</tr>
<tr>
<td>Adams, Frank</td>
<td>Baldewitz, Teri</td>
</tr>
<tr>
<td>Adams, Susan J.</td>
<td>Balken, James C.</td>
</tr>
<tr>
<td>Addington, Donald E.</td>
<td>Salon, Richard</td>
</tr>
<tr>
<td>Addison, Jean M.</td>
<td>Band, David M.</td>
</tr>
<tr>
<td>Agran, W. Stewart</td>
<td>Bar-El, Yar C.</td>
</tr>
<tr>
<td>Alger, Kenneth S.</td>
<td>Barak, Yoaram</td>
</tr>
<tr>
<td>Alisenti, Howard S.</td>
<td>Barakat, Samia</td>
</tr>
<tr>
<td>Andrade, Andrea</td>
<td>Barasch, Alan S.</td>
</tr>
<tr>
<td>Anderson, Donald G.</td>
<td>Barda, Raphael E.</td>
</tr>
<tr>
<td>Andreason, Nancy C.</td>
<td>Barklage, Nancy E.</td>
</tr>
<tr>
<td>Angel, Tania B.</td>
<td>Barnes, Anna</td>
</tr>
<tr>
<td>Almeida, Osvaldo P.</td>
<td>Barry, John</td>
</tr>
<tr>
<td>Alpert, Jonathan E.</td>
<td>Barsky III, Arthur J.</td>
</tr>
<tr>
<td>Altemus, Margaret</td>
<td>Bartik, Barbara D.</td>
</tr>
<tr>
<td>Allender, John</td>
<td>Baruchin, Andrea</td>
</tr>
<tr>
<td>Altchuler, Steven</td>
<td>Basco, Monica A.</td>
</tr>
<tr>
<td>Amin, Abdel F.</td>
<td>Bassi, Mariano</td>
</tr>
<tr>
<td>Althoff, Carolyn L.</td>
<td>Bastan, Lori A.</td>
</tr>
<tr>
<td>Altshuler, Lor L.</td>
<td>Bates, Artie A.</td>
</tr>
<tr>
<td>Altshuler, Lor L.</td>
<td>Barti, Steven L.</td>
</tr>
<tr>
<td>Amin, Farnoq</td>
<td>Bauer, Michael</td>
</tr>
<tr>
<td>Amani, Ravi</td>
<td>Baum, Antonia L.</td>
</tr>
<tr>
<td>Arnand, Jambrum V.</td>
<td>Baum, Bernard H.</td>
</tr>
<tr>
<td>Anderson, Amold D.</td>
<td>Baum, Daniel B.</td>
</tr>
<tr>
<td>Anderson, Donald L.</td>
<td>Baxter, Elizabeth A.</td>
</tr>
<tr>
<td>Andradeiro, Roberta</td>
<td>Beale, Mark D.</td>
</tr>
<tr>
<td>Andreason, Nancy C.</td>
<td>Beasley, Jr., Charles M.</td>
</tr>
<tr>
<td>Angel, Kanyr</td>
<td>Beck, B.</td>
</tr>
<tr>
<td>Antip, Tony M.</td>
<td>Beck, Judith S.</td>
</tr>
<tr>
<td>Antip, Fadil T.</td>
<td>Becker, Daniel F.</td>
</tr>
<tr>
<td>Anyan, Walter</td>
<td>Begatz, Tomer</td>
</tr>
<tr>
<td>Appelbaum, Paul S.</td>
<td>Belcher, Jack M.</td>
</tr>
<tr>
<td>Arboleda-Florez, Julio</td>
<td>Bellavance, Francois</td>
</tr>
<tr>
<td>Aringhaus, Kimberly A.</td>
<td>Belfox, Eric</td>
</tr>
<tr>
<td>Aronowitz, Bonnie A.</td>
<td>Bender, Donna S.</td>
</tr>
<tr>
<td>Aron, Bernard S.</td>
<td>Benedek, Elissa P.</td>
</tr>
<tr>
<td>Aronson, Stephen M.</td>
<td>Bennett, Michael J.</td>
</tr>
<tr>
<td>Arroyo, William</td>
<td>Berg, Paul S. D.</td>
</tr>
<tr>
<td>Ashley, Kenneth B.</td>
<td>Berger, Carlene</td>
</tr>
<tr>
<td>Atthey, Jennifer B.</td>
<td>Berger, Joey</td>
</tr>
<tr>
<td>Atkinson, Roland M.</td>
<td>Berkan, Alan</td>
</tr>
<tr>
<td>Atkinson, J. Hampton</td>
<td>Berman, Jeffrey A.</td>
</tr>
<tr>
<td>Ayers, George W.</td>
<td>Berman, Robert M.</td>
</tr>
<tr>
<td>Aymar, Max A.</td>
<td>Bernitz, Ricardo</td>
</tr>
<tr>
<td>Azen, Henrick</td>
<td>Bernstein, Carol A.</td>
</tr>
<tr>
<td>Azizi, Nasim</td>
<td>Bernstein, Robert</td>
</tr>
<tr>
<td>Bartsch, Michael</td>
<td>Bernstein, Wade H.</td>
</tr>
<tr>
<td>Baskin, Michael</td>
<td>Botz, Connie L.</td>
</tr>
<tr>
<td>Bashu, Suzanne</td>
<td>Betz, Peter</td>
</tr>
<tr>
<td>Baski, Amber</td>
<td>Bird, Abby</td>
</tr>
<tr>
<td>Basu, Jeffrey</td>
<td>Binder, Renee E.</td>
</tr>
<tr>
<td>Baski, Amber</td>
<td>Bingham, C. Raymond</td>
</tr>
<tr>
<td>Basu, Jeffrey</td>
<td>Binkley, Mark</td>
</tr>
<tr>
<td>Baski, Amber</td>
<td>Bissag, Katelyna</td>
</tr>
<tr>
<td>Bask, Michael</td>
<td>Bisallon, S.</td>
</tr>
<tr>
<td>Bax, Donald W.</td>
<td>Black, Donald W.</td>
</tr>
<tr>
<td>Bax, Max A.</td>
<td>Blackshaw, Stella L.</td>
</tr>
<tr>
<td>Bax, Jack D.</td>
<td>Blair, Allison</td>
</tr>
<tr>
<td>Blair, Jennifer M.</td>
<td>Blais, Mark A.</td>
</tr>
<tr>
<td>Blair, Jennifer M.</td>
<td>Blanco, Carlos</td>
</tr>
<tr>
<td>Blashy, Nancy T.</td>
<td>Blaney, Thomas</td>
</tr>
<tr>
<td>Blake, James C.</td>
<td>Blanding, Mark</td>
</tr>
<tr>
<td>Bloch, Sydney M.</td>
<td>Block, Susan D.</td>
</tr>
<tr>
<td>Blume, Howard E.</td>
<td>Blount, Harvey</td>
</tr>
<tr>
<td>Blumenfeld, Michael</td>
<td>Blumer, Stella B.</td>
</tr>
<tr>
<td>Blumenfeld, Michael</td>
<td>Blumenfeld, Susan J.</td>
</tr>
<tr>
<td>Blum, Michael</td>
<td>Bliemer, Dietrich P.</td>
</tr>
<tr>
<td>Blum, Michael</td>
<td>Bokhsay, Istan J.</td>
</tr>
<tr>
<td>Blum, Michael</td>
<td>Bock, Howard E.</td>
</tr>
<tr>
<td>Blum, Michael</td>
<td>Boone, Kyle</td>
</tr>
<tr>
<td>Blum, Michael</td>
<td>Boorstein, Seymour</td>
</tr>
<tr>
<td>Blurton, Thomas M.</td>
<td>Boothroyd, Roger</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Borchers, Paul A.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Borus, Jonathan F.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bouguereau, Karen L.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bourne, Mark J.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Boutros, Nashaat N.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bow-Thomas, C. Christine</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bowden, Charles L.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bowers, Therion C.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bowers, Wayne A.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Boyajian, Levon Z.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bradford, John W.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brandwein, Jacques</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brady, Kathleen T.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brady, Thomas M.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Braunig, Jenny</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Breier, Alan F.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brettbart, William</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brewster, Timothy D.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brink, Johann</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brockway, Stephen S.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Brockley, Amy C.</td>
</tr>
<tr>
<td>Bloom, Peter</td>
<td>Bromberger, Joyce T.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Arin E.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Daniel</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Gregory J.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Richard A.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Richard P.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brown, Thomas E.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Browning, Don S.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Bruce, Martha L.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brunet, Alain</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Brunshaw, Jocelyn B.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Bucan, Maja</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Buchanan, Robert W.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Buchsbaum, Monte S.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Buckley, Peter F.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Bullen, Commissioner</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Bulucu, Can</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Burney, Jr., William E.</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Burbridge, Jennifer</td>
</tr>
<tr>
<td>Bloom, Robert A.</td>
<td>Burkhalter, Jack</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>DiCori, Fernuccio A</td>
<td>67</td>
</tr>
<tr>
<td>Dieter, Thomas</td>
<td>20</td>
</tr>
<tr>
<td>di Giannantonio, Massimo</td>
<td>77</td>
</tr>
<tr>
<td>Dillon, James E</td>
<td>84</td>
</tr>
<tr>
<td>Dixon, Lisa B</td>
<td>33</td>
</tr>
<tr>
<td>Dluty, John M</td>
<td>72</td>
</tr>
<tr>
<td>Docherty, John P</td>
<td>49</td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>8</td>
</tr>
<tr>
<td>Dolan, Regina</td>
<td>78</td>
</tr>
<tr>
<td>Domhoff, G. William</td>
<td>98</td>
</tr>
<tr>
<td>Dominguez, Lourdes M</td>
<td>64</td>
</tr>
<tr>
<td>Doreamy, John G</td>
<td>44</td>
</tr>
<tr>
<td>Donovan, Stephen J</td>
<td>28</td>
</tr>
<tr>
<td>Doody, Rachel S</td>
<td>9</td>
</tr>
<tr>
<td>Doratlawny, P. Muriel</td>
<td>42</td>
</tr>
<tr>
<td>Dorer, David</td>
<td>74</td>
</tr>
<tr>
<td>Doreis, Susan</td>
<td>69</td>
</tr>
<tr>
<td>Downey, Jennifer I</td>
<td>38</td>
</tr>
<tr>
<td>Downs, Susan R</td>
<td>6</td>
</tr>
<tr>
<td>Druss, Benjamin G</td>
<td>68</td>
</tr>
<tr>
<td>Dryden-Edwards, Roxanne</td>
<td>86</td>
</tr>
<tr>
<td>Dubuis, Jacques</td>
<td>94</td>
</tr>
<tr>
<td>Duffy, James D</td>
<td>13</td>
</tr>
<tr>
<td>Dulioh, Michael C</td>
<td>40</td>
</tr>
<tr>
<td>Dult, Rebecca A</td>
<td>49</td>
</tr>
<tr>
<td>Dunkin, Jennifer</td>
<td>82</td>
</tr>
<tr>
<td>Dunner, David L</td>
<td>5</td>
</tr>
<tr>
<td>Dunstone, David C</td>
<td>42</td>
</tr>
<tr>
<td>Dutro, Michael P</td>
<td>20</td>
</tr>
<tr>
<td>Dutta, Eamon E</td>
<td>75</td>
</tr>
<tr>
<td>Dyk, Geoffrey</td>
<td>28</td>
</tr>
<tr>
<td>Dvorak, Ramonda</td>
<td>3,5</td>
</tr>
<tr>
<td>Dy, Allen R</td>
<td>91</td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>Eagleson, Kathe</td>
<td>51</td>
</tr>
<tr>
<td>Ebert, Michael H</td>
<td>16</td>
</tr>
<tr>
<td>Eddy, Dan M</td>
<td>97</td>
</tr>
<tr>
<td>Eddy, Sara</td>
<td>45</td>
</tr>
<tr>
<td>Edell, William S</td>
<td>21</td>
</tr>
<tr>
<td>Edling, Jack D</td>
<td>34</td>
</tr>
<tr>
<td>Edwards, Cathleen</td>
<td>29</td>
</tr>
<tr>
<td>Emicke, Joseph</td>
<td>68</td>
</tr>
<tr>
<td>Eldenfors, Carl</td>
<td>89</td>
</tr>
<tr>
<td>Ellen, Jane L</td>
<td>33</td>
</tr>
<tr>
<td>Eisenberg, Carolia</td>
<td>92</td>
</tr>
<tr>
<td>Eisenberg, Leon</td>
<td>27</td>
</tr>
<tr>
<td>Eilenrud, Stuart J</td>
<td>22</td>
</tr>
<tr>
<td>El, Ann M</td>
<td>14</td>
</tr>
<tr>
<td>El, Harold I</td>
<td>16</td>
</tr>
<tr>
<td>Ekelbald, Elizabeth</td>
<td>74</td>
</tr>
<tr>
<td>El-Gebaly, Nadiy</td>
<td>51</td>
</tr>
<tr>
<td>Elphr, Anner E</td>
<td>85</td>
</tr>
<tr>
<td>Ellis, Ronald O</td>
<td>34</td>
</tr>
<tr>
<td>Emde, Robert N</td>
<td>69</td>
</tr>
<tr>
<td>Emden-Boas, Walter V</td>
<td>28</td>
</tr>
<tr>
<td>Emssie, Graham J</td>
<td>61</td>
</tr>
<tr>
<td>England, Mary Jane</td>
<td>48</td>
</tr>
<tr>
<td>English, Michael</td>
<td>64</td>
</tr>
<tr>
<td>Epstein, Richard S</td>
<td>8</td>
</tr>
<tr>
<td>Ereshefsky, Larry</td>
<td>54</td>
</tr>
<tr>
<td>Errer, David</td>
<td>95</td>
</tr>
<tr>
<td>Escobar, Javier J</td>
<td>34</td>
</tr>
<tr>
<td>Espinall, Eduardo</td>
<td>19</td>
</tr>
<tr>
<td>Ether, James W</td>
<td>95</td>
</tr>
<tr>
<td>Elkin, Mark S</td>
<td>17</td>
</tr>
<tr>
<td>Evans, Dwight L</td>
<td>11</td>
</tr>
<tr>
<td>Evans, Karen K</td>
<td>90</td>
</tr>
<tr>
<td>Evans, Suzette</td>
<td>50</td>
</tr>
<tr>
<td>Eventt, Barry J</td>
<td>28</td>
</tr>
<tr>
<td>Eyler Zornia, Lisa</td>
<td>76</td>
</tr>
<tr>
<td>Eyler, Ariel</td>
<td>96</td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>Faehnle, Rodolfo D</td>
<td>29</td>
</tr>
<tr>
<td>Fallica, A.</td>
<td>29</td>
</tr>
<tr>
<td>Fallon, Brian A</td>
<td>20</td>
</tr>
<tr>
<td>Farabaugh, Amy</td>
<td>11</td>
</tr>
<tr>
<td>Fararpe, Stephen V</td>
<td>28</td>
</tr>
<tr>
<td>Farra, Benedetto</td>
<td>77</td>
</tr>
<tr>
<td>Farrel, E. Kathleen</td>
<td>44</td>
</tr>
<tr>
<td>Fast, Diane K.</td>
<td>21</td>
</tr>
<tr>
<td>Faulkner, Larry R</td>
<td>16</td>
</tr>
<tr>
<td>Fauman, Beverly J</td>
<td>16</td>
</tr>
<tr>
<td>Favaro, Maurizio</td>
<td>5, 11, 41, 43, 69</td>
</tr>
<tr>
<td>Favell, Jennifer</td>
<td>84</td>
</tr>
<tr>
<td>Fawcett, Jan A</td>
<td>9</td>
</tr>
<tr>
<td>Fawzy, Fawzy G</td>
<td>41</td>
</tr>
<tr>
<td>Fehley, Frank</td>
<td>15</td>
</tr>
<tr>
<td>Fehlan, Dwain C</td>
<td>20</td>
</tr>
<tr>
<td>Feinstein, Carl B</td>
<td>86</td>
</tr>
<tr>
<td>Feldman, Lynn S</td>
<td>70</td>
</tr>
<tr>
<td>Feldman, Marc D</td>
<td>22</td>
</tr>
<tr>
<td>Felix, Alan D</td>
<td>91</td>
</tr>
<tr>
<td>Fenton, Wayne S</td>
<td>20</td>
</tr>
<tr>
<td>Ferguson, John F</td>
<td>39</td>
</tr>
<tr>
<td>Fernandez, Francisco J.</td>
<td>16, 44, 64, 65</td>
</tr>
<tr>
<td>Ferrar, Jr., Ernesto</td>
<td>68</td>
</tr>
<tr>
<td>Ferraro, Stephen J</td>
<td>16</td>
</tr>
<tr>
<td>Fennemin, Luigi</td>
<td>78</td>
</tr>
<tr>
<td>Felkewicz, Janet M</td>
<td>38</td>
</tr>
<tr>
<td>Fields, Richard A</td>
<td>67</td>
</tr>
<tr>
<td>Fife, Alison</td>
<td>50</td>
</tr>
<tr>
<td>Filling, Janet I</td>
<td>58</td>
</tr>
<tr>
<td>Fincher, Ellen R</td>
<td>15</td>
</tr>
<tr>
<td>Fisher, Kathleen M</td>
<td>52</td>
</tr>
<tr>
<td>Fishman, Marc</td>
<td>51</td>
</tr>
<tr>
<td>Fitzgerald, Louise F</td>
<td>44</td>
</tr>
<tr>
<td>Fitzsimons, Linde</td>
<td>76</td>
</tr>
<tr>
<td>Fishery, Joseph A</td>
<td>58</td>
</tr>
<tr>
<td>Fishery, Louis T</td>
<td>21</td>
</tr>
<tr>
<td>Fleming, Candace M</td>
<td>3</td>
</tr>
<tr>
<td>Fleming, Kristen</td>
<td>54</td>
</tr>
<tr>
<td>Flores, Andrea</td>
<td>74</td>
</tr>
<tr>
<td>Flynn, Laurie M</td>
<td>11, 33, 43, 70, 71, 76</td>
</tr>
<tr>
<td>Foehl, Patricia</td>
<td>92</td>
</tr>
<tr>
<td>Folkmann, Susan</td>
<td>46</td>
</tr>
<tr>
<td>Foote, William W</td>
<td>1, 61</td>
</tr>
<tr>
<td>Ford, Charles V</td>
<td>22</td>
</tr>
<tr>
<td>Fore, Peter F</td>
<td>37</td>
</tr>
<tr>
<td>Fore Arcand, Lisa</td>
<td>41</td>
</tr>
<tr>
<td>Foroud, Tattiana</td>
<td>74</td>
</tr>
<tr>
<td>Forstein, Marshall</td>
<td>16, 22, 34, 55, 60</td>
</tr>
<tr>
<td>Fort, David G</td>
<td>69</td>
</tr>
<tr>
<td>Fox, Ellen</td>
<td>44</td>
</tr>
<tr>
<td>Fox, Michael R</td>
<td>87</td>
</tr>
<tr>
<td>Frances, Allen J</td>
<td>44</td>
</tr>
<tr>
<td>Frances, Richard J</td>
<td>70</td>
</tr>
<tr>
<td>Fransoe, Shona</td>
<td>6</td>
</tr>
<tr>
<td>Francis, Jr., Andrew J</td>
<td>27</td>
</tr>
<tr>
<td>Frank, Ellen</td>
<td>2, 5</td>
</tr>
<tr>
<td>Frank, Guido</td>
<td>50</td>
</tr>
<tr>
<td>Frank, Julia B</td>
<td>87</td>
</tr>
<tr>
<td>Frankel, Debra N</td>
<td>26</td>
</tr>
<tr>
<td>Frankenburg, Frances R</td>
<td>21</td>
</tr>
<tr>
<td>Frazer, Alan</td>
<td>80</td>
</tr>
<tr>
<td>Freeman, Phillip S</td>
<td>92</td>
</tr>
<tr>
<td>Freundlich, Oliver</td>
<td>12</td>
</tr>
<tr>
<td>Frickee, Gregory L</td>
<td>27</td>
</tr>
<tr>
<td>Friedman, Richard C</td>
<td>26</td>
</tr>
<tr>
<td>Friedman, Seth D</td>
<td>57</td>
</tr>
<tr>
<td>Fridich, Brightt</td>
<td>56</td>
</tr>
<tr>
<td>Fristad, Mary A</td>
<td>1</td>
</tr>
<tr>
<td>Frye, Mark A</td>
<td>34</td>
</tr>
<tr>
<td>Fulflove, Mindy J</td>
<td>39</td>
</tr>
<tr>
<td>Fulton, P. M</td>
<td>77</td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>Gabbard, Glen O</td>
<td>14</td>
</tr>
<tr>
<td>Gabel, Stewart</td>
<td>39</td>
</tr>
<tr>
<td>Gabriel, Geoffrey M</td>
<td>38</td>
</tr>
<tr>
<td>Gabriel, Roy</td>
<td>21</td>
</tr>
<tr>
<td>Gabel, Prof. Dr. Wolfgang</td>
<td>42</td>
</tr>
<tr>
<td>Galanter, Marc</td>
<td>26</td>
</tr>
<tr>
<td>Galanzer, Nestor J</td>
<td>15</td>
</tr>
<tr>
<td>Galbs, Ricardo</td>
<td>64</td>
</tr>
<tr>
<td>Gallagher, Michelle</td>
<td>51</td>
</tr>
<tr>
<td>Gallaghcr, Illon M</td>
<td>16</td>
</tr>
<tr>
<td>Gallagher-Thompson, Dolores</td>
<td>21</td>
</tr>
<tr>
<td>Galynker, I.</td>
<td>75</td>
</tr>
<tr>
<td>Gammm, Sue</td>
<td>52</td>
</tr>
<tr>
<td>Ganey, Charles J</td>
<td>96</td>
</tr>
<tr>
<td>Ganzini, Linda K</td>
<td>29</td>
</tr>
<tr>
<td>Garbarino, James</td>
<td>29, 45</td>
</tr>
<tr>
<td>Gardine, Roberta</td>
<td>65</td>
</tr>
<tr>
<td>Gardner, James F</td>
<td>69</td>
</tr>
<tr>
<td>Garside, Sarah</td>
<td>3</td>
</tr>
<tr>
<td>Gastfriend, David R</td>
<td>93</td>
</tr>
<tr>
<td>Gantin, John O</td>
<td>57</td>
</tr>
<tr>
<td>Gatti, Vincenzo</td>
<td>78</td>
</tr>
<tr>
<td>Gavina, F. Moses</td>
<td>4, 20, 69, 84</td>
</tr>
<tr>
<td>Gw, Albert C</td>
<td>41, 57</td>
</tr>
<tr>
<td>Gelli, Stefano</td>
<td>77</td>
</tr>
<tr>
<td>Gelenberg, Alan J</td>
<td>80</td>
</tr>
<tr>
<td>Gelemter, Joel</td>
<td>7</td>
</tr>
<tr>
<td>Gemignani, Alfredo</td>
<td>19</td>
</tr>
<tr>
<td>George, Charles J</td>
<td>53</td>
</tr>
<tr>
<td>George, Mark S</td>
<td>18</td>
</tr>
<tr>
<td>George, Robert A</td>
<td>87</td>
</tr>
<tr>
<td>Germano, Dominic</td>
<td>6</td>
</tr>
<tr>
<td>Gerstner, Elliott S</td>
<td>74</td>
</tr>
<tr>
<td>Gesser, Elizabeth V</td>
<td>86</td>
</tr>
<tr>
<td>Ghaemi, S. Nassiri</td>
<td>6</td>
</tr>
<tr>
<td>Giannamara, Manlio</td>
<td>77</td>
</tr>
<tr>
<td>Giulii, Michele</td>
<td>91</td>
</tr>
<tr>
<td>Gill, Michele</td>
<td>49</td>
</tr>
<tr>
<td>Gill, Sukhumki R</td>
<td>86</td>
</tr>
<tr>
<td>Gilles, Lauret A</td>
<td>26</td>
</tr>
<tr>
<td>Gillin, J. Christian</td>
<td>8, 74</td>
</tr>
<tr>
<td>Gissburg, Milton M</td>
<td>19</td>
</tr>
<tr>
<td>Girsh, Faye</td>
<td>74</td>
</tr>
<tr>
<td>Gillin, Michael J</td>
<td>54, 67, 97</td>
</tr>
<tr>
<td>Glassman, Alexander H</td>
<td>26</td>
</tr>
<tr>
<td>Glazer, William M</td>
<td>53</td>
</tr>
<tr>
<td>Glof, Ira D</td>
<td>42</td>
</tr>
<tr>
<td>Goebel, Rainer</td>
<td>20</td>
</tr>
<tr>
<td>Goethe, John W</td>
<td>69</td>
</tr>
<tr>
<td>Goff, Donald C</td>
<td>97</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lowenkopf, Eugene L.</td>
<td>71, 91</td>
</tr>
<tr>
<td>Lowry, The Honorable</td>
<td>77</td>
</tr>
<tr>
<td>Lu, Francis G.</td>
<td>1, 3, 10, 27, 34, 62, 70, 80, 94</td>
</tr>
<tr>
<td>Lu, John</td>
<td>36, 62, 67</td>
</tr>
<tr>
<td>Lydon, John, Bruce</td>
<td>11, 33</td>
</tr>
<tr>
<td>Lyketsos, Constantine G.</td>
<td>51</td>
</tr>
<tr>
<td>Lymbert, Maria T.</td>
<td>5, 17, 92</td>
</tr>
<tr>
<td>Lynch, Denis J.</td>
<td>43, 68</td>
</tr>
<tr>
<td>Lynch, Kevin G.</td>
<td>20</td>
</tr>
<tr>
<td>Maaas, Louis C.</td>
<td>97</td>
</tr>
<tr>
<td>MacDonald, Shelagh</td>
<td>91</td>
</tr>
<tr>
<td>Mackenzie, K. Roy</td>
<td>20, 84</td>
</tr>
<tr>
<td>MacQueen, Glenda M.</td>
<td>25, 26</td>
</tr>
<tr>
<td>Magnerud, Kathryn M.</td>
<td>27</td>
</tr>
<tr>
<td>Maguire, Marcella A.</td>
<td>70</td>
</tr>
<tr>
<td>Mahmud, Syed A.</td>
<td>96</td>
</tr>
<tr>
<td>Maier, Gary J.</td>
<td>13, 38</td>
</tr>
<tr>
<td>Makkyyro, Tanu H.</td>
<td>90</td>
</tr>
<tr>
<td>Maldonado, Jose R.</td>
<td>4, 43, 49, 60</td>
</tr>
<tr>
<td>Malla, Ashok K.</td>
<td>96</td>
</tr>
<tr>
<td>Mallipedd, Madhavi</td>
<td>3, 19</td>
</tr>
<tr>
<td>Maimikrit, Carl P.</td>
<td>56, 65</td>
</tr>
<tr>
<td>Malone, Kevin M.</td>
<td>20</td>
</tr>
<tr>
<td>Maloney, Ann S.</td>
<td>71</td>
</tr>
<tr>
<td>Malikberger, John T.</td>
<td>51</td>
</tr>
<tr>
<td>Manber, Rachel</td>
<td>94</td>
</tr>
<tr>
<td>Manchanda, Rahul</td>
<td>96</td>
</tr>
<tr>
<td>Menji, Husseini K.</td>
<td>97</td>
</tr>
<tr>
<td>Menn, J. Randh</td>
<td>20, 49</td>
</tr>
<tr>
<td>Manning, William G.</td>
<td>79</td>
</tr>
<tr>
<td>Manos, Peter J.</td>
<td>34</td>
</tr>
<tr>
<td>Manzzotti, Donatella</td>
<td>19</td>
</tr>
<tr>
<td>marcaccio, Giovanni</td>
<td>67</td>
</tr>
<tr>
<td>Marcot, Eric</td>
<td>56</td>
</tr>
<tr>
<td>March, John S.</td>
<td>59, 76</td>
</tr>
<tr>
<td>Merchant, Nestor F.</td>
<td>29</td>
</tr>
<tr>
<td>Marotte, David B.</td>
<td>65</td>
</tr>
<tr>
<td>Marcus, Eric R.</td>
<td>27</td>
</tr>
<tr>
<td>Marner, Karen</td>
<td>79</td>
</tr>
<tr>
<td>Marder, Stephen R.</td>
<td>21, 71, 79</td>
</tr>
<tr>
<td>Marr, Robert S</td>
<td>75</td>
</tr>
<tr>
<td>Mark, Nordho</td>
<td>37, 12, 41</td>
</tr>
<tr>
<td>Markman, Irene</td>
<td>68</td>
</tr>
<tr>
<td>Markowitz, John C.</td>
<td>3, 8, 26, 33</td>
</tr>
<tr>
<td>Newmar, Charles R.</td>
<td>28, 83</td>
</tr>
<tr>
<td>Marshall, Randol D.</td>
<td>41</td>
</tr>
<tr>
<td>Martin, Elizabeth</td>
<td>26</td>
</tr>
<tr>
<td>Martin, Marilyn L.</td>
<td>74</td>
</tr>
<tr>
<td>Martin, Stephen D.</td>
<td>26</td>
</tr>
<tr>
<td>Martinez, Humberto L.</td>
<td>26, 64</td>
</tr>
<tr>
<td>Martino, Steve</td>
<td>20, 68</td>
</tr>
<tr>
<td>Masand, Prakash S.</td>
<td>4</td>
</tr>
<tr>
<td>Mastella, Mario</td>
<td>90</td>
</tr>
<tr>
<td>Masliah, Eliza E.</td>
<td>92</td>
</tr>
<tr>
<td>Mason, Barbara J.</td>
<td>54</td>
</tr>
<tr>
<td>Masterson, James F.</td>
<td>13</td>
</tr>
<tr>
<td>Matthew, Elizabeth</td>
<td>81</td>
</tr>
<tr>
<td>Mascia, Danina</td>
<td>48</td>
</tr>
<tr>
<td>Maurer, Professor Konrad</td>
<td>20</td>
</tr>
<tr>
<td>Mavissakalain, Matig R.</td>
<td>68</td>
</tr>
<tr>
<td>Mavroveliotes, George</td>
<td>42</td>
</tr>
<tr>
<td>Mayeda, Annie R.</td>
<td>74</td>
</tr>
<tr>
<td>Mayer, Laurel</td>
<td>50</td>
</tr>
<tr>
<td>Mayeux, Richard</td>
<td>79</td>
</tr>
<tr>
<td>Maynard, Brian T.</td>
<td>56</td>
</tr>
<tr>
<td>Mazurek, Michael F.</td>
<td>3, 90</td>
</tr>
<tr>
<td>McCall, W. Vaughn</td>
<td>34, 76</td>
</tr>
<tr>
<td>McCarthay, John</td>
<td>21</td>
</tr>
<tr>
<td>McCarthay, Mary K.</td>
<td>70</td>
</tr>
<tr>
<td>McCauley, Herb</td>
<td>61</td>
</tr>
<tr>
<td>McCall, Rachel</td>
<td>41</td>
</tr>
<tr>
<td>McConaha, Claire</td>
<td>50</td>
</tr>
<tr>
<td>McCor, Emily A</td>
<td>15</td>
</tr>
<tr>
<td>McCutchan, J. Allen</td>
<td>51</td>
</tr>
<tr>
<td>McDaniel, J. Stephen</td>
<td>22, 43</td>
</tr>
<tr>
<td>McDermott, Jr., John F.</td>
<td>56</td>
</tr>
<tr>
<td>McDevitt, Robert J.</td>
<td>9</td>
</tr>
<tr>
<td>McDougle, Christopher F.</td>
<td>76</td>
</tr>
<tr>
<td>McDowell, David M.</td>
<td>49, 50, 61, 89</td>
</tr>
<tr>
<td>McDuff, David R.</td>
<td>16</td>
</tr>
<tr>
<td>McElroy, Susan L.</td>
<td>7, 77, 95</td>
</tr>
<tr>
<td>McElroy, Jr., Ross A</td>
<td>74</td>
</tr>
<tr>
<td>McFarland, Benton H.</td>
<td>87, 94</td>
</tr>
<tr>
<td>McGlashan, Thomas H.</td>
<td>2, 6, 21, 69, 78</td>
</tr>
<tr>
<td>McGorry, Patrick D.</td>
<td>5, 36, 34</td>
</tr>
<tr>
<td>McGreg, James D.</td>
<td>16</td>
</tr>
<tr>
<td>McGurk, Susan R.</td>
<td>2</td>
</tr>
<tr>
<td>McInrugh, Paul R.</td>
<td>51, 56</td>
</tr>
<tr>
<td>McIniry, John S.</td>
<td>8, 17, 22, 27, 70, 77, 81, 82, 87</td>
</tr>
<tr>
<td>McIntyre, Lauren M.</td>
<td>76</td>
</tr>
<tr>
<td>McKay, Judithy S.</td>
<td>21</td>
</tr>
<tr>
<td>McLaughlin, David F.</td>
<td>92</td>
</tr>
<tr>
<td>McNaughton, Clifford A.</td>
<td>71</td>
</tr>
<tr>
<td>Meador-Woodruff, James H.</td>
<td>28</td>
</tr>
<tr>
<td>Mead-Lee, David</td>
<td>12</td>
</tr>
<tr>
<td>Meg, Leslie T.</td>
<td>88</td>
</tr>
<tr>
<td>Meier, Diane E.</td>
<td>51</td>
</tr>
<tr>
<td>Meilman, Lisa A.</td>
<td>22</td>
</tr>
<tr>
<td>Meillon, Thomas A.</td>
<td>33, 56</td>
</tr>
<tr>
<td>Melzer, Carolyn</td>
<td>50</td>
</tr>
<tr>
<td>Metzler, Herbert F.</td>
<td>73</td>
</tr>
<tr>
<td>Metzler-Brody, Samantha E.</td>
<td>15</td>
</tr>
<tr>
<td>Mercacci, Claudio</td>
<td>78</td>
</tr>
<tr>
<td>Mendlewicz, Julien</td>
<td>4</td>
</tr>
<tr>
<td>Men, Anita</td>
<td>94</td>
</tr>
<tr>
<td>Menninger, Roy W.</td>
<td>92</td>
</tr>
<tr>
<td>Menninger, W. Walter</td>
<td>30, 43, 59, 64, 83</td>
</tr>
<tr>
<td>Mercer, Delinda</td>
<td>77</td>
</tr>
<tr>
<td>Mendish, Philip T.</td>
<td>95</td>
</tr>
<tr>
<td>Menan, Andrea J.</td>
<td>21</td>
</tr>
<tr>
<td>Merrick, Thomas J.</td>
<td>93</td>
</tr>
<tr>
<td>Meski, Alexander A.</td>
<td>70</td>
</tr>
<tr>
<td>Messina, John</td>
<td>54</td>
</tr>
<tr>
<td>Metzger, Eran D.</td>
<td>50</td>
</tr>
<tr>
<td>Metzel, Jonathan M.</td>
<td>73</td>
</tr>
<tr>
<td>Metzler, Thomas</td>
<td>28, 83</td>
</tr>
<tr>
<td>Metzler, Jeffrey L.</td>
<td>97</td>
</tr>
<tr>
<td>Meyers, Balmert S.</td>
<td>94, 98</td>
</tr>
<tr>
<td>Meyerson, Arthur T.</td>
<td>57, 64</td>
</tr>
<tr>
<td>Mezzich, Juan E</td>
<td>77, 82, 96</td>
</tr>
<tr>
<td>Michels, Robert</td>
<td>26, 56, 66</td>
</tr>
<tr>
<td>Michelon, David</td>
<td>20</td>
</tr>
<tr>
<td>Miller, Alexander L.</td>
<td>11</td>
</tr>
<tr>
<td>Miller, Bruce L.</td>
<td>75</td>
</tr>
<tr>
<td>Miller, Diana C.</td>
<td>86</td>
</tr>
<tr>
<td>Miller, Gary E.</td>
<td>64</td>
</tr>
<tr>
<td>Miller, Ivan W.</td>
<td>91</td>
</tr>
<tr>
<td>Miller, Jean B.</td>
<td>27, 71</td>
</tr>
<tr>
<td>Miller, Mark D.</td>
<td>59</td>
</tr>
<tr>
<td>Miller, Nina L.</td>
<td>26</td>
</tr>
<tr>
<td>Miller, Norman S.</td>
<td>45, 92</td>
</tr>
<tr>
<td>Miller, Paul R.</td>
<td>3</td>
</tr>
<tr>
<td>Miller, Sheldon I.</td>
<td>16, 38, 70</td>
</tr>
<tr>
<td>Millman, Robert B.</td>
<td>70</td>
</tr>
<tr>
<td>Participant Index</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>Particular Index</td>
<td>116</td>
</tr>
<tr>
<td>Millman, Stephen J</td>
<td>20</td>
</tr>
<tr>
<td>Miklo, Barbara L</td>
<td>1, 26</td>
</tr>
<tr>
<td>Mindo, James W</td>
<td>16</td>
</tr>
<tr>
<td>Minden, Sarah I</td>
<td>50</td>
</tr>
<tr>
<td>Minckoff, Kenneth</td>
<td>45, 50</td>
</tr>
<tr>
<td>Minor, Edward A</td>
<td>95</td>
</tr>
<tr>
<td>Mintz, Jim</td>
<td>67</td>
</tr>
<tr>
<td>Mintzer, Jacobo E</td>
<td>35</td>
</tr>
<tr>
<td>Miranda, Jeanne</td>
<td>26</td>
</tr>
<tr>
<td>Minn, Steven M</td>
<td>5, 22</td>
</tr>
<tr>
<td>Microw, Susan</td>
<td>22</td>
</tr>
<tr>
<td>Micich, Donald A</td>
<td>65, 95</td>
</tr>
<tr>
<td>Mischouk, David</td>
<td>41, 89</td>
</tr>
<tr>
<td>Malmgren, Thomas M</td>
<td>20</td>
</tr>
<tr>
<td>Miele, Salvatore</td>
<td>2, 74</td>
</tr>
<tr>
<td>Moussev, James R</td>
<td>60</td>
</tr>
<tr>
<td>Mitchell, James E</td>
<td>1, 73, 74</td>
</tr>
<tr>
<td>Mitchell, Robert J</td>
<td>72</td>
</tr>
<tr>
<td>Moak, Darlene H</td>
<td>66</td>
</tr>
<tr>
<td>Moffic, H. Steven</td>
<td>17</td>
</tr>
<tr>
<td>Mohs, Richard</td>
<td>76</td>
</tr>
<tr>
<td>Motzai, Ramila</td>
<td>67</td>
</tr>
<tr>
<td>Molcho, Andrew B</td>
<td>30</td>
</tr>
<tr>
<td>Molin, Steven O</td>
<td>27</td>
</tr>
<tr>
<td>Monahan, John</td>
<td>29</td>
</tr>
<tr>
<td>Monahan, Albert Jr.</td>
<td>29</td>
</tr>
<tr>
<td>Mondor, Maureen</td>
<td>87</td>
</tr>
<tr>
<td>Montenegro, James C</td>
<td>16</td>
</tr>
<tr>
<td>Montoya, Ivan D</td>
<td>22, 27</td>
</tr>
<tr>
<td>Moreno, Francisco A</td>
<td>2</td>
</tr>
<tr>
<td>Mott, Leslie C</td>
<td>69, 78</td>
</tr>
<tr>
<td>Morgan III, Charles A</td>
<td>76</td>
</tr>
<tr>
<td>Morgan-Minott, Melodie</td>
<td>91</td>
</tr>
<tr>
<td>Moring, Julia</td>
<td>90</td>
</tr>
<tr>
<td>Morris, John C</td>
<td>5, 53</td>
</tr>
<tr>
<td>Morrissey, Joseph P</td>
<td>94</td>
</tr>
<tr>
<td>Mosheva, Tanya</td>
<td>94</td>
</tr>
<tr>
<td>Mosovich, Sergei A</td>
<td>33</td>
</tr>
<tr>
<td>Moss, Andrew D</td>
<td>51</td>
</tr>
<tr>
<td>Muhlbauer, Helen G</td>
<td>42</td>
</tr>
<tr>
<td>Mullen, Linda S</td>
<td>95</td>
</tr>
<tr>
<td>Mulsant, Benoit H</td>
<td>52, 59, 83</td>
</tr>
<tr>
<td>Munt, Karin M</td>
<td>60</td>
</tr>
<tr>
<td>Muniz, Camille</td>
<td>78</td>
</tr>
<tr>
<td>Munoz, Rodrigo A</td>
<td>5, 8, 12, 16, 22, 30, 43, 48, 57, 74, 93</td>
</tr>
<tr>
<td>Murray, Acelo M</td>
<td>59</td>
</tr>
<tr>
<td>Musacchio de Zan, Amelie E</td>
<td>52</td>
</tr>
<tr>
<td>Murskin, Philip R</td>
<td>28, 29, 37</td>
</tr>
<tr>
<td>Myers, Michael F</td>
<td>1, 22, 47, 70, 71, 75, 92</td>
</tr>
<tr>
<td>N</td>
<td>186</td>
</tr>
<tr>
<td>Nadelsohn, Carol C</td>
<td>16, 44, 57</td>
</tr>
<tr>
<td>Nagel, Rollin</td>
<td>43</td>
</tr>
<tr>
<td>Nageotte, Catherine A</td>
<td>68</td>
</tr>
<tr>
<td>Nagle, Rollin W</td>
<td>68</td>
</tr>
<tr>
<td>Nagy, Thomas</td>
<td>4, 50</td>
</tr>
<tr>
<td>Naddo, Umadevi</td>
<td>92</td>
</tr>
<tr>
<td>Nakashima, Joanne</td>
<td>81</td>
</tr>
<tr>
<td>Nanda, Kavita</td>
<td>76</td>
</tr>
<tr>
<td>Napoletello, Michael J</td>
<td>69</td>
</tr>
<tr>
<td>Narrow, William E</td>
<td>75</td>
</tr>
<tr>
<td>Naseem, Atia A</td>
<td>69</td>
</tr>
<tr>
<td>Nash, James L</td>
<td>24</td>
</tr>
<tr>
<td>Nasrallah, Henry A</td>
<td>11, 33</td>
</tr>
<tr>
<td>Naswas, Sheilah</td>
<td>56</td>
</tr>
<tr>
<td>Nazarey, Margaret</td>
<td>3</td>
</tr>
<tr>
<td>Ndete, J. Charles</td>
<td>3</td>
</tr>
<tr>
<td>Nebes, Robert</td>
<td>46, 79</td>
</tr>
<tr>
<td>Nelson, J. Craig</td>
<td>5</td>
</tr>
<tr>
<td>Nelson III, Henry B</td>
<td>87</td>
</tr>
<tr>
<td>Nemeroff, Charles B</td>
<td>6, 72, 80, 95</td>
</tr>
<tr>
<td>Nester, Ioanis N</td>
<td>43</td>
</tr>
<tr>
<td>New, Antonietta S</td>
<td>7, 49</td>
</tr>
<tr>
<td>Newkirk, Cassandra F</td>
<td>91</td>
</tr>
<tr>
<td>Newman, Raine</td>
<td>22, 44</td>
</tr>
<tr>
<td>Newton, D. Jeffrey</td>
<td>11</td>
</tr>
<tr>
<td>Newton, Patricia A</td>
<td>8</td>
</tr>
<tr>
<td>Ng, Bernardo</td>
<td>41</td>
</tr>
<tr>
<td>Nguyen, Hoang A</td>
<td>51, 83, 95</td>
</tr>
<tr>
<td>Nguyen, Khon-Vang T</td>
<td>38</td>
</tr>
<tr>
<td>Niaura, Raymond S</td>
<td>2</td>
</tr>
<tr>
<td>Nichols, John A</td>
<td>57</td>
</tr>
<tr>
<td>Nicholson, Robert J</td>
<td>97</td>
</tr>
<tr>
<td>Nieminen, Ponnello</td>
<td>90</td>
</tr>
<tr>
<td>Nierenberg, Andrew A</td>
<td>11, 41, 43, 69, 77, 79, 80</td>
</tr>
<tr>
<td>Nims, Chloe</td>
<td>86</td>
</tr>
<tr>
<td>Ninan, Philip T</td>
<td>11</td>
</tr>
<tr>
<td>Nobier, Mitchell S</td>
<td>76</td>
</tr>
<tr>
<td>Nolan, Bruce</td>
<td>56</td>
</tr>
<tr>
<td>Noll, Jennifer</td>
<td>28</td>
</tr>
<tr>
<td>Notac, Rudi</td>
<td>42, 69</td>
</tr>
<tr>
<td>Napolitan, Peg O</td>
<td>96</td>
</tr>
<tr>
<td>Norman, Ross M.G</td>
<td>96</td>
</tr>
<tr>
<td>Norquist, Grayson</td>
<td>75</td>
</tr>
<tr>
<td>Noves, Donnie M</td>
<td>5, 13, 43, 49</td>
</tr>
<tr>
<td>North, Carol S</td>
<td>55</td>
</tr>
<tr>
<td>Northoff, George</td>
<td>27</td>
</tr>
<tr>
<td>Norton, Ilena M</td>
<td>74</td>
</tr>
<tr>
<td>Norwood, Ann E</td>
<td>60, 71, 92</td>
</tr>
<tr>
<td>Notman, Malcik T</td>
<td>85, 86</td>
</tr>
<tr>
<td>Novak, Andrei</td>
<td>22</td>
</tr>
<tr>
<td>Novotny, Sterlie</td>
<td>56, 59, 77, 83</td>
</tr>
<tr>
<td>Noyes, William</td>
<td>34</td>
</tr>
<tr>
<td>Nuñez, Keith H</td>
<td>67</td>
</tr>
<tr>
<td>Nuñez, Edward V</td>
<td>49, 50</td>
</tr>
<tr>
<td>Nunberg, Linda</td>
<td>20</td>
</tr>
<tr>
<td>Nunnberger, Jr., John</td>
<td>74</td>
</tr>
<tr>
<td>Oberman, Michelle</td>
<td>52</td>
</tr>
<tr>
<td>O'Brien, Charles P</td>
<td>64, 68</td>
</tr>
<tr>
<td>Oddone, Michael W</td>
<td>53</td>
</tr>
<tr>
<td>O'Keeffe, Donald C</td>
<td>70</td>
</tr>
<tr>
<td>Okasha, Ahmed M.F</td>
<td>22, 41, 57, 82, 93</td>
</tr>
<tr>
<td>Okasha, Tarek A</td>
<td>44</td>
</tr>
<tr>
<td>Okasaki, Samuel O</td>
<td>49</td>
</tr>
<tr>
<td>Orland, Marcelo L</td>
<td>39</td>
</tr>
<tr>
<td>Orta, Silvia W</td>
<td>6, 36, 46, 74, 84</td>
</tr>
<tr>
<td>Oldham, John M</td>
<td>7, 28, 38, 62, 70, 78</td>
</tr>
<tr>
<td>Oliver, Karen</td>
<td>87</td>
</tr>
<tr>
<td>Olson, David P</td>
<td>87</td>
</tr>
<tr>
<td>Olson, Kenneth C</td>
<td>64</td>
</tr>
<tr>
<td>O'Malley, Stephanie S</td>
<td>56</td>
</tr>
<tr>
<td>Ongers, Pakikai</td>
<td>75</td>
</tr>
<tr>
<td>O'Nken, Lisa S</td>
<td>77</td>
</tr>
<tr>
<td>Opler, Lewis A</td>
<td>2, 22</td>
</tr>
<tr>
<td>Orav, John</td>
<td>50</td>
</tr>
<tr>
<td>Ordonez, Patricia</td>
<td>68</td>
</tr>
<tr>
<td>Ordoay, Janet</td>
<td>45</td>
</tr>
<tr>
<td>Ortiz-Medina, Enrique</td>
<td>51</td>
</tr>
<tr>
<td>Ortega, reserva</td>
<td>78</td>
</tr>
<tr>
<td>O'Shaughnessy, Roy J</td>
<td>29</td>
</tr>
<tr>
<td>Osher, Fred C</td>
<td>50, 78</td>
</tr>
<tr>
<td>Osin, David W</td>
<td>92</td>
</tr>
<tr>
<td>Osman, Osama T</td>
<td>52, 56</td>
</tr>
<tr>
<td>Osse, David N</td>
<td>62</td>
</tr>
<tr>
<td>Osterheld, Jessica R</td>
<td>42</td>
</tr>
<tr>
<td>Ostier, Kevin</td>
<td>68</td>
</tr>
<tr>
<td>Otto, Michael W</td>
<td>83</td>
</tr>
</tbody>
</table>

**P**

Pacheco-Hernandez, Antonio | 29 |
Paine, Susan S | 20 |
Pai, Albert F | 3, 5 |
Palaianeprom, Vapapr | 19 |
Palaci, C | 78 |
Palmer, Barton W | 76 |
Palmer, Christopher M | 68, 86 |
Palmer, Robert C | 38 |
Pamment, Barbara A | 12 |
Pare, Norma C | 4, 46 |
Pandya, Jose | 15, 39 |
Panzer, Paul G | 18, 61 |
Papadopoulos, Nikos A | 43 |
Papadoglou, Alexander | 67 |
Papp, Laszlo A | 33 |
Pardue, Herbert | 17, 35, 57, 91 |
Parikh, Ramesh | 20 |
Park, Joel | 19, 26 |
Park, Thomas | 56 |
Park, David | 20 |
Park, John | 81 |
Paries, Joseph | 34 |
Parrella, Michael | 4 |
Parrillo, Karen | 15 |
Parr, Delores | 75 |
Perry, Barbara L | 74, 97 |
Pascual, Charles E | 56 |
Pasnau, Robert D | 22, 51, 93 |
Pasternak, Rena A | 2 |
Patal, Ramandith | 86 |
Patrik, Stefania | 20 |
Pati, Aswin A | 90 |
Pato, Michele T | 34 |
Patterson, Raymond F | 78 |
Patterson, Thomas L | 76 |
Pattison, George D | 43 |
Pava, Joel | 43 |
Pye, Jennifer L | 87 |
Pearson, Steven D | 79 |
Pape, Julie K | 54 |
Peele, Roger | 42, 67, 78, 91 |
Pendall, Kathleen | 42 |
Pendelton, James L | 92 |
Pepper, Linda | 78 |
Pequignot, Wild | 81, 96 |
Pere, James | 68 |
Perez, Carlos | 96 |
Perez, Eduardo | 15 |
Perez, Oscar E | 38 |
Perrins, Diana O | 27 |
Perry, Bruce D | 66 |
Peel, John R | 94 |
Petersen, Michael | 40 |
Petersen, Ronald C | 9 |
Pettigrew, Karen | 75 |
Peterson, Shoahama | 36 |
Pfanner, Chiara | 15 |
Pfeffer, Cynthia R | 95 |
Pfleger, Betty | 55, 56 |
Pfenni, Bruce M | 21, 78 |
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharma, Rajiv P</td>
<td>42, 71</td>
</tr>
<tr>
<td>Shea, M.</td>
<td>69, 78, 80</td>
</tr>
<tr>
<td>Shaw, Seana H</td>
<td>63, 90</td>
</tr>
<tr>
<td>Shaw, Jon A</td>
<td>60</td>
</tr>
<tr>
<td>Sharou, Julie</td>
<td>67</td>
</tr>
<tr>
<td>Sharif, Zafar A</td>
<td>91</td>
</tr>
<tr>
<td>Sharfstein, Steven S</td>
<td>75</td>
</tr>
<tr>
<td>Shapiro, Jerome E</td>
<td>81</td>
</tr>
<tr>
<td>Shen, Winston W</td>
<td>4, 69, 90</td>
</tr>
<tr>
<td>Sherer, Artef G</td>
<td>44</td>
</tr>
<tr>
<td>Shen, David L</td>
<td>69</td>
</tr>
<tr>
<td>Shelig, Ariel</td>
<td>39</td>
</tr>
<tr>
<td>Shin, Naoeke</td>
<td>93</td>
</tr>
<tr>
<td>Shik, Jakov</td>
<td>54</td>
</tr>
<tr>
<td>Shiner, Z.</td>
<td>52</td>
</tr>
<tr>
<td>Shon, Steven P</td>
<td>16</td>
</tr>
<tr>
<td>Shroud, Patrick E</td>
<td>91</td>
</tr>
<tr>
<td>Shuer, Marjorie L</td>
<td>35</td>
</tr>
<tr>
<td>Shugart, Margaret A</td>
<td>92</td>
</tr>
<tr>
<td>Sia, Andrew</td>
<td>50</td>
</tr>
<tr>
<td>Siegel, Andrew</td>
<td>64</td>
</tr>
<tr>
<td>Sirkies, Frederick S</td>
<td>42</td>
</tr>
<tr>
<td>Siron, Victor</td>
<td>90</td>
</tr>
<tr>
<td>Silver, Larry J</td>
<td>7, 49, 90</td>
</tr>
<tr>
<td>Sikorski, John B</td>
<td>59</td>
</tr>
<tr>
<td>Silverman, Edward K</td>
<td></td>
</tr>
<tr>
<td>Silk, Kenneth R</td>
<td>7, 21</td>
</tr>
<tr>
<td>Silver, Barbara</td>
<td>22</td>
</tr>
<tr>
<td>Silver, Eric</td>
<td>29</td>
</tr>
<tr>
<td>Silver, Blaine</td>
<td>64</td>
</tr>
<tr>
<td>Silverman, Jeremy M</td>
<td>90</td>
</tr>
<tr>
<td>Silverstein, Marshall L</td>
<td>42</td>
</tr>
<tr>
<td>Simmer, Edward D</td>
<td>19</td>
</tr>
<tr>
<td>Simon, Gary L</td>
<td>41</td>
</tr>
<tr>
<td>Simon, Gregory E</td>
<td>79</td>
</tr>
<tr>
<td>Simon, Lot</td>
<td>38</td>
</tr>
<tr>
<td>Simpson, George M</td>
<td>88</td>
</tr>
<tr>
<td>Simpson, William</td>
<td>81</td>
</tr>
<tr>
<td>Singer, Melanie B</td>
<td>1</td>
</tr>
<tr>
<td>Singer, William M</td>
<td>8</td>
</tr>
<tr>
<td>Sirt, Samuel G</td>
<td>22</td>
</tr>
<tr>
<td>Siro, Pinkhas</td>
<td>61, 91</td>
</tr>
<tr>
<td>Simon, Joseph H</td>
<td>15</td>
</tr>
<tr>
<td>Szwert, Kristin S</td>
<td>2</td>
</tr>
<tr>
<td>Sklarew, Bruce H</td>
<td>10, 20</td>
</tr>
<tr>
<td>Skolowski, Patrick H</td>
<td>28, 68, 78</td>
</tr>
<tr>
<td>Sloan, James M</td>
<td>15</td>
</tr>
<tr>
<td>Slodge, William H</td>
<td>45, 75, 91</td>
</tr>
<tr>
<td>Soupko, Ralph</td>
<td>74</td>
</tr>
<tr>
<td>Slovick, Lois S</td>
<td>35</td>
</tr>
<tr>
<td>Small, Gary W</td>
<td>34, 94</td>
</tr>
<tr>
<td>Smiley, Carson</td>
<td>20</td>
</tr>
<tr>
<td>Smith, Christopher J</td>
<td>90</td>
</tr>
<tr>
<td>Smith, Leslie G</td>
<td>24</td>
</tr>
<tr>
<td>Smith, Mary Kay</td>
<td>43, 68</td>
</tr>
<tr>
<td>Smith, Michael W</td>
<td>3</td>
</tr>
<tr>
<td>Snidman, Nancy</td>
<td>28</td>
</tr>
<tr>
<td>Sokol, Marc S</td>
<td>60</td>
</tr>
<tr>
<td>Sokolov, Howard H</td>
<td>42</td>
</tr>
<tr>
<td>Soldo, Daniela</td>
<td>74</td>
</tr>
<tr>
<td>Solms, Mark L</td>
<td>98</td>
</tr>
<tr>
<td>Soloff, Paul H</td>
<td>7, 20</td>
</tr>
<tr>
<td>Solomon, David A</td>
<td>80</td>
</tr>
<tr>
<td>Soltycs, Stephen M</td>
<td>34</td>
</tr>
<tr>
<td>Solurich, Lionel</td>
<td>70</td>
</tr>
<tr>
<td>Sonawalla, Shamshah B</td>
<td>20, 43, 69</td>
</tr>
<tr>
<td>Sore, Elise</td>
<td>52, 71</td>
</tr>
<tr>
<td>Soskik, Martin M</td>
<td>75</td>
</tr>
<tr>
<td>Southwick, Steven M</td>
<td>20</td>
</tr>
<tr>
<td>Sowers, Wesley E</td>
<td>53</td>
</tr>
<tr>
<td>Spadafora, F</td>
<td>78</td>
</tr>
<tr>
<td>Sparr, Sandy F</td>
<td>39</td>
</tr>
<tr>
<td>Spyry, Leonard T</td>
<td>16</td>
</tr>
<tr>
<td>Spiegel, David</td>
<td>4, 28, 43, 49, 60</td>
</tr>
<tr>
<td>Spinelli, Margaret G</td>
<td>52</td>
</tr>
<tr>
<td>Spinhoven, Philip</td>
<td>28</td>
</tr>
<tr>
<td>Spitz, Deborah</td>
<td>15</td>
</tr>
<tr>
<td>Springer, David T</td>
<td>92</td>
</tr>
<tr>
<td>Spungen, Deborah</td>
<td>97</td>
</tr>
<tr>
<td>Spurlock, Lisa A</td>
<td>69</td>
</tr>
<tr>
<td>Stack, Jackie</td>
<td>59</td>
</tr>
<tr>
<td>Stack, Kathleen M</td>
<td>41</td>
</tr>
<tr>
<td>Stahl, Stephen M</td>
<td>53, 54, 79</td>
</tr>
<tr>
<td>Stanley, Barbara</td>
<td>49</td>
</tr>
<tr>
<td>Stark, Evan</td>
<td>66</td>
</tr>
<tr>
<td>Stark, Michael</td>
<td>94</td>
</tr>
<tr>
<td>Slager, Sara A</td>
<td>94</td>
</tr>
<tr>
<td>Stochuchak, Karen</td>
<td>76</td>
</tr>
<tr>
<td>Steinberg, Marlene</td>
<td>28</td>
</tr>
<tr>
<td>Steinberg, Martin A</td>
<td>56</td>
</tr>
<tr>
<td>Steinberg, Suzanne I</td>
<td>43, 74</td>
</tr>
<tr>
<td>Steiner, Hans</td>
<td>63</td>
</tr>
<tr>
<td>Steiner, Mir</td>
<td>43</td>
</tr>
<tr>
<td>Sterling, Robert</td>
<td>68, 90</td>
</tr>
<tr>
<td>Steri, Robert A</td>
<td>75</td>
</tr>
<tr>
<td>Stern, Yaakov</td>
<td>79</td>
</tr>
<tr>
<td>Strebel, Fay</td>
<td>28</td>
</tr>
<tr>
<td>Stevenson, Lee</td>
<td>33, 90</td>
</tr>
<tr>
<td>Stewart, Alida E</td>
<td>43</td>
</tr>
<tr>
<td>Stewart, Donna E</td>
<td>19, 43, 52</td>
</tr>
<tr>
<td>Stewart, Shelley</td>
<td>91</td>
</tr>
<tr>
<td>Stinnett, James L</td>
<td>34</td>
</tr>
<tr>
<td>Stock, Howard F</td>
<td>92</td>
</tr>
<tr>
<td>Stoff, David</td>
<td>81</td>
</tr>
<tr>
<td>Stolar, M</td>
<td>91</td>
</tr>
<tr>
<td>Stoll, Andrew L</td>
<td>49, 51</td>
</tr>
<tr>
<td>Stone, Alan A</td>
<td>24, 39</td>
</tr>
<tr>
<td>Stone, Michael H</td>
<td>95</td>
</tr>
<tr>
<td>Stotland, Nada L</td>
<td>43, 62, 76</td>
</tr>
<tr>
<td>Studenurte, G. Alan</td>
<td>61</td>
</tr>
<tr>
<td>Stout, Robert</td>
<td>33, 69, 78</td>
</tr>
<tr>
<td>Stower, Ellen</td>
<td>47, 76</td>
</tr>
<tr>
<td>Stowe, Zachary N</td>
<td>54, 69, 74</td>
</tr>
<tr>
<td>Strain, James J</td>
<td>50</td>
</tr>
<tr>
<td>Strakowski, Stephen M</td>
<td>51</td>
</tr>
<tr>
<td>Strak, Bishop</td>
<td>43, 74</td>
</tr>
<tr>
<td>Strauss, John S</td>
<td>33</td>
</tr>
<tr>
<td>Strauss, Wayne</td>
<td>97</td>
</tr>
<tr>
<td>Striar, Sharna L</td>
<td>93</td>
</tr>
<tr>
<td>Strout, Scott</td>
<td>75</td>
</tr>
<tr>
<td>Stubben, William L</td>
<td>82</td>
</tr>
<tr>
<td>Stubbelefield, Matthew S</td>
<td>61</td>
</tr>
<tr>
<td>Stuenkel, Christine</td>
<td>74</td>
</tr>
<tr>
<td>Styra, Rima</td>
<td>47, 63</td>
</tr>
<tr>
<td>Suarez, Ana</td>
<td>22</td>
</tr>
<tr>
<td>Subotnick, Kenneth L</td>
<td>67</td>
</tr>
<tr>
<td>Suchinsky, Richard T</td>
<td>38</td>
</tr>
<tr>
<td>Sullivan, Rani A</td>
<td>48</td>
</tr>
<tr>
<td>Sullivan, Timothy B</td>
<td>44, 86</td>
</tr>
<tr>
<td>Sultzer, David L</td>
<td>35, 79</td>
</tr>
<tr>
<td>Summerfield, William T</td>
<td>6</td>
</tr>
<tr>
<td>Sunderland, Trey</td>
<td>9</td>
</tr>
<tr>
<td>Susser, Ezra S</td>
<td>51, 67, 81</td>
</tr>
<tr>
<td>Susman, Norman</td>
<td>8, 11</td>
</tr>
<tr>
<td>Swed, Margery S</td>
<td>44</td>
</tr>
<tr>
<td>Swartz, Holly A</td>
<td>26</td>
</tr>
<tr>
<td>Swedo, Susan E</td>
<td>46, 68</td>
</tr>
<tr>
<td>Sweet, Robert A</td>
<td>52</td>
</tr>
<tr>
<td>Swenson, Charles R</td>
<td>13</td>
</tr>
<tr>
<td>Swiller, Hillel I</td>
<td>8</td>
</tr>
<tr>
<td>Swin, Richard P</td>
<td>45</td>
</tr>
<tr>
<td>Szark, Bonnie L</td>
<td>69</td>
</tr>
<tr>
<td>Szuba, Martin P</td>
<td>54, 97</td>
</tr>
<tr>
<td>Szynarski, Lukwitz S</td>
<td>60</td>
</tr>
</tbody>
</table>

**T**

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tager, Felicia</td>
<td>20</td>
</tr>
<tr>
<td>Talcott, Zeillon C</td>
<td>16, 42, 92, 93, 94</td>
</tr>
<tr>
<td>Talbott, John A</td>
<td>56</td>
</tr>
<tr>
<td>Tam, Leslie W</td>
<td>74</td>
</tr>
<tr>
<td>Tamburelo, Manolo B</td>
<td>43, 68</td>
</tr>
<tr>
<td>Tamminga, Carol A</td>
<td>36, 52, 73</td>
</tr>
<tr>
<td>Tananl, Tem L</td>
<td>22</td>
</tr>
<tr>
<td>Tanskien, Andi</td>
<td>20</td>
</tr>
<tr>
<td>Tanzi, Rudolph E</td>
<td>27</td>
</tr>
<tr>
<td>Targ, Elizabeth F</td>
<td>1, 26, 94</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX
Washington National Cathedral - Begun in 1907 and completed in 1990, the Washington National Cathedral stands as one of the world's largest churches. President Woodrow Wilson's tomb is housed in the cathedral, along with countless examples of Gothic-style stonecutting and stained glass. (Photo courtesy of the Washington, DC Convention and Visitors Association/1991.)
Psychiatric Association
51st Institute on Psychiatric Services
October 29-November 2, 1999 • New Orleans, LA

“Integrating Research Advances with Clinical Wisdom”

- Symposia • Workshops • CME Courses •
- Computer and Video Sessions • Debates •
- Full-Day Sessions • Poster Sessions • Forums •
- Discussion Groups • Innovative Programs
- Industry-Supported Symposia • Medical Updates •
- Distinguished Lecturers • Clinical Consultations •

INSTITUTE OBJECTIVES: At the conclusion of the 1999 Institute on Psychiatric Services, the participant should be able to understand more about clinical aspects of psychiatry in the current health care system, and review clinical applications in private practice and other settings.

Did you know that…

★ The 1998 Institute received the highest attendee-rated evaluations?
★ APA members receive a 40% discount on their cost for registration?
★ All scientific sessions will be held in the Hyatt Regency New Orleans Hotel?
★ Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?
★ You can earn up to 48 hours of category 1 credit for attending the Institute?
★ There are prize drawings, beverages and receptions held daily in the exhibit hall?

For further information, please write to:

Office to Coordinate Annual Meetings
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20005
Telephone: 1 (888) 357-7924 (Toll Free)
Fax: (202) 682-6345

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Your Bookstore at the 1999 APA Annual Meeting

At this year’s annual meeting be sure and stop by Your Bookstore, conveniently located adjacent to the registration area. You’ll find all the new and essential titles you need— from child and adolescent psychiatry to geriatric psychiatry, psychopharmacology to psychotherapy, and the all-new The American Psychiatric Press Textbook of Psychiatry, Third Edition edited by Drs. Hales, Yudofsky and Talbott. We will also be offering a special selection of books on sale which you won’t want to miss. Pick up that title you’ve always wanted or fill in holes in your series collections and annual reviews. We look forward to seeing you!

BOOKSTORE HOURS:
Saturday, May 15 11:00 a.m. - 5:00 p.m.
Sunday, May 16 11:00 a.m. - 5:00 p.m.
Monday, May 17 10:00 a.m. - 6:00 p.m.
Tuesday, May 18 10:00 a.m. - 6:00 p.m.
Wednesday, May 19 10:00 a.m. - 3:00 p.m.

NEW in 1999

Let’s Talk Facts About Anxiety Disorders
By the American Psychiatric Association Division of Public Affairs
8 pages • ISBN 0-88048-350-9 • $12.50, 6 or more: $10.00 • Order #2580

Let’s Talk Facts About Choosing a Psychiatrist
By the American Psychiatric Association Division of Public Affairs
3 pages • ISBN 0-88048-361-X • $12.50, 6 or more: $10.00 • Order #2261

Let’s Talk Facts About Panic Disorder
By the American Psychiatric Association Division of Public Affairs
8 pages • ISBN 0-88048-357-7 • 1-5 packets=$12.50, 6 or more: $10.00 • Order #2577

Let’s Talk Facts About Substance Abuse
By the American Psychiatric Association Division of Public Affairs
8 pages • ISBN 0-88048-359-9 • 1-5 packets=$12.50, 6 or more: $10.00 • Order #2589

American Psychiatric Press Reference Library
(on CD-ROM), Version 2.0
By American Psychiatric Press, Inc.
Order #9853
2-5 Users: $595.00 • Order #9205
6-10 Users: $1,850.00 • Order #9306
11-20 Users: $2,325.00 • Order #9033

Study Guide to The American Psychiatric Press Textbook of Consultation-Liaison Psychiatry
By Jude Berman, Ed.D., James R. Rundoll, M.D., and Michael G. Wise, M.D.
224 pages • ISBN 0-88048-405-0 • paperback • $25.00
Order #9805

Assessment of Neuropsychological Functions in Psychiatric Disorders
Edited by Avraham Calov, D.Phl.
608 pages • ISBN 0-88048-912-X • hardcover • $72.95
Order #9812

Countertransference Issues in Psychiatric Treatment
Edited by Glen O. Gabbard, M.D.
348 pages • ISBN 0-88048-783-1 • hardcover • $50.00
Order #8761

Disruptive Behavior Disorders in Children and Adolescents
Edited by Robert L. Hendren, D.O.
214 pages • ISBN 0-88048-962-6 • paperback • $26.50 • Order #8960

Gender Differences in Mood and Anxiety Disorders From Bench to Bedside
Edited by Ellen Leibenluft, M.D.
214 pages • ISBN 0-88048-958-8 • paperback • $26.50 • Order #8958

Schizophrenia in a Molecular Age
Edited by Carol A. Tamminga, M.D.
214 pages • ISBN 0-88048-961-8 • paperback • $26.50 • Order #8961

American Psychiatric Association

Annual Review of Psychiatry 1999
Volume 18
Series Editors:
John M. Oldham, M.D., and Michelle B. Riba, M.D.

Available in May...

Countertransference Issues in Psychiatric Treatment
Edited by Glen O. Gabbard, M.D.
160 pages • ISBN 0-88048-959-6 • paperback • $26.50 • Order #8959

Disruptive Behavior Disorders in Children and Adolescents
Edited by Robert L. Hendren, D.O.
214 pages • ISBN 0-88048-960-X • paperback • $26.50 • Order #8960

Gender Differences in Mood and Anxiety Disorders
Edited by Ellen Leibenluft, M.D.
214 pages • ISBN 0-88048-958-8 • paperback • $26.50 • Order #8958

Available this Summer 1999...

Masculinity and Sexuality
Selected Topics in the Psychology of Men
Edited by Richard C. Friedman, M.D. and Jennifer I. Downey, M.D.
214 pages • ISBN 0-88048-962-6 • paperback • $26.50 • Order #8962

Schizophrenia in a Molecular Age
Edited by Carol A. Tamminga, M.D.
214 pages • ISBN 0-88048-961-8 • paperback • $26.50 • Order #8961

Available in Summer...
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 15, 7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

The Complex Face of Depression
Clinical Challenges in the Diagnosis and Treatment of Depressive Disorders

Saturday, May 15, 1999
7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B
Grand Hyatt, Washington, DC

Reception
6:00 p.m. - 7:00 p.m.

David J. Kupfer, MD
Chairman

Diagnosis and Treatment of Childhood Mania
Elizabeth B. Weller, MD
Children's Hospital of Philadelphia

Treatment of Adolescent Depression
Richard Harrington, MD
University of Manchester

Decision Points in the Treatment of Bipolar Depression
Gary S. Sachs, MD
Massachusetts General Hospital

Therapy for Traumatic Grief
M. Katherine Shear, MD
University of Massachusetts School of Medicine

A Life-Cycle Approach to the Diagnosis and Treatment of Depressive Disorders
David J. Kupfer, MD
University of Pittsburgh School of Medicine

Depressive disorders occur throughout the life cycle, however; the presentation of symptoms and response to treatment may vary according to age of onset, existing comorbidities, and/or the presence of a precipitating life event. This symposium will address challenges that face every clinician in the diagnosis and treatment of depressive disorders, and provide practice recommendations to improve patient assessment and management.

The program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories and the Parke-Davis division of Warner-Lambert Company.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 15, 7:00 p.m. - 10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

Redefining Treatment-Resistant Schizophrenia

Saturday, May 15, 1999
Dinner Reception 6:00 PM
Symposium 7:00 - 10:00 PM
Presidential Ballroom, Second Floor
Capital Hilton, Washington, DC

Chairman's Introduction
Alan I. Green, MD

Natural Course and Outcome of Schizophrenia
Thomas H. McGlashan, MD

Pathogenesis of Treatment and Resistance in Schizophrenia
Jeffrey A. Lieberman, MD

Alleviation of Functional Impairment in Treatment-Resistant Schizophrenia
Herbert Y. Meltzer, MD

Early Intervention: Approach to Comorbid Substance Abuse/Substance Use Disorder
Alan I. Green, MD

Discussant
David Picker, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation

NOVARTIS
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 15, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

Chairperson:
Jack M. Gorman, MD

Saturday, May 15, 1999
7:00 pm - 10:00 pm
Grand Ballroom + Renaissance Hotel
Washington, D.C.

Reception precedes the symposium at 6:30 pm

Spectrum of Depression: New Treatment Approaches

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 4
Sunday, May 16, 9:00 a.m. - 12 noon
Constitution Ballroom, Level 3B, Grand Hyatt

Sponsored by the APA at the 1999 APA Annual Meeting

Alternatives to SSRIs in the Treatment of Depression
Jack M. Gorman, MD

Role of Norepinephrine in Depression
Pedro L. Delgado, MD

New Approaches to the Treatment of Refractory Depression
Maurizio Fava, MD

Treatment of Severe Depression
Michael E. Thase, MD

Social Functioning in the Patient with Depression
Myrna M. Weissman, PhD

Supported by an unrestricted educational grant from Pharmacia & Upjohn.

Typical Patients—Atypical Care: An Interactive Case Study

CHAIR:
Prakash S. Masand, MD

DISTINGUISHED FACULTY:
David Pickar, MD
Gary S. Sachs, MD
Philip D. Harvey, MD
Robert R. Conley, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Janssen Pharmaceutica
SOCIETAL IMPACT OF ANXIETY DISORDERS:
New Data and Implications for Outcome

SUNDAY, MAY 16, 1999
9:00 AM TO NOON

Grand Hyatt Washington
Independence Ballroom

JONATHAN R.T. DAVIDSON, MD
SYMPOSIUM CHAIRMAN
Professor
Department of Psychiatry and Behavioral Sciences
Duke University Medical Center
Durham, North Carolina

Economic Burden of Anxiety Disorders
RONALD C. KESSLER, PhD
Professor
Department of Health Care Policy
Harvard Medical School
Boston, Massachusetts

The Direct and Indirect Costs of Social Anxiety Disorder in Managed Care Patients
DAVID J. KATZELNICK, MD
Distinguished Scientist
Dean Foundation for Health, Research and Education
Madison Institute of Medicine
Madison, Wisconsin

Treatment-Seeking for Medically Unexplained Symptoms: Relationship with Generalized Anxiety Disorder and Panic Disorder
WAYNE J. KATON, MD
Professor and Vice Chair
Chief, Division of Health Services and Psychiatric Epidemiology
Department of Psychiatry
University of Washington Medical School
Seattle, Washington

Anxiety and Substance Use Disorders: Prevalence, Diagnosis, and Treatment Issues
HENRY R. KRANZLIER, MD
Professor of Psychiatry
University of Connecticut School of Medicine
Farmington, Connecticut

How Treatable are Anxiety Disorders?
DAVID V. SHEEHAN, MD
Professor of Psychiatry
University of South Florida College of Medicine
Director, Office of Psychiatric Research
USF Institute for Research in Psychiatry
Tampa, Florida

* Light refreshments will follow the symposium.

TREATMENT RESISTANT DEPRESSION: U.S. and European Perspectives

CHAIR
Professor Lewis L. Judd
University of CA, San Diego, USA

CHAIR
Professor Julien Mendlewicz
Erasme Hospital, Brussele, Belgium

Treatment Resistant Depression: Guidelines for Early Diagnosis and Recognition
Professor Lewis L. Judd

Risk Factors in Treatment Resistant Depression (TRD)
Professor Michael E. Thase
University of Pittsburgh, USA

Treatment Algorithms in TRD: European Perspective
Professor Julien Mendlewicz

Treatment Algorithms in TRD: U.S. Perspective
Professor Madhukar H. Trivedi
University of Texas Medical Center, USA

Treatment Resistance in Geriatric Depression
Professor Cornelius Katona
University College Medical School, UK

Discussants:
Professor Giorgio Racagni
University of Milan, Italy
Professor Julien Mendlewicz

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category I credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from the International Academy for Biomedical and Drug Research.

Registration and Breakfast to be begin at 8.00 am in the Ballroom Foyer.

Sunday, May 16, 1999
9:00 am - 12:00 pm
Presidential Ballroom, Capital Hilton
INDUSTRY-SUPPORTED SYMPOSIUM 7
Sunday, May 16, 9:00 a.m. - 12 noon
Grand Ballroom, Ballroom Level, Renaissance Washington

A Decade of Serotonin Studies: Beyond Depression

Sunday, May 16, 1999 • Renaissance Washington Hotel • Grand Ballroom, Ballroom Level • Washington, DC
8:30 AM Breakfast • 9:00 AM - 12:00 NOON Educational Program

Welcome & Introduction .......................................................................................... John F. Greis, MD
OCD: Serotonin Specificity Suras Pariet .......................................................... John H. Greis, MD
Panic Disorder: Epidemiology & Treatment .................................................. Mark H. Pollack, MD
Dysthmic Disorder: SSRI Treatment Update .................................................. David L. Dunner, MD
Premenstrual Dysphoric Disorder: A Role for Serotonin? ............................ Tane A. Grady-Weilby, MD
The Neurobiology & Treatment of PTSD: A Focus on Serotonin................. Dennis S. Charney, MD
Summary of Highlights .................................................................................. John F. Greis, MD

John F. Greis, MD
Program Chair
Nerlsh Health Research Institute
University of Michigan Health System
Ann Arbor, Michigan

John H. Greis, MD
Nerlsh Institute of Medicine, Inc.
University of Wisconsin
Madison, Wisconsin

Mark H. Pollack, MD
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

David L. Dunner, MD
University of Washington
Medical Center
Seattle, Washington

Tane A. Grady-Weilby, MD
University of Washington School of Medicine
Seattle, Washington

Dennis S. Charney, MD
Yale University School of Medicine
New Haven, Connecticut

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly and Company

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Optimizing Treatment Outcome in Depression

Sunday, May 16, 1999
9:00 a.m. - 12:00 noon
Renaissance Ballroom
Ballroom Level
Renaissance Washington
Washington, DC
Breakfast will be served at 8:30 AM.

Approaches to the Enhancement of Patient Compliance
Pedro L. Delgado, MD

Management of Nonresponse and Intolerance: Switching Strategies
Maurizio Fava, MD

Combined Drug Treatments: Pros and Cons
J. Craig Nelson, MD

Clinical Issues in Long-Term Treatment With Antidepressants
John M. Zajecka, MD

Combining Psychotherapy and Pharmacotherapy: What Are the Advantages?
Ellen Frank, PhD

Maurizio Fava, MD
Program Chair

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

127
Mood and the Mind:
The Science and Art of New and Emerging Treatments Alternative 1755

Chair:
Ned H. Kalin, MD

Distinguished Faculty:
Charles B. Nemeroff, MD, PhD
K.N. Roy Chergappa, MD
Jack M. Gorman, MD, FACNP
Lili C. Kopala, MD, FRCPC
S. Nassir Ghaemi, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Janssen Pharmaceutica

Indoey-Supported Symposium 10
Sunday, May 16, 1:30 p.m. - 4:30 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

Anxiety and Depression in the Adolescent:
Clinical Implications of Emerging Data

Sunday, May 16, 1999
1:30 PM TO 4:30 PM
Grand Hyatt Washington
Independence Ballroom

Sponsored by the American Psychiatric Association
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from
SmithKline Beecham Pharmaceuticals

Neal D. Ryan, MD
Symposium Chairman
Joanna P. Antich Professor in Child and Adolescent Psychiatry
Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Current Status of the Diagnosis and Treatment of Depression and Anxiety in Adolescents
Karen Disley Wagner, MD, PhD
Clarence Ross Miller Professor and Vice Chair
Department of Psychiatry and Behavioral Sciences
Director, Division of Child and Adolescent Psychiatry
University of Texas Medical Branch
Galveston, Texas

Developments in the Treatment of Adolescent Depression
Rachel G. Keer, PhD
Professor of Clinical Psychology
Columbia University College of Physicians and Surgeons
New York State Psychiatric Institute
New York, New York

Treatment of the Adolescent With Obsessive-Compulsive Disorder
Henrietta L. Leonard, MD
Professor of Psychiatry and Human Behavior
Brown University School of Medicine
Director of Training, Division of Child Psychiatry
Rhode Island Hospital
Providence, Rhode Island

Social Phobia/Social Anxiety Disorder
Stan Kutcher, MD, FRCP(C)
Professor and Head
Department of Psychiatry
Dalhousie University
Psychiatrist in Chief
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia

Safety Considerations for the Use of Antidepressants in Adolescents
Neal D. Ryan, MD

*Light refreshments precede the symposium.
Intervening During the Prodromal Phase of Schizophrenia

**Symposium**

*Sunday, May 16, 1999 - 1:30-4:30 p.m.*

Presidential Ballroom, Second Floor, Capital Hilton, Washington, D.C.

- **Cognitive Function and the Course of Schizophrenia**
  - Herbert Y. Melzter, MD
  - Chairperson
  - Vanderbilt University, Department of Psychiatry, Nashville, TN, USA

- **Predicting Schizophrenia**
  - Michael Davidson, MD
  - Tel-Aviv University, Department of Psychiatry, Tel-HaShomer, Israel

- **Prepsychotic Intervention in Schizophrenia: A Stitch in Time?**
  - Patrick D. McGorry, PhD
  - University of Melbourne, Department of Psychiatry, Parkville, Australia

- **Prodromal Signs: Crucial Information at both the Theoretical and Practical Level**
  - Yves Lecrubier, MD
  - Hopital de la Salpêtrière, University, Paris, France

- **The Prodrome: Clinical Features and Early Detection**
  - Thomas H. McGlashan MD
  - Yale Psychiatric Institute, New Haven, CT, USA

Supported by an unrestricted educational grant from **Sandoz**

**INDUSTRY-SUPPORTED SYMPOSIUM 12**

*Sunday, May 16, 1:30 p.m. - 4:30 p.m.*

Grand Ballroom, Ballroom Level, Renaissance Washington, D.C.

---

**Are Atypical Antipsychotics Also Mood Stabilizers?**

**Sunday, May 16, 1999 • Renaissance Washington Hotel • Grand Ballroom, Ballroom Level • Washington, DC**

1:00 PM Luncheon • 1:30 - 4:30 PM Educational Program

- **Welcome & Introduction**
  - Paul E. Keck, Jr., MD
  - Program Chair

- **Pharmacologic Mechanisms of Mood Stabilization Among Atypical Antipsychotics**
  - Paul E. Keck, Jr., MD

- **Atypical Antipsychotics: Treatment of Acute Mania**
  - Susan L. McElroy, MD

- **Atypical Antipsychotics: Treatment of Depression**
  - Richard C. Shelton, MD

- **Efficacy & Tolerability of Maintenance Pharmacotherapy in Bipolar Disorders**
  - John M. Zajecka, MD

- **Health Beliefs & Compliance in Bipolar Disorder**
  - Peter J. Weiden, MD

*Sponsored by the American Psychiatric Association*

*Supported by an unrestricted educational grant from E.R. Squibb & Sons*

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The ACP designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**APR 1999 Annual Meeting**
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 16, 1:30 p.m. - 4:30 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

LUNCH SYMPOSIUM

COMPLEXITY: PHARMACOLOGIC MANAGEMENT ISSUES IN BORDERLINE PERSONALITY DISORDER

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Glaxo Wellcome Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 16, 7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

Clinical Frontiers in the Sleep/Psychiatry Interface

Chair: KARL DOGHRAJMI, MD

Insomnia and Hypersomnia: Old Problems with Newer Treatments
KARL DOGHRAJMI, MD
Jefferson Medical College

Emerging Links Between Depression and Sleep
J. CHRISTIAN GILLIN, MD
University of California San Diego

Management of Sleep Disturbances in PTSD
THOMAS NEYLAN, MD
University of California San Francisco

Pain and Sleep: Neurobiological and Clinical Issues
MITCHELL J. M. COHEN, MD
Thomas Jefferson University

Sunday, May 16, 1999 = 7:00 to 10:00 p.m.
(Buffet Dinner 6:00 p.m.)
Grand Hyatt = Constitution Ballroom = Level 3B

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 4 hours in Category 1 credit towards the APA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours that he/she actually spent in the educational activity.
Depression: Achieving Remission and Compliance
CLINICAL CHALLENGES AND SOLUTIONS

Chair: Paula J. Clayton, M.D.
Discussant: Robert M.A. Hirschfeld, M.D.
Faculty: Norman Sussman, M.D.
John C. Markowitz, M.D.
Martin B. Keller, M.D.
Russell T. Joffe, M.D.

8:15 - 8:45 p.m. Registration and Dinner
7:00 - 10:00 p.m. Scientific Program

This symposium is sponsored by the American Psychiatric Association.

INDUSTRY-SUPPORTED SYMPOSIUM 16
Sunday, May 16, 7:00 p.m. - 10:00 p.m.
Presidential Ballroom, Second Floor, Capital Hilton

Featuring Interactive Audience Response System
132nd APA Annual Meeting Sunday May 16, 1999 7:00 - 10:00 P.M.

Longitudinal Aspects
of Alzheimer's Disease

Management

The American Psychiatric Association (APA) is accredited by the Accreditation
Council for Continuing Medical Education to sponsor continuing medical education for
physicians.

The APA designates this educational activity for up to 1 hour in Category 1 credit
towards the AMA Physician's Recognition Award and for the CME requirement of
the APA. Each physician should claim only those hours of credit that he/she actually
spends in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Elan Inc.
and Pfizer Inc.
### INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 16, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

#### Suicide: Clinical/Risk Management Issues for Psychiatrists

- **Program Chairperson**: Douglas G. Jacobo, MD
- **Program Co-Chairperson**: Ross J. Baldessarini, MD

#### Program

- **A Protocol for the Assessment of Suicide**
  - Douglas G. Jacobo, MD
  - Harvard Medical School
  - Boston, Massachusetts

- **Bipolar Disorder and Suicide**
  - Kay Redfield Jamison, PhD
  - Johns Hopkins University School of Medicine
  - Baltimore, Maryland

- **Lithium Discontinuation and Suicide**
  - Ross J. Baldessarini, MD
  - Harvard Medical School
  - Boston, Massachusetts

- **Profiles of Completed Suicide**
  - Jan A. Fawcett, MD
  - Rush-Presbyterian-St Luke’s Medical Center
  - Chicago, Illinois

- **Suicide, Assisted Suicide, and Euthanasia**
  - Herbert Hendin, MD
  - New York Medical College
  - New York, New York

- **Liability and Suicide**
  - Thomas G. Gulbri, MD
  - Harvard Medical School
  - Boston, Massachusetts

### INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 16, 7:00 p.m. - 10:00 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

#### 152nd APA Annual Meeting
**Optimizing Wellness Across the Life Cycle of Schizophrenia**

- **Agenda**
  - **6:30 PM**
    - Reception
  - **7:00**
    - **Welcome/Introduction**
      - Daniel E. Casey, MD, Chairperson
      - Department of Mental Health, VA Medical Center
      - Portland, Oregon
  - **7:15**
    - **Managing the First Episode**
      - John M. Kane, MD
      - Department of Psychiatry, Hillside Hospital
      - Glen Oaks, New York
  - **7:45**
    - **Meeting Long-Term Treatment Goals: Relapse Prevention and More**
      - Nina R. Schouls, PhD
      - Department of Research, Hillside Hospital
      - Glen Oaks, New York
  - **8:15**
    - **Improving Compliance and Building Alliances**
      - Peter J. Weston, MD
      - Department of Psychiatry
      - St. Luke's - Roosevelt Hospital Center
      - New York, New York
  - **8:45**
    - **Schizophrenia Toward the End of the Life Cycle**
      - Troy Sunderland, MD
      - Department of Geriatric Psychiatry
      - National Institute of Mental Health
      - Bethesda, Maryland
  - **9:15**
    - **Morbidity and Mortality in Schizophrenia**
      - Daniel E. Casey, MD
  - **9:45**
    - **Questions & Answers**
  - **10:00**
    - Adjourn
# Industry-Supported Symposium 19

**Monday, May 17 and Tuesday, May 18, 7:00 a.m. - 8:30 a.m.**

Constitution Ballroom, Level 3B, Grand Hyatt

**Breakfast Symposium in Two Parts**

**Monday, May 17**

**Chair:**
R. Bruce Lydiard, Ph.D., M.D.

**Neurobiology of Anxiety and Mood Disorders**
Jeremy Coplan, M.D.
Columbia University

**Why Do Anxious People Become Depressed?**
Philip T. Ninan, M.D.
Emory University

**Treatment of Anxious/Depressed Patients**
R. Bruce Lydiard, Ph.D., M.D.
Medical University of South Carolina

**Discussion**
R. Bruce Lydiard, Ph.D., M.D.
Faculty and Audience

**Tuesday, May 18**

**Chair:**
R. Bruce Lydiard, Ph.D., M.D.

**Impact of Depression on the Course of Anxiety Disorders**
Jane Eisen, M.D.
Brown University

**Anxious Depression: Clinical Characteristics and Treatment Options**
James C. Ballegan, M.D.
Medical University of South Carolina

**Discussion**
R. Bruce Lydiard, Ph.D., M.D.
Faculty and Audience

---

# Industry-Supported Symposium 20

**Monday, May 17 and Tuesday, May 18, 7:00 a.m. - 8:30 a.m.**

Independence Ballroom, Level 5B, Grand Hyatt

**New Clinical Advances in Managing Anxiety and Depressive Disorders Throughout the Life Cycle**

**Chair:**
Robert E. Hales, M.D., M.B.A.

**Co-Chair:**
Stuart C. Yudofsky, M.D.

**Faculty:**
Norman S. Saxman, M.D.
Anthony J. Rothschild, M.D.
Thomas A. Mellman, M.D.
Jastine M. Kent, M.D.

**Monday and Tuesday May 17 & 18, 1999**

**Accreditation**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates each day of this educational activity for up to 6.5 hours of credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Beyond Efficacy in Psychosis: Patient Satisfaction, Compliance, and Outcomes

A 2-Part Breakfast Symposium at the Annual Meeting of the American Psychiatric Association

Chairperson
Henry A. Nasrallah, MD
Co-Chairperson
Laurie Flynn, MSW
Faculty
Soo Bevan, MD
John M. Kane, MD
Lili C. Kopala, MD
Alexander L. Miller, MD

Beginning Monday, May 17th and continuing Tuesday, May 18th

Part I
Monday, May 17th, 1999
Capital Hilton Hotel • Washington, DC
6:30 am  Breakfast
7:00 am  Introduction
7:10 am  Antipsychotic Medication and Cognition
          Alexander Miller, MD
7:35 am  Practical Management of Agitation and Aggression
          See Berson, MD
8:00 am  Extrapyramidal Side Effects and Tardive Dyskinesia: Impact on Compliance and Outcome
          John M. Kane, MD
8:25 am  Summary/Preview Part II
          Henry A. Nasrallah, MD
8:30 am  Adjourn

Part II
Tuesday, May 18th, 1999
Capital Hilton Hotel • Washington, DC
6:30 am  Breakfast
7:00 am  Introduction/Recap
7:10 am  Sexual Dysfunction: Relationship to Patient Satisfaction and Adherence
          Henry A. Nasrallah, MD
          Lili C. Kopala, MD
7:35 am  Involving the Caregiver to Optimize Outcomes in Psychosis
          Laurie Flynn, MSW
8:00 am  Panel Discussion
8:30 am  Adjourn

This symposium is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Zeneca Pharmaceuticals.

INDUSTRY-SUPPORTED SYMPOSIUM
Monday, May 17 and Tuesday, May 18, 7:00 a.m. - 8:30 a.m.
Presidential Ballroom, Second Floor, Capital Hilton

Strategies and Tactics to Manage Depressed Patients

A. John Rush, MD
Program Chair
Lorrin M. Koran, MD
Program Co-Chair

Monday, May 17, 1999, 7:00 AM—8:30 AM
Which Baseline Symptom Features Predict Response to Particular Antidepressant Medications?
A. John Rush, MD

Response Versus Remission: A Distinction With a Clinical Difference?
Madhukar H. Trivedi, MD

Are There Faster and Slower Responders to Antidepressant Medication and Who Are They?
Andrew A. Nierenberg, MD

Tuesday, May 18, 1999, 7:00 AM—8:30 AM
Are There Faster and Slower Psychotherapy Responders?
John C. Markowitz, MD

Early Antidepressant Response as a Predictor
Lorrin M. Koran, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates each day of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by American Psychiatric Association

Supported by an unrestricted educational grant from

134
INDUSTRY-SUPPORTED SYMPOSIUM 23
Monday, May 17 and Tuesday, May 18, 7:00 a.m. - 8:30 a.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

Controversies and Treatment Strategies in BIPOLAR DISORDERS
Sponsored by the American Psychiatric Association
Monday, May 17 & Tuesday, May 18 • 7:00-8:30 a.m.
Renaissance Ballroom • Renaissance Washington
A complimentary Continental breakfast will be served each morning from 6:30-7:00 a.m.

Dwight L. Evans, M.D., Program Chairperson
Professor and Chairman of Psychiatry, University of Pennsylvania

Monday, May 17
Bipolar II: Diagnostic and Therapeutic Controversies
Hagop S. Akiskal, M.D.
Professor of Psychiatry
University of California, San Diego

Promises and Predictions for the Atypical Antipsychotics in Bipolar Disorder
Robert N. Golden, M.D.
Professor and Chairman of Psychiatry
University of North Carolina

Current Update on Bipolar Disorder: Where Do We Go from Here?
Charles L. Bowden, M.D.
Professor and Chairman of Psychiatry
University of Texas Health Science Center at San Antonio

This program is supported by an unrestricted educational grant from Abbott Laboratories.

Tuesday, May 18
Compliance and Safety: Issues Integral to Successful Bipolar Therapy
Carlos A. Zarate Jr., M.D.
Assistant Professor of Psychiatry
Harvard

What's New in Pharmacoeconomic Treatment Outcomes in Bipolar Disorder
Lisa S. Dixon, M.D.
Director of Education and Residency Training in Psychiatry
University of Maryland

Alzheimer's Disease
Translating Clinical Trials Into Clinical Care
Jeffrey L. Cummings, M.D. - Chair
Tuesday, May 18, 1999
Rooms 39/40, Upper Level, Washington Convention Center
Complimentary Dining Hour 6:00 PM
Educational Program 7:00-10:00 PM
Welcome and Introduction
Assessment Tools for Global Function
P. Murali Doraiswamy, M.D.
Duke University, Durham, North Carolina

Scales Used to Assess Cognition
John C. Morris, M.D.
Washington University, St. Louis, Missouri

Activities of Daily Living:
A Key Parameter in Alzheimer's Disease
Linda Tolle, Ph.D.
University of Washington, Seattle

Assessment of Neuropsychiatric Disorders
Jeffrey L. Cummings, M.D.
University of California, Los Angeles

Assessment of Disease Progression
Mary Sano, Ph.D.
Columbia University, New York, New York

Concluding Remarks and Audience Interaction

Seating for this symposium is limited.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates each of this educational activity for up to 3.0 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

Bayer

Supported by an unrestricted educational grant from Bayer Corporation

Learn how to interpret the increasing body of information obtained from Alzheimer's disease clinical trials. Translate these results into improved patient care in your clinical practice.
INDUSTRY-SUPPORTED SYMPOSIUM 25
Tuesday, May 18, 7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

MAKE IT A POINT TO REMEMBER

“What Makes an Antipsychotic Atypical?”
A Dinner Symposium

Tuesday, May 18, 1999
Dinner 6:30 p.m. • Symposium 7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B
Grand Hyatt (across from convention center)

Moderator:
William M. Glazer, MD, Chair
Stephen M. Stahl, MD, PhD, Co-chair
Peter F. Buckley, MD
Larry Evershed, PharmD
Gary Remington, MD, PhD

Sponsored by:
The American Psychiatric Association
Supported by:
An unrestricted educational grant from Watson Laboratories, Inc.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the APA Physicians' Recognition Award and for the MEE requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 26
Tuesday, May 18, 7:00 p.m. - 10:00 p.m.
Independence Ballroom, Level 5B, Grand Hyatt

136
Gender Issues in Diagnosis and Response to Treatment

Incidence and Treatment of Migraine in Women
ANITA L.H. CLAYTON, MD, SYMPOSIUM CHAIR
Department of Psychiatry, University of Virginia, Charlottesville, Virginia

Gender Issues in the Assessment and Treatment of Depression
SUSAN G. KOPNICK, MD, SYMPOSIUM CoCHAIR
Department of Psychiatry, Medical College of Virginia, Richmond, Virginia

Gender Issues in Diagnosis and Treatment of Anxiety Disorders
Tereasa A. Figgie, MD
Department of Psychiatric Medicine, University of Texas Medical Center, Galveston, Texas

Treatment of Women with Bipolar Disorder
Ellen Leibenluft, MD
National Institute of Mental Health, Bethesda, Maryland

Sexual Disorders in Women: Diagnosis and Treatment
Thomaias H. Wise, MD
Department of Psychiatric Medicine, inset Kurtzbe Hospital, Falls Church, Virginia

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 1 credit hour in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This symposium is supported by an unrestricted educational grant from Glaxo Wellcome, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 29
Tuesday, May 18, 7:00 p.m. - 10:00 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

Managing Depression
ACROSS THE LIFE CYCLE

Graham J. Emslie, MD
Zachary N. Stone, MD
Peter J. Schmidt, MD
Jerold F. Rosenbaum, MD
Barnett S. Meyers, MD

Depression in Children and Adolescents
Course and Treatment of Mood Disorders During Pregnancy and the Postpartum Period
Depression in the Perimenopausal Woman
Long-term Management of Recurrent Adult Depression
Late-life Depression: Biology, Vulnerability, Phenomenology and Course

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 30
Wednesday, May 19, and Thursday, May 20, 7:00 a.m. - 8:30 a.m.
Rooms 39/40, Upper Level, Convention Center

Novel Approaches to the Treatment of Impulsivity

Wednesday, May 19, 1999
Thursday, May 20, 1999
Symposium: 7:00 AM-8:30 AM
Breakfast: 6:15 AM
Convention Center
Rooms 39/40, Upper Level
902 9th Street NW
Washington, DC

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 1.5 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that have actually been spent in the educational activity.
Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly Pharmaceuticals, Inc., and Pharmacia & Upjohn Company

Program Chairperson
Eric Hollander, MD
Mount Sinai School of Medicine
New York, New York

Program
Novel Approaches to the Treatment of Pathological Gambling
Eric Hollander, MD
Mount Sinai School of Medicine
New York, New York

Treatment of Impulsivity and Aggressivity in PTSD
Charles R. Marmar, MD
Veterans Affairs Medical Center
San Francisco, California

Treatment of Compulsive Shopping and Sex Addiction
Donnell W. Black, MD
University of Iowa College of Medicine
Iowa City, Iowa

The Relationship Between ODD and Impulsivity
Joseph Zuckar, MD
Cleveland Clinic Foundation
Cleveland, Ohio

The Relationship Between Bipolar Spectrum and Impulse Control Disorders
Concerta M. DeVita, PhD
Mount Sinai School of Medicine
New York, New York
INDUSTRY-SUPPORTED SYMPOSIUM 31
Wednesday, May 19, and Thursday, May 20, 7:00 a.m. - 8:30 a.m.
Constitution Ballroom, Level 3B, Grand Hyatt

Mood & Psychotic Disorders in Women: An Update on Treatment

Welcome & Introduction
Lee S. Cohen, MD
Effects of Gonadal Steroids on Brain & Behavior
David R. Rubinow, MD
Mood & Psychotic Disorders in Women During the Childbearing Years
Lee S. Cohen, MD
Course & Treatment of Bipolar Illness During Pregnancy & the Postpartum Period
Adele C. Vignera, MD
Gender & the Secular Generation of Antipsychotics
Ruth A. Dickson, MD, FRCP
Estrogen & Mood in Perimenopausal Women
Catherine A. Roa, MD

Lee S. Cohen, MD
Program Chair
Harvard Medical School
Boston, Massachusetts

Adele C. Vignera, MD
Massachusetts General Hospital
Boston, Massachusetts

David R. Rubinow, MD
National Institute of Mental Health
Bethesda, Maryland

Catherine A. Roa, MD
National Institute of Mental Health
Bethesda, Maryland

Sponsored by the American Psychiatric Association

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates each day of this educational activity for up to 1.5 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 32
Wednesday, May 19, and Thursday, May 20, 7:00 a.m. - 8:30 a.m.
Independence Ballroom, Level 5B, Grand Hyatt

Anxiety Disorders
From Scientific Research to Clinical Practice

Wednesday, May 19, 1999
6:30 AM Breakfast
7:00 Welcome and Introduction
Mark H. Pallick, MD, Chairman
7:15 Recognition and Prevention of Anxiety in Children and Adolescents
John S. March, MD, MPH
7:35 Panic Disorder: Initial Treatment Strategies and Beyond
Mark H. Pallick, MD, Chairman
7:55 Management Strategies for Post-Traumatic Stress Disorder
Kathleen Brady, MD, PhD
8:15 Question and Answer Session
8:30 Adjourn

Thursday, May 20, 1999
6:30 AM Breakfast
7:00 Welcome and Introduction
Mark H. Pallick, MD, Chairman
7:15 Social Phobia: Course, Complications, and Therapeutics
John H. Greist, MD
7:35 Understanding Quality of Life in Anxiety Disorders
Mark H. Pallick, MD, Chairman
7:55 Applying Cognitive-Behavior Therapy to Clinical Pharmacotherapy
Michael W. Otto, PhD
8:15 Question and Answer Session
8:30 Adjourn

1999 APA Annual Meeting - May 19-20, 1999 - Grand Hyatt Hotel - Washington, DC
ASSESSMENT AND TREATMENT OF PSYCHIATRIC DISORDERS IN THE ELDERLY

CHAIR:
W. Walter Menninger, MD

DISTINGUISHED FACULTY:
Stephen M. Aronson, MD
Dilip V. Jeste, MD
Stuart C. Yudofsky, MD
George T. Grossberg, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates each day of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Janssen Pharmaceuticals.

ADVANCES IN THE TREATMENT OF GERIATRIC DEPRESSION

WEDNESDAY, MAY 19, 1999
Pharmacology of Antidepressants Pertinent to Older Patients
BRUCE G. POLLOCK, MD, PhD
SYMPOSIUM CHAIRMAN
Professor of Psychiatry and Pharmacology
University of Pittsburgh School of Medicine
Director of the Geriatric Psychopharmacology Program
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Treating Severe Melancholic Depression: New Data
BENEFIT H. MULSAN, MD
Associate Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Treating Depression in the Oldest-Old: Findings from the Harvard/TIRA Study
CARL SALZMAN, MD
Professor of Psychiatry
Harvard Medical School
Director of Psychopharmacology and Education
Massachusetts Mental Health Center
Boston, Massachusetts

THURSDAY, MAY 20, 1999
Treating Depression in the Older Patient With Comorbid Ischemic Disease
STEVEN P. ROSS, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons of Columbia University
Co-Director, Late Life Depression Clinic
New York State Psychiatric Institute
New York, New York

The Current Role of Electroconvulsive Therapy in the Treatment of Geriatric Depression
HAROLD A. SACKEIM, PhD
Professor, Departments of Psychiatry and Radiology
College of Physicians and Surgeons of Columbia University
Chief, Department of Biological Psychiatry
New York State Psychiatric Institute
New York, New York

*Breakfast precedes the symposium.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM SMITHKLINE BEECHAM PHARMACEUTICALS.
INDUSTRY-SUPPORTED SYMPOSIUM 35
Wednesday, May 19, and Thursday, May 20, 7:00 a.m. - 8:30 a.m.
Rooms 39/40, Upper Level, Convention Center

THE INTERFACE BETWEEN
DEPRESSION & DEMENTIA

WEDNESDAY, MAY 19, 1999
Rooms 39/40, Upper Level Convention Center, Washington, D.C.
6:30 - 7:00 a.m. - Dinner Reception
7:00 - 10:00 a.m. - Symposium
SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION

DAVID L. SULTER, M.D.
Clinical Assessment: Mood, Cognition and Their Interaction in the Elderly

DEVANGER P. DEYANAND, M.D.
Depressed Mood and Dementia in Elderly Patients in the Community

STEVEN P. ROOSE, M.D.
Treatment of Depression in the Old-Old

BRUCE C. POLLOCK, M.D., PH.D.
Pharmacotherapy of the Cognitive Impaired

K. RANGA RAMA KRISHNAJ, M.D.
Cardiovascular Changes in Depression and Dementia

INDUSTRY-SUPPORTED SYMPOSIUM 36
Wednesday, May 19, 7:00 p.m. - 10:00 p.m.
Constitution Ballroom, Level 3B, Grand Hyatt

ANTIDEPRESSANT COMBINATIONS
for
DRUG-RESISTANT and INTOLERANT CASES

Wednesday May 19, 1999
7:00 p.m. - 10:00 p.m.
(Buffet Dinner 6:00 p.m.)
Grand Hyatt
Constitution Ballroom
Level 3B

Chair: Stephen M. Stahl, MD, PhD

Cellular Mechanisms of
Antidepressant Action
RICHARD C. SHELTON, M.D.
Vanderbilt University

How to Combine Two
Antidepressants for Treatment
Synergy and Side Effect Reductions
STEPHEN M. STAHL, M.D., PhD
University of California San Diego

When Is Polypharmacy Good in
Treating Major Depression?
JEFFREY E. KELSEY, M.D., PhD
Emory University
INDUSTRY-SUPPORTED SYMPOSIUM 39
Wednesday, May 19, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

Time and Depression
Andrew A. Nierenberg, MD
Program Chair
Mark H. Rapaport, MD
Program Co-Chair

Wednesday, May 19, 1999
7:00 p.m. - 10:00 p.m.
Grand Ballroom
Ballroom Level
Renaissance Washington
Washington, DC
Dinner will be served at 6:30 PM.

Depressive Spectrum Disorder and Treatment
Mark H. Rapaport, MD

Depressed Children: Growing and Grown Up
Neal D. Ryan, MD

When Do Depressed Patients Start to Respond to Antidepressants?
Alan J. Gelenberg, MD

Personality and Depression Over Time
M. Tracie Shea, PhD

Residual Symptoms After Response to Antidepressants
Andrew A. Nierenberg, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 19, 7:00 p.m. - 10:00 p.m.
Renaissance Ballroom, Ballroom Level, Renaissance Washington

Sponsored by the APA at the 1999 APA Annual Meeting

Norepinephrine: Neurotransmitter for the Millennium

Charles B. Nemeroff, MD, PhD
Dennis S. Charney, MD

Chairperson
Co-Chairperson

Problems with Currently Available Antidepressants
Charles B. Nemeroff, MD, PhD

Norepinephrine Involvement in Antidepressant Action
Alan Frazer, PhD

Norepinephrine Dysfunction in Depression
Dennis S. Charney, MD

Clinical Efficacy of Reboxetine in Major Depression
Alan F. Schatzberg, MD

Genetic Ablation of the Norepinephrine Transporter in Mice
Marc G. Caron, PhD

Wednesday, May 19, 1999 7:00 pm - 10:00 pm
Renaissance Ballroom + Renaissance Hotel
Washington, D.C.

Reception precedes the symposium at 6:30 pm

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category I credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Pharmacia & Upjohn.
APA RESOURCE CENTER
AMERICAN PSYCHIATRIC ASSOCIATION

1999 ANNUAL MEETING

- Pick up Annual Meeting abstracts on disk
- Receive your personalized CME certificate of attendance
- Search the APA Job Bank
- Get the latest issues of
  - The American Journal of Psychiatry
  - Psychiatric News
  - Psychiatric Services
  - Psychiatric Practice & Managed Care newsletter
  - Psychiatric Research Report
- Save time and money with APA-Sponsored programs, e.g. car rentals, magazine subscriptions and the APA credit card
- Find out about the new practice guideline on Delirium
- Tap into local and national HIV/AIDS resources including curricula and publications and training information
- See the exciting new “Let’s Talk Facts” brochures
- Send a letter to Congress
- Pick up the new Congressional Directory

WIN FANTASTIC PRIZES

APA Resource Center
Convention Center
Exhibit Halls A/B Upper Level

Saturday May 15 11 am – 5 pm
Sunday May 16  8 am – 5 pm
Monday May 17 10 am – 6 pm
Tuesday May 18 10 am – 6 pm
Wednesday May 19 10 am – 3 pm

The Clinician

American Psychiatric Association
1999 Annual Meeting
Washington, DC  May 15-20, 1999

American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20005 USA

Toll Free number: 1-888-35-PSYCH
or: 202-682-6000

Web Site: www.psych.org
e-mail: apa@psych.org